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Abstract 
Peroxisome proliferator-activated receptors (PPARs) are the members of the 
steroid/retinoid nuclear receptor family. PPARs include three isoforms: a , 5/(3, and 
y. PPARa is the isoform responsible for lipid metabolism and peroxisome proliferator 
(PP)-induced pleiotropic responses and hepatocarcinogenesis. Short-term (2 weeks) 
administration of PP causes peroxisome proliferation, hepatomegaly and induction of 
gene expressions that involved in fatty acid P-oxidation. Long-term (11 months) 
administration of PP causes hepatocarcinogenesis. PP is a group of chemicals 
include some plasticizers such as DEHP di(2-ethylhexyl)phtalate) and hyperlipidemic 
drugs such as clofibrate and Wy-14,643. As humans are exposed to peroxisome 
proliferators chronically, the long-term effect of peroxisome proliferators on human 
should be identified. 
In my study, Wy-14,643 compound was selected as 100% hepatocarcinogenic 
effect was observed after long-term treatment. PPARa wild-type and PPARa (-/-) 
mice were fed with a control or a 0.1% Wy-14,643 diet for 11 months in order to find 
out the genes that are PPARa dependent and Wy-14,643 responsive. In order to 
study the time-dependent liver damage and genes expression that are induced by 
Wy-14,643, 24 hours gavage feeding, 1 week, 2 weeks and 6 months feeding 
experiments were also performed. 
i 
Hepatomegaly was observed in the PPARa (+/+) fed with 0.1% Wy-14,643 
after 1 week treatment and the level of liver enlargement was increased with 
prolonged period of treatment. The relative organ weights of white fat, brown fat and 
spleen in the 0.1% Wy-14,643 fed PPARa mice were lower compared to their controls. 
Serum cholesterol and triglyceride levels were also measured for different time points. 
Serum cholesterol level was significantly higher in 0.1% Wy-14,643 fed PPARa (+/+) 
mice at 11 months treatment. Time-dependent decrease in serum triglyceride level 
was observed in PPARa (+/+) mice fed with 0.1% Wy-14,643. The time-dependent 
decrease was started at 24 hours gavage feeding and continued to 11 months treatment. 
Histology was performed to study the liver damage that induced by Wy-14,643 
after chronic exposure. Irregular hepatocytes arrangement, enlarged sinusoidal 
spaces and trabecular cell clusters were observed in PPARa (+/+) mice fed with 0.1% 
Wy-14,643. In PPARa (-/-) ice, with the disruption of PPARa gene, lipid 
accumulation was found in both control and 0.1% Wy-14,643 treatment group started 
at 24 hours gavage feeding. 
After 11 months feeding experiment, fluorescent differential display was 
employed to screen out the genes in liver that are PPARa—dependent and Wy-14,643 
responsive as fluorescent differential display is able to compare several treatment 
groups at the same time. A total of eleven fluoroDD gels were performed and 
ii 
seventeen PPARa-dependent and Wy-14,643 responsive genes were confirmed in this 
project. They include peroxisomal delta 3, delta 2-enoyl-Coenzyme A isomerase, 
mouse cysteine sulfinic acid decarboxylase, mouse acetyl-Coenzyme A dehydrogenase, 
medium chain, peroxisome biogenesis factor 16, mouse Cyp4al4, mouse peroxisomal 
bifunctional enzyme, mouse Cyp4al0，very-long-chain acyl-CoA synthetase, mouse 
peroxisomal acyl-CoA oxidase, mouse hydroxysteroid (17-beta) dehydrogenase 11, 
mouse adipose differentiation related protein and mouse carnitine 
0-octanoyltransferase were confirmed to be up-regulated by 0.1% Wy-14,643 and 
PPARa-dependent. Mouse apolipoprotein A-V, mouse UDP-glucuronosyltransferase 
2 family member 5，mouse serine protease inhibitor 1-1, mouse major urinary protein 
II and mouse carboxyesterase were confirmed to be down-regulated by 0.1% 
Wy-14,643 and PPARa dependent. 
Temporal expression of all the seventeen genes (except mouse apolipoprotein 
A-V) was also performed to observe the time-dependent changes of these genes 
expression. Up-regulation of mouse peroxisomal delta 3, delta 2-enoyl-Coenzyme 
A isomerase, mouse acetyl-Coenzyme A dehydrogenase, medium chain, peroxisome 
biogenesis factor 16, mouse Cyp4al4，mouse peroxisomal bifunctional enzyme, mouse 
Cyp4al0, very-long-chain acyl-CoA synthetase, mouse peroxisomal acyl-CoA oxidase, 
mouse hydroxysteroid (17-beta) dehydrogenase 11，mouse adipose differentiation 
iii 
related protein and mouse carnitine 0-octanoyltransferase were started at 24 hours and 
persisted to 11 months treatment while up-regulation of mouse cysteine sulfinic acid 
decarboxylase was started at 1 week and persisted to 11 months. Down-regulation of 
mouse serine protease inhibitor 1-1, mouse major urinary protein II and mouse 
carboxyesterase was started at 1 week and continued to 11 months. Mouse 
UDP-glucuronosyltransferase 2 family member 5 was down-regulated at 2 weeks and 
persisted to 11 months. 
Based on the genes identified, oxidative stress is suggested to be the 
mechanism of PP-induced hepatocarcinogenesis. However, we still not know 
whether other mechanisms are involved in the PP-induced hepatocarcinogenesis. It 
is suggested that PP-induced hepatocarcinogenesis is due to the combined effect of 
oxidative stress and inhibition of apoptosis and increase in cell replication. Further 
studies are necessary to find out the relationship of different mechanisms and the 
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Chapter 1 Literature review 
Peroxsiome proliferator activated receptor (Aldridge et al) was first cloned 
from mouse liver in 1990 (Issemann and Green, 1990). There are three isoforms: 
PPARa, PPAR5 (also known as NUCI and PPARp), and PPARy. Among the three 
isoforms, PPARa is involved in lipid metabolism (Dreyer et al., 1993), short-term 
peroxisome proliferator-induced pleiotropic responses (Lee et al, 1995) and long-term 
hepatocarcinogenesis (Peters et al., 1997). Identification of the genes that regulated 
by PPARa and affected by peroxisome proliferators can help us to understand more ; 
I 
about the mechanism(s) of peroxisome proliferator-induced liver cancer. Monitoring 
；I 
the early expression of peroxisome proliferators-responsive and PPARa-dependent 
genes can be useful to prevent the induction of cancer by new peroxisome proliferator 
chemical. 
1.1 Peroxisome proliferator activator receptors 
Peroxisome proliferator activated receptors (PPARs) are belonging to the large 
steroid/retinoid nuclear receptor family which has a common modular structure. It 
consists of six functional domains, defined as A and B (transact!vation), C 
(DNA-binding), and D, E, and F (ligand-binding, dimerization and transactivation) 
(Motojima, 1993; Mangelsdorf er al.’ 1995; Kota et al., 2005). The A and B domains 
1 
A 
are ligand-independent transcriptional activation domains (activation function-1) 
(Weraian et al., 1997; Kota et al,, 2005). They are active in some cell types and 
responsible for phosphorylation of PPAR. The C domain that is DNA-binding 
domain (DBD) consisting of two zinc finger DNA binding motifs. The 
DNA-binding domain promotes the binding of PPAR to the PPRE in the promoter 
region of target genes. The D domain is the docking region for cofactors. The E 
domain (LBD) is responsible for ligand specificity and activation of PPAR binding to 
the PPRE that increases the target gene expressions. Modulators of transcription 
such as coactivators and corepressors interact with ligand-dependent activation 
function 2 (AF-2), which located in the E/F domain . 
1 
PPARs heterodimerize with the retinoid X receptors (RXRs) and bind to the 
PPRE of target genes. In vitro, when the PPARs and RXRs present at high t 
concentrations, they will heterodimerize, but stimulation by ligands are required at the 
lower concentrations of the receptors in cells (Forman et al., 1997; Kliewer et al., 
1997). The heterodimer binds to a consensus motif named peroxisome proliferator 
response element (PPRE), which most commonly consisting of the hexad 
[A/G]GGTCA directly repeated with a one nucleotide spacer (DR-1 elements) 
(Kliewer et al., 1992). It is reported that PPARs also bind other sites such as DR-2 
elements (Everett et al.’ 2000). PPAR-RXR heterodimers interacting at a PPRE can 
2 
i 
respond to either PPs or the RXR ligand, 9-cw-retinoic acid. Some retinoids can 
activate the PPAR-RXR heterodimer through binding RXRs. They exhibit 
peroxisome proliferation and induction of the enzymes that involved in P-oxidation of 
fatty acids, which is induced by peroxisome proliferators. PPARs cannot bind to the 
PPREs of the target genes without interacting with the RXR to form the heterodimer 
(Gearing et al., 1993; Keller et al, 1993). PPRE is identified in the 5' upstream 
regions of several target genes and as an almost perfect direct repeat of the sequence 
TG(A/T)CCT separated by one base pair in the genes of the peroxisomal acyl CoA 
oxidase (AXO), bi-functional enzyme (PBFE), and thiolase, the microsomal CYP4A 
subfamily and the cytosolic L-FABP (Lee et al., 1995). 
To date, there are three major types of PPAR have been identified: PPARa, 
PPARp/5 and PPARy which perform different physiological functions based on their 
tissue-specific expression (Table 1.1.1). PPARa is highly expressed in liver, kidney, 
muscle and fat body in rodents (Kliewer et al., 1994; Braissant and Wahli, 1998). 
However, the level of PPARa expression in humans is lower than in rodents (Palmer 
et al., 1998) and higher levels in heart, kidney, skeletal muscle and large intestine 
kidney and muscle (Mukherjee et al., 1997). PPARa regulates the fatty acid 
metabolism through stimulating peroxisomal and mitochondrial P-oxidation and 
microsomal co-oxidation. PPARa also involves in detoxification of endogenous and 
3 
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Table 1.1.1. Tissue distribution and physiological role of PPARa, p & 丫 in 
rodents 
Isoforms Tissue distribution Physiological role 
a Liver, kidney, Lipid metabolism 
muscle and adipose Regulation of inflammation 
tissue Detoxification of endogenous and exogenous 
chemcials 
p/5 Expressed Embryo implantation 
ubiquitously Decidualization 
y Adipose tissue, Adipocyte differentiation 




exogenous active molecules, some of which may be PPAR ligands (Beck et al., 1992) 
and down-regulates inflammatory responses (Devchand et al., 1996; Staels et al, 
1998). PP-induced pleiotropic responses shown in recombinant adenovirus that 
expresses human and mouse PPARa indicated that human PPARa is functionally 
competent and is equally as dose-sensitive as mouse PPARa in inducing peroxisome 
proliferation (Yu et al., 2001). PPARp/6 is ubiquitously expressed in both rodents 
and humans and it is expressed at low level in liver and kidney (Kliewer et al., 1994; 
Braissant et al., 1996). The physiological function of PPAR|3/5 is not yet well 
defined, previous reports have mentioned that it is involved in embryo implantation 
and decidualization (Lim et al., 1999). PPARy exists in two distinct isoforms 
PPARyl and PPARyl, which PPARy 1 is expressed in liver but expressed in lower 
I ！ 
levels in adipose tissue and PPARy2 is expressed in adipose tissue and is a potent 
regulator of adipocyte differentiation. It is also expressed in marcrophages, 
fat-storing cells such as hepatic stellate cells, liver, lung, kidney, placenta and colon. 
The expression of PPARy in liver is at higher level in human when compared with that 
in rodent (Tugwood et al., 1996). PPARy inhibits angiogenesis and inflammatory 
processes, plays a role in adipocyte differentiation and regulates adipocyte-specific 
gene expression (Tontonoz et al., 1994; MacDougald and Lane, 1995). 
PPARa is qualitatively and quantitatively different between rodent and human. 
5 
i 
The levels of PPARa mRNA and DNA binding activity are considerably lower in 
human liver samples than in rat liver. There is sequence variation of the human 
PPARa that results in a truncated protein incapable of binding DNA that makes up 
10-40% of human PPAR mRNA in liver. It is reported that human liver contains a 
functionally active PPARa, however, the human PPARa is expressed only about 10% 
of that in mouse liver, and extracts from human liver contain little PPARa that can 
bind to a PPRE (Palmer et aL, 1998). Sequence variant of PPAR (hPPAR6/29) that 
varies at three residues from the first cloned sequences is also found. This sequence 
variant can bind DNA but is not activiated by PPAR ligands, which plays a role as 
dominant negative suppressor. 
I 
1.2 Peroxisome proliferators L 
Peroxisome proliferators (PPs) are the group of chemicals which stimulate 
proliferation of peroxisomes. They consist of a broad spectrum of chemicals with 
little structural similarity, except for the presence of an aromatic ring, carboxylic acid 
and aliphatic chain. Most peroxisome proliferators are amphipathic molecules 
containing a hydrophobic backbone (aliphatic or aromatic) linked to an acidic function, 
which is essential for ligand activity. (Gorton et al., 2000). 
This group of chemicals (Table 1.2.1) include naturally occurring steroids such 
6 
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Table 1.2.1. Natural and synthetic PPARa ligands 
Natural ligands 
Saturated fatty acids 
Palmitic (16:0) 
Stearic (18:0) 




Polyunsaturated fatty acids 
Linoleic (18:2, n-6) 
Arachidonic (20:4, n-3) 
Eicosapentaenoic (22:5, n-3) 
Docosahexaenoic (22:6, n-3) 
Eicosanoids 丨 
Prostaglandins AI ；„ 


















as dehydroepiandrosterone (DHEA) (Frenkel et al., 1990), fatty acid such as 
including palmitic acid, oleic acid, linoleic acid and arachidonic acid (Gottlicher et al., 
1992) and ecosanoids (Forman et al., 1997) such as the inflammatory mediator 
leukotriene B4 (Devchand et al., 1996). 
PP also includes some synthetic compounds (Table 1.2.1) such as 
di(2-ethylhexyl)phthalate (DEHP) (Okita and Chance, 1984) which has been listed by 
the International Agency for Research on Cancer (lARC) and by the National 
Toxicology Program as a possible or reasonably anticipated human carcinogen 
丨』: 
because it induces dose-related increases in liver tumors in both sexes of rats and mice 
•I’： 
(lARC, 1982; Melnick, 2001) and di-(2-ethylhexylexyl)adipate (DEHA) (Bell, 1983). 1 
Hypolipidemic drugs such as clofibrate (Reddy and Qureshi, 1979), Wy-14,643 
A 丨 
[4-chloro-6(2,3-xylidino)-2-pyrimidinyl-thio] acetic acid (Reddy and Krishnakantha, “ 
1975) and nafenopin also have marked hepatomegalic and peroxisome-proliferative 
properties. Chronic nafenopin treatment developed hepatocellular carcinomas, some 
of which metastasized to the lungs in acatalasemic mice (Reddy et al” 1976). Other 
synthetic peroxisome proliferators include herbicides such as lactofen 
(r[carboethoxy] ethyl 5 - [2-chloro-4- [trifluoro-methy 1] phenoxy]-2-nitrobenzoate) 
which induces liver tumor in mice, pure and technical grade lactofen appear to induce 
murine liver tumors through a mechanism similar to epigenetic hepatocarcinogens of 
8 
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the peroxisome proliferating type (Butler et al,, 1988), fomesafen that causes 
peroxisome-related tumours in the mouse, man is neither susceptible nor sensitive to 
this mechanism (Smith and Elcombe, 1989) and haloxyfop 
2-(4-((3-chloro-5-(trifluoromethyl)-2- pyridinyl)oxy)phenoxy)propanoic acid] . 
Ingestion of haloxyfop by rats and/or mice (0.1-14 mg/kg/day for 2 to 4 weeks) 
f 
resulted in significant dose-related PP as evidenced by hepatocellular hypertrophy, 
increased peroxisome volume density (VD) and induction of peroxisomal enzymes 
and CYP4A1 (Stott et al., 1995). Trichloroethylene (TCE) is an industrial solvent 
I" 
and a widespread environmental contaminant and identified as a weak PP (Zhou and 
！i> ] 
l' 




Peroxisome proliferators may activate PPARs by binding directly to the 
I 
I 
receptor or indirectly to generate PPAR ligands by perturbing lipid metabolism L 
(Gorton et al., 2000). Peroxisome proliferators may act indirectly by increasing the 
level of the free fatty acids as some peroxisome proliferators can bind to liver 
fatty-binding protein and displace fatty acids such as oleic acid (Green, 1995). 
1.2.1 Hepatomegaly 
Treatment with PP results in rodents in pleiotropic responses, one of the 
morphological changes is hepatomegaly. A histological method utilizing the optical 
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dissector principle indicated that the hepatomegaly induced by the peroxisome 
proliferator gemfibrozil is a combination effect of hypertrophy and hyperplasia 
(Carthew et al., 1998). Treatment with clofibrate, nafenopin, tibric acid and 
Wy-14,643 produced a marked hepatomegaly in the mice. The increase in liver weight 
correlated well with the increase in total hepatic DNA and in the collective volume of 
hepatocyte peroxisomes (Moody and Reddy, 1978). Treatment with different 
peroxisome proliferators，including clofibrate, ciproflbrate, nafenopin, gemfibrozil, 
Wy-14,643, DEHP and DEHA at carcinogenic doses on male F-344 rats for 1 week 
shown a close correlation between relative liver weights and hepatocarcinogenicity (r 
丨: 
=0.910). (Takagi et al., 1992). This suggested that the hepatomegaly may be an [! 
i" 
i， 
early biomarker for prediction of the potential hepatocarcinogenicity of peroxisome 
丨i.‘ 
proliferators. A strong correlation between the animal thyroid status and both u 
hepatocyte proliferation (r2 = 0.62) and hepatocyte surface area (r2 = 0.83) suggested 
that the thyroid status of the animal was important in PPARa-mediated hepatocellular 
proliferation and liver cell enlargement (Wang et al,, 2004). Treatment with 
clofibrate and Wy-14,643 did not result in significant hepatomegaly in the PPARa (-/-) 
mice when compare with the untreated PPARa (+/+) mice (Lee et al., 1995). This 
indicated that the PP-induced hepatomegaly is mediated by PPARa. 
10 
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1.2.2 Peroxisome proliferation 
Peroxisome proliferation means the increase in both the sizes and the number 
of peroxisomes and is induced by peroxisome proliferators such as clofibrates and 
Wy-14,643. High fat diets, starvation and cold termperatures may also stimuate 
peroxisome proliferation (Gonzalez, 1997). Peroxisome proliferation has been 
r 
L 
reported to be strongly associated with but not causally to tumour formation (Green, 
1995). Di(2-ethylhexyl) adipate (DEHA) is a strong peroxisome proliferator but 
weakly carcinogenic. It is reported that the peroxisome proliferator such as DEHA • 
may only partially activate peroxisome proliferators-activated receptors (PPARs) 
i< 
i 
I l y 
while some chemicals may fully activate PPARs. Chemicals, which stimulate only ？ 
I I ！: 
part of the receptor's activity will cause peroxisome proliferation while complete 
I；' 
I'c 
activation is required to stimulate tumourigenesis. Peroxisome proliferation is also U 
proposed as a biomarker of exposure to a variety of pollutants in the environmental 
pollution assessment (Cajaraville et al., 2003). 
It is suggested that the PP-induced peroxisome proliferation was due to the 
increase in rate of transcription of genes encoding peroxisomal fatty acid P-oxidation 
enzymes. The increase in level of mRNA of specific genes will lead to increase in 
expression of specific protein that will accumulate within smooth membrane channels 
and result in peroxisome proliferation (Dzhekova-Stojkova et al., 2001). 
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PP-induced peroxisome proliferation is not observed in PPARa (-/-) mice with 
the administration of classical peroxisome proliferators, clofibrate and Wy-14,643. It 
indicates that PPARa is the major isoform required for mediating PP-induced 
peroxisome proliferations (Lee et al., 1995). PPARa-humanized mice shown 
induction of genes involved in peroxisomal and mitochondrial fatty acid metabolism 
I 
and resultant decrease of serum triglycerides upon treatment with Wy-14,643. • 
V； 
However, hepatocellular proliferation was not observed in PPARa-humanized mice. i) 
iv ：丨 
This suggested that the PPARa-mediated pathways controlling lipid metabolism are -
(J 丨、， 









1.2.3 Target genes regulation (二 
Induction of enzymes that involved in peroxisomal and mitochondrial 
P-oxidation and microsomal co-oxidation of fatty acids is observed after administration 
of peroxisome proliferators. For peroxisomal |3-oxidation, induction of acyl 
coenzyme A (acyl-CoA) oxidase (AXO), bifunctional enzymes (PBFE) and 
3-ketoacylCoA thiolase (thiolase) that located in the peroxisomal matrix are induced 
with the administration of peroxisome proliferators and they are direct targets of 
PPARa (Desvergne and Wahli, 1999). The fold of induction of AXO, BIEN and 
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thiolase is about 10- to 30-fold, whereas catalase and urate oxidase activities are 
increased 2- to 3-fold (Reddy et al., 1986; Nemali et al., 1988; Nemali et al., 1989). 
Soluble epoxide hydrolase (sEPHX) is also induced in rat liver with the 
peroxisomal P-oxidation by peroxisome proliferators with 5- to 10-fold increase 
(Grant et al., 1993). Dramatic increases in the activities of other peroxisomal 
enzymes, such as carnitine acetyltransferase and carnitine octanoyltransferase also j 




modulating the expression of medium-chain acyl-CoA dehydrogenase (MCAD) gene ！” 
j 
r'丨彳 
(Desvergne and Wahli, 1999). The microsomal p450 4A family (Cyp4al, 4a2 and 
4a3) that involved in the ©-hydroxylation is induced upon the treatment with f' 
peroxisome proliferators and with 2- to 5-fold induction (Reddy and Mannaerts, ：； 
丨、 
i： 
1994). t 二 
PPARa also mediates the expressions of genes that involved in other 
metabolisms including biotransformation, ketogenesis, fatty acid activation, fatty acid 
binding and transport, lipoprotein metabolism, lipogenesis, inflammation, triglyceride 
clearance, gluconeogenesis, phospholipids secretion, cholesterol catabolim and amino 
acid metabolism (Mandard et al., 2004) (Table 1.2.3.1). 
There are sequence variations in PPAR target genes that alter the response to 
peroxisome proliferators. For example, human acyl-CoA oxidase promoter is 
13 
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Table 1.2.3.1. List of PPARa regulated genes in liver 
Function of gene Genes 
Amino acid metabolism Alanine aminotransferase 
Alanine glyoxylate transaminase Cytosolic aspartate 
aminotransferase 
Arginase Glutaminase 
Arginino-succinate lyase Hydroxypyruvate/ gloxylate 
reductase 
Arginino-succinate synthase Mitochondrial aspartate 
aminotransferase 
Carbamoyl-phosphate synthase-I Ornithine transcarbamoylase 
Acute phase response Alpha-1 acid glycoprotein/serine Fibrinogen 
protease inhibitor 
Bile acid metabolism Cytochrome P450 7A1 
Bile salt transport Na+ taurocholate cotransporting [' 
polypeptide 
Biotransformation Aldehyde dehydrogenase type 3 Glutathione-S-transferase alpha | 
Cytochrome P450 2A5 Cytochrome P450 3A11 
Cytochrome P450 2C29 UDP-glycuronosyltransferase 1A9 
Cytosolic epoxide hydrolase 
Cell cycle c-myc Cyclin D1 
Cell cycle regulation GO/Gl switch gene 2 
Cellular proliferation glucose-regulated protein-94 : 
Cholesterol metabolism Cytochrome P450 12A1 Liver X receptor a 
Cytochrome P450 27A1 
Cholesterol transport ABCA-a (via LXRa) ABCG-8 (via LXRa) ：,< 
ABCG-5 (via LXRa) ;� 
Desaturation of fatty acid Delta-6-Desaturase Stearoyl-CoA desaturase ：• 
Delta-5-desaturase -
Fatty acid activation Long-chain acyl-CoA synthetase ‘ 
Fatty acid Cytosolic fatty acid binding : 
binding/transport protein � 
Fatty acid transport Fatty acid transport protein-1 Fatty acid translocase 
Fatty acid P-oxidation Acyl-CoA oxidase Medium-chain acyl-CoA ‘ 一 
dehydrogenase 
ATP-binding cassette Long-chain acyl-CoA 
half-transporter type 2 dehydrogenase 
ATP-binding cassette Short-chain-specific 
half-transporter type 3 3-ketoacyl-CoA thiolase 
Bifunctional enzyme Short-chain acyl-CoA 
Carnitine palmitoyl-transferase I Sterol carrier protein-X 
Carnitine palmitoyl-transferase II Thiolase B 
Dodecenoyl-CoA delta-isomerase Very long chain acyl-CoA 
dehydrogenase 
Fatty acid Cytochrome P450 4A1 Cytochrome P450 4A10 
co-hydroxylation Cytochrome P450 4A3 Cytochrome P450 4A14 
Cytochrome P450 4A6-Z 
Fatty acid synthesis Malic enzyme 
Fatty acyl-CoA ester Acyl-CoA binding protein 
transport 
Gluconeogenesis Lactate dehydrogenase A4 
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Table 1.2.3.1. List of PPARa regulated genes in liver (con't) 
Function of gene Genes 
Glucose oxidation Pyruvate dehydrogenase kinase 
isoform 4 
Heme biosynthesis Coproporphyrinogen oxidase 
Hepatic sterol Famesoid X receptor/Bile acid 
receptor 
Hepatobiluary lipid Multidrug resistance 2 
transport 
Hydrolysis of Acyl-CoA Cytosolic acyl-CoA thioesterase-I Peroxisomal acyl-CoA 
thioesterase lA 
Cytosolic acyl-CoA thioesterase-II Peroxisomal acyl-CoA 
thioesterase IB 
Mitochondrial acyl-CoA Peroxisomal acyl-CoA 
thioesterase-I thioesterase 2 J 
Iron-binding protein Lactoferrin ( 
Inflammation/ apoptosis IkBoc 
Iron transport Transferrin ‘ 
Ketogenesis Mitochondrial HMG-CoA Mitochondrial HMG CoA 
synthase synthase ji 
Oxygen-free radical Superoxide dimutase 丨: 
metabolism ,1 
Plasma HDL metabolism Apolipoprotein-AI Apolipoprotein-AV ！: 
Apolipoprotein-A I (via rev-erba) Apolipoprotein-CIII ,7 
Apolipoprotein-AII Phospholipid transfer protein 
Apolipoprotein-A IV Scavenger receptor B-type I • 
Pheromone carrier Alpha-2 urinary globulin/MUP-I 丨, 
Repressor of gene Rev-erba ') 
transcription _ 
ROS production Uncoupling protein-2 ‘ 
Triglyceride clearance Lipoprotein lipase 
Steroid metabolism 11 -beta-Hydroxysteroid 17-beta-hydroxysteroid ；• 
dehydrogenase I dehydrogenase IV 
Steroid hydroxylase Cytochrome P450 2C11 Cytochrome P450 2C12 — ：二 
Vascular inflammation Interleukin-6 Interleukin-6 receptor 
Interleukin-1 recpetor-type 1 
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differed from the rat sequence, which leads to the unresponsive of PPARa in 
transfection studies. On the other hand, the apoAI promoter in humans is responsive 
to fibrates whereas it is unresponsive for rat promoter as it is differed at three 
nucleotides. It is reported that PPARa is active in human liver as the human 
promoter has been shown to respond to fibrates in transgenic animals. This indicates 
K 
1 
that the responses to peroxisome proliferators between species differs quantitatively ！ 





1.2.4 Hypolipidemic effect 
K 
I 
Numerous research suggested the causative relationship between dyslipidemia 
I 
and coronary artery disease (CAD). Hypercholesterolemia (high LDL-cholesterol ：； 
r� 
li? 
levels), hypoalphalipoproteinmia (low plasma HDL) and hypertriglyceridemia are L 
considered as the risk factors (alone or combined) for CAD (Gervois et al., 2000). 
Fibrates are the first efficient and widely used lipid-lowering drugs to be used for the 
treatment of dyslipidemia. High doses (300-1200 mg/day) of fibrates were suggested 
to achieve efficacious lipid-lowering activity in human (Berger and Moller, 2002). 
Clofibrate (ethyl-a-p-chlorophenoxyisobutyrate) is probably the most widely used 
hypolipidemic drug and believed to be low in toxicity (Havel and Kane, 1973). 
PPARa mediates the hypolipidemic action of hypolipidemic drugs (e.g. fibrate 
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and Wy-14,643) in the treatment of hypertriglyceridemia and 
hypoalphalipoproteinemia (low plasma HDL). The main effect of the hypolipidemic 
drugs is to lower the triglyceride and cholesterol levels in the plasma (Issemann and 
Green, 1990). The hypolipidemic effect of the peroxisome proliferators is the 
enhancement of catabolism of plasma triglyceride-rich lipoprotein due to a decrease in 
plasma apolipoprotein C-III through the suppression of the apolipoprotein C-III gene 
j丨 
expression (Hertz et al., 1995). Gene expression of the lipoprotein lipase, which is ； 
\ 丨 
I 
important in triglyceride metabolism, is also induced with the treatment of -
hypolipidemic drugs (Desvergne and Wahli, 1999; Yamazaki et al., 2002). The 
!•< 
I � 
induction of expression of lipoprotein lipase and increase accessibility of TG-rich y 
r' 
I: 
lipoprotein particles for lipolysis due to reduced TG-rich lipoprotein apo C-III content :：; 
！ 
. . 丨( 
will lead to the induction of lipoprotein lipolysis. 
PPARa also upregulates HDL that is inversely correlated with the incidence of 
CAD. It is suggested that HDL play a role from removing and recycling of 
cholesterol excess from peripheral tissues to liver. The upregulation of HDL is 
related to the changes in Apo A-I and Apo A-II. However, the responsive was of Apo 
A-I and Apo A-II in rodents and human are opposite with the application of 
peroxisome proliferators. Apo A-I and Apo A-II gene transcription is induced in 
human while their gene transcription is repressed in rodents (Gervois et al., 2000). 
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Hepatic and cardiac lipid accumulation is observed in the PPARa (-/-) mice as a result 
of specific inhibition of mitochondrial fatty acid import. 
PPARa, which also mediates the lipid metabolism, upregulates the gene 
expression of enzymes involved in conversion of fatty acids in acyl-CoA esters, fatty 
acid entry into mitochondria and peroxisomal and mitochondiral fatty acid catabolism 
•1 
(Gervois et al., 2000). These results in the limitation of hepatic TG synthesis and 
I i" 
I 
very low density lipoprotein VLDL production. 
1.2.5 Hepatocarcinogenesis 丨 
I 
I� 
Long term administration (11 months) of Wy-14,643 leads to multiple 丨 
卜 
hepatocellular neoplasms, including adenomas and carcinomas (Reddy and Qureshi, ：; 
I � 
1979; Peters et al., 1997). The hepatocarcinogenicity of peroxisome proliferators 
must be nongenotoxic mechanisms as they will not cause DNA damage directly (von 
Daniken et al., 1981). It is reported that there is correlation between the ability of a 
PP to bind to and/or activate PPARa and the potency of the PP as an inducer of 
hepatocarcinogenesis. The strongest inducers of hepatocarcinogenesis, Wy-14,643, 
binds strongly to PPARa and activates PPARa to high levels. In contrast, 
bezafibrate is a relatively weak hepatocarcinogen and, binds and activates PPARa 
weakly (Krey et al, 1997). 
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The hepatocarcinogenesis induced by PPs is a multistage process consisting of 
hepatocellular hyperplasia and formation of altered hepatocellular foci, adenoma, and 
carcinoma. This process is reversible before the formation of carcinoma. The 
progression of PP-induced foci to hepatocellular adenomas requires continual 
exposure of PPs. Regression of the lesions (decrease proliferation and increase 
apoptosis) are observed after PP withdrawal (Marsman and Popp, 1994). After 
removal of nafenopin for five weeks, there is a 20% reduction in the number of 
hepatocytes in noninvolved tissue and 85% reduction of cells in foci, adenomas, and 
carcinomas. The data indicates that continual activation of PPARa is necessary for 
the growth and maintenance of initiated cells in foci, adenomas and carcinomas in the 
liver ofPP-treated rodents (Peters et al., 1997; Kitamura et al., 1999). 
Some studies suggested that peroxisome proliferators act as tumour promoters 
rather than tumour initiators (Cattley et al, 1989; Cattley and Popp, 1989) and these 
chemicals act upon spontaneously initiated lesions to produce tumours (Cattley et al., 
1991; Kraupp-Grasl et al., 1991; Green, 1995). The carcinogenicity of DEHP and 
Wy-14,643 are related to sustained DNA replication, which induce tumours by 
influencing the growth of initiated lesion. DEHA and Wy-14,643 are more effective 
promoting agents in old rats compared with young rats. Since the number of 
preneoplastic hepatic foci is greater in the older rats, it is suggested that peroxisome 
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proliferators promote the growth of these ‘spontaneously，initiated cells. Identifying 
any peroxisome proliferator regulated genes that are relevant to the growth of 
hepatocytes will provide support for this model. 
It is reported that there are species differences in response to peroxisome 
proliferators. PP-induced pleiotropic responses (hepatic hypertrophy, peroxisome 
proliferation and hepatocellular carcinoma) occured in rodents are not observed in 
human and primates. Gemfibrozil and fibrates, hypolipidemic drugs used for many 
years, however, no evidence of elevated peroxisomes and increased liver cancer have 
shown in the patients (Peters et al., 1997; Everett et al, 2000). 
1.3 Mode of actions 
Long term (11 months) administration of peroxisome proliferators will cause 
liver cancer. However, peroxisome proliferators are not directly mutagenic or 
genotoxic, the mechanism(s) of peroxisome proliferators induced liver is/are not yet 
confirmed. Many evidences suggest that hepatocarcinogenesis is a multifactorial 
process consisting of sustained oxidative stress, inhibition of apoptosis and increased 
cellular proliferation (alteration of cell cycle control). 
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1.3.1 Oxidative stress 
The increase in peroxisomal fatty acid P-oxidation due to administration of 
peroxisome proliferators (both short-term and long-term) results in a greater 
production of hydrogen peroxide. The first enzyme in the peroxisomal P-oxidation, 
acyl-CoA oxidase, generates H2O2 during the first step of P-oxidation. However, 
peroxisomal catalase, which is responsible for the detoxification of hydrogen peroxide, 
is increase less than 2- to 3-fold (Nemali et al., 1989). The increase in peroxisomal 
P-oxidation but no induction in catalase will result in an increase in H2O2 levels 
(oxidation stress). This effect is mediated by PPARa as treatment with anti-oxidants 
can reduce the incidence of tumor formation in rats, which exposed to peroxisome 
proliferators chronically (Rao et al., 1984). 
Excess H2O2 can cause DNA damage through formation of adducts such as 
8 -hydroxy guanime or strand breaks and possibly tumour initiation. 
8-Hydorxydeoxyguanosine (8-OH-dG) is a frequently used marker of DNA damage 
produced by oxygen radicals. It is observed that PPs increase 8-OH-dG levels in 
livers of treated rodents, but there is no clear link between the observed increase and 
carcinogenesis (Sausen et al., 1995). 
Hypolipidemic drugs such as fibrates have been used for many years, however, 
no evidence of elevated increased liver cancer have shown in the patients (Peters et al., 
21 
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1997; Everett et al” 2000). This may be due to the activity of catalase in rodents is 
located primarily in the peroxisome, whereas it is mainly in the cytoplasm in humans, 
which make humans have greater protection against oxidative stress. 
1.3.2 Inhibition of apoptosis 
Apoptosis is one of the defense mechanism against neoplastic transformation. 
Inhibition of apoptosis is observed with the administration of peroxisome proliferators. 
Nafenopin and Wy-14,643 inhibit transforming growth factor-pi-induced apoptosis in 
vitro (Bayly et al, 1994). This interferes the eliminations of cells with damaged or 
mutated DNA. The inhibition of apoptosis is mediated by PPARa since inhibition of 
apoptosis by the PPARa ligand nafeopin can be blocked by a dominant negative form 
of the receptor (James et al., 1998). i 
1.3.3 Cell proliferation 
PP-induced increase in cell-proliferation is observed within 48 hours of PP 
treatment. With chronic Wy-14,643 treament, cell proliferation is sustained whereas 
cell proliferation in the liver returns to control levels with weaker PPs e.g. nafenopin. 
The early increase in cell replication induced by PPs can increase the frequency of 
spontaneous mutations, which can be fixed by further rounds of cell division or clonal 
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expansion (Ashby et al., 1994). 
1.3.4 Alterations in cell cycle control 
It is suggested that peroxisome proliferators will cause alterations in cell cycle 
control, which might contribute to underlying mechanism of peroxisome 
proliferator-induced carcinogenesis including inhibition in apoptosis, increase in DNA 
synthesis and cell replication and alterations in cell division in liver (Marsman et al., 
1988). 
1.4 Objectives 
In order to study the carcinogenic effect of peroxisome prolifertor, Wy-14,643, 
a potent peroxisome proliferator and hyperlipidemic drug, was selected for the study. 
It is reported that the treatment of Wy-14,643 will lead to liver cancer in rodents after 
1 year treatment, 11 months treatment was performed to identify the PPARa 
dependent and peroxisome prolifeator-responsive genes at the tumor stage. As the 
mechanism(s) of PP-induced hepatpcarcinogenesis is/are still not clear, identification 
of the genes that are PPARa and Wy-14,643 responsive can help to explain the 
mechanism(s). In order to identify the PPARa-dependent and Wy-14,643-responsive 
genes that are at the tumor stage, Wy-14,643 was selected for 11 months treatment of 
the PPARa (+/+) and PPARa (-/-) mice. Temporal expressions of the 
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PPARa-dependent and Wy-14,643 responsive genes were also studied. 
Fluorescent differential display was used to identify the genes, which are 
regulated by PPARa and affected by peroxisome proliferators, as its sensitive and 
ability of comparison of more than two treatment groups. Histology was performed 
to identify the liver damage caused by the chronic administration of Wy-14,643. 
The objects of this project are as follows: 
1. To examine the liver damage caused by chronic exposure of Wy-14,643. 
2. To identify PPARa-dependent and Wy-14,643-responsive genes at the tumor stage 
3. To identify the temporal expression of PPARa-dependent and Wy-14,643-
responsive genes. 
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Chapter 2 Materials and Methods 
2.1 Animal tail-genotyping 
The genotypes of PPARa (+/+) and PPARa (-/-) mice were confirmed by PCR 
tail-genotyping before the animals were used for feeding treatment as there was no 
external phenotypic difference between PPARa (+/+) and PPARa (-/-) mice (Figure 
2.1.1). PCR tail-genotyping was performed by using a pair of forward (Fl, 5'-
GCCTGGCCTTCTAAACAT-3') and reverse (R3，5,-ACTCGGTCTTCTTGATGA_ 
3，）primers which located before the Pstl (1330-1347) and after the Sphl (1503-1520) 
sites of exon 8 of PPARa gene, respectively (Figure 2.1.2). The expected size of PCR 
product amplified from genomic tail DNA of PPARa (+/+) mice was 191 bp. Due to 
the replacement of a 83 bp genomic fragment by a 1.14 kb neo gene between Pstl and 
Sphl sites in exon 8 of PPARa gene, the expected size of PCR product amplified from 
genomic tail DNA of PPARa (-/-) mice was 1248 bp (Lee et al., 2002). i 
2.1.1 Materials 
Isopropanol was purchased from BDH (England). dNTP mix was purchased 
from Roche (Germany). EDTA was obtained from Riedel-de Haen (Germany). 
Proteinase K was purchased from Roche (Germany). DNA markers were from 
Invitrogen (USA). Ethidium bromide and SDS were obtained from Sigma (USA). 
Forward and reverse primers were synthesized and purchased from Invitrogen (USA). 
Agarose, boric acid, sodium chloride and trizma base were purchased from USB 
(USA). Taq polymerase and PCR buffer were from GenSys (UK). 
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Figure 2.1.1. External morphology of 3 months old PPARa (+/+) and PPARa (-/-) ^ 
male mice. 
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Figure 2.1.2. A schematic representation of PPARa (+/+) and PPARa (-/-) mouse 
genomic organization and the location of PCR primers designed for tail-genotyping. { 
i 
For PPARa (-/-) mice, a 83 bp genomic fragment between the Pstl and Sphl sites in ^ 
exon 8 was replaced by a 1140 bp neo gene. A pair of primers, F1 and R3, which 
locate before the Pstl and after Sphl sites, respectively were designed for PCR. The 
expected sizes of PCR products for PPARa (+/+) mice was 191 bp, while that of 




About 1 cm tail tip from PPARa (+/+) and PPARa (-/-) mice was excised and 
incubated in 0.5 ml of lysis buffer [100 mM Tris-HCl (pH 8.5), 5 mM EDTA (pH 
8.0)，0.2% SDS, 200 mM NaCl and 100 /ig/ml proteinase K] in a 15 ml Falcon tube at 
with shaking for overnight digestion. After an overnight incubation, the Falcon 
tube was vortexed and incubated for an additional 2 hr. Then the Falcon tube was 
centrifuged at 3,000 rpm at room temperature for 10 min and the supernatant was 
collected into a new 1.5 ml eppendrof tube. The supernatant was centrifuged at 
14,000 rpm at room temperature for 10 min and the resulting supernatant was 
transferred into a new 1.5 ml eppendrof tube which containing 0.5 ml isopropanol. 
The mixture was shaken laterally to precipitate the DNA and the DNA strand was 
transferred into a new 1.5 ml eppendrof tube using a P-100 pipette tip. The DNA 
strand was air-dried, dissolved in 100 jitl Tris-EDTA buffer [10 mM Tris-HCl (pH 7.5) 
and 0.1 mM EDTA (pH 7.5)] and incubated at 55�C water bath overnight. Next day 
I 
the DNA pellet was resuspended by pipetting up and down and used for PCR reaction. 
For each PCR reaction, 1 ii\ of resuspended tail DNA was mixed with IX PCR 
buffer, 0.05 mM dNTP mix, 0.35 /xM forward primer (Fl), 0.35 fiM reverse primer 
(R3) and 0.1 UZ/xl Tag polymerase (Appendix A, Table AI). The PCR reaction was 
performed in a thermal cycler (GeneAmp®PCR system 9700) and the PCR cycle was 
as follows: 95�C for 2 min, followed by 34 cycles of 92�C for 15 sec and 72�C for 2 
min and followed by 72�C for 7 min and hold at 4�C. The PCR products of 
PPARa (+/+) and PPARa (-/-) mice were resolved on 2% and 1% agarose gel, 
respectively and 0.5X TBE gels with ethidium bromide staining. 
28 
2.2 Animal treatment 
PPARa (+/+) and PPARa (-/-) mice were used to study the molecular 
mechanism of PPARa—mediated Wy-14,643 induced hepatocarcinogenesis. 
2.2.1 Materials 
For all the experiments, PPARa (+/+) and PPARa (-/-) mice on SV129 genetic 
background were used and they were the offspring of breeder mice obtained from the 
National Cancer Institute (USA). Wy-14,643 ([4-chloro-6-(2,3-xylidino)-2-
pyrimidinylthio]-acetate) was purchased from Chemsyn Science Laboratories (USA) 
and methylcellulose was obtained from Sigma (USA). Formaldehyde was purchased 
from Riedel-de Haen (Germany).The mouse chow diet containing 0.0% (control diet) 
or 0.1% Wy-14,643 was custom-made by Bioserv Company (USA). 
2.2.2 Methods 
Three months old PPARa (+/+) and PPARa (-/-) male mice were kept in i 
groups of 2-4 mice per cage and provided with ozonated water ad libitum on a 12 hr 
light/dark cycle. For 24 hr gavage treatment, PPARa (+/+) and PPARa (-/-) were 
given a single dose of 1% methylcellulose (control vehicle) or Wy-14,643 (50 mg/kg 
bw) in 1% methylcellulose by intragastic infusion. For feeding study, both PPARa 
(+/+) and PPARa (-/-) mice were either fed with a 0.0% (control) or a 0.1% Wy-
14,643 rodent diet for 1 wk, 2 wk, 6 mo and 11 mo ad libitum. The body weight of 
mice was measured before and during (once per week)the feeding periods. At the end 
of experiment, mice were dissected and blood was collected for serum cholesterol and 
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triglyceride analyses. Other organs including liver, brown fat, white fat, spleen, 
kidney, heart, brain and testis were removed and weighed. About 1 cm^ of liver 
samples was fixed in 10% phosphate-buffered formalin (10-fold diluted 37% 
formaldehyde with IX PBS) for histological analysis. The remaining organs were 
wrapped in aluminum foil and stored frozen in liquid nitrogen. 
2.3 Serum cholesterol and triglyceride analyses 
Previous studies have reported that the main effect of the hypolipidemic 
peroxisome proliferators is to lower the serum triglycerides and cholesterol levels 
(Havel and Kane, 1973). 
Serum cholesterol was determined based on a modification of method 
described by Allain et al. (1974). Cholesterol ester in the serum is first hydrolyzed by 
cholesterol esterase to cholesterol and fatty acid. The cholesterol is then oxidized by 
cholesterol oxidase to cholesterone and hydrogen peroxide. In the presence of 
peroxidase, hydrogen peroxide produced is then coupled with 4-aminoantipyrine and | 
1 
phenol to yield quinoneimine, a dye which can be measured at 500 nm. The intensity 
of the dye is directly proportional to the concentration of serum cholesterol. 
Serum triglyceride was determined based on a modification of method 
described by Bucolo and David (1973). Serum triglyceride is first hydrolyzed by 
lipase to glycerol and fatty acids. The glycerol is then phosphorylated by adenosine 
triphosphate (ATP) to glycerol-3-phosphate and adenosine-5'-diphosphate (GDP) 
which catalyzed by glycerokinase. The glycerol-3 -phosphate is then oxidized by 
glycerol-3 -phosphate oxidase to dihydroxyacetone phosphate and hydrogen peroxide. 
In the presence of peroxidase, hydrogen peroxide produced is then coupled with 4-
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aminoantipyrine and 4-chlorophenol to form quinoneimine which can be measured at 
500 nm. The intensity of the colour is directly proportional to the serum triglyceride 
concentration in the sample. 
2.3.1 Materials 
Cholesterol and triglyceride determination enzyme kits were obtained from 
BioSystems (Spain). Plastic curvets were purchased from Niimbrecht (Germany). 
2.3.2 Methods 
2.3.2.1 Serum preparation 
Blood samples were allowed to clot for 30 min at room temperature. The 
clotted blood samples were then centrifuged at 2,400 rpm at room temperature for 20 
min. The supernatant which containing the serum was then transferred to a new 1.5 
ml eppendrof tube and centrifuged at 2,400 rpm for 20 min. The clear serum was then 
transferred to a new 1.5 ml eppendrof tube and stored at -20°C. 
[ 
2.3.2.2 Serum cholesterol analysis 
Cholesterol reagent and cholesterol standard (200 mg/dl) were warmed to 
room temperature before use. Four microliters of cholesterol standard or serum 
samples from each mouse were added to curvets containing 400 /xl of cholesterol 
reagent. The contents were mixed and the samples were incubated for 15 min at room 
temperature. The absorbances (A) of standard and samples at 500 nm were measured 
using a spectrophotometer (Beckman DU® 640, USA) against the blank which 
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containing 400 |LI1 of cholesterol reagent. The concentration of serum cholesterol 
(mg/dl) was calculated using the following formula: 
Cone, of serum cholesterol (mg/dl)= Asampie / Astandard X conc. of cholesterol standard 
2.3.2.3 Serum triglyceride analysis 
Triglyceride reagent and triglyceride standard (200 mg/dl) were warmed to 
room temperature. Four microliters of triglyceride standard or serum samples from 
each mouse were added to curvets containing 400 fil of triglyceride reagent. The 
contents were mixed and the samples were incubated for 15 min at room temperature. 
The absorbances (A) of standard and samples at 500 nm were measured using a 
spectrophotometer (Beckman DU® 640, USA) against the blank which containing 400 j 
I 
of triglyceride reagent. The concentration of serum triglyceride was calculated 
i I 
using the following equation: | 
I 
Conc. of serum triglyceride (mg/dl)= Asampie 丨 Astandard X conc. of triglyceride standard ！ 
I' 
I 
2.4 Histological analysis 
To assess the liver damage induced by Wy-14,643, hematoxylin and eosin 
staining was performed from each treatment group at 24 hr, 1 wk, 2 wk, 6 mo and 11 
mo. 
2.4.1 Materials 
Mayer's hematoxylin was from Polysciences (USA). Concentrated HCl, 
ethanol and eosin were purchased from BDH (England). Paraffin was obtained from 
Merck (USA). Permount was purchased from Fisher (USA). Xylene was from Merck 
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(USA). Magnesium sulfate and sodium hydrogen carbonate were purchased from 
BDH (England). 
2.4.2 Methods 
The flow chart showing the steps for histological analysis is summarized in 
Figure. 2.4.1. The fixed liver samples were processed in an enclosed tissue processor 
(Shandon, England) with the following program: 70% ethanol at room temperature 
for 2 hr, 80% ethanol at room temperature for 2 hr, 95% ethanol at room temperature 
for 2 hr, 100% ethanol at room temperature for 2 hr three times, xylene at room 
temperature for 1 hr twice and paraffin at 6(rC for 2 hr four times. The processed 
samples were then embedded in paraffin. Liver sections of 5 /rni thick were cut by 
microtome (Jung, Germany) and then dried at 40°C. For staining, the liver sections 
were first rinsed with xylene for 1 min three times and then in a serial graded ethanol | 
I 
i 
(100%, 95%, 80% and 70%) for 1 min. The liver sections were stained with Mayer's ！ 
hematoxylin for 5 min and washed with tap water. The sections were then rinsed with j； 
丨 
Scott tap water (0.04 M sodium hydrogen carbonate and 0.15 M magnesium sulfate) � 
and washed with tap water. Excess staining was washed by dipping the section in acid 
alcohol (100-fold diluted concentrated HCl with 70% alcohol) for 1 sec and then 
washed with tap water. The sections were stained with eosin for 5 min. Excess 
staining was removed with tap water and the sections were rinsed with a serial graded 
ethanol (70%, 80% and 95%) for 1 min. The sections were then rinsed with absolute 
ethanol for 1 min and then followed by rinsing with xylene for 1 min three times. The 
sections were mounted with permount and photographs were taken with Integrated 
Biological Imaging System (Axiophot 2 unviersal microscope: Zeiss, Germany; spot 
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cooled colour digital camera and software-Spot 32: Diagnostic Instruments, USA; 
Software-MetaMorph 4.0: Universal Imaging Corporation, USA) (Figure 2.4.1). 
2.5 Total RNA isolation 
Total liver RNA of PPARa (+/+) and PPARa (-/-) mice treated with a 0.0% 
(control diet) or a 0.1% Wy-14,643 for 11 mo was isolated for non-fluoroDD, 
fluoroDD and Northern blot analyses. Liver RNA samples of 24 hr gavage feeding 
and 1 wk, 2 wk and 6 mo feeding treatments were used to study the temporal gene 
expression. 
2.5.1 Materials 
Chloroform was from Merck (USA). Ethanol and isopropanol were purchased 
from BDH (England). Trizol reagent was obtained from Invitrogen (USA). 
[ 
2.5.2 Methods 丨 
I. 
The steps for isolation total RNA are summarized in Figure 2.5.2.1. Frozen 
liver samples were mixed with Trizol reagent (10 ml/g) and homogenized with a tissue 
tearor (Dremel®, USA). The homogenate was allowed to stand for 5 min and then 1 
ml of homogenate was added to a new 2 ml eppendrof tube which containing 0.2 ml 
chloroform. After vortexing, the mixture was allowed to stand for 2 min and then 
centrifuged at 14,000 rpm at 4°C for 15 min. The supernatant which containing the 
RNA was transferred into a new 1.5 ml eppendrof tube which containing 500 fA of 
isopropanol. The sample was vortexed and then allowed to stand for 10 min at room 
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Fix � 1 cm liver slice in 10% formalin 
1 r 
Process the fixed samples in an enclosed tissue processor 
70% ethanol for 2 hr � 
—80% ethanol for 2 hr 
-> 95% ethanol for 2 hr f ""eom 
—100% ethanol for 2 hr3X t e m p e _ r e 
• xylene for 1 hr 2X 
Paraffin for 2 hr4X at 60°C 
1 r 
Embed the processed samples in paraffin 
Cut liver section at 5 i^m thickness 
，r 
Stain liver sections with H & E 
Xylene for 1 min 3X 
—100% ethanol for 1 min ‘ 
—95% ethanol for 1 min 
—80% ethanol for 1 min 
70% ethanol for 1 min 
Hematoxylin for 5 min 
Tap water for several min i 
Scott tap water for 1 min � 
今 Tap water for several min 
Acid alcohol for 1 sec 
Tap water for several min 
Eosin for 5 min 
—Tap water for several min 
70% ethanol for 1 min 
80% ethanol for 1 min 
95% ethanol for 1 min 
—100% ethanol for 1 min 
Xylene for 1 min 3X 
Mount with permount 
Take photograph with Integrated Biological Imaging System 
Figure 2.4.1. Flowchart showing the steps for histological analysis. 
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Homogenize liver samples with Trizol reagent 
y 
Transfer 1 ml of homogenate to new 2 ml eppendrof tube 
y 
Add 200 |Lil chloroform 
，r 
Vortex the mixture and stand for 2 min 
Y 
Centrifuge at 14,000 rpm at 4 � C for 15 min 
y 
Transfer supernatant to new 1.5 ml eppendrof tube 
y 
Add 500 jLil isopropanol to each eppendrof tube 
i 
Y 
Vortex the mixture and stand for 10 min 
y 
Centrifuge at 14,000 rpm at 4 � C for 10 min | | 
T 
Discard the supernatant and wash pellet with 1 ml 70% ethanol 丨 , 
_ T I 
Centrifuge at 14,000 rpm at 4 � C for 10 n ^ •‘ 
y 
Repeat washing step twice 
y 
Add 1 ml 100% ethanol to the pellet and store at -8Q°C 
Figure 2.5.2.1 Flowchart showing the steps for isolation of total RNA. 
36 
temperature. The mixture was centrifuged at 14,000 rpm at 4 � C for 10 min. After 
discarding the supernatant, the pellet was washed with 1 ml 70% ethanol. The sample 
was centriftiged at 14,000 rpm at 4 � C for 10 min and the supernatant was discarded. 
The washing steps were repeated twice. For long-term storage, 1 ml of absolute 
ethanol was added to the pellet and the sample was stored at -80°C. 
2.6 DNase I treatment of total liver RNA 
DNase I treatment was used to remove any genomic DNA contamination in the 
RNA samples, as they will give false positive fluoroDD patterns during RT-PCR. 
Negative control was performed for checking any genomic DNA contamination after 
DNase I treatment. 丨 
I 
2.6.1 Materials \ 
i I 
i 
Magnesium chloride and sodium acetate were obtained from Sigma (USA). 
I 
Nuclease-free water was purchased from Promega (USA). Phenol: chloroform: 丨 
isoamyl alcohol (25:24:1) was purchased from Invitrogen (USA). RNase-free DNase 
I, HPLC pure grade was from Amersham Biosciences (England). Trizma base was 
purchased from USB (USA). 
2.6.2 Methods 
Fifty micrograms of total liver RNA were mixed with 10 mM MgCl2,0.3 U/)li1 
RNase-free DNase I and 50 mM Tris-HCl (pH 7.5) (AppendixA, Table A2). The 
mixture was then mixed by finger-tapping and incubated in 37°C water bath for 30 
min. The sample was then diluted to 500 fil with nuclease-free water and 500 /xl of 
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. — ^ 
phenol/chloroform was added to each sample. After vortexing and centrifUged at 
14,000 ipm at 4°C for 30 min, 400 /xl of supernatant was transferred to a new 1.5 ml 
eppendrof tube. Forty microliters of 3 M sodium acetate were added to each 
eppendrof tube and vortexed. Eight hundred microliters of absolute ethanol were 
added to each sample. The mixture was vortexed and allowed for overnight 
precipitation at -80°C. The precipitated RNA was centrifuged at 14,000 rpm at 4°C 
for 30 min. The supernatant was discarded and the pellet was washed with 70% 
ethanol and centrifuged at 14,000 rpm at 4°C for 30 mine. The washing steps were 
repeated twice and the pellet was air-dried. The RNA pellet was resuspended in 35 /xl 
nuclease-free water and stored at -80°C. 
I 
2.7 Reverse transcription (RT) of mRNA and non-
• i 1 I 
fluorescent PCR (non-fluoroDD PCR) [ 
The first-strand cDNA synthesis was carried out by using the 
r, 
HIEROGLYPHTm profile kit. This kit consists of 12 different 3'-oligo(dT) anchored r 
primers (APs) (Figure 2.7.1) which are two-base different on the 3’ end and it divides 
the mRNA pool into 12 first-strand cDNA pools. The double-strand DNA was 
performed by the fluoroDD adapter kit. It contains 20 ten-base different 5'-arbitrary 
primers (ARPs) (Figure 2.7.2) and 12 different 3 '-tetramethylrhodamine-labeled 
oligo(dT) anchored primers (TMR-APs) (Figure 2.7.3) which have same sequence to 
their corresponding anchored primers (APs) in the HIEROGLYPH^^ profile kit. 
There are total 240 different combinations of primers with 12 different APs and 20 
different ARPs. However, not all the 240 primer combinations will give our desired 
differential display patterns, non-fluorescent PCR (non-fluoroDD PCR) (Figure 2.7.4) 
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T7 promoter sequence oligo(dTi2) 
r � ( ^ 
API 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTGA 3 ’ 
AP2 5 ‘ ACGACTCACTATAGGGCTTTTTTTTTTTTGC 3 ’ 
AP3 5 ‘ ACGACTCACTATAGGGCTTTTTTTTTTTTGG3 ‘ 
AP4 5, ACGACTCACTATAGGGCTTTTTTTTTTTTGI3, 
AP5 5 ‘ ACGACTCACTATAGGGCTTTTTTTTTTTTCA 3 ‘ 
AP6 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCC 3 ’ 
AP7 5 ‘ ACGACTCACTATAGGGCTTTTTTTTTTTTCG 3 ’ 
I 
i 
AP8 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTAA 3 ’ I 
AP9 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTAC 3 ‘ 
AP10 5' ACGACTCACTATAGGGCTTTTTTTTTTTTAG 3’ 丨  
API 1 5 ‘ ACGACTCACTATAGGGCTTTTTTTTTTTTAT 3 ’ 丨 
AP12 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3 ’ 丨 
L 
Figure 2.7.1 Sequences of 12 different 3’-oligo(dTi2) anchored primers (APs). Each 
AP primer contains three domains and they are the same for the T7 (17-mer) promoter 
sequence for amplification and the oligo(dTi2) for annealing to polyA tail of mRNA. 
However, the 12 different APs are two-base different at the 3,end which divide mRNA 
pool into 12 subsets (adapted from fluoroDD manual, Beckman). 
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M 1 3 reverse primer s e q u e n c e Core anneal ing s e q u e n c e 
r ^ 
ARPl 5 ’ ACAATTTCACACAGGACGACTCCAAG 3, 
ARP2 5，ACAATTTCACACAGGAGCTAGCATGG 3 ’ 
ARP3 5, ACAATTTCACACAGGAGACCATTGCA 3, 
ARP4 5，ACAATTTCACACAGGAGCTAGCAGAC 3 ’ 
ARPS 5, ACAATTTCACACAGGAATGGTAGTCT 3 ’ 
ARP6 5, ACAATTTCACACAGGATACAACGAGG 3 ’ 
ARP7 5 ’ ACAATTTCACACAGGATGGATTGGTC 3 ’ 
ARPS 5，ACAATTTCACACAGGATGGTAAAGGG 3 ’ 1 
ARP9 5 ’ ACAATTTCACACAGGATAAGACTAGC 3 ’ | 
A R P l 0 5 ’ ACAATTTCACACAGGAGATCTCAGAC 3 ’ 丨 
A R P l 1 5，ACAATTTCACACAGGAACGCTAGTGT 3 ’ I 丨 
i 
A R P l 2 5 ’ ACAATTTCACACAGGAGGTACTAAGG 3 ’ 丨 
卜 
lirr 
ARP13 5 ’ ACAATTTCACACAGGAGTTGCACCAT 3 ’ \ 
U . 
ARP14 5，ACAATTTCACACAGGATCCATGACTC 3 ’ ： 
ARP15 5 ’ ACAATTTCACACAGGACTTTCTACCC 3 ’ ‘； 
1' 
ARP16 5，ACAATTTCACACAGGATCGGTCATAG 3 ’ 丨 
ARP17 5，ACAATTTCACACAGGACTGCTAGGTA 3 ’ 
ARP18 5 ’ ACAATTTCACACAGGATGATGCTACC 3 ’ jl 
ARP19 5，ACAATTTCACACAGGATTTTGGCTCC 3， ‘ 
ARP20 5’ ACAATTTCACACAGGATCGATACAGG 3 ’ 
Figure 2.7.2 Sequences of 20 different 5'-arbitrary primers (ARPs). Each ARP primer 
contains the same M13 (16-mer) reverse primer sequence for reamplification but they 
have ten-base different for the core annealing sequence for priming gene specific 
sequence in RT-PCR (adapted from fluoroDD manual, Beckman). 
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T7 promotor sequence oligo(dTi2) 
TMR-APl • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTGA 3， 
TMR-AP2 • 5，ACGACTCACTATAGGGCTTTTTTTTTTTTGC 3 ’ 
TMR-AP3 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTGG3 ‘ 
TMR-AP4 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3 ’ 
TMR-AP5 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCA 3 ‘ 
TMR-AP6 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCC 3, 
TMR-AP7 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCG 3, ： 
TMR-AP8 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTAA 3 ‘ 
TMR-AP9 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTAC 3 ’ 1；： 
丨  
TMR-AP10 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTAG 3 ‘ 丨: 
TMR-APl 1 • 5，ACGACTCACTATAGGGCTTTTTTTTTTTTAI3 ’ '；-
TMR-AP12 • 5 ’ ACGACTCACTATAGGGCTTTTTTTTTTTTCT 3 ’ 丨：；、 
一 1；^ 
；I 
" ‘ � 
L： 
Figure 2.7.3 Sequences of 12 different 3 '-tetramethylrhodamine-labeled oligo(dTi2) 
anchored primers (TMR-APs). Each TMR-AP primer has same sequence 
corresponding to the non-fluorescent-labeled anchored primer used for first-strand 
cDNA synthesis and the TMR fluorescent tag is indicated by the star (adapted from 
fluoroDD manual, Beckman). 
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^ 
Arbitrary primer (API) 
M13 (16-mer) 10-base core 
reverse primer sequence annealing sequence 
广 、广 、 
5，| ACAATTTCACACAGGACGACTCCAX^ 3, 
3, IGCTGAGGTTC ^TTTTTTTTTTTTCGGGATATCACTCAGCA\ 5' 
First-strand cDNA 
，r 
5,1ACAATTTCACACAGGACGACTCCAAG / � TCAAAAAAAAAAAAGCCCTATAGTGAGTCGT [ 3， 
< 3,1 AQTTTTTTTTTTTTCGGGATATCACTCAGCA I 5' 
5,1 ACAATTTCACACAGGACGACTCCAAGI 3， 
3, ITGTTAAAGTGTGTCCTGCTGAGGTTC / / AGTTTTTTTTTTTTCGGGATATCACTCAGC^ 5， 
1 r 
5,1 ACAATTTCACACAGGACGACTCCAAG / / TCAAAAAAAAAAAAGCCCTATAGTGAGTCGTI 3， 
3, I TGTTAAAGTGTGTCCTGCTGAGGTTC / / A g r m m T T T T T C G G G A T A T C A C T C A G O ^ 5' 
Figure 2.7.4. A schematic diagram showing the synthesis of non-fluoroDD PCR. Anchored primer (AP) and arbitrary primer (ARP) 
are used for the double-strand cDNA synthesis (adapted from fluoroDD manual, Genoymx). 
to 
r -:: — , - - - - - _ — 一 一 
was performed for initial screening of primer combinations which produced our 
desired differential display patterns. Non-fluorescent labeled APs were used in the 
non-fluoroDD RT-PCR which provides a cheaper and faster screening method. 
2.7.1 Materials 
DTT, Superscript^^ II RT buffer and Superscript™ II RNase H_ reverse 
transcriptase, non-fluorescent labeled 3’-oligo(dT) anchored primers (APs), 5'-
arbitrary primers (ARPs), dNTP mix (1:1:1:1), Taq polymerase and PCR buffer were ； 




2.7.2 Methods 丨:’' 
1 1 
A schematic diagram showing the synthesis of non-fluoroDD PCR is shown in 丄 
Figure 4.7.5. First-strand cDNA was synthesized from DNase I treated total RNA (0.2 |'卜 
丨i: 
fig) by mixing with 0.2 /xM AP, 10 mM DTT, 25 fiM dNTP mix (1:1:1:1), IX 
-
Superscript^'^ 
II RT buffer and 2 U/jul Superscript^^ II RNase H reverse transcriptase i; 
(Appendix A, Table A3). For negative control, Superscript^^ II RNase H reverse 
transcriptase was not added for the first-strand cDNA synthesis. The reverse 
transcription reaction was performed in a thermal cycler (GeneAmp®PCR system 
9700) and the RT program was as follows: 42�C for 5 min, 50�C for 50 min, 70�C for 
15 min and hold at 4°C. The synthesized first-strand cDNA was stored at 
After first-strand cDNA synthesis, 4 jitl RT mixture was used for the non-
fluorescent RT-PCR (non-fluoroDD PCR). For each PCR reaction, the RT mixture 
was mixed with 0 .35 [IM A P , 0 .35 )LIM A R P , 50 |LIM dNTP mix (1 :1:1:1) , I X P C R 
buffer and 0.05 U/^il of Taq polymerase (Appendix A, Table A4). The PCR was 
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^ 
performed in a thermal cycler (GeneAmp®PCR system 9700) and the PCR program 
was as follows: 95�C for 2 min, followed by 4 cycles of 92�C for 15 sec, 50�C for 30 
sec, 72�C for 2 min and followed by 30 cycles of 92�C for 15 sec, 60�C for 30 sec, 
72°C for 2 min and 72�C for 7 min and hold at 4°C. The double-strand cDNA 
synthesized was resolved on 1.5% agarose, 0.5X TBE gels with ethidium bromide 
staining. 
2.8 Reverse transcription (RT) of mRNA and fluorescent 
PCR (fluoroDD PCR) |l 
The AP-ARP primer combinations which showed differential display patterns in 
non-fluoro RT-PCR were chosen for fluorescent PCR (fluoroDD PCR). | 
,k 
ir 
2.8.1 Materials |,ij 
HIEROGLYPH™ mRNA profile and fluoroDD adpater kits were purchased 丨;..� 
丨V.I 
from Beckman (USA). L:: 
2.8.2 Methods 
FluoroDD RT-PCR was the same as non-fluoroDD RT-PCR described in 
sections 4.7.1 and 4.7.2 except that APs and dNTP mix (1:1:1:1) for first-strand cDNA 
synthesis were purchased from HIEROGLYPH^^ mRNA profile kit, while TMR-APs, 
ARPs and dNTP mix (1:1:1:1) for fluoroDD PCR were obtained from fluoroDD kit. 
The TMR-labeled cDNA fragments were stored at -20°C. 
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^ 
2.9 Fluorescent differential display (fluoroDD) 
The TMR-labeled cDNA fragments were electrophoretically separated on high 
resolution polyacrylamide gel and detected by fluorescent scanning using 
GenomyxSC™ fluorescent imaging system. 
2.9.1 Materials 
FluoroDD loading dye, HR-1000™ 5.6% denaturing polyacrylamide gel, 0.5X : 
TBE buffer, IX TBE buffer and TMR-labeled molecular weight DNA marker were <； 
I: 
obtained from Beckman (USA). Ammonium persulfate and TEMED were purchased :丨 
from Sigma (USA). GenomyxLR^^ electrophoresis system and genomyxSC™ 
I丨: 
fluorescent imaging system were from Genomyx (USA). ！、 
( ； 
丨,N 
2.9.2 Methods I 
I,丨、 
2.9.2.1 FluoroDD gel preparation 
High resolution polycarylamide gel was prepared by mixing 70 ml of 5.6% 1 球 
denaturing HR-1000 gel with 320 jul of freshly prepared 10% ammonium persulfate 
and 32 /xl TEMED. The fluoroDD gel was allowed to polymerize for overnight at 
room temperature. 
2.9.2.2 Sample preparation and electrophoresis 
Four microliters of fluoroDD PCR products were mixed with 2 jul fluoroDD 
loading dye, while 1.2 /il TMR-molecular weight marker was mixed with 1.5 \x\ 
fluoroDD loading dye. They were denatured at 95°C for 4 min in a thermal cycler 
(GeneAmp®PCR system 9700) before loading. The lower and upper buffer chambers 
45 
^ 
were filled with 250 ml IX TBE buffer and 125 ml 0.5X TBE buffer, respectively. 
The TMR-molecular weight marker and fluoroDD PCR samples were loaded and run 
at 3000 V, 100 W at 50�C for 4 to 4.5 hr using a GenomyxLRTM DNA electrophoresis 
system (Genomyx, USA). The gel was then washed with double distilled water 3 
times and dried at 55°C for 20 min. The image was scanned in G e n o m y x S C ™ 
fluorescent imaging scanner (Genomyx, USA). 
2.10 Excision of differentially expressed cDNA fragments I 
r 
The cDNA fragments which showed differential expression patterns in the 
r； 
Wy-14,643 treated PPARa (+/+) group but not in the Wy-14,643 treated PPARa (-/-) I'i 
I-' 
1；1 
group compared with their corresponding control groups were excised from the n 
I ‘ 







A virtual grid was purchased from Genomyx (USA). Sterile blades were If! 
purchased from Swann-Morton® (England). 
2.10.2 Methods 
The computer-scanned image of the fluoroDD gel was aligned with a physical 
grid to accurately locate the positions of cDNA fragments which showed differential 
display patterns on the fluoroDD gel before gel excision. The fragments which 
showed differential display patterns were marked on the virtual grid. The cDNA 
fragments were excised by putting the fluoroDD gel on the virtual grid and excised 
46 
^ 
Table 2.10.1. The expected differential expression patterns of cDNA fragments 
displayed on non-fluoroDD and fluoroDD gels. 
P P A R a (+/+) PPARa (-/-) Description 
dd 0.1% I 0.1% 
Patttens Control Wy- Control Wy-
14,643 14,643 
Up-regulated in 0.1% Wy-
I + 14,643 treatment and 
PPARa dependent 
Up-regulated in 0.1% Wy-
II + ++ + + 14,643 treatment and 
PPARa dependent 
Down-regulated in 0.1% 
III + + + Wy-14,643 treatment and 
PPARa dependent 
Down-regulated in 0.1% 
IV ++ + ++ ++ Wy-14,643 treatment and 
PPARa dependent 
Up-regulated in 0.1% Wy-
A - + - + 14,643 treatment but 
PPARg-independent � 
Down-regulated in 0.1 % 
B + - + - Wy-14,643 treatment but 
I PPARg-independent 
'+'represents the presence of a band (cDNA) on fluoroDD gel and the relative tl 
intensity of the gene expression among the four treatment groups is indicated by the 
number of ‘+，，while ‘+’ represents the corresponding band (cDNA) was not observed 
on the fluoroDD gel. Those AP and ARP combinations which shown the desired 
differential display pattern (I-IV) in the non-fluoroDD gels were selected for band 
excision. Differential display patterns A & B are 0.1% Wy-14,643 treatment 
responsive but they are not PPARa dependent, so they are not chosen for fluoroDD 
RT-PCR and gel band excision. 
47 
with sterile blades. The excised gel bands were incubated in 20 |ul TE buffer [10 mM 
Tris-HCl (pH 7.5) and 0.1 mM EDTA (pH 7.5)] at 37�C for 1 hr for DNA elution and 
stored at -20�C. After gel excision, the gels were re-scanned to confirm the target 
bands were excised accurately. 
2.11 Reamplification of differentially expressed cDNA 
fragments | 
The excised cDNA fragments were reamplified by PCR reaction with ftill 
length M13 reverse (-48) 24-mer (5'-AGCGGATAACAATTTCACACAGGA-3') and 
T7 promoter 22-mer (5'-GTAATACGACTCACTATAGGGC-3') primers. The partial i : 
I.: 
sequences of M13 reverse (16-mer) and T7 promoter (17-mer) were present in the 5，- 丨 
i ‘ 
ARP and 3,-AP primers of double-strand cDNA synthesis, respectively. As the M13 ； 
I : 
reverse primer was lengthened by 8 nucleotides and the T7 promoter primer was 丨 
I" 
lengthened by 5 nucleotides, the expected size of reamplified PCR product is 13 
nucleotides longer than the size of fluoroDD fragment size (Figure 2.11.1). '�‘ 
2.11.1 Materials 
Agarose and trizma base were from USB (USA). dNTP mix (1:1:1:1), Taq 
polymerase and PCR buffer were obtained from Invitrogen (USA). Full-length T7 
promoter 22-mer and M13 reverse (-48) 24-mer primers were purchased from 























































































































































































































































































































































































































































































Four microliters of gel band elute were reamplified by mixing with 20 |iM 
dNTP mix (1 :1 :1 :1) , 0.2 |LIM M L 3 reverse (-48) 24-mer primer, 0.2 [iM T7 promoter 
22-mer primer, IX PCR buffer and 0.05 U/^il of Taq polymerase (Appendix A, Table 
A5). The PCR reaction was performed in a thermal cycler (GeneAmp®PCR system 
9700) and the program was as follows: 95°C for 2 min, followed by 4 cycles of 92°C 
for 30 sec, 50°C for 30 sec, 72"C for 2 min, followed by 25 cycles o f 9 2 T for 30 sec, < 
I 
60°C for 30 sec, 72�C for 2 min and 72°C for 7 min and hold at 4�C. Two microliters j! 
i: 
of reamplified PCR product were resolved on 1% or 2% agarose, 0.5X TBE with ！1 
「丨 
ijii 





2.12 Subcloning of reamplified cDNA fragments < 
11 
f i ) 
Subcloning of reamplified cDNA fragments was performed by either 
！“‘ 
AdvaTAge丁M PCR or TOPO TA cloning kits. The reamplified cDNA fragments with ：; 
I':� 丨丨:.(「 
3,-A overhang were subcloned by T/A cloning using either pT-Adv or pCR®II- j^ r 
TOPO® vector derived from AdvanTAge'^^ PCR or TOPO TA cloning kit， 
respectively. The screening of recombinant subclones was preformed by using 
phenol-chloroform extraction method (Ohyama, 1997) in which the recombinant 
plasmid DNA should be longer than the vector only [size of pT-Adv is 3.9 kb (Figure 
2.12.1) and that of pCR®II-TOPO® is 4.0 kb (Figure 2.12.2)]. The size of the insert 
subcloned into the vector was further confirmed with BcoRI digestion. 
50 
^ 
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2Ce MIS Reverse Primer 和 
GAAACAGCTATGACCATGATTACGCCAAGCTTGGTACCGAGCTCGGATCCACTAGT 
H ia^m Hind III Kpn\ Ssc\ Spei 
AACGGCCGCCAGTGTGCTGGAATTCGGCffrl • JJ J J I W f B l A AG C CG AATTCT G G A 
^ 8stXr fcoRr 
GATATCCATCACACTGGCGGCCGCTCGAGCATGCATCTAGAGGGCCCAATTCG 
^ fcoRV ffstXr Afotl Aval Nsi\ Xba\ Apa\ a 
, Xho I • �� 
CCCTATAGTGAGTCGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAAC 
T7 Promoter ^ M 1 3 Sequencing Primer fW 丨3 ("40丨 forward primer 
Figure 2.12.1 The restriction map and multiple cloning site (MCS) of pT-Adv vector 
used for subcloning of reamplified cDNA fragments (adapted from AdvanTAge^'^ 
PCR cloning kit user manual). 
51 
tecZuATG 
M13 Reverse Primer | Sp6 Promoter y 
CAG GAA ACA GCT 畔 ATC ATT A03 CCA AGC TlAT TTA GGT GAC ACT ATA G(AA 
GTC CTT TGT CGA. TAC TAC TAA TGC GGT TCG PfTA AAT CCA CTG TGA TAT c j lT 
Wsrl Hrodlll Kpnl Sad BamH I Spa� 
I I 1 I I r 
TAC TCA AGC TAT GCA TCA AGC TTG GTA CCG AGC TCG GAT CCA CTA GTA ACG GCC 
ATX5 AGT TOT ATA 03T AGT TCG AAC CAT GGC TCG AGC CTA GGT GAT CAT TGC CG<3 
BsOU fooRI eccRI eccRV 
GCC AGT GTG'CTG GLA TK： GCC CTT . U - J • 歷 _ I I L | A G OGC JpA TTC TGC AGA T'AT 
COG TCA CAC GAC CTT AAG CGG G A Q B l i i l i l j M i l l l ^ C CCG CTT AAG AOG TCT ATA 
Bsexi Noil Xhof A/srI Xbal I 
CCA TCA c J c nSG JGG CCG "JpC GAG CAT GCA' i t r AGA GGG CCC AAT TCG ICCC TAT 
CGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGQ TTA AGC GOG ATA 
T7 Promoter M13 (-20) Forward Primer 
、 AGT GAG TCG TAT TA)C AAT TCA ICTC GCC GTC GTT TTA dAA OGT CGT GAC TiXJ GAA AAC , 
\ TCA CTC AGC ATA A ip TTA AGT |GAC CTC CAG CAA AAT 中T GCA GCA CTC ACC CTT TTG / “ 
B p C R , - T O P O W 
\ 4 。 k b J f 






Figure 2.12.2 The restriction map and multiple cloning site (MCS) of PCR® II-TOPO® 
vector used for subcloning of reamplified cDNA fragments (adapted from TOPO 




Agarose, 5-bromo-4-chloro-3-indolyl-D-thiogalactoside (X-gal), Isopropyl-P-
D-thiogalactoside (IPTG) and sodium chloride were obtained from USB (USA). 
AdvanTAgeTM PCR cloning kit was purchased from Clontech (USA). TOPO TA 
cloning kit was from Invitrogen (USA). Ethidium bromide and ampicillin were 
purchased from Sigma (USA). Restriction enzymes and buffers were obtained from 
New England Biolabs (UK). Trypton peptone, yeast extract and bacto agar were . 
purchased from Becton Dickinson (USA). QIAGEN® spin miniprep kit was 
purchased from QIAGEN (Germany). 
2.12.2 Methods 
2.12.2.1 Ligation y 
Subcloning of reamplified cDNA fragments was performed either by 
AdvaTAgeTM pCR or TOPO TA cloning kits. For AdvaTAge™ PCR subcloning kit, 
1 jil of reamplified PCR product was mixed with IX ligation buffer, 5 ng/^il of pT-
Adv vector and 4 U/|LI1 of T4 DNA ligase for ligation. The mixture was then incubated 
at 14�C overnight. For TOPO TA cloning kits, 1 fi\ of reamplified PCR product was 
mixed up with 0.2 M NaCl, 0.01 M MgClz and 0.17 ng/^il pCR®II-TOPO® vector. 
The mixture was then incubated at room temperature for 5 min. 
2.12.2.2 Transformation 
Two microliters of ligation products were then mixed with TOP 10F' E. coli 
competent cells and chilled on ice for 30 min. The mixture was then incubated in 
42°C water bath for 90 sec, chilled on ice immediately for 2 min. and then diluted to 1 
53 
ml by LB medium. Then the mixture was incubated at TTC with shaking for 1 hr and 
centrifiiged at 2,500 rpm at 4°C for 8 min. The supernatant was discarded and the cell 
pellet was resuspended with 300 jul LB medium. The transformed cells were spreaded 
on LB agar plates containing 100 \xg/m\ ampicillin, 40 |LI1 of 100 mM IPTG and 40 jiil 
of 40 mg/ml X-Gal. The plates were incubated at 3TC incubator for 16 hr. 
2.12.2.3 Phenol-chloroform extraction 
、 
丨I 
Single white colony was incubated in 3 ml LB medium containing 100 /xg/ml j 
of ampicillin at 37°C for 16 hours with shaking. Thirty microliters of bacterial culture j,； 
‘ 
i 
were mixed with 30 /xl of phenol: chloroform: isoamyl alcohol (25:24:1) for screening liil, 
it 
recombinant clones. The mixture was vortexed vigorously and then centrifuged at ；^  
Kl 
14,000 rpm at room temperature for 2 min. Ten microliters of the supernatant were i ! 
resolved on 0.6% agarose, 0.5X TBE gels with ethidium bromide staining. 
h 
I»丨 
2.12.2.4 Confirmation of insert size by EcoRl digestion i � 
The recombinant clones which showed positive result in the phenol-cholorform U 
extraction were selected for EcoKL digestion for further confirmation of the insert 
sizes. One milliliter of bacterial culture was centrifuged at 14,000 rpm at 4°C for 1 
min. The supernatant was discarded and the cell pellet was resuspended with 17 [xl 
autoclaved distilled water containing 250 jug/ml RNase A. The resuspended cells 
were boiled for 1 min and then centrifuged at 14,000 rpm at room temperature for 1 
min. Seventeen microliters of supernatant were digested with 10 units of^'coRI in IX 
EcoRI buffer at 37�C for 2 hr. The mixture was then resolved on 1% or 2% agarose, 
0.5X TBE gels with ethidium bromide staining. 
54 
^ 
2.12.2.5 Mini-preparation of plasmid DNA from recombinant clones 
Plasmid DNA of cDNA fragments was prepared for by QIAGEN® spin 
miniprep kit. Ten milliliters of bacterial culture were centrifuged at 2,500 rpm at 4°C 
for 10 min. The supernatant was discarded and cell pellet was resuspended in 250 /xl 
of buffer PI containing 100 |Lig/ml RNase A. The resuspended cells were then mixed 
with 250 /xl of buffer P2 by inverting several times. The mixture was incubated at 
room temperature for about 5 min. Three hundred and fifty microliters of buffer P3 
5 
were added to the mixture and mixed by inverting several times. The mixture was ；」 丨1 
centrifuged at 14,000 rpm at room temperature for 15 min. The supernatant was {；y 
IV' 
transferred to QIAprep spin columns in 2 ml collection tubes and centrifuged at | 
•J： 
14,000 rpm for 1 min. The flow-through was discarded and the columns were washed 
j ‘ I 
with 750 jLtl buffer PE. The columns were transferred to new 1.5 ml eppendrof tube. � 
'；< 
The plasmid DNA was eluted by adding 50 jtil of nuclease free water and centrifuged '^！)' 
at 14,000 rpm at room temperature for 1 min twice. The samples were diluted to 6 \x\ 
with sterile water and stored at 4°C. 
i:丨 
2.13 Sequencing of subcloned cDNA fragments 
After confirming the sizes of the cDNA fragments, sequencing was performed 
by using CEQ dye terminator cycle sequencing kit, M13 forward (-20) (5'-





CEQ dye terminator cycle sequencing kit was purchased from Beckman 
(USA). EDTA, sterile water and sodium acetate were purchased from Sigma (USA). 
M13 forward (-20) and M13 reverse primers were obtained from Invitrogen (USA). 
2.13.2 Methods 
2.13.2.1 Sequencing of fluoroDD cDNA fragments 
if 
DNA sequencing reaction was prepared by mixing 100 fmol dsDNA in 6 |li1 
s 
sterile water with 2 )LI1 of lOX sequencing reaction buffer, 1 \x\ of dNTP mix, 2 )LI1 of t 
i)! 
III!: 
ddUTP dye terminator, 2 of ddGTP dye terminator, 2 i^l of ddCTP dye terminator, i> 
2 |Lil of ddATP dye terminator, 2 |li1 of 1.6 |aM M13 forward (-20) or Ml3 reverse Ij 
{ 
primer and 1 |LI1 of Taq polymerase in a 0.2 ml thin-wall PCR tube (Appendix A, : 
i!�j 
in 
Table A6). The mixture was mixed by finger-tapping and spinned down. PCR was 
I J i 
；‘:.' I 
performed in a thermal cycler (GeneAmp® PCR system 9700) and the PCR program i 
liip 
was as follows: 30 cycles of 96�C for 20 sec, 50�C for 20 sec, 60�C for 4 min and hold il:: 
at 4°C. Stop solution (final concentration of 1.5 M sodium acetate and 50 mM EDTA) 
was freshly prepared and 4 jul stop solution was added to new 1.5 ml eppendrof tube. 
The mixture was transferred to a new 1.5 ml eppendrof tube and 1 j^ l of 20 mg/ml of 
glycogen was added to each eppendrof tube. The mixture was vortexed vigorously 
and 60 i^l of cold 95% ethanol were added to the mixture and vortexed. The samples 
were then centrifuged at 14,000 rpm at 4°C for 20 min and the supernatant was 
discarded carefully to avoid disturbing the pellet. The pellet was washed with 200 |li1 
cold 70% ethanol and then centrifuged immediately at 14,000 rpm at for 25 min. 
56 
^ ^ 
The supernatant was discarded carefully and the washing steps were repeated. The 
DNA pellet was vacuum dried for at least 45 min until all solvent was evaporated. 
Forty microliters of sample loading buffer (from the Beckman sequencing kit) were 
added to the DNA pellet. The DNA pellet was rehydrated for 30 min and then 
resuspended by pipetting up and down. The resuspended DNA samples were 
transferred to a 96-well polypropylene sample plate recommended for the CEQ 
automated DNA sequencer (Beckman). One drop of light mineral oil (provided by the 
fs 
sequencing kit) was added to each sample. The sample plate was loaded into the CEQ | 
•'< 
丨'!,丨 
DNA sequencer and DTCS-2 method was used for dsDNA plasmid sequencing using i,,； 
I I I 
rii 




2.13.2.2 BLAST search against computer database j 丨 
After DNA sequencing, sequence homology was performed by searching the i!� 
！‘卜 丨丨^ 
computer database of Basic Local Alignment Search Tool of non-redundant, mouse I'h-
and human ESTs (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). 
ifir 
S 
2.14 Northern blot analysis of sequenced cDNA fragments 
After sequencing and sequence homology searching, the differential display 
patterns of fluoroDD were further confirmed by Northern blot analysis. The plasmid 
DNA used for sequencing was used for the preparation of the probe for Northern blot 




DIG Easy Hyb，Tween 20，blocking reagent, anti-DIG-alkaline phosphatase 
antibody, DIG-labeled RNA molecular weight marker I (0.39-6.9 kb), DIG RNA 
labeling mix, T7 polymerase, PCR-DIG labeling mix, nitro blue tetrazolium chloride 
(NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) were obtained from Roche 
(Germany). Agarose, MOPS and sodium chloride were purchased from USB (USA). 
Magnesium chloride, PCR buffer and Taq polymerase were from GenSys (UK). � 
；c 
Formaldehyde (37%) was obtained from Riedel-de Haen (Germany). Biodyne® I'i'l 
ii j.c 
membrane was purchased from Pall (USA). Gel blotting paper was obtained from 
丨(i  
Schleicher & Schuell (Germany). Three MM filter paper was purchased from | 
丨i 
Whatman® (UK). Kapak SealPAK pouches were from KAPAK® (USA). Ethidium f 
丨 
bromide, maleic acid and sodium citrate were purchased from Sigma (USA). “V 
2.14.2 Methods ，: 
：丨；丨 
11 
2.14.2.1 Formaldehyde agarose gel electrophoresis of total RNA • 
»一丨 
Three mice from each treatment groups including PPARa (+/+) control, 
PPARa (+/+) 0.1% Wy-14,643, PPARa (-/-) control and PPARa (-/-) 0.1% Wy-
14,643 were used for Northern blot analysis. For temporal study of gene expression, 
two mice from each treatment groups at 24 hr, 1 wk, 2 wk, 6 mo and 11 mo were used 
for Northern blot analysis. Total RNA (20 or 30 fig in 10 /xl of formamide) samples 
and 10 fil RNA molecular marker were mixed with 2 fil of lOX MOPS, 3 /xl of 37% 
formaldehyde, 2 /jlI of loading dye and 5 fil of nuclease-free water. RNA samples 
were then denatured by heating at 68°C for 15 min and then chilled on ice 
immediately. RNA samples were then separated on a 1% formaldehyde-agarose gel at 
58 
^ 
30 V for about 15 hr. For temporal study of gene expression, the RNA samples of the 
5 different treatment time points were resolved on two gels: PPARa (+/+) control and 
PPARa (+/+) 0.1% Wy-14,643 on one gel, while PPARa (-/-) control and PPARa (-/-
)0 .1% Wy-14,643 on another gel. The RNA gel was post-stained with 0.5 )Lig/)il 
ethidium bromide for 45 min and wash with distilled water for 20 min 3 times. After 
taking photos, RNA gel was washed in lOX SSC for 30 min and then transferred to a 
positively charged nylon membrane in lOX SSC buffer by capillary action for 24 hr. ,� 
iC 
After washing with 5X SSC for 5 min, the membrane was baked for 2 hrs at 80°C for 
； 
j »： 
fixing the RNA onto the membrane. 




2.14.2.2 Preparation of DIG-labeled RNA probes for hybridization fd 
�J丨 
Two nanograms of plasmid DNA were mixed with 80 |liM dNTP mix (1:1:1:1) , jy 
0.2 |liM AP, 0.2 |aM T7 ARP (same the primer pairs used for running the fluoroDD [；)! 
I ' 丨 、 
RT-PCR), IX PCR buffer and 0.05 U/|li1 of Taq polymerase (Appendix A, Table A7). 
i�<_ 
PCR reaction was performed in a thermal cycler (GeneAmp®PCR system 9700) and ! i丨 
the program was as follows: 95°C for 2 min, followed by 29 cycles of 92°C for 30 sec, 
60°C for 30 sec, 72�C for 2 min and 72�C for 7 min and hold at 4�C. Two microliters 
of reamplified PCR product were resolved on 1% or 2 % agarose, 0.5X TBE with 
ethidium bromide staining. After confirming the size and specificity of the PCR 
product, 1 jig of PCR product was used for DIG RNA labeling. For each reaction, 
PCR product was mixed with 1 mM of DIG RNA labeling mix, IX transcriptional 
buffer and 2 U/jLtl of T7 polymerase. The mixture was mixed by finger-tapping and 
incubated at 37�C for 2 hr. The labeling was stopped by adding 2 |li1 of 0.2 M EDTA 
at pH 8.0. One microliter labeled probe was resolved on 1% or 2% agarose, 0.5X 
59 
^ 
TBE gel with ethidium bromide. The labeled probe was stored at -80°C or used 
immediately. 
2.14.2.3 Preparation of PCR-DIG labeled cDNA probe for hybridization 
Twenty nanograms of plasmid DNA were mixed with 200 |LIM PCR DIG 
labeling mix ( 1 : 1 : 1 : 1 ) , 1 J^IM AP, 1 |LIM T 7 ARP (same the primer pairs used for 
running the fluoroDD RT-PCR), I X PCR buffer and 0.04 U/ |LI1 of Tag polymerase ’� 
s 
(Appendix A, Table A8). PCR reaction was performed in a thermal cycler ！：丨：丨丨 
I 丨 
(GeneAmp®PCR system 9700) and the program was as follows: 95°C for 7 min, 丨:; 
�-
' ‘ - ' ‘ 丨 ；、.丨, 
followed by 30 cycles of95°C for 45 sec, 60°C for 1 min, 72�C for 2 min and 72�C for if 
7 min and hold at 4�C. One microliter of PCR-DIG labeled cDNA probe was resolved 
on 1% or 2 % agarose, 0.5X TBE with ethidium bromide staining. After confirming ‘ 
the size and specificity of the PCR DIG-labeled cDNA probe, the labeled probe was ； 
！ I I 
!r 
stored at or used immediately. t ’ 
J丨 
i':�丨 
2.14.2.4 Hybridization and colour development � 
The membrane was pre-hybridized with 20 ml DIG Easy Hyb buffer in a 
scalable bag at 42 for PCR DIG-labeled cDNA probe or 60°C for DIG-labeled 
RNA probe for 2 hr. For RNA probe, the labeled probe was added to the pre-
hybridized buffer and mixed well in a 50 ml Falcon tube. For PCR DIG-labeled probe, 
the probe was first denatured by boiling for 10 min and then chilled on ice 
immediately. The denatured probe was added to the pre-hybridized buffer and mixed 
well in a 50 ml Falcon tube. The pre-hybridized buffer containing the labeled probe 
was added to the seablable bags and hybridized for overnight at 42 for PCR DIG-
60 
^ 
labeled cDNA probe or 60�C for DIG-labeled RNA probe. For temporal study of gene 
expression, two membranes of PPARa (+/+) and PPARa (-/-) control and 0.1% Wy-
14,643 groups were pre-hybridized and hybridized in 40 ml DIG-Easy Hyb buffer 
back to back in a scalable bag. The hybridized membrane was washed in 2X SSC (3 
M sodium chloride and 0.3 M sodium citrate, pH 7.0) / 0.1% SDS at room temperature 
for 5 min twice and in either O.IX SSC / 0.1% SDS at 6 8 T or 0.5X SSC / 0.1% SDS 
at 60°C for 5 min twice. The membrane was washed in washing buffer [0.3% Tween 
20 in maleic acid buffer (pH 7.5)] for 5 min and then incubated with IX blocking 
solution [IX blocking solution in maleic acid buffer (pH 7.5)] for 1 hr. After washing, 
the membrane was incubated with anti-DIG-alkaline phosphatase antibody in a final 
concentration of 0.075 U/ml of IX blocking solution for 1 hr. The membrane was 
washed in washing buffer twice and then equilibrated in detection buffer [0.1 M Tris-
HCl (pH 9.5), 0.1 M MgCl2 0.1 M NaCl] for 5 min. The membrane was allowed to 
develop colour in 25 ml of detection buffer containing 125 )li1 and 93.8 \x\ of NBT and 




Chapter 3 Results 
3.1 Confirmation of genotypes by PCR 
As there are no observable phenotypic differences between the PPARa (+/+) 
and PPARa (-/-) mice, the genotypes of these mice were confirmed before animal 
feeding. The sizes of the PCR products of PPARa (+/+) and PPARa (-/-) mice were 
191 and 1248 bp, respectively (Figures 3.1.1-3.1.2), which was matched with the 
results from the previous study (Lee et al., 2002). 
I 
3.2 Body weight changes ： 
！, i I 
I 
Body weight was significantly lower in the PPARa (+/+) fed with 0.1% Wy- i' 
I 
14,643 compared to the controls (6 and 11 months feeding experiments). In Figure i 
i 
3.2.1, lower body weight was shown in 0.1% Wy-14,643 treated PPARa (+/+) mice 
‘ I 
1:1 
when compared to the control fed PPARa (+/+) mice since 1 week feeding. After 6 ； 
months of feeding, there was a 9% decrease in body weight when compared with the 
original body weight. However, increase in body weight in the PPARa (+/+) mice fed 
with control diet, PPARa (-/-) mice fed with control and 0.1% Wy-14,643 were 
observed (21%, 17% and 21% of the original body weights, respectively). A 
significant decrease in body weight of 0.1% Wy-14,643 fed PPARa (+/+) mice was 
also observed in the 11 months feeding on 0.1% Wy-14,643 diet (Figure 3.2.2). After 
11 months feeding, there was a 14% decrease in body weight in the 0.1% Wy-14,643 
fed PPARa (+/+) mice. When compared with the body weight before starting the 
experiment, there were 23%, 22 % and 17% increase in body weight for the PPARa 
62 
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Figure 3.1.1. Confirmation of genotypes of PPARa (+/+) and PPARa (-/-) mice 
used for (A) 24 hours, (B) 1 week and (C) 2 weeks treatment. Tail genotypings of 
PPARa (+/+) and PPARa (-/-) mice fed with a control (CTL) or 0.1% (w/w) Wy-
14,643 (Wy) diet for 24 hours, 1 week and 2 weeks were performed. The PGR 
products of PPARa (+/+) and PPARa (-/-) mice were resolved on 2% and 1% 
agarose, 0.5X TBE gels with ethidium bromide staining, respectively. The 
expected sizes of PGR products of PPARa (+/+) and PPARa (-/-) mice were 191 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(+/+) mice fed with control diet, PPARa (-/-) mice fed with control and 0.1% Wy-
14,643, respectively. The lower body weight of 0.1% Wy-14,643 treatment of 
PPARa (+/+) mice when compared with the other three treatment groups was matched 
with the previous study (Peters et al., 1997). 
Some of the PPARa (+/+) mice treated with the 0.1% Wy-14,643 diet died 
before the end of the 6 and 11 months feeding experiment. The high mortality rate 
observed in PPARa (+/+) mice fed with 0.1% Wy-14,643 treatment was also reported 
i ( 
in the previous study (Peters et al., 1997). Two out of ten mice died (after weeks 13 
and 24) in the 6 months feeding experiment. The mortality rate was increased with 
i: 
1/i 
prolonged treatment. Fifty-two percent of the PPARa (+/+) mice fed with 0.1% Wy- j 
I 
I ^ 
14,643 started to in the 11 months feeding experiment. The high mortality in PPARa 
I k i ^ 
(+/+) mice fed with 0.1% Wy-14,643 might be due to the enlargement of liver and 广、 
I,' 
liver tumor formation. 丨卜 
乂、 ；.1. 3.3 Organ weight changes 馆 
A time-dependent increase in liver weight was observed in PPARa (+/+) mice 
fed with the 0.1% Wy-14,643 for 24 hours, 1 week, 2 weeks, 6 months and 11 months 
(Figure 3.3.1). The liver weights (% of body weight) of the PPARa (+/+) mice fed 
with the 0.1% Wy-14,643 diet for 24 hours (1.14-fold), 1 week (1.56-fold), 2 weeks 
(2.23-fold), 6 months (3-fold) and 11 months (3.88-fold) higher than the PPARa (+/+) 
mice fed with control diet. However, liver enlargement was not observed in the 0.1% 
Wy-14,643-treated PPARa (-/-) mice at all time points investigated. This observation 
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In contrast to the liver weight, there was a time-dependent decrease in white fat 
weight PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet for 2 weeks (47%), 6 
months (75%) and 11 months (86%) (Figure 3.3.2) compared with their corresponding 
controls. However, this time-dependent decrease in white fat weight was not observed 
in the 0.1% Wy-14,643-treated PPARa (-/-) mice when compared to the controls. The 
decrease in white fat weight was due to the well-documented hypolipidemic effect of 
the Wy-14,643 compound. 
Similar to the white fat weight, a significant time-dependent decrease in the 
relative brown fat weight was also found in the PPARa (+/+) mice fed with the 0.1% 
Wy-14,643 diet for 2 weeks, 6 months and 11 months (Figure 3.3.3). The decrease in 
brown fat weight for 2 weeks, 6 months and 11 months was 29%, 53% and 62%, i 
j 
i 
respectively and was due to the hypolipidemic action of Wy-14,643 compound. | 
j 
There was a significant decrease in spleen weight in PPARa (+/+) mice '丨 
i f 
following 11 months Wy-14,643 treatment (48%) (Figure 3.3.4). The decrease in size 
of spleen was reported in a previous study (Yang et al, 2000). 厂 
!；1 L 
No significant change in the brain, heart, lung and testis weights observed in 
both PPARa (+/+) and (-/-) mice fed the Wy-14,643 diet at all time points studied 
compared with their controls (Table 3.3.1). 
3.4 Serum cholesterol and triglyceride levels 
Previous studies have shown that Wy-14,643 treatment decreased the serum 
cholesterol and triglyceride levels in PPARa (+/+) mice (Issemann and Green, 1990). 
To determine the hypolipidemic effect of Wy-14,643, the serum cholesterol and 
triglyceride levels of all the treatment groups at different feeding treatments were 
70 
j 
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Table 3.3.1. Effect of Wy-14,643 feeding on kidney, heart, brain, lung and testis 
weight change of 24 hours, 1 week, 2 weeks, 6 months and 11 months feeding 
experiment. 
Group Kidney Heart Brain Lung Testis 
W W TO W (%) 
24 hr PPARa (+/+)/CTL 1.48 ± 0 . 1 3 0.54 ± 0.04 1.63 ± 0 . 1 9 0.65 ± 0 . 1 1 0.94 ± 0 . 1 4 
PPARa (+/+)AVy 1.49 ± 0 . 1 5 0.54 ± 0.07 1.73 ± 0 . 1 9 0.71 土 0.11 0.74 ± 0.09 
PPARa ( - / - ) /CTL 1.45 ± 0 . 1 6 0.58 ± 0 . 0 7 1.66 ± 0 . 1 5 0.62 ± 0.09 0.79 ± 0.04 
PPARa ( - / - )AVy 1.55 ± 0 . 3 8 0.59 ± 0.07 1.51 ± 0 . 1 5 0.67 士 0.23 0.79 ± 0.06 
I wk PPARa (+/+)/CTL 1.55 ± 0 . 1 3 0.56 ± 0.08 1.76 ± 0 . 3 1 0.72 ± 0.23 0.86 ± 0.04 
PPARa (+/+)AVy 1.60 ± 0 . 1 6 0.59 ± 0 . 1 2 2.04 ± 0 . 1 3 0.78 ± 0.24 0.94 ± 0.06 | 
PPARa ( - / - ) /CTL 1.51 ± 0 . 2 1 0.55 ± 0 . 1 1 1.53 ± 0 , 0 7 0.74 ± 0 . 2 3 1.08 ± 0 . 3 6 j 
PPARa ( - / - )AVy 1.54 士 0.23 0.56 ± 0 . 1 0 1.64 ± 0 . 1 4 0.91 ± 0 . 2 5 0.74 ± 0 . 0 6 | 
2 w k PPARa (+/+)/CTL 1.51 ± 0 . 0 9 0.53 ± 0.03 1.74 ± 0 . 0 6 0.81 ± 0 . 1 6 0.87 ± 0 . 2 3 j 
PPARa (+/+)AVy 1 . 6 0 ± 0 . 0 9 0.55 ± 0 . 0 5 1 . 9 2 ± 0 . 1 2 0.71 ± 0 . 1 5 0 . 7 9 ± 0 . 1 2 |[ 
PPARa ( - / - ) /CTL 1.43 ± 0 . 1 2 0.51 ± 0 . 0 7 1.65 ± 0 . 1 7 0.69 ± 0 . 1 0 0.90 ± 0 . 3 8 if 
PPARa ( - / - )AVy 1.51 ± 0 . 1 8 0.53 ± 0.04 1.48 ± 0 . 1 4 0.65 ± 0 . 1 6 0.73 ± 0.05 \ 
6 mo PPARa (+/+)/CTL 1.51 士 0.10 0.50 ± 0.06 1.44 ± 0 . 1 4 0.67 ± 0 . 1 3 0.66 ± 0 . 1 0 
PPARa (+/+)AVy 1 . 4 7 ± 0 . 1 1 0.71 土 0.06 1 . 9 0 ± 0 . 1 6 0.95 土 0.21 0.73 ± 0.05 
PPARa ( - / - ) /CTL 1.58 ±0.19 0.56 土 0.06 1.47 ± 0 . 1 8 0.77 ±0.17 0.68 士 0.13 jt 
PPARa ( - / - )AVy 1.57 ± 0 . 2 1 0.52 士 0.06 1.43 士 0.16 0.71 ± 0 . 1 4 0.67 ± 0 . 1 6 ；= 
i “ 
II mo PPARa (+/+)/CTL 1.62 ± 0 . 1 3 0.54 士 0.07 1.43 ± 0 . 1 5 0.63 ± 0 . 1 1 0.68 ± 0.07 
Ll 
PPARa (+/+)AVy 1.50 ± 0 . 1 7 0.75 ± 0 . 1 0 1.90 土 0.22 0.93 ± 0 . 1 6 0.64 ± 0.08 
PPARa ( - / - ) /CTL 1.57 士 0.18 0.54 ± 0 . 0 5 1.35 土 0.18 0.61 土 0.10 0.60 ± 0 . 1 4 
PPARa ( - / - )AVy 1.54 ± 0 . 1 1 0.53 土 0.05 1.42 ± 0 . 1 2 0.61 ± 0 . 0 9 0.64 ± 0 . 1 4 
Relative body weight was expressed as organ weight (g)/ body weight (g) X 100%. 
77 
measured in this study. There were no significant differences in serum cholesterol 
level among the four treatment groups at 24 hours gavage, 1 week, 2 weeks and 6 
months feeding (Figure 3.4.1). There was a 29% increase in serum cholesterol level in 
PPARa (+/+) mice fed the Wy-14,643 diet for 11 months when compared with the 
PPARa (+/+) mice fed the control diet. This increase was not observed in the PPARa 
(-/-) mice fed with 0.1% Wy-14,643. In contrast, a time-dependent decrease in serum 
triglyceride level was observed in the PPARa (+/+) mice fed with the 0.1% Wy- 丨, 
14,643 diet for 24 hours (44%), 1 week (38%), 2 weeks (35%), 6 months (66%) and 
11 months (77%) (Figure 3.4.2) feeding studies were observed. However, no 
significant changes were found in the PPARa (-/-) mice fed with the 0.1% Wy-14,643 || 
il? 
diet when compared with the controls. 丨丨】 
ik, 丨r 
Ij 
3.5 Liver histology ii 
ii-
To examine the liver damage resulting from Wy-14,643 treatment, liver 
li'.； 
sections from 24 hour, 1 week, 2 weeks, 6 months and 11 months Wy-14,643 fSJl 
treatment were used for histological studies. Figures 3.5.1 and 3.5.2 showed the 
central vein region of the four treatment groups after 24 hours gavage treatment with 
Wy-14,643 compound. Normal hepatocytes were arranged in a series of anastomosing 
plates with one cell thick. Between the anastomosing plates were sinusoidal spaces. 
These plates extended from the periphery of a lobule to the central vein at its center. 
Normal liver histology was found in the central vein (Figure s3.5.1A, 3.5.IB, 3.5.2A, 
3.5.2B), middle zone (Figures 3.5.3A, 3.5.3B, 3.5.4A, 3.5.4B) and portal vein region 
(Figures 3.5.5A, 3.5.5B, 3.5.6A，3.5.6B) of the PPARa (+/+) mice fed with a control 






















































































































































































































































































































































































































































































































































































































Central vein region (20X) 
• PPARa _ / CTL ^ f i ^ ^ PPARa ( - / - ) / C T I ^ ^ ^ g 
I PPARa (+/+)/Wy { PPARa ( - / - ) / W y 雜 f 織 
Figure 3.5.1. Hematoxylin and eosin staining of the central vein region (2OX) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 24 hours 
gavage feeding with 1% methylcellulose (control vehicle) (panels A, B) or Wy-
14,643 (50 mg/kg bw) (panels C, D) (n=3). Hepatocytes were arranged radially from 
the central vein. Normal liver histology was found in the central vein region of both 
control vehicle and Wy-14,643 fed PPARa (+/+) mice. Severe lipid accumulation 
(arrows) was found around the central vein region in both control vehicle and Wy-
14,643 fed PPARa (-/-) mice. V, central vein. Bars, 50 jiim. 
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24 hours 
Central vein region (40X) 
• ” � ‘ � TV . ： f j l # / 
\ V � . 4 ， V ^ 
权 , - 成 丨 : 
i PPARa (+/+)/CTL 3 PPARa ( - / - ) / C T L ^ ^ 
I PPARa(+/+)/Wy ^ ^ M f PPARa ( - / - ) / W y 
Figure 3.5.2. Hematoxylin and eosin staining of the central vein region (40X) of 
liver sections (5 jim) taken from PPARa (+/+) and PPARa (-/-) mice after 24 hours 
gavage feeding with 1% methylcellulose (control vehicle) (panels A, B) or Wy-
14,643 (50 mg/kg bw) (panels C, D) (n=3). Normal liver histology was found in the 
central vein region of both control vehicle and Wy-14,643 fed PPARa (+/+) mice. 
Severe lipid accumulation (arrows) was found around the central vein region in both 
control vehicle and Wy-14,643 fed PPARa (-/-) mice. Macrovesicular droplets were 
formed inside the hepatocytes which displaced the nuclei to the periphery of the 
hepatocytes. V, central vein. Bars, 50 ^im. 
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24 hours 
Middle zone (20X) 
, 麵 轉 ^ ^ m m I 
S P P A R a (+/+) / C T L j P P A R a ( - / - ) / C T L 、 ） 辨 
I P P A R a ( + / + ) / W y 織 • 丄 PPARoc ( - / - ) / W y 纖 Figure 3.5.3. Hematoxylin and eosin staining of the middle zone (20X) of liver sections (5 jam) taken from PPARa (+/+) and PPARa ( /-) mic  after 24 hoursgavage feeding with 1% ethylcellulo e (co tr l vehicle) (panels A, B r Wy-14,643 (50 mg/kg bw) (panels C, D) ( =3). Normal liver histology w s found in themiddl zone of both cont l vehicl  d Wy-14,643 f d PPARa (+/+) mice. Sevelipid accumulati n (arrows) wer  found ar und th  central vei regi n in bothcont ol v hic e and y-14,643 f d PPAR  (-/-) mic . , portal vein. V, centralvein. Bars, 50 \xm.
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24 hours 
� i T 春 C • , • Middle zone (40X) 
- ' • • � - - • - • , ^'S^mmmm^ mmmtkJi jt^ i 
酸 
l p P A R a _ / W y ^ ^ ^ I PPARa ( - / - ) / W y 
Figure 3.5.4. Hematoxylin and eosin staining of the middle zone (40X) of liver 
sections (5 [im) taken from PPARa (+/+) and PPARa (-/-) mice after 24 hours 
gavage feeding with 1% methylcellulose (control vehicle) (panels A, B) or Wy-
14,643 (50 mg/kg bw) (panels C, D) (n=3). Normal liver histology was found in the 
middle zone of both control vehicle and Wy-14,643 fed PPARa (+/+) mice. P, 
portal triad. Bars, 50 [im. 
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24 hours 
Portal vein region (20X) 
^ PPARa (+/+) / CTL ； i P P A R a ( - / - ) / CTL if 
^^ t • � “ ‘ t » wm mm m larr—‘ ‘ mm！MtfBlilBMM y 
幽 阔 
Figure 3.5.5. Hematoxylin and eosin staining of the portal vein region (20X) of liver 
sections (5 [im) taken from PPARa (+/+) and PPARa (-/-) mice after 24 hours 
gavage feeding with 1% methylcellulose (control vehicle) (panels A, B) or Wy-
14,643 (50 mg/kg bw) (panels C, D) (n=3). Normal liver histology was found in the 
portal vein region of both control vehicle and Wy-14,643 fed PPARa (+/+) mice fed. 
P, portal triad. Bars, 50 |Lim. 
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24 hours 
Portal vein region (40X) 
• P P A R a (+/+)/CTL | PPARa / CTL ^ J L ^ ： t 
_ _ s 
Figure 3.5.6. Hematoxylin and eosin staining of the portal vein region (40X) of liver 
sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 24 hours 
gavage feeding with 1% methylcellulose (control vehicle) (panels A, B) or Wy-
14,643 (50 mg/kg bw) (panels C, D) (n=3). Normal liver histology was found in the 
portal vein region of both control vehicle and Wy-14,543 fed PPARa (+/+) mice. P, 
portal triad. Bars, 50 [im. 
86 
observed near the central vein for both the control (Figure 3.5.IC) and 0.1% Wy-
14,643 fed PPARa (-/-) mice (Figure 5.5.ID). Macrovesicular droplets were formed 
inside the hepatocytes which displaced the nuclei to the periphery of the hepatocytes 
(Figures 3.5.2C, 3.5.2D). The accumulation of the lipid droplets in both the control 
and treatment groups of the PPARa (-/-) mice suggesting that the disruption of 
PPARa gene is involved in the lipid metabolism. 
Similar to the 24 hour gavage feeding, normal liver histology was found in the � 
*丨 
central vein (Figures 3.5.7A, 3.5.8A), middle zone (Figures 3.5.9A, 3.5.1 OA) and L? 
i.'V 
portal vein region (Figures 3.5.11 A, 3.5.12A) in PPARa (+/+) mice fed with control 5 :if: i'-u 
I 丨丨: 
diet. However, the normal arrangement of the hepatocytes was not found in the | 
！；:〒 PPARa (+/+) mice fed with 0.1% Wy-14,643 (Figures 3.5.7B, 3.5.8B). The sinusoids 
|1丨，丨1 
between hepatocytes become larger in the 0.1% Wy-14,643- treated PPARa (+/+) 、：J 
I:) 
I,卜J 
mice. Accumulation of the lipid droplets were found around the central veins in both fh 
the control and treated groups of the PPARa (-/-) mice (Figures 3.5.7C, 3.5.7D, ："'；, 
'••'j I 
3.5.8C, 3.5.8D). 丨丨 
1,1'—I 
Large sinusoidal spaces were observed in the PPARa (+/+) mice treated with 
0.1% Wy-14,643 at 2 week feeding study in the central vein region (Figures 3.5.13B, 
3.5.14B), middle zone (Figures 3.5.15B, 3.5.16B) and portal vein region (Figures 
3.5.17B, 3.5.18B). In addition, abnormal and irregular hepatocytes arrangement was 
also found in the Wy-14,643-treated group in PPARa (+/+) mice in the central vein 
region (Figures 3.5.13B, 3.5.14B), middle zone (Figures 3.5.15B, 3.5.16B) and portal 
vein region (Figures 3.5.17B，3.5.18B). Lipid accumulation was found in central vein 
region of both the control and treatment groups of the PPARa (-/-) mice (Figures 
3.5.13C, 3.5.14D, 3.5.13C, 3.5.14D). 
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1 week 
Central vein region (20X) 
賺 
( p P A R a (+/+) / C T L | P P A R a ( - / - ) / C T l J | | ^ g 
i P P A R a (+/+) / W y ^ ^ ^ g | P P A R a (一/一) / W y m g ^ m 
Figure 3.5.7. Hematoxylin and eosin staining of the central vein region (2OX) of 
liver sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in central vein region of 
PPARa (+/+) mice fed with control diet. Increased sinusoid spaces was found in the 
0.1% Wy-14,643 fed PPARa (+/+) mice. Severe lipid accumulation (arrows) was 
found around the central vein region in both control and Wy-14,643 fed PPARa (-/-) 
mice. V, central vein. Bars, 50 [im. 
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1 week 
Central vein region (40X) 
i i 
？ PPARa _ / CTL fpPARa (-/-) / CTL ^ f P | 
；PPARa (+/+)/Wy W i l l i 2 PPARa ( - / - ) / W y 
Figure 3.5.8. Hematoxylin and eosin staining of the central vein region (40X) of 
liver sections (5 \xm) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n-3). Sinusoidal spaces between hepatocytes of PPARa (+/+) 
0.1% Wy-14,643 treated mice were more obvious. Severe lipid accumulation 
(arrows) was found around the central vein region in both control and Wy-14,643 
diet fed PPARa (-/-) mice. Macrovesicular droplets were formed inside the 
hepatocytes and displace the nuclei to the periphery of the hepatocytes. V，central 
vein. Bars, 50 um. 89 
1 week 
Middle zone (20X) 
PPARcc _ / C T L ^ ^ j jPARcc ( - / - ) / CTL ^ ^ 
灘 擊 i 
‘PPARa (+/+) / Wy ‘ PPARa (- / - ) / Wy ^t^i^^'MI 
Figure 3.5.9. Hematoxylin and eosin staining of the middle zone (20X) of liver 
sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C，D) (n二3). Severe lipid accumulation (arrows) was found around the 
central vein region in both control and Wy-14,643 fed PPARa (-/-) mice. P, portal 
triad. V, central vein. Bars, 50 |Lim. 
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1 week 
Middle zone (40X) 
瞧 
i PPARa (+/+) / CTL g S ^ ^ g y PPARa ( - / - ) / CTL 驚 
_ 丨 
j p P A R a ( + / + ) / W y ， J PPARa ( - / - ) / W y ‘ '^Hs^, 
_ III i i i iw m f - m m m m m m m s m t , i M b i . > H - • ^ 
Figure 3.5.10. Hematoxylin and eosin staining of the middle zone (40X) of liver 
sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C，D) (n=3). Lipid accumulation (arrows) was found around the central 
vein region in both control and Wy-14,643 fed PPARa (-/-) mice. P, portal triad. V， 
central vein. Bars, 50 )Lim. 
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1 week 
Portal vein region (20X) 
HQ i 
I P P A R a ( - / - ) / C T L W U g m 1*：： 
^ ^ ^ m m ^ I 
賤 譲 
P P A R a ( + / + ) / W y 紐 I P P A R a ( - / - ) / W y ^ 乂 
Figure 3.5.11. Hematoxylin and eosin staining of the portal vein region (20X) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the portal vein region 
of control fed PPARa (+/+) mice. Sinusoidal spaces between hepatocytes of 
PPARa (+/+) 0.1% Wy-14,643 treated mice were more obvious. P, portal triad. 
Bars, 50 [im. 
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1 week 
Portal vein region (40X) 
i 
I PPARa (+/+) / CTL | PPARa ( - / - ) / CTL {,5： 
I v ^ i i R y t f M i ^ 驅 • 观 ‘ H i i l l T m m w m m H r j M W j m i i i t H M I；；-
f PPARa (+/+) / Wy 3 PPARa (- / - ) / Wy � 象 ‘ O 
Figure 3.5.12. Hematoxylin and eosin staining of the portal vein region (40X) of 
liver sections (5 jiim) taken from PPARa (+/+) and PPARa (-/-) mice after 1 week 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the portal vein region 
of control fed PPARa (+/+) mice. Sinusoidal spaces between hepatocytes of PPARa 
(+/+) 0.1% Wy-14,643 treated mice were more obvious. P, portal triad. Bars, 50 jiim. 
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2 weeks 
Central vein region (20X) mm 
y PPARa (+/+) / C T l ^ m ^ m f PPARa ( - / - ) / C T L ^ ^ , ！|： 
Figure 3.5.13. Hematoxylin and eosin staining of the central vein region (2OX) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the central vein region 
of PPARa (+/+) mice fed with control diet. Larger sinusoidal spaces were observed 
in the 0.1% Wy-14,643 fed PPARa (+/+) mice. Severe lipid accumulation (arrows) 
was found around the central vein region in both control and Wy-14,643 fed PPARa 
(-/-) mice. V，central vein. Bars, 50 \xm. 
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2 week 
Central vein region (40X) 
m S m m t _ ： 鄉 i 
I P P A R a (+/+) / C T L M ^ M P P A R a ( - / - ) / C T L fe 
Mr^i^m^iummmi • • m ^ m M I J I 藝 I 雜 绅 ： : ' ！ 
_ 丨 
！ P P A R a ( + / + ) / W y I P P A R a ( - / - ) / W y S ^ M i 
I m mm I I mm • im i • M E ^ ^ K m hmamimmmHmmanmJtmMma^ 
Figure 3.5.14. Hematoxylin and eosin staining of the central vein region (40X) of 
liver sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C，D) (n二3). Severe lipid accumulation (arrows) was found around the 
central vein region in both control and Wy-14,643 fed PPARa (-/-) mice. 
Macrovesicular droplets were formed inside the hepatocytes. The nuclei were 
displaced to the periphery of the hepatocytes. V, central vein. Bars, 50 |Lim. 
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2 weeks 
Middle z � ; ; : : ^ ^ � � ; : � : ; ^ ^ 
H_ 丨 
% PPARa ( - / - ) / CTL 丨 J 
_ • 丨 
l l p a ， • ， 邀 ^ j ^ m m 
Figure 3.5.15. Hematoxylin and eosin staining of the middle zone (20X) of liver 
sections (5 [im) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the middle zone 
region of PPARa (+/+) mice fed with control diet. Larger sinusoidal spaces were 
observed in the 0.1% Wy-14,643 fed PPARa (+/+) mice. Severe lipid accumulation 
(arrows) was found around the central vein region in both control and Wy-14,643 fed 
PPARa (-/-) mice. P, portal triad. V，central vein. Bars, 50 \im, 
96 
2 weeks 
Middle zone (40X) , 
• H i 
！ P P A R a (+/+) / C T L | P P A R a ( - / - ) / C T L B 
圓 • 丨 
I P P A R a ( + / + ) / W y ， / % " % , I P P A R a ( - / - ) / W ^ J S n 
HTIITHIIR G G森欣C J I -丄 m U V I w，JMBMHMBHPIHKMEP 
Figure 3.5.16. Hematoxylin and eosin staining of the middle zone (40X) of liver 
sections (5 jam) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Lipid accumulation (arrows) was found in both control and 
Wy-14,643 fed PPARa (-/-) mice. P，portal triad. V, central vein. Bars, 50 ^im. 
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2 weeks 
Portal vein region (20X) 
• 隱 
_ • S 
I P P A R a ( + / + ) / W y ^ I ^ S m I P P A R a ( - / - ) / W y I f l H ^ n 
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Figure 3.5.17. Hematoxylin and eosin staining of the portal vein region (20X) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the portal vein region 
of control fed PPARa (+/+) mice. Abnormal arrangement of hepatocytes in the 0.1 % 
Wy-14,643 treated PPARa (+/+) was observed. P, portal triad. Bars, 50 jam. 
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2 weeks 
Portal vein region (40X) 
I PPARa (+/+) / CTL ^ PPARa ( - / - ) / CTL 丨; 
I 
_ _ � 
Figure 3.5,18. Hematoxylin and eosin staining of the portal vein region (40X) of 
liver sections (5 |im) taken from PPARa (+/+) and PPARa (-/-) mice after 2 weeks 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n二3). Normal liver histology was found in the portal vein region 
of control fed PPARa (+/+) mice. Abnormal arrangement of hepatocytes in the 
0.1% Wy-14,643 treated PPARa (+/+) was observed. P, portal triad. Bars, 50 jiim. 
99 
Abnormal hepatocytes arrangement and large sinusoids were more obvious in 
the 6 months feeding study. Trabecular cell clusters were observed in PPARa (+/+) 
mice fed with the 0.1% Wy-14,643 diet in the central vein region (Figures 3.5.19B, 
3.5.20B), middle zone (Figure 3.5.2IB, 3.5.22B) and portal vein region (Figures 
3.5.23B, 3.5.24B). In addition, lipid droplets were accumulated near the portal vein 
region of the PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet (Figure 3.5.22B, 
3.5.24B). For PPARa (-/-) mice, both control and Wy-14,643-treated groups showed � 
! | j ' 
accumulation of the lipid droplets around the central vein (Figures 3.5.19C, 3.5.19D, 
Ifl 
3.5.20C, 3.5.20D). 窗 
；：〒i 
After 11 months Wy-14,643 treatment, abnormal hepatocytes arrangement, 
. . \i large sinusoids in the central vein region (Figures 3.5.25B, 2.5.26B), middle zone 丨〉巧 
(Figures 3.5.27B, 3.5.28B) and portal vein region (Figure 3.5.29B, 3.5.30B) and lipid ！ v 
I,'丨 
accumulation (Figures 3.5.29B, 3.5.SOB) around the portal vein region were more |j)人 
obvious in the Wy-14,643 treated group of PPARa (+/+) mice. The accumulation of I丨) 
",、丨 lipid droplets around the central vein for the PPARa (-/-) mice (Figures 3.5.25C, 
s 
3.5.25D) was very severe as the lipid metabolism was affected with the removal of 
peroxisome proliferators-activated receptor alpha. Irregular and trabecular cell 
clusters were found in the 0.1% Wy-14,643 fed PPARa (+/+) mice (Figures 3.5.25B, 
3.5.27B, 3.5.29B). 
Hepatocytes without nuclei (Figures 3.5.31 A, 3.5.3ID), trabecular cell clusters 
(Figure 3.5.3IB, 3.5.3IE) and invasion of blood, dark nucleus (Figures 3.5.3IC, 
3.5.3IF) were observed in Wy-14,643-treated PPARa (+/+) after 11 months treatment. 
Trabecular cell clusters observed in 0.1% Wy-14,643 fed PPARa (+/+) mice was 
reported in previous study (Peters et al, 1997). 
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Figure 3.5.19. Hematoxylin and eosin staining of the central vein region (20X) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A，B) or a 0.1% Wy-14,643 
diet (panels C, D) (n二3). Normal liver histology was found in the central vein region 
of PPARa (+/+) mice fed with control diet. Severe lipid accumulation (arrows) was 
found around the central vein region in both control and Wy-14,643 fed PPARa (-/-) 
mice. Irregular and trabecular cell clusters were observed in Wy-14,643 treated 
PPARa (+/+) mice. V, central vein. Bars, 50 )Lim. 
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Figure 3.5.20. Hematoxylin and eosin staining of the central vein region (40X) of 
liver sections (5 |am) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n二3). Normal liver histology was found in the central vein 
region of PPARa (+/+) mice fed with control diet. Severe lipid accumulation 
(arrows) was found around the central vein region in both control and Wy-14,643 fed 
PPARa (-/-) mice. Macrovesicular droplets were formed inside the hepatocytes and 
the nuclei were displaced to the periphery of the hepatocytes. V, central vein. Bars, 
50 |am. 102 
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Figure 3.5.21. Hematoxylin and eosin staining of the middle zone (20X) of liver 
sections (5 jam) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Severe lipid accumulation (arrows) was found around the 
central vein region in both control and Wy-14,643 fed PPARa (-/-) mice. Irregular 
and trabecular cell clusters were observed in Wy-14,643 treated PPARa (+/+) mice. 
P, portal triad. V，central vein. Bars, 50 [im. 
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Figure 3.5.22. Hematoxylin and eosin staining of the middle zone (40X) of liver 
sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A，B) or a 0.1% Wy-14,643 
diet (panels C，D) (n二3). Normal liver histology was found in PPARa (+/+) mice 
fed with control diet. Severe lipid accumulation (arrows) were found in both control 
and Wy-14,643 fed PPARa (-/-) mice. Lipid accumulation was also observed in 
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Figure 3.5.23. Hematoxylin and eosin staining of the portal vein region (20X) of 
liver sections (5 |im) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in the portal vein region 
of both PPARa (+/+) and PPARa (-/-) mice fed with control diet. P, portal triad. 
Bars, 50 jam. 
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Figure 3.5.24. Hematoxylin and eosin staining of the portal vein region (40X) of 
liver sections (5 [im) taken from PPARa (+/+) and PPARa (-/-) mice after 6 months 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C, D) (n=3). Normal liver histology was found in portal vein region 
both PPARa (+/+) and PPARa (-/-) mice fed with control diet. Lipid accumulation 
(arrows) was found in PPARa (+/+) mice fed with 0.1% Wy-14,643 diet. P, portal 
triad. Bars, 50 |Lim. 
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Figure 3.5.25. Hematoxylin and eosin staining of the central vein region (20X) of 
liver sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 11 
months treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-
14,643 diet (panels C, D) (n=3). Normal liver histology was found in PPARa (+/+) 
mice fed with control diet. Severe lipid accumulation (arrows) were found around 
the central vein region in both control and Wy-14,643 fed PPARa (-/-) mice. 
Irregular and trabecular cell clusters were observed in PPARa (+/+) fed with Wy-
14643. V，central vein. Bars, 50 jiim. 
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Figure 3.5.26. Hematoxylin and eosin staining of the central vein region (40X) of 
liver sections (5 jam) taken from PPARa (+/+) and PPARa (-/-) mice after 11 
treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-14,643 
diet (panels C，D) (n二3). Normal liver histology was found in the central vein region 
of PPARa (+/+) mice fed with control diet. Severe lipid accumulation (arrows) was 
found around the central vein region in both control and Wy-14,643 fed PPARa (-/-) 
mice. Macrovesicular droplets were formed inside the hepatocytes and the nuclei 
were displaced to the periphery of the hypatocytes. V，central vein. Bars, 50 jum. 
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I PPARa (+/+)/Wy ^ ^ ^ 麗 PPARa ㈩ / Figure 3.5.27. Hematoxylin and eosin staining of the middle zone (20X) of liver sections (5 |im) taken from PPARa (+/+) and PP a (-/-) mice after 11 monthstreatment with a 0.0% W -14,643 (panels A, B) or a 0.1% Wy-14,643 diet (panels C， D) (n=3). Norm l live histology was fou d in the central vein region of PPARa(+/+) fed control diet while irregular a trabecul r cell clustes were obs rved in Wy-14,643 fed PPARa (+/+) mic . Lipid accumulation (ar ows) was f unaro d the central v in r g on i  both con rol and Wy- 4,643 f d PPARa -/-) m c .P, portal triad V，c tral vei . Ba s, 50 \xm. 
109 
11 months 
Middle zone (40X) mm 
圓 關 ！ , 
P P A R c x ( + / + ) / C T L ^PARa(-/-)/CTL V ^ 爆 ^ 
9 PPARa (+/+)/Wy S ^ M S i PPARa (-/-) / Wy * • • HH IP , mmmir ^ ^ lalM mmmmmmrnimm^-' ‘ ： .‘ w- • ^M . Figure 3.5.28. Hematoxylin and eosin staining of the iddle zone (40X) of liversections (5 )Lim) taken fro  PPARa (+/+) and PPARa (-/-) mice after 11 monthstreatment with a 0.0% W -14,643 (panels A, B) or a 0.1% Wy-14,643 diet (pane s C,D) (n=3) Severe lipid accumulation (arrows) were found around i  both control andWy-14,643 fed PPARa (-/-) mice. M crovesicular droplets were form d i side e h patocytes and the nuclei were dis laced to the periphery of the hepa ocytes. B r ,50 |Lim. 
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i PPARa (+/+) / Wy | PPARa (-/-) / W ^ ^ ^ B Figure 3.5.29. Hematoxylin and eosin staining of the portal vein region (20X) of liver sections (5 jim) take from PPAR  (+/+) and PPARa (-/-) mice after 11months tre tment with a 0.0% Wy-14,643 (control diet) (pane s A, B or a 0.1% Wy-14,643 diet panels C, D) (n=3). Severe lipid accumul tion (arrows) was foundar nd th  central vein reg on i  both con rol and Wy-14,643 fed PPAR  (-/-) mice.P, portal riad Bar , 50 |Lim. 
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Figure 3.5.30. Hematoxylin and eosin staining of the portal vein region (40X) of 
liver sections (5 |Lim) taken from PPARa (+/+) and PPARa (-/-) mice after 11 
months treatment with a 0.0% Wy-14,643 (control diet) (panels A, B) or a 0.1% Wy-
14,643 diet (panels C, D) (n=3). Lipid accumulation (arrows) was found in both 
PPARa (+/+) and PPARa (-/-) mice fed with 0.1% Wy-14,643 diet and PPARa (-/-) 


































































































































































































































3.6 Reverse transcription (RT) of mRNA and non-
fluorescent PCR (non-fluoroDD PCR) 
Since there are twelve different anchored primers (AP) and twenty different 
arbitrary primers (ARP), a total of 240 different combinations of AP and ARP can be 
used for the RT-PCR. However, not all the combinations will generate our desired 
differential display patterns (fluoroDD patterns) (Figure 2.10.1). In order to screen out 
the primer pairs which will show our desired fluoroDD patterns, reverse transcription life 
(RT) of mRNA with non-fluorescent PCR (non-fluoroDD PCR), a faster and more _ 
economic way, were performed in this study. � 
_ 丨4'丨 
j |丨丨“ 
Forty-three different primer combinations (API & ARP2, ARP3, ARP6, 
丨丨！ 
ARP 10, ARP16 and ARP20; AP2+ARP1, ARP3, ARP 10, ARP 12, ARP 16, ARP18 11,1 ；y 
and ARP19; AP3 & ARP3; AP5 & ARPl , ARP2, ARP3, ARP 10, ARP12 and ARP18; ；、 ‘< i ；, 
AP6 & ARPl，ARP4, ARP5, ARP8, ARP12 and ARP14; APT & ARPIO and ARP15; 
！ h�,.; •iti ‘‘t 
APIO & ARPl , ARP6, ARPIO, ARP 12, ARP13 and ARP 16; A P l l & ARPl , ARP3, I 
.11 
ARP5, ARP8, ARP 12, ARP 17, ARP19 and ARP20; and AP12 & ARP2) were used to [f: 
perform non-fluoroDD RT-PCR. Twenty-six primer pairs including API & ARP2, 
ARP3 and ARP20 (Figure 3.6.1); AP2 & ARPl，ARPIO, ARP 12, ARP18 and ARP19 
(Figure 3.6.2); AP3 & ARP3 (Figure 3.6.3); AP5 & ARPl , ARP2, ARP3, ARPIO and 
ARP12 (Figure 3.6.4); AP6 & ARPl , ARP4 and ARP14 (Figure 3.6.5); AP7 & 
ARP15 (Figure 3.6.6); APIO & ARPl，ARP12 and ARP13 (Figure 3,6.7); A P l l & 
ARPl , ARP3, ARP12 and ARP19 (Figure 3.6.8); and AP12 & ARP2 (Figure 3.6.9) 
showed differential display patterns, while the others did not show obvious differential 
display patterns or gave inconsistent patterns (Table 3.6.1). Eleven primer pairs, 
including API & ARP2 (Figure 3.6.1); AP2 & ARP18 and ARP19 (Figure 3.6.2); 
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Figure 3.6.1. Preliminary screening for differential display patterns using non-
fluorescent API in combinations with ARP2, ARPS, ARP6, ARPIO, ARP 16 and 
ARP20. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months 
was reverse transcribed with API primer and amplified by PCR using 3’-API and 
5'-ARPs (ARP2, ARP3, ARP6, ARPIO, ARP16 and ARP20). Each treatment 
group consists of two mice and the PCR products were resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. Arrow heads indicate the Wy-
14,643 responsive and PPARa-dependent cDNA fragments. *Primer pair used for 
subsequent fluorescent differential display analysis. 
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Figure 3.6.2. Preliminary screening for differential display patterns using non-
fluorescent AP2 in combinations with ARPl, ARP3, ARPIO, ARP 12, ARP 16, 
ARP 18 and ARP 19. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers 
treated with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 
months was reverse transcribed with AP2 primer and amplified by PCR using 3'-
AP2 and 5'-ARPs (ARPl, ARP3, ARPIO, ARP 12, ARP 16, ARP18 and ARP 19). 
Each treatment group consists of two or three mice and the PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Arrow 
heads indicate the Wy-14,643 responsive and PPARa-dependent cDNA fragments. 
*Primer pairs used for subsequent fluorescent differential display analysis. 
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Figure 3.6.3. Preliminary screening for differential display patterns using non- 、一 
fluorescent AP3 in combination with ARP3. Total RNA from PPARa (+/+) and 
PPARa (-/-) mouse livers treated with a 0.0% control (CTL) or 0.1% (w/w) Wy-
14,643 (Wy) diet for 11 months was reverse transcribed with AP3 primer and 
amplified by PCR using 3，-AP3 and 5’-ARP3. Each treatment group consists of 
two mice and the PCR products were resolved on 1% agarose, 0.5X TBE gels with 
ethidium bromide staining. Arrow heads indicate the Wy-14,643 responsive and 
PPARa-dependent cDNA fragments. *Primer pair used for subsequent fluorescent 
differential display analysis. 
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Figure 3.6.4. Preliminary screening for differential display patterns using non-
fluorescent AP5 in combinations with ARPl, ARP2, ARPS, ARPIO, ARP 12 and 
ARP 18. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months 
was reverse transcribed with AP5 primer and amplified by PCR using 3，-AP5 and 
5'-ARPs (ARPl, ARP2, ARP3, ARPIO, ARP12 and ARP 18). Each treatment 
group consists of two mice and the PCR products were resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. Arrow heads indicate the Wy-
14,643 responsive and PPARa-dependent cDNA fragments. *Primer pair used for 
subsequent fluorescent differential display analysis. 
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Figure 3.6.5. Preliminary screening for differential display patterns using non-
fluorescent AP6 in combinations with ARPl, ARP4, ARP5, ARPS, ARP 12 and 
ARP 14. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months 
was reverse transcribed with AP6 primer and amplified by PCR using 3’-AP6 and 
5'-ARPs (ARPl, ARP4, ARPS, ARPS, ARP12 and ARP14). Each treatment group 
consists of two mice and the PCR products were resolved on 1% agarose, 0.5X 
TBE gels with ethidium bromide staining. Arrow heads indicate the Wy-14,643 
responsive and PPARa-dependent cDNA fragments. *Primer pairs used for 
subsequent fluorescent differential display analysis. 
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Figure 3.6.6. Preliminary screening for differential display patterns using non- � - • � 
fluorescent AP7 in combinations with ARPIO and ARP 15. Total RNA from 
PPARa (+/+) and PPARa (-/-) mouse livers treated with a 0.0% control (CTL) or 
0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse transcribed with AP7 
primer and amplified by PCR using 3,-AP7 and 5'-ARPs (ARPIO and ARP 15). 
Each treatment group consists of two mice and the PCR products were resolved on 
1% agarose, 0.5X TBE gels with ethidium bromide staining. Arrow heads 
indicate the Wy-14,643 responsive and PPARa-dependent cDNA fragments. 
*Primer pair used for subsequent fluorescent differential display analysis. 
120 
P P A R a (+ /+) P P A R a (-/-) P P A R a (+/+) P P A R a (-/-) 
CTL Wy CTL Wy CTL Wy CTL Wy 
p N O N p N O ^ o o o o o o o o O ^ o ^ o ^ o ^ o o o o o o o o 
u u u u m w p q w U U U U W W W p q 
l^ t^f&ti 圏 j^ fl 、 
a = f c ± ± ± ± B r n i m f _ 
A P I O & A R P I AP10&ARP12 丨；丨 
.1 H B S H H I r T M I l T T l • ^ • H I 
I f 1 1 1 1 1 f AP10 & ARP6 AP10 & ARP13 * V� 
I'm 
N — i i J j f f y ^ I 
r i � 丨 i - j g a ^ i a i m l i n l i i i i B H B S S ^ ^ B H u 
APIO & ARPIO APIO & ARP16 
Figure 3.6.7. Preliminary screening for differential display patterns using non-
fluorescent APIO in combinations with ARPl, ARP6, ARPIO, ARP 12, ARP 13 
and ARP 16. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months 
was reverse transcribed with APIO primer and amplified by PCR using 3'-APIO 
and 5'-ARPs (ARPl, ARP6, ARPIO, ARP 12, ARP13 and ARP 16). Each treatment 
group consists of two mice and the PCR products were resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. Arrow heads indicate the Wy-
14,643 responsive and PPARa-dependent cDNA fragments. *Primer pair used for 
subsequent fluorescent differential display analysis. 
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Figure 3.6.8. Preliminary screening for differential display patterns using non-
fluorescent A P l l in combinations with ARPl, ARP3, ARP5, ARP8, ARP 12, 
ARP 17, ARP 19 and ARP20. Total RNA from PPARa (+/+) and PPARa (-/-) 
mouse livers treated with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) 
diet for 11 months was reverse transcribed with A P l l primer and amplified by 
PCR using 3,-APll and 5，-ARPs (ARPl, ARP3，ARP5, ARP8, ARP 12, ARP 17, 
ARP 19 and ARP20). Each treatment group consists of two mice and the PCR 
products were resolved on 1% agarose, 0.5X TBE gels with ethidium bromide 
staining. Arrow heads indicate the Wy-14,643 responsive and PPARa-dependent 
cDNA fragments. *Primer pairs used for subsequent fluorescent differential 
display analysis. 
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Figure 3.6.9. Preliminary screening for differential display patterns using non- 、一 
fluorescent AP12 in combinations with ARP2. Total RNA from PPARa (+/+) and 
PPARa (-/-) mouse livers treated with a 0.0% control (CTL) or 0.1% (w/w) Wy-
14,643 (Wy) diet for 11 months was reverse transcribed with API2 primer and 
amplified by PCR using 3,-API2 and 5'-ARP2. Each treatment group consists of 
two mice and the PCR products were resolved on 1% agarose, 0.5X TBE gels with 
ethidium bromide staining. Arrow head indicates the Wy-14,643 responsive and 
PPARa-dependent cDNA fragments. *Primer pair used for subsequent fluorescent 


















































































































































































































































































































































































































AP3 & ARP3 (Figure 3.6.3); AP5 & ARPIO (Figure 3.6.4); AP6 & ARP4 and ARP14 
(Figure 3.6.5); AP7 & ARP 15 (Figure 3.6.6); APIO & ARP 13 (Figure 3.6.7); APl l & 
ARP19 (Figure 3.6.8); and AP12必 ARP2 (Figure 3.6.9)，which showed differential 
display patterns in the fast screening of non-fluoro PCR were used for fluorescent RT-
PCR (fluoroDD RT-PCR). 
3.7 Reverse transcription (RT) of mRNA and fluorescent � 
PCR (fluoroDD PCR) 錦 
…I) 
Eleven fluoroDD gels were performed with eleven AP-ARP primer pairs 〒丨! 
• I 
！ .ji丨广l 
which yield desired differential display patterns. They included gels AA (API & 
ARP2) (Figure 3.7.1), AB (AP3 & ARP3) (Figure 3.7.2)，AC (AP2 & ARP19) (Figure j, 
3.7.3), AD (AP2 & ARP18) (Figure 3.7.4), AF (APIO & ARP13) (Figure 3.7.5), AH � 
(APll & ARP19) (Figure 3.7.6), AI (AP6 & ARP4) (Figure 3.7.7), AJ (AP6 & 
ARP 14) (Figure 3.7.8)，AL (AP7 & ARP15) (Figure 3.7.9), AO (AP5 & ARPIO) ；|| 
S, I 
(Figure 3.7.10) and AP (API2 & ARP2) (Figure 3.7.11). _丨 
One hundred fifty-seven fluoroDD fragments which showed our desired 
differential display patterns were excised from the eleven fluoroDD gels (Tables 3.7.1-
3.7.10). All together, forty-one fluoroDD fragments were down-regulated by 0.1% 
Wy-14,643 in PPARa (+/+) group, whereas the other one hundred and sixteen 
fluoroDD fragments were up-regulated by 0.1% Wy-14,643 in PPARa (+/+) mice. 
For gel AA, sixteen bands were excised (AAl, AA2, AA3, AA4, AA5, AA6, AA7, 
AA8, AA9, AAIO, AAl l , AAl2, AA14, AA15, AA16 and AAl7) (Figure 3.7.1) 
(Table 3.7.1). For gel AB, thirty-four bands were excised (ABl, AB2, AB3, AB4, 
AB5, AB6, AB7, AB8, AB9, ABIO, ABl l , ABl2, AB13, AB14，ABl5, ABl6, 
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Figure 3.7.1. Fluorescent differential display of gel AA performed with API and 
ARP2. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with API and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled API (ACGACTCACTATAGGGCTTTTTTTTTTTTGA) and 
5'-ARP2 (ACAATTTCACACAGGAGCTAGCATGG). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In 
gel AA, sixteen cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M，TMR-labeled molecular weight DNA 
marker. 126 
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Figure 3.7.2. Fluorescent differential display of gel AB performed with APS and 
ARP3. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP3 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled APS (ACGACTCACTATAGGGCTTTTTTTTTTTTGG) and 
5 ’-ARP3 (ACAATTTCACACAGGAGACCATTGCA). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AB, thirty-four cDNA fragments showing differential display patterns were excised. 
^Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 
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Figure 3.7.3. Fluorescent differential display of gel AC performed with AP2 and 
ARP 19. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP2 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP2 (ACGACTCACTATAGGGCTTTTTTTTTTTTGC) and 
5'-ARP 19 (ACAATTTCACACAGGATTTTGGCTCC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AC, eleven cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 
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Figure 3.7.4. Fluorescent differential display of gel AD performed with AP2 and 
ARP 18. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP2 and duplicate PCR reactions were performed for each mouse 
with 3,-TMR-labeled AP2 (ACGACTCACTATAGGGCTTTTTTTTTTTTGC) and 
5'-ARP 18 (ACAATTTCACACAGGATGATGCTACC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AD, nine cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M，TMR-labeled molecular weight DNA 
marker. 
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Figure 3.7.5. Fluorescent differential display of gel AF performed with APIO and 
ARP 13. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with APIO and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled APIO (ACGACTCACTATAGGGCTTTTTTTTTTTTAG) 
and 5，-ARP13 (ACAATTTCACACAGGAGTTGCACCAT). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AF, thirty-three cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reampliflcation. M，TMR-labeled molecular weight DNA 
marker. 130 
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Figure 3.7.6. Fluorescent differential display of gel AH performed with API 1 and 
ARP 19. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with A P l l and duplicate PCR reactions were performed for each mouse 
with 3,-TMR-labded A P l l (ACGACTCACTATAGGGCTTTTTTTTTTTTAT) and 
5'-ARP 19 (ACAATTTCACACAGGATTTTGGCTCC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AH, nine cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 131 
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Figure 3.7.7. Fluorescent differential display of gel AI performed with AP6 and 
ARP4. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP6 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP6 (ACGACTCACTATAGGGCTTTTTTTTTTTTCC) and 
5'-ARP4 (ACAATTTCACACAGGAGCTAGCAGAC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AI, eighteen cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 
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Figure 3.7.8. Fluorescent differential display of gel AJ performed with AP6 and 
ARP 14. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP6 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP6 (ACGACTCACTATAGGGCTTTTTTTTTTTTCC) and 
5, - ARP 14 (AC AATTTC AC AC AGGATCC ATGACTC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AJ, eight cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 133 
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Figure 3.7.9. Fluorescent differential display of gel AL performed with AP7 and 
ARP 15. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with AP7 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP7 (ACGACTCACTATAGGGCTTTTTTTTTTTTCG) and 
5'-ARP 15 (ACAATTTCACACAGGACTTTCTACCC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AL, three cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M, TMR-labeled molecular weight DNA 
marker. 134 
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Figure 3.7.10. Fluorescent differential display of gel AO performed with AP5 and 
ARP 10. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with APS and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP5 (ACGACTCACTATAGGGCTTTTTTTTTTTTCA) and 
5，-ARP 10 (AC AATTTC AC AC AGGAGATCTC AGAC). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AO, ten cDNA fragments showing differential display patterns were excised. 
*Fragments selected for reamplification. M，TMR-labeled molecular weight DNA 
marker. 135 
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Figure 3.7.11. Fluorescent differential display of gel AP performed with API2 and 
ARP2. Total RNA from PPARa (+/+) and PPARa (-/-) mouse livers treated with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was reverse 
transcribed with API2 and duplicate PCR reactions were performed for each mouse 
with 3'-TMR-labeled AP12 (ACGACTCACTATAGGGCTTTTTTTTTTTTCT) 
and 5'-ARP2 (ACAATTTCACACAGGAGCTAGCATGG). The TMR-labeled 
fluorescent PCR products were run on a 5.6% denaturing polyacrylamide gel. In gel 
AP, six cDNA fragments showing differential display patterns were excised. 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AB17，AB18, AB19, AB20, AB21, AB22, AB23, AB24, AB25, AB26, AB27, AB28, 
AB29, AB30, AB31，AB32, AB33 and AB34) (Figure 3.7.2) (Tables 3.7.2-3.7.3). For 
gel AC, eleven bands were excised (ACl, AC2, ACS, AC4, AC5, AC6, AC7, ACS, 
AC9, ACIO and A C l l ) (Figure 3.7.3) (Table 3.7.4). For gel AD, nine bands were 
excised (ADl, AD2, AD3, AD4, AD5, AD6, AD7, ADS and AD9) (Figure 3.7.4) 
(Table 3.7.5). For gel AF, thirty-three bands were excised (AFl, AF2, AF3, AF4, 
AF5, AF6, AF7, AF8, AF9 AFIO, AFl l , AFl2, AF13, AFl4, AFl5, AFl6, AFl7, 
AFl8, AFl9, AF20, AF21, AF22, AF23, AF24, AF25, AF26, AF27, AF28, AF29, 
AF30, AF31, AF32 and AF33) (Figure 3.7.5) (Tables 3.7.6-3.7.7). Nine fragments Sj 
.、:仏丨， 丄丨 
were excised from gel AH (AHl, AH2, AH3, AH4, AH5, AH6, AH7, AH8 and AH9) 
(Figure 3.7.6) (Table 3.7.8). For gel Al, eighteen fragments were selected for excision [ � 
(All, AI2, AI3, AI4, AI5, AI6, AI7, AI8, AI9, AIIO, AI l l , All2, AI13，All4, All8, 
� 
All9, AI20 and AI21) (Figure 3.7.7) (Table 3.7.9). For gel AJ，eight fragments were , j 
'h | 
selected for excision (AJl, AJ2, AJ3, AJ4, AJ5, AJ6, AJ9 and AJIO) (Figure 3.7.8) 4" 
�.:.li 
(Table 3.7.10). For gel AL, three fragments were excised (ALl，AL2 and AL3) 、.丨 
丨ill 
(Figure 3.7.9) (Table 3.7.10). Ten fragments were excised from gel AO (AOl, A02, 二：二丨 
A03, A04, A05, A06, A07, AOS, A09 and AO 10) (Figure 3.7.10) (Table 3.7.11). 
For gel AP, six fragments were excised (API, AP2, APS, AP4, AP5 and AP6) (Figure 
3.7.11) (Table 3.7.11). 
3.8 Reamplification of fluorescent differential display 
(fluoroDD) fragments 
The cDNA fragments were reamplified with full-length M13 reverse (-48) 24-




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































GTAATACGACTCACTATAGGGC-3') primers. As partial sequences of Ml3 
reverse (16-mer) and T7 promoter (17-mer) were present in the 5'-ARP and 3'-AP 
primers of double-strand cDNA synthesis, respectively, the reamplified PCR products 
were lengthened by 8 nucleotides from the Ml3 reverse primer and 5 nucleotides from 
the T7 promoter primer. The expected size of reamplified PCR product was 13 
nucleotides longer than the size of fluoroDD fragments. A total of sixty-four (41%) 
cDNA fragments were chosen for reamplification [AAl, AA2, AA3, AA4，AA5, 
� t t i 
1fV 
AA6, AA7, AA8, AA9，AAIO and AA12 (Figure 3.8.1) (Table 3.8.1); AB7, ABIO, ！ 
I；.卞 
ABl7, ABl8, ABl9, AB22, AB23, AB24, AB25, AB26, AB27, AB28, AB29 and 考 
1 
AB30 (Figures 3.8.2-3.8.3) (Table 3.8.2); ACl, AC2, AC3, AC4, AC7, AD6, AD7， 4 | 
ADS, AD9, AFl, AF3, AF5, AF7, AF15, AF19，AF20, AF21, AF25 and AF30 ！ 
(Figures 3.8.4-3.5.5) (Table 3.8.3); AHl，AH2, AH5, All , AI2, AI4, All8, AJl，AJ2, 1: 
：乂 
AJ3，AJ6, AJ9，ALl，AL2，AL3, AOl, A02, AOS, AOlO and AP4 (Figures 3.8.6- ',]' 
3.8.7) (Tables 3.8.4-3.8.5)]. The sizes of fragments AB19 and AB26 (Table 3.8.2); 1,, 
AD6 and AF30 (Table 3.8.3); AH2 (Table 3.8.4); and AL3 (Table 3.8.5) were bigger 
than the expected sizes, while the fragment sizes of AA2 (Table 3.8.1); ABIO (Table .1„J 
3.8.2); AC7 (Table 3.8.3); and AOl (Table 3.8.5) were smaller than the expected sizes. 
These might be due to the contamination during band excision. cDNA fragments AAl 
and AA5 (Table 3.8.1); AB23 (Table 3.8.2); AC2 and AF7 (Table 3.83); and AJ6 
(Table 3.8.4) contained extra PCR products, which might be due to contamination of 
co-migration and/or nearby cDNA fragments during bands excision. All the 
reamplified fragments with expected sizes were selected for subcloning. 
14’ 
• ^ 
迪 M2 AAl AA2 AA3 AA5 AA6 AA8 AA9 AAIO Ml 迪 
1636 - 1500 
101S 1000 





迪 Ml AA4 AA12 迪 Ml AA7 
WmMKm F ^ H 
800 - B B M | 800 
' ' ' m f l 600 
• • • ” 400 
Figure 3.8.1. Reamplification of cDNA fragments excised from fluoroDD gel 
AA (API and ARP2). The cDNA fragments excised from the gel were amplified 
by PCR using full-length Ml 3 reverse (-48) 24-mer (5'-
AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3,) primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 















































































































































































































































































































迪 M l AB7 迪 Ml ABIO AB22 
Bill i.,__„, I 
E S ^ ^ ^ ^ ^ H 800 - ^ ^ H U p I ^ ^ I 
9 � � j n ^ g _ 
B H ^ ^ ^ H 500 
r^l；) 
如 M l AB17 扯 M l AB18 舊 
Im 
800 
J [ H 
600 • 
Figure 3.8.2. Reamplification of cDNA fragments excised from fluoroDD gel 
AB (AP3 and ARP3) Part I. The cDNA fragments excised from the gel were 
amplified by PCR using flilMength Ml3 reverse (-48) 24-mer (5'-
AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5’-
GTAATACGACTCACTATAGGGC-3') primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 
100 bp DNA marker. 152 
^ Ml AB19 AB24 AB27 AB29 AB30 政 Ml AB23 AB25 
• M 
I H H • • “ I 
.丨4丨 
扯 Ml AB26 如 Ml AB28 | | I 
l i H I 
600 H H I ^ ^ H 
I ^ B I ^ H 
400 4 0 0 - ^ ^ ^ H H 
300 
Figure 3.8.3. Reamplification of cDNA fragments excised from fluoroDD gel 
AB (AP3 and ARP3) Part II. The cDNA fragments excised from the gel were 
amplified by PCR using fUll-length Ml 3 reverse (-48) 24-mer (5'-
AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3') primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 


























































































































































































































































































































































迪 M2 ACl AC2 AC4 ^ M2 AC3 m^^^^m I mm 
J ^ l 脳 誦 
… 腿 — I 
迪 Ml AC7 | i 
H H ^ ^ H I bp Ml AD6AD7 ADS AD9 
800 
1000 -^^BBSmBSKtBlM 
600 800 : 
Figure 3.8.4. Reampliflcation of cDNA fragments excised from fluoroDD gels 
AC (AP2 and ARP 19) and AD (AP2 and ARP 18). The cDNA fragments excised 
from the gel were amplified by PCR using flill-length M13 reverse (-48) 24-mer 
(5'-AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3') primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 
100 bp DNA marker; M2, 1 kb DNA marker. 
155 
^ 
纽 Ml AFl 迪 Ml AF3 AF5 AF20 AF21 AF25 AF30 
nynn 200 
纽 Ml AF7 迪 Ml AFl5 AFl9 • • 
^Hm 400 
800 ^ ^ ^ ^ m n 
700 
Figure 3.8.5. Reamplification of cDNA fragments excised from fluoroDD gel 
AF (APIO and ARP 13). The cDNA fragments excised from the gel were 
amplified by PCR using flill-length M13 reverse (-48) 24-mer (5'-
AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3,) primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 
































































































































































































































































































































































































































































































































扯 Ml AI2 迪 Ml AI4 bn Ml All 8 4 H H i H H f t b i J.I 
J H 
8 � m IHH 
Figure 3.8.6. Reamplification of cDNA fragments excised from fluoroDD gels 
AH (API 1 and ARP 19) and Al (AP6 and ARP4). The cDNA fragments excised 
from the gel were amplified by PCR using full-length M13 reverse (-48) 24-mer 
(5'-AGCGGATAACAATTTCACACAGGA-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3,) primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 
100 bp DNA marker; M2, 1 kb DNA marker. 
158 
如 M2 AJl 迪 Ml AJ2 迪 Ml AJ3 AJ9 
^^ Bi^n 800 - H ^ m 
2 0 3 6 - . k j ^ H 
m M B M 600 
1200 - j y i u m i | 
1 0 1 8 1 0 0 0 
^ H j H 800 400 - ^ ^ ^ H j H 
H i _ - B H 300 
扯 Ml AJ6 
•
迪 Ml ALl AL2 AL3 ‘ 
600 
_ - ^ H 300 
^ Ml AOl A02 如 Ml AOS AOlO 迪 Ml AP4 ' | 
600 600 
n . 
Figure 3.8.7. Reamplification of cDNA fragments excised from fluoroDD gels 
AJ (AP6 and ARP 14), AL (AP7 and ARP 15)，AO (AP5 and ARPIO) and AP 
(API2 and ARP2). The cDNA fragments excised from the gel were amplified by 
PCR using ftill-length M13 reverse (-48) 24-mer (5'-
AGCGG AT AAC AATTTC AC AC AGG A-3') and T7 promoter 22-mer (5'-
GTAATACGACTCACTATAGGGC-3') primers. The PCR products were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 









































































































































































































































































































































































































































































































































































































































































3.9 Subcloning of reamplified fluoroDD fragments 
A total of forty-two reamplifed cDNA fragments were chosen for subcloning. 
For the cDNA fragments which subcloned into pT-Adv vector, the sizes of the inserts 
released by EcoRl digestion were 18 bp longer than the reamplifed PCR products as 
extra 8 nucleotides were added before and after T/A cloning site and 10 nucleotides 
were added after EcoRI digestion. They included AAl, AA5, AA6, AA7, AAIO and 
AA12 (Figure 3.9.1) (Table 3.9.1); AB18 and AB26 (Figure 3.9.2) (Table 3.9.2); � 
,1:丨丨丨， 
AC3 and AC7 (Figure3.9.4) (Table 3.9.3); and AD8 and AD9 (Figure 3.9.5) (Table 
."li' 
3.9.3). For the cDNA fragments that subcloned into PCR®II-TOPO®, including AA4 :| 
(Figure 3.9.1) (Table 3.9.1); AB7，AB17, AB19, AB22, AB24, AB27 and AB29 ' | 
(Figures 3.9.2-3.9.3) (Table 3.9.2); ACl, AC2 and AC4 (Figure 3.9.4) (Table 3.9.3); ‘ 
AD6 (Figure 3.9.5) (Table 3.9.3); AFl, AF21, AF25 and AF30 (Figure 3.9.5) (Table : j 
3.9.4); AHl, AH2, All and AI18 (Figure 3.9.6) (Table 3.9.4); AJl, AJ2 and AJ9 
- i 
(Figure 3.9.7) (Table 3.9.4); AL2, AL3, AOl, A02, AOS and AP4 (Figure3.9.8) i' 
I 
(Table 3.9.5)，the sizes of the inserts released by EcoRI digestion were 20 bp longer •： 
：'1 
than the reamplified PCR products as extra 10 nucleotides were added before and 
after T/A cloning sites, and 10 nucleotides were added after BcoRI digestion. 
Some of the subcloned cDNA fragments showed did not release the expected 
insert sizes after EcoRl digestion. cDNA fragments AAl (Figure 3.9.1) (Table 3.9.1); 
AB17 and AB19 (Figure 3.9.2) (Table 3.9.2); ACl and AC2 (Figure 3.9.4) (Table 
3.9.3); AD6 (Figure 3.9.5) (Table 3.9.3) and A02 (Figure 3.9.8) (Table 3.9.5) 
contained different subclones that showed different EcoRI restriction patterns while 
cDNA fragments AAl, AA6 and AA7 (Figure 3.9.1) (Table 3.9.1); AC2 (Figure 3.9.4) 
(Table 3.9.3); ADS (Figure 3.9.5) (Table 3.9.3); and A02 (Figure 3.9.8) (Table 3.9.5) 
showed larger insert sizes after EcoRI digestion. The different EcoRI restriction 
162 
AAl 
迪 M2 PCR #2 #3 #4 #20 Ml ^ 
“ V ^ ^ ^ ^ l l A d f (3.9 kb) 
2 0 3 6 - 1 . : J H H ^ H R ^ 1 - 2 0 7 2 
^ ^ M H M f H i ^ ^ L J - 1 2 0 0 
•；g-lOOO 
AA4 AA12 I 丨 
迪 Ml PCR #1 #9 ^ Ml PCR #4 , 5：' 
g ^ i ^ l vector 产 r :: 
M 3 
AA5 AA6 AA7 AAIO ! 
to Ml PCR #5 PCR #1 杯9 PCR #3 #5 Ml PCR #1 
資 暫 纖 • 鄉 靈 爾 l ^ e c t o r p i ^ ^ Vector 
(3.9 kb) ^ ^^ (3.9 kb) 
I i I^K 
500 
Figure 3.9.1. EcoBJ digested cDNA fragments excised from gel AA (API and 
ARP2). The EcoRl digested cDNA fragments were resolved on 1% agarose, 0.5X 
TBE gels with ethidium bromide staining. Ml, 100 bp DNA marker; M2, 1 kb 



































































































































































































































































































































































































































































































^ Ml PCR #2 m 
^ ^ ^ ^ ^ ^ ^ ^ H H H H B I ^ Vector 
(3.9 kb) 
A B l 7 A B l 8 AB26 
迪 Ml PCR #9 #16 PCR #4 PCR #17 #30 1 
• • • Vector 




ABl 9 AB24 AB27 J 
迪 Ml PCR #2 #10 PCR #9 PCR #6 | 
• • • • % • f • B i d ^ ^ ^ B 
• Vector 
i (3.9 kb) 
800 -
600 
Figure 3.9.2. EcoRl digested cDNA fragments excised from gel AB (AP3 and 
ARP3) Part I. The EcoBl digested cDNA fragments were resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. Ml , 100 bp DNA marker. PCR, 
reamplified PCR product of the corresponding cDNA fragment. 
165 
AB22 






AB25 AB29 I 如 Ml PCR #6 #7 ^ Ml PCR #7 ； | 
& I ^ Vector P ^ V H . Vector ：丨 
(3.9 kb) r (3.9 kb) ：：：| 
600 fcS^^H 
Figure 3.9.3. EcoRI digested cDNA fragments excised from gel AB (AP3 and 
ARP3) Part II. The EcoRI digested cDNA fragments were resolved on 1% agarose, 
0.5X TBE gels with ethidium bromide staining. Ml，100 bp DNA marker. PCR, 










































































































































































































































































































































































































































































































































































































































































ACl AC2 AC4 
^ M2 PCR #1 #2 #4 PCR # 2 # 5 #6 P ^ W Ml ^ 
Vector 
禍 : L , (3.9 kb) 
1636 
H H ^ ^ ^ H K Q Q H I H B m i i m P H r 
:J ；1,1 
AC3 AC7 丨 
^ Ml PCR #9 #13 M2 迪 迪 Ml PCR #5 #9 (丨 
f Vector • n r i ^ Vector 
800 
Figure 3.9.4. EcoBJ digested cDNA fragments excised from gel AC (AP2 and 
ARP 19). The EcoBJ digested cDNA fragments were resolved on 1% agarose, 0.5X 
TBE gels with ethidium bromide staining. Ml , 100 bp DNA marker; M2, 1 kb 




^ Ml PCR #4 #10 
^ ^ ^ ^ ^ ^ ^ H B B H H B ^ Vector 
(3.9 kb) 
600 
ADS AD9 AFl � 
^ Ml PCR #2 #7 PCR #2 #3 ^ M2 PCR #8 | j j 
Vector 
kb) Vector 
_ - 1636 ：：' 
^ ^ m m m i j l j m i j m m i l 1018 
H W E I 
；丨I 
AF21 AF25 AF30 
如 Ml PCR #5 PCR #6 #7 迪 Ml PCR # 4 ^ :l 
•
Vector 隱 、 “ 
400 200 - ^ H B E S ^ ^ ^ ^ Q 
Figure 3.9.5. EcoRl digested cDNA fragments excised from gels AD (AP2 and 
ARP 18) and AF (APIO and ARP 13). The EcoRl digested cDNA fragments were 
resolved on 1% agarose, 0.5X TBE gels with ethidium bromide staining. Ml, 100 
bp DNA marker; M2, 1 kb DNA marker. PCR, reamplified PCR product of the 
corresponding cDNA fragment. 
169 
=邏粉工 
A l l ^ ^ ^ 
处 Ml T ^ i i ^ ： 
^ ^ ^ ^ b e M l 观 
^ ^ ^ ^ ^ ^ ^ ^ ^ Vector P ^ t e ' * - ； 
P I . V e c t o . 
F i g u r e 3 .9 .6 . EcoRI digested cDNA fragments excised from gels AH (APll and 
A R P 19) and A I (AP6 and ARP4). The EcoRI digested cDNA fragments were 
r e s o l v e d o n 1 % agarose，0.5X TBE gels with ethidium bromide staining. Ml, 100 




纽 M2 PCR #4 #5 Ml 迪 
Vector 
2 0 3 6 ( 3 . 9 kb) 
1636 
1018 H : 1000 
^ ^ m m i g g i i ^ i ^ j ^ - 800 
H H H B 
I^ ^BIDBI^ H" 200 
I'll 
dl 丨 
AJ2 AJ9 丨 
迪 M2 PCR #8 #10 迪 Ml PCR #1 
Vector Vector 
kb) I (3.9 kb) 
1018 
Figure 3.9.7. EcoRI digested cDNA fragments excised from gel AJ (AP6 and 
ARP 14). The EcoRI digested cDNA fragments were resolved on 1% agarose, 0.5X 
TBE gels with ethidium bromide staining. Ml , 100 bp DNA marker; M2, 1 kb 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































^ Ml PCR #8 #9 PCR #3 
1 ^ � ^ Vector 
(3.9 kb) 
• H i H M i H I H I l A02 : 
API 迪 Ml PCR #6 #8 :::j 
扯 Ml PCR #2 #5 Vector . .;.jj 
K Vector 
AOS AP4 
to Ml PCR #2 迪 Ml PCR #4 
Vector 
Vector kb) 
600 - ；; 
^ ^ H m 600 
Figure 3.9.8. EcoRI digested cDNA fragments excised from gels AL (AP7 and 
ARP 15), AO (AP5 and ARP 10) and AP (API2 and ARP2). The EcoRI digested 
cDNA fragments were resolved on 1% agarose, 0.5X TBE gels with ethidium 
bromide staining. Ml , 100 bp DNA marker. PCR, reamplified PCR product of the 































































































































































































































































































































































































































































































































































































patterns and larger insert sizes might be due to contamination and/or nearby co-
migrated cDNA fragments. In contrast, cDNA fragments AAl (Figure 3.9.1) (Table 
3.9.1); ACl, AC3 and AC4 (Figure 3.9.4) (Table 3.9.3); AD6 (Figure 3.9.5) (Table 
3.9.3); All (Figure 3.9.6) (Table 3.9.4); AJl (Figure 3.9.7) (Table3.9.4) and AOS 
(Figure 3.9.8) (Table 3.9.5) showed smaller insert sizes and these might be due to the 
presence of ^coRI site in those inserts. In addition, contamination of nearby co-
migrated cDNA fragments or other cDNA fragments during bands excision would also 
：1 
give small sizes of inserts after EcoRI digestion. ,! 
.'I 
:.,! I 
3.10 Sequencing of subcloned cDNA fragments 
丨  { 
A total of forty-two subcloned cDNA fragments (seventy subclones) were 
.'1 
sequenced and twenty-six different know genes and one expressed sequence tags (EST) j 
'1,：； ,I 
were obtained. They included mouse peroxisomal deltaS, delta2-enoyl-Coenzyme A | 
isomerase (Feci) [subclones AA1#2，AA1#3, AA1#4 and #20 (Table 3.10.1)]; mouse j 
I 
apolipoprotein A-V (Apoa5) [subclones AA4#1 and AA4#9 (Table 3.10.1)]; mouse ！ 
complete mitochondrial genome (mitochondria) [subclones AA5#5, AA6#1 and 
AA6#9 (Tables. 10.1); AA7#3 and AA7#5 (Table 3.10.2); AB17#16 and AB18#4 
(Table 3.10.3); AB19#2 and AB19#10 (Table 3.10.4); AF30#5 (Table 3.10.11) and 
AP4#4 (Table 3.10.16)]; mouse cysteine sulfinic acid decarboxylase (Csad) [subclone 
AA10#1 (Table 3.10.2)]; mouse acetyl-Coenzyme A dehydrogenase, medium chain 
(MCAD) [subclone AA12#4 (Table 3.10.2)]; mouse UDP-glucuronosyltransferase 
(UGT2b5) [subclones AB7#2 and AB7#8 (Table 3.10.3)]; mouse peroxisome 
biogenesis factor 16 (Pex 16) [subclone AB22#9 (Table 3.10.4)]; mouse cytochrome 
P450 (Cyp4al4) [subclones AB24#9 and AB25#6 (Table 3.10.4); AB26#17 and 
AB26#30 (Table 3.10.5)], mouse catalase [subclones AB29#7 (Table 3.10.5); AC2#5 
176 
(Table 3.10.7) and AJ9#1 (Table 3.10.13)]; mouse serine (or cysteine) proteinase 
inhibitor, clade F, member 2 (SerpinfZ) [subclones AC1#1 (Table 3.10.6) and AC2#6 
(Table 3.10.7)]; serine (or cysteine) proteinase inhibitor, clade A, member la (SPI) 
[subclone AC1#2 (Table 3.10.6); AC4#3 and AC7#5 (Table 3.10.8)]; serine (or 
cysteine) proteinase inhibitor, clade A, member 3K (Spi2) [subclone All#5 (Table 
3.10.12)]; mouse peroxisomal bifunctional enzyme (PBFE) [subclone AC2#2 (Table 
3.10.7)]; mouse cytochrome P450 2a5 (Cyp2a5) [subclone AC4#3 (Table 3.10.8)]; 
mouse N-terminal Asn amidase [subclone AD6#4 (Table 3.10.9)]; mouse cytochrome 、以j 
P450 4al0 (Cyp4al0) [subclones AD6#10, AD8#2, AD8#7, AD9#2 and AD9#3 
.! .1 I 
(Table 3.10.9)]; mouse very-long-chain acyl-CoA synthetase (VLACS) [subclone 丨 I 
AFl#8 (Table 3.10.10)]; mouse cell death-inducing DNA fragmentation factor, alpha ij 
：：.| 
subunit-like effector B (Cidef) [subclone AF21#5 (Table 3.10.10)]; mouse major ! 
• 1； 
urinary protein II (MUP II) [subclone AF25#6 and AF25#7 (Table 3.10.10)]; mouse 
I 1 
suppressor of actin mutations (SACl gene) [subclone AF30#4 (Table 3.10.11) and | 
i 丨  
AJ9#1 (Table 3.10.13)]; mouse expressed sequence tags (EST) [subclone AH1#1 | 
I , 
(Table 3.10.11)]; mouse argininosuccinate lyase (Asl) [subclone AI18#6 (Table J 
3.10.12)]; mouse carboxyesterase [subclones AJ1#4 and AJ1#5 (Table 3.10.13)]; 
mouse peroxisomal acyl-CoA oxidase (AOX) [subclone AJ2#10 (Table 3.10.13)]; 
mouse hydroxysteroid (17-beta) dehydrogenase 11 (HsdlTpi l ) [subclones AL2#8 and 
AL3#3 (Table 3.10.14)]; mouse adipose differentiation related protein (ADRP) 
subclone A01#2 (Table 3.10.15)]; mouse carnitine 0-octanoyltransferase (Crot) 
subclones A01#5 and A02#8 (Table 3.10.15)]; mouse ribonuclease, RNase A family 
4 (RNase4) [subclones A02#6 and A08#2 (Table 3.10.15)] (Appendix B, Bl.1-16.1). 
The abundance of genes were shown in Figure 3.10.1, including mitochondrial 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(4.8%), Hsd l7p l l (4.8%), Rnase 4 (4.8%), SACl gene (4.8%) and SerpinfZ (4.8%) > 
ADRP (2.4%), Apoa5 (2.4%), Asl (2.4%), Asn amidase (2.4%), AOX (2.4%), 
Carboxyesterase (2.4%), Cidef (2.4%), Csad (2.4%), Cyp2a5 (2.4%), EST (2.4%), 
MCAD (2.40/0), MUP II (2.40/0)，PBFE (2.4%), Feci (2.4%), Pexl6 (2.4%), Spi2 
(2.40/0), UGT2b5 (2.40/0) and VLACS (2.4%). 
3.11 Northern blot analysis of sequenced cDNA fragments ! 
1:: 
A total of seventeen subcloned cDNA fragments were confirmed. They :: 
included AAl#2 [mouse peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase 
J 
(Feci) (Figure 3.11.1)]; AA4#9 [mouse apolipoprotein A-V (Apoa5) (Figure 3.11.2)]; j 
AA10#1 [cysteine sulfinic acid decarboxylase (Csad) (Figure 3.11.3)]; AA12#4 
[mouse acetyl-Coenzyme A dehydrogenase, medium chain (MCAD) (Figure 3.11.4)]; f 
I 
AB7#2 [mouse UDP-glucuronosyltransferase 2 family member 5, (UDP2b5) (Figure “ 
3.11.5)]; AB22#9 [peroxisome biogenesis factor 16 (Pex 16) (Figure 3.11.6)]; j 
AB25#6 [mouse cytochrome P450 4al4 (Cyp4al4) (Figure 3.11.7)]; AC1#2 [mouse | 
serine protease inhibitor, clade A, member la (SPI) (Figure 3.11.8)]; AC2#2 [mouse 
peroxisomal bifunctional enzyme (PBFE) (Figure 3.11.9)]; AD8#2 [mouse 
cytochrome P450 4al0 (Cyp4al0) (Figure 3.11.10)]; AFl#8 [very-long-chain acyl-
CoA synthetase (VLACS) (Figure 3.11.11)]; AF25#7 [mouse major urinary protein II 
(MUP II) (Figure 3.11.12)]; AJl#5 [mouse carboxyesterase (carboxyesterase) (Figure 
3.11.13)]; AJ2#10 [mouse peroxisomal acyl-CoA oxidase (AOX) (Figure 3.11.14)]; 
AL3#3 [mouse hydroxysteroid (17-beta) dehydrogenase 11, (HsdlVpi 1) (Figure 
3.11.15)]; A01#2 [mouse adipose differentiation related protein (ADRP) (Figure 
3.11.16)] and A02#8 [mouse carnitine 0-octanoyltransferase (Crot) (Figure 3.11.17)]. 
The results of the Northern blot analysis were then quantified by MultiAnalyst and the 
195 
fold changes of Wy-14,643 / Control of PPARa (+/+) and PPARa (-/-) mice were 
calculated. 
For loading normalization, the RNA gel photo for each Northern blot analysis 
was showed. Housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was not used for normalization of northern blot analysis as its expression 
was up-regulated in the Wy-14,643 treated PPARa (+/+) mice after 11 months 
treatment (Figure 3.11.18) and this observation was also mentioned in previous studie .！ 
I； 
(Anderson et al., 1999). , 
Some of the subcloned cDNA fragments could not be confirmed by Northern i 
:i 
blot analysis as no differential display pattern was observed. They included AA7#3, .'j 
；! 
AB19#10 and AP4#4 [mouse complete mitochondrial genome (mitochondria) (Figure 丨丨 
3.11.19)]; AC1#1 [mouse serine (or cysteine) proteinase inhibitor, clade F, member 2 ！ 
(Seipinf2)]; AF21#5 [mouse cell death-inducing DNA fragmentation factor, alpha ！ 
subunit-like effector B (Cidef)]; AJ9#1 [mouse suppressor of actin mutations (SACl 1 
li 
i! 
gene)] and AI18#6 [mouse argininosuccinate lyase (Asl)]. In addition, some of the j 
subcloned cDNA fragments did not give any signal in the Northern blot analysis, 丨丨' 
including AB29#7 [mouse catalase]; AD6#4 [mouse N-terminal Asn amidase]; 
AH1#1 [mouse expressed sequence tags (EST) (Figure 3.11.20)] and A02#6 [mouse 
ribonuclease, RNase A family 4 (RNase4)]. 
Up-regulation in PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet was 
observed in subcloned cDNA fragments AAW2 [mouse peroxisomal deltaS, delta2-
enoyl-Coenzyme A isomerase (Feci) (3-fold) (Figure 3.11.1) (Table3.11.1)]; AA 10# 1 
[cysteine sulfinic acid decarboxylase (Csad) (20-fold) (Figure 3.11.3) (Table 3.11.1)]; 
AA12#4 [mouse acetyl-Coenzyme A dehydrogenase, medium chain (MCAD) (3.35-
fold) (Figure 3.11.4) (Table 3.11.1)]; AB22#9 [peroxisome biogenesis factor 16 (Pex 
196 
PPARa (+/+) PPARa (-/-) 
CTL Wy CTL Wy 
t ^ o o c ^ ^ o ^ ^ 00 寸 o^ i / ^ O O — — t~I o , ~ — 卜 卜 1 � f 0 0 O ^ o ^ o ^ o ^ o ^ o o oo oo oo oo oo bp M w o c j u u u w w w w w w 
Mouse 
delta delta 
0.68 2.12 0.10 0.10 ： 
A isomerase ！ 
(1581 bp) I 
I I 
Figure 3.11.1. Confirmation of fluoroDD expression pattern of subclone AA1#2 
(peroxisomal delta 3，delta 2-enoyl-coenzyme A isomerase) by Northern blot 
analysis. Total liver RNA (30 |Lig) of three mice each of PPARa (+/+) and PPARa 
(-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 
months was separated on a 1% agarose-formaldehyde gel and transferred to a nylon 
membrane. The membrane was then hybridized with a PCR DIG-labeled cDNA 
probe and signals were detected by colorimetric method with NBT and BCIP 
reagents. For normalization, ethidium bromide staining of RNA gel was used. M, 
RNA molecular weight marker I，DIG-labeled. 
197 
P P A R a (+/+) P P A R a (-/-) 
CTL Wy CTL Wy 
卜 o o o ^ o — O o o 寸 l o m o o o\ 
lO o o ^ — — o — — 卜 卜 ^ l , o o 0 ^ o ^ o ^ o ^ o ^ o o oo oo oo oo oo 
b p M p q O U U U U p q p q p q w w w 
1821 apoiipo. 
0.91 0.47 1.08 1.07 | 
a i L … 一 丄 i 
I .ji 
Figure 3.11.2. Confirmation of fluoroDD expression pattern of subclone AA4#9 
(apolipoprotein A-V) by Northern blot analysis. Total liver RNA (30 jj,g) of three 
mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% 
(w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-
formaldehyde gel and transferred to a nylon membrane. The membrane was then 
hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I, DIG-
labeled. 
198 
P P A R a (+/+) P P A R a (-/-) 
CTL Wy CTL Wy 
卜 o o o ^ o ^ ^ 00 寸 i n r ^ o o o^ l / ^ O O — — T ~ H O r—t ^ 1-H 卜 1 , , OO o^ o^ o^ G ^ o ^ o o oo oo oo oo oo 
b p M w u u u u u m w w w w w 
^ ~ “ AA10#1 
266 卜 4 Mouse 
•• • S m n k a c i d .丨 
1 5 1 7 - 々 鄉 署 decarboxylase 
^ — — — — * (2265 bp) • I 
0.01 0.20 0.02 0.02 :! 
— . ： 丨 
Figure 3.11.3. Confirmation of fluoroDD expression pattern of subclone AA10#1 
(cysteine sulfmic acid decarboxylase) by Northern blot analysis. Total liver RNA 
(30 [ig) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control 
(CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane 
was then hybridized with a DIG-labeled RNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I, DIG-
labeled. 
199 
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Figure 3.11.4. Confirmation of fluoroDD expression pattern of subclone AA12#4 
(acetyl-Coenzyme A dehydrogenase, medium chain) by Northern blot analysis. 
Total liver RNA (30 iLig) of three mice each of PPARa (+/+) and PPARa (-/-) fed 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was 
separated on a 1% agarose-formaldehyde gel and transferred to a nylon membrane. 
The membrane was then hybridized with a DIG-labeled RNA probe and signals were 
detected by colorimetric method with NBT and BCIP reagents. For normalization, 
































































































































































































































































































































































































































































































































































































































































































































16) (4-fold) (Figure 3.11.6) (Table 3.11.2)]; AB25#6 [mouse cytochrome P450 4al4 
(Cyp4al4) (105-fold) (Figure 3.11.7) (Table 3.11.2)]; AC2#2 [mouse peroxisomal 
bifunctional enzyme (PBFE) (20-fold) (Figure 3.11.9) (Table 3.11.3)]; AD8#2 [mouse 
cytochrome P450 4alO (Cyp4al0) (115-fold) (Figure 3.11.10) (Table 3.11.3)]; AFl#8 
[very-long-chain acyl-CoA synthetase (VLACS) (2-fold) (Figure 3.11.20) (Table 
3.11.4)]; AJ2#10 [mouse peroxisomal acyl-CoA oxidase (AOX) (10-fold) (Figure 
3.11.14) (Table 3.11.4)]; AL3#3 [mouse hydroxysteroid (17-beta) dehydrogenase 11, � 
(Hsdl7pll) (10-fold) (Figure 3.11.15) (Table 3.11.5)]; AOl#2 [mouse adipose ；] 
differentiation related protein (ADRP) (16-fold) (Figure 3.11.16) (Table 3.11.5)] and :j 
•j 
A02#8 [mouse carnitine 0-octanoyltransferase (Crot) (4-fold) (Figure 3.11.17) (Table 丨？ 
I I 
3.11.5)] were confirmed. 
Subcloned cDNA fragments AA4#9 [mouse apolipoprotein A-V (Apoa5) (0.5- ?! 
I； 
fold) (Figure 3.11.2) (Table 3.11.1)]; AB7#2 [mouse UDP-glucuronosyltransferase 2 j 
I 
family member 5, (UDP2b5) (0.5-fold) (Figure 3.11.5) (Table 3.11.2)]; ACl#2 j! 
•i i丨 
[mouse serine protease inhibitor, clade A, member la (SPI) (0.24-fold) (Figure 3.11.8) [ 
(Table 3.11.3)]; AF25#7 [mouse major urinary protein II (MUP II) (0.08-fold) (Figure I 
3.11.12) (Table 3.11.4)] and AJ1#5 [mouse carboxyesterase (carboxyesterase) (0.08-
fold) (Figure 3.11.13) (Table 3.11.4)] were confirmed to be down-regulated by 0.1% 
Wy-14,643 and PPARa-dependent. 
Subcloned cDNA fragments AB7#2 [mouse UDP-glucuronosyltransferase 2 
family member 5, (UDP2b5)], AC1#2 [mouse serine protease inhibitor, clade A, 
member la (SPI)], AD8#2 [mouse cytochrome P450 4a 10 (Cyp4alO)] and AF25#7 
[mouse major urinary protein II (MUP II)] showed several bands in the Northern blot 
analysis. The different bands might be different isoforms of the genes. Subcloned 
cDNA fragments AB7#2 [mouse UDP-glucuronosyltransferase 2 family member 5, 
202 
P P A R a ( + / + ) P P A R a ( - / - ) 
CTL Wy CTL Wy 
卜 o o o ^ o ^ ^ oo 寸 1 0 ( ^ 0 0 o^ ID O O 1—I 1—( 1—H O r—( \0 —卜卜 1 � f 0 0 O ^ o ^ o ^ o^ o^ oo oo oo oo oo oo bp M w o o u u u p q w w w w w 
HBHI^ S••画•疆漏 
1821 giucuronsyi-
transferase • H B s R l U n M H 0648 bp) 
3.40 1.31 3.00 2.40 i 
• W L ‘ 
^ H ^ ^ H ^ v 18 s 
I 
Figure 3.11.5. Confirmation of fluoroDD expression pattern of subclone AB7#2 
(UDP-glucuronsyltransferase 2b5) by Northern blot analysis. Total liver RNA (30 
lag) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control 
(CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane was 
then hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 
colorimetric method with NET and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I，DIG-
labeled. 
203 
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IAB22#9 Mouse peroxisome • biogenesis 
factor 16 丨 
(1221 bp) •：' 
0.21 0.83 0.10 0.09 j 
I 
18S j 
i i S： 
I I 
Figure 3.11.6. Confirmation of fluoroDD expression pattern of subclone AB22#9 
(peroxisome biogenesis factor 16) by Northern blot analysis. Total liver RNA (30 
jag) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control 
(CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane was 
then hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 
colorimetric method with NET and BCEP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M，RNA molecular weight marker I, DIG-
labeled. 
204 
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Figure 3.11.7. Confirmation of fluoroDD expression pattern of subclone AB25#6 
(cytochrome P450, family 4，subfamily a, polypeptide 14) by Northern blot analysis. 
Total liver RNA (30 jug) of three mice each of PPARa (+/+) and PPARa (-/-) fed 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was 
separated on a 1% agarose-formaldehyde gel and transferred to a nylon membrane. 
The membrane was then hybridized with a PCR DIG-labeled cDNA probe and 
signals were detected by colorimetric method with NBT and BCIP reagents. For 
normalization, ethidium bromide staining of RNA gel was used. M, RNA molecular 
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Figure 3.11.8. Confirmation of fluoroDD expression pattern of subclone AC1#2 
(serine protease inhibitor) by Northern blot analysis. Total liver RNA (30 jug) of 
three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) 
or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane 
was then hybridized with a DIG-labeled RNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I, DIG-
labeled. 
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Figure 3.11.9. Confirmation of fluoroDD expression pattern of subclone AC2#2 
(peroxisomal bifunctional enzyme) by Northern blot analysis. Total liver RNA (30 
|Lig) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control 
(CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane 
was then hybridized with a DIG-labeled RNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I, DIG-
labeled. 
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Figure 3.11.10. Confirmation of fluoroDD expression pattern of subclone AD8#2 
(cytochrome P450, family 4, subfamily a, polypeptide 10) by Northern blot analysis. 
Total liver RNA (30 jug) of three mice each of PPARa (+/+) and PPARa (-/-) fed 
with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was 
separated on a 1% agarose-formaldehyde gel and transferred to a nylon membrane. 
The membrane was then hybridized with a DIG-labeled RNA probe and signals 
were detected by colorimetric method with NBT and BCIP reagents. For 
normalization, ethidium bromide staining of RNA gel was used. M, RNA 
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Figure 3.11.11. Confirmation of fluoroDD expression pattern of subclone AFl#8 
(very long chain acyl-CoA synthetase) by Northern blot analysis. Total liver RNA 
(30 [ig) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control 
(CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% 
agarose-formaldehyde gel and transferred to a nylon membrane. The membrane was 
then hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I，DIG-
labeled. 
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Figure 3.11.12. Confirmation of fluoroDD expression pattern of subclone AF25#7 
(mouse major urinary protein II) by Northern blot analysis. Total liver RNA (30 jiig) 
of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) 
or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-
formaldehyde gel and transferred to a nylon membrane. The membrane was then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 
method with NBT and BCIP reagents. For normalization, ethidium bromide staining 
of RNA gel was used. M, RNA molecular weight marker I，DIG-labeled. 
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Figure 3.11.13. Confirmation of fluoroDD expression pattern of subclone AJ1#5 
(carboxylesterase) by Northern blot analysis. Total liver RNA (30 jug) of three mice 
each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) 
Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-formaldehyde 
gel and transferred to a nylon membrane. The membrane was then hybridized with 
a DIG-labeled RNA probe and signals were detected by colorimetric method with 
NBT and BCIP reagents. For normalization, ethidium bromide staining of RNA gel 
was used. M, RNA molecular weight marker I, DIG-labeled. 
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Figure 3.11.14. Confirmation of fluoroDD expression pattern of subclone AJ2#10 
(peroxisomal acyl-CoA oxidase) by Northern blot analysis. Total liver RNA (30 |ag) 
of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) 
or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-
formaldehyde gel and transferred to a nylon membrane. The membrane was then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 
method with NBT and BCIP reagents. For normalization, ethidium bromide staining 
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Figure 3.11.15. Confirmation of fluoroDD expression pattern of subclone AL3#3 
[hydroxysteroid (17-beta) dehydrogenase 11] by Northern blot analysis. Total liver 
RNA (30 lag) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% 
control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 
1% agarose-formaldehyde gel and transferred to a nylon membrane. The membrane 
was then hybridized with a DIG-labeled RNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I，DIG-
labeled. 
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Figure 3.11.16. Confirmation of fluoroDD expression pattern of subclone AOl#2 
(adipose differentiation related protein, ADFP) by Northern blot analysis. Total liver 
RNA (30 lag) of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% 
control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 
1% agarose-formaldehyde gel and transferred to a nylon membrane. The membrane 
was then hybridized with a DIG-labeled RNA probe and signals were detected by 
colorimetric method with NBT and BCIP reagents. For normalization, ethidium 
bromide staining of RNA gel was used. M, RNA molecular weight marker I，DIG-
labeled. 
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Figure 3.11.17. Confirmation of fluoroDD expression pattern of subclone A02#8 
(carnitine 0-octanoyltransferase) by Northern blot analysis. Total liver RNA (30 jiig) 
of three mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) 
or 0.1% (w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-
formaldehyde gel and transferred to a nylon membrane. The membrane was then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 
method with NBT and BCIP reagents. For normalization, ethidium bromide staining 
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Figure 3.11.18. Up-regulation of GAPDH was observed in PPARa (+/+) mice fed 
with a 0.1% (w/w) Wy-14,643 diet for 11 months. Total liver RNA (30 jig) of three 
mice each of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% 
(w/w) Wy-14,643 (Wy) diet for 11 months was separated on a 1% agarose-
formaldehyde gel and transferred to a nylon membrane. The membrane was then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 
method with NBT and BCIP reagents. For normalization, ethidium bromide staining 
of RNA gel was used. M，RNA molecular weight marker I, DIG-labeled. 
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Figure 3.11.19. Confirmation of fluoroDD expression pattern of mitochondria by 
Northern blot analysis. Total liver RNA (30 jiig) of three mice each of PPARa (+/+) 
and PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet 
for 11 months was separated on a 1% agarose-formaldehyde gel and transferred to a 
nylon membrane. The membrane was then hybridized with a DIG-labeled RNA 
probe and signals were detected by colorimetric method with NBT and BCIP 
reagents. For normalization, ethidium bromide staining of RNA gel was used. M， 
RNA molecular weight marker I, DIG-labeled. 
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Figure 3.11.20. Confirmation of fluoroDD expression pattern of EST by Northern 
blot analysis. Total liver RNA (30 jiig) of three mice each of PPARa (+/+) and 
PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 
II months was separated on a 1% agarose-formaldehyde gel and transferred to a 
nylon membrane. The membrane was then hybridized with a DIG-labeled RNA 
probe and signals were detected by colorimetric method with NBT and BCIP 
reagents. For normalization, ethidium bromide staining of RNA gel was used. M, 
RNA molecular weight marker I，DIG-labeled. 
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(UDP2b5)] gave different patterns from fluoroDD patterns in Northern blot analysis. 
It might be due to the co-migrated cDNA fragments in fluoroDD gel which have other 
fluoroDD pattern. 
In order to study the time effect of the Wy-14,643 on the PPARa regulated 
gene, Northern blot analysis was performed with RNA samples from 24 hour, 1 week, 
2 weeks, 6 months and 11 months feeding mice of all the four treatment groups. A 
total of sixteen were performed successfully. They included AA1#2 [mouse 
peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase (Feci)]; AA10#1 [cysteine 
sulfinic acid decarboxylase (Csad)]; AA12#4 [mouse acetyl-Coenzyme A 
dehydrogenase, medium chain (MCAD)]; AB7#2 [mouse UDP-
glucuronosyltransferase 2 family member 5, (UDP2b5)]; AB22#9 [peroxisome 
biogenesis factor 16 (Pex 16)]; AB25#6 [mouse cytochrome P450 4al4 (Cyp4al4)]; 
AC1#2 [mouse serine protease inhibitor, clade A, member la (SPI)]; AC2#2 [mouse 
peroxisomal bifunctional enzyme (PBFE)]; AD8#2 [mouse cytochrome P450 4a 10 
(Cyp4al0)]; AF1#8 [very-long-chain acyl-CoA synthetase (VLACS)]; AF25#7 
[mouse major urinary protein II (MUP II)]; AJ1#5 [mouse carboxyesterase 
(carboxyesterase)]； AJ2#10 [mouse peroxisomal acyl-CoA oxidase (AOX)]; AL3#3 
[mouse hydroxysteroid (17-beta) dehydrogenase 11, (Hsdl7pl 1)]; A01#2 [mouse 
adipose differentiation related protein (ADRP)] and A02#8 [mouse carnitine O-
octanoyltransferase (Crot)]. The signals were quantified by MultiAnalyst and fold 
change was calculated. 
Up-regulation of AA1#2 [mouse peroxisomal deltaS, delta2-enoyl-Coenzyme 
A isomerase (Feci) (Figure 3.11.21) (Table 3.11.6)] in PPARa (+/+) mice fed with the 
0.1% Wy-14,643 diet was started at 24 hours gavage feeding and continued to 11 
months feeding. Maximum induction was observed at 24 hours gavage feeding (6.6-
223 
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fold). However, no induction was observed in PPARa (-/-) mice fed with 0.1% Wy-
14,643 when compared with the controls. 
Very weak signal was obtained for the Northern blot analysis of time-
dependent expression of fragment AA4#9 [mouse apolipoprotein A-V (Apoa5)]. 
Although weak signals were observed in the temporal expression of fragment 
AA10#1 [mouse cysteine sulfinic acid decarboxylase (Csad) (Figure 3.11.22) (Table 
3.11.6)] consistent induction (2 to 5-fold) in 0.1% Wy-14,643 fed PPARa (+/+) was 
started at 1 week and continued to 11 months treatment. The PPARa (-/-) mice fed | 
i 
with the 0.1% Wy-14,643 diet did not show any induction when compared with the 
controls. 
Similar to AA10#1, weak signals were found in the temporal expression of 
AA12#4 [mouse acetyl-Coenzyme A dehydrogenase, medium chain, MCAD (Figure 
3.11.23) (Table 3.11.6)]. Consistent up-regulation (2 to 4-fold) started at 24 hours and 
continued to 11 months treatment of AA12#4 was observed. The up-regulation was 
not shown in 0.1% Wy-14,643-treated PPARa (-/-) after short-term and long-term 
treatment. 
cDNA fragment AB7#2 [mouse UDP-glucuronosyltransferase 2 family 
member 5, UGT2b5 (Figure 3.11.24) (Table 3.11.7)] showed down-regulation which 
started at 2 weeks and continued to 11 months treatment. Maximum down-regulation 
(0.39-fold) was observed at 11 months treatment. However, down-regulation was not 
observed in the PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet. Down-
regulation bands were observed at about 2661 bp transcript in Wy-treated PPARa 
(+/+) mice. This might be the other member of the UDP-glucuronosyltransferase 2 
family that has similar homology to UGT2b5, e.g. UGT2b4 which transcriptional size 
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Figure 3.11.24. Temporal expression of AB7#2 (UDP-glucuronosyltransferase 2b5). 
Total liver RNA (30 [ig) of two mice of PPARa (+/+) and PPARa (-/-) fed with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 week, 2 
weeks, 6 months and 11 months treatment were separated on 1% agarose-
formaldehyde gels and transferred to nylon membranes. The membranes were then 
hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Subcloned cDNA fragment AB22#9 [mouse peroxisome biogenesis factor 16 
(Pex 16) (Figure 3.11.25) (Table 3.11.7)] showed consistent (2 to 3-fold) induction 
which started at 24 hours and continued to 11 months treatment. In PPARa (-/-) mice 
fed with the 0.1% Wy-14,643 diet, no induction was observed after both short-term 
and long-term treatment. 
Very obvious up-regulation of AB25#6 [mouse cytochrome P450 4a 14 
(Cyp4al4) (Figure 3.11.26) (Table 3.11.7)] started at 24 hours and induced 
consistently until 11 months treatment was observed. The induction was not observed 
in PPARa (-/-) mice fed with the 0.1% Wy-14,643. 
cDNA fragment ACl#2 [mouse serine protease inhibitor, clade A, member la, 
(SPI) (Figure 3.11.27) (Table 3.11.8)] showed down-regulation in the PPARa (+/+) 
mice fed with the 0.1% Wy-14,643 diet. The down-regulation was started at Iweek 
and persisted to 11 months treatment. Maximum down-regulation was observed at 
11 months treatment (0.17-fold). Down-regulation was not observed in the PPARa (-
/-) mice fed with the 0.1% Wy-14,643 diet. 
Subcloned cDNA fragment AC2#2 [mouse peroxisomal bifunctional enzyme 
(PBFE) (Figure 3.11.28) (Table 3.11.8)] was consistently up-regulated at 24 hours, 1 
week, 2 weeks, 6 months and 11 months in the 0.1% Wy-14,643 fed PPARa (+/+) 
mice. In PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet, no induction was 
observed after both short-term and long-term treatment. 
cDNA fragment AD8#2 [mouse cytochrome P450 4al0 (Cyp4al0) (Figure 
3.11.29) (Table 3.11.8)] was induced in 0.1% Wy-14,643 fed PPARa (+/+) mice. The 
induction was observed since 24 hours. Maximum induction was observed at 1 week 
(33-fold) and up-regulation was continued to 11 months (13-fold). No induction was 
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Figure 3.11.27. Temporal expression of ACl#2 (serine protease inhibitor). Total 
liver RNA (30 |Lig) of two mice of PPARa (+/+) and PPARa (-/-) fed with a 0.0% 
control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 week, 2 weeks, 6 
months and 11 months treatment were separated on 1% agarose-formaldehyde gels 
and transferred to nylon membranes. The membranes were then hybridized with a 
DIG-labeled RNA probe and signals were detected by colorimetric method with 
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Figure 3.11.29. Temporal expression of ADM2 (cytochrome P450, family 4, 
subfamily a, polypeptide 10). Total liver RNA (30 jig) of two mice of PPARa (+/+) 
and PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet 
for 24 hours, 1 week, 2 weeks, 6 months and 11 months treatment were separated on 
1% agarose-formaldehyde gels and transferred to nylon membranes. The 
membranes were then hybridized with a DIG-labeled RNA probe and signals were 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cDNA fragment AFl#8 [mouse very-long-chain acyl-CoA synthetase (VLACS) 
(Figure 3.11.30) (Table 3.11.9)] was up-regulated consistently (about 2-fold which 
was started at 24 hours and continued to 11 months. The up-regulation was not shown 
in PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet. 
cDNA fragment AF25#7 [mouse major urinary protein II (MUP II) (Figure 
3.11.31) (Table 3.11.9)] was down-regulated in PPARa (+/+) mice fed with the 0.1% 
Wy-14,643 diet. This down-regulation was started at 2 weeks and maximum down-
regulation was found at 11 months treatment (0.01-fold). No down-regulation was 
observed in the PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet after short-term 
and long-term treatment. 
Down-regulation of AJ1#5 [mouse carboxyesterase (carboxyestersae) (Figure 
3.11.32) (Table 3.11.10)] started at 1 week and maximum down-regulation (0.05-fold) 
was found at 11 months 0.1% Wy-14,643 treatment. No down-regulation was 
observed in the PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet after short-term 
and long-term treatment. 
cDNA fragment AJ2#10 [mouse peroxisomal acyl-CoA oxidase (AOX) 
(Figure 3.11.33) (Table 3.11.10)] was up-regulated in 0.1% Wy-14,643 treated 
PPARa (+/+) mice when compared with the controls. Maximum induction was 
observed at 24 hours and 1 week 0.1% Wy-14,643 treatment of PPARa (+/+) mice. 
The induction was persisted to 11 months and not found in PPARa (-/-) mice fed with 
the 0.1% Wy-14,643 diet. 
Up-regulation of AL3#3 [mouse hydroxysteroid (17-beta) dehydrogenase 11 
(HSDlTpll) (Figure 3.11.34) (Table 3.11.10)] was found in 0.1% Wy-14,643 treated 
PPARa (+/+) mice. Induction of AL3#3 was started at 24 hours and continued to 11 
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Figure 3.11.30. Temporal expression of AF1#8 (very long chain acyl-CoA 
synthetase). Total liver RNA (30 |Lig) of two mice of PPARa (+/+) and PPARa (-/-) 
fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 
week, 2 weeks, 6 months and 11 months treatment were separated on 1% agarose-
formaldehyde gels and transferred to nylon membranes. The membranes were then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 
method with NBT and BCIP reagents. 
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Figure 3.11.31. Temporal expression of AF25#7 (mouse major urinary protein II). 
Total liver RNA (30 jiig) of two mice of PPARa (+/+) and PPARa (-/-) fed with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 week, 2 
weeks, 6 months and 11 months treatment were separated on 1% agarose-
formaldehyde gels and transferred to nylon membranes. The membranes were then 
hybridized with a DIG-labeled RNA probe and signals were detected by colorimetric 

























































































































































































































































































































































































































































































































































































































































































































































































P P A R a ( + / + ) 
24 hr 1 wk 2 wk 6 mo 11 mo 
CTL Wy CTL Wy CTL Wy CTL Wy CTL Wy 
H H H ^ H H I I H H H H I I H i l l ^ B l ^ l v i B s 
PPARa (_/-� 
24 hr 1 wk 2 wk 6 mo 11 mo 
CTL Wy CTL Wy CTL Wy CTL Wy CTL Wy 




奶 • W T / W y 
•g 4.0 - J L M KO / CTL 
§ H KO / Wy 
^ N ^ 養 I I I m I m l a . l L i . n i . 
24 hours 1 week 2 weeks 6 months 11 months 
Figure 3.11.32. Temporal expression of AJ1#5 (carboxylesterase). Total liver RNA 
(30 |ig) of two mice of PPARa (+/+) and PPARa (-/-) fed with a 0.0% control (CTL) 
or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 week, 2 weeks, 6 months and 11 
months treatment were separated on 1% agarose-formaldehyde gels and transferred 
to nylon membranes. The membranes were then hybridized with a DIG-labeled 
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Figure 3.11.34. Temporal expression of AL3#3 (hydroxysteroid (17-beta) 
dehydrogenase 11). Total liver RNA (30 jug) of two mice of PPARa (+/+) and 
PPARa (-/-) fed with a 0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 
24 hours, 1 week, 2 weeks, 6 months and 11 months treatment were separated on 1 % 
agarose-formaldehyde gels and transferred to nylon membranes. The membranes 
were then hybridized with a DIG-labeled RNA probe and signals were detected by 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































months. Maximum induction was found at 1 week 0.1% Wy-14,643 treatment. In 
PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet, no induction was found after 
short-term and long-term exposure. 
Fragment AOl#2 [mouse adipose differentiation related protein (ADRP) 
(Figure 3.11.35) (Table 3.11.11)] was up-regulated in 0.1% Wy-14,643 treated 
PPARa (+/+) mice. The up-regulation was started at 24 hours and consistently 
induced to 11 months. No induction was observed in the PPARa (-/-) mice fed with 
the 0.1% Wy-14,643 diet after short-term and long-term treatment. 
Up-regulation of A02#8 [mouse carnitine 0-octanoyltransferase (Crot) (Figure 
3.11.36) (Table 3.11.11)] was found in 0.1% Wy-14,643 treated PPARa (+/+) mice. 
The up-regulation of A02#8 was started at 24 hours and continued to 11 months 
treatment. In PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet, no induction was 
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Figure 3.11.36. Temporal expression of A02#8 (carnitine 0-octanoyltransferase). 
Total liver RNA (30 ^ig) of two mice of PPARa (+/+) and PPARa (-/-) fed with a 
0.0% control (CTL) or 0.1% (w/w) Wy-14,643 (Wy) diet for 24 hours, 1 week, 2 
weeks, 6 months and 11 months treatment were separated on 1% agarose-
formaldehyde gels and transferred to nylon membranes. The membranes were then 
hybridized with a PCR DIG-labeled cDNA probe and signals were detected by 





























































































































































































































































































































































































































































































































































































































































































































Chapter 4 Discussion 
4.1 Body weight changes 
There was significant decrease in body weights of the PPARa (+/+) mice after 
chronic exposure (6 and 11 months) of the Wy-14,643 diet. Decrease in body 
weights of rodents after Wy-14,643 treatment were reported in previous studies 
(Biegel et al., 1992; Peters et al., 1997; Biegel et al., 2001). These decrease in body 
weights were due to the hypolipidemic effect of the Wy-14,643 compound but not due 
to starvation of mice. Enough food was provided and food consumption of different 
treatment groups was more or less the same for both short-term and long-term 
treatment. In this project, we mentioned that the expression of genes that involved in 
lipid metabolism was enhanced after Wy-14,643 treatment. The up-regulation of 
genes that involved in lipid metabolism lead to the decrease of the body weight. 
Besides, the serum triglyceride level was decreased due to the hypolipidemic effect of 
Wy-14,643 compound. The combined effect of enhancement of lipid metabolism 
and triglyceride catabolism result in the loss of body weight in PPARa (+/+) mice. 
The decrease in body weights were not observed in PPARa (-/-) mice that fed with 
Wy-14,643 as the hypolipidemic effect is mediated by PPARa (Peters et al, 1997). 
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High mortality rate that found in the 0.1% Wy-14,643 treated PPARa (+/+) 
mice was mentioned in the previous study (Peters et al., 1997; Biegel et al, 2001) and 
might be due to the liver enlargement and probably liver cancer. Besides, no mice 
died in the other treatment groups during the 6 and 11 months treatment suggested that 
the high mortality rate was Wy-14,643-induced and mediated by PPARa. 
4.2 Organ weight changes 
Hepatomegaly was observed in PPARa (+/+) mice after short term (1 week) 
exposure with the 0.1% Wy-14,643 diet and the level of hepatomegaly was increased 
during the chronic administration of Wy-14,643. Liver enlargement of rodent 
induced after acute and chronic exposure of Wy-14,643 was reported in previous 
studies (Marsman et al., 1988; Crunkhom et al., 2004). As hepatomegaly was not 
observed in PPARa (-/-) mice fed with the 0.1% Wy-14,643 diet for both short-term 
and long-term treatment, it indicated that the enlargement of liver was mediated by 
PPARa (Lee et al., 1995; Peters et al., 1997). Liver enlargement in 
Wy-14,643-treated PPARa (+/+) is due to the increase in cell replication and size of 
the hepatocytes (Carthew et al., 1998; Gorton et al., 2000). 
Relative white fat and brown fat weights were decreased in the 0.1% 
Wy-14,643 treated PPARa (+/+) mice started at 2 weeks treatment. However, these 
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were not observed in the PPARa (-/-) mice for short-term and long-term Wy-14,643 
treatment. The decrease in the white fat and brown fat support the hypolipidemic 
effect of Wy-14,643 compound. Genes that involved in the lipid metabolism were 
up-regulated after Wy-14,643 treatment. With the enhancement of lipid catabolism, 
fat that stored in white fat and brown fat will be burnt that lead to the decrease in sizes 
of white fat and brown fat. 
Relative spleen weight was also decreased after 11 months treatment in PPARa 
(+/+) mice fed with the 0.1% Wy-14,643 diet. Significant atrophy of spleen after 
treatment with potent peroxisome proliferators such as perfluorooctanoic acid (PFOA), 
di(2-ethylhexyl)phthalate (DEHP), Wy-14643 and nafenopin was reported in the 
previous study (Yang et al., 2000). Decrease in the number of splenocytes (about 
50%) was greater than the decrease in spleen weight after treatment with PFOA. 
This suggested that the loss of splenocytes rather than the organ matrix. The 
decrease in no. of splenocytes might be due to enhancement of apoptotsis and/or 
decrease in cell proliferation. The decrease in size of spleen might be also due to the 
decrease in size of the splenocytes. 
The relative organ weights of brain, heart and lung were higher in 0.1% 
Wy-14,643 fed PPARa (+/+) mice compared to controls. The body weights were 
decrease with the hypolipidemic effect of Wy-14,643, however, the sizes and absolute 
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weights of brain, heart and lung were not change. Hence, the relative organ weights 
of brain, heart and lung were higher when compared with the controls (David et al., 
2000). 
4.3 Serum cholesterol and triglyceride levels 
The level of serum cholesterol is significantly increased at 11 months 0.1% 
Wy-14,643-treated PPARa (+/+). However, this result was not matched to previous 
reported that serum cholesterol level was lowered with the administration of 
Wy-14,643 (Issemann and Green, 1990). Increase in serum cholesterol level induced 
by perfluorooctanoic acid (PFOA) was mentioned in a previous study (Xie et al., 
2003). The serum cholesterol level was first decreased by PFOA but increase after 
seventh day of treatment. Xie et al suggested that the increase in serum cholesterol 
level might be due to other changes caused by peroxisome proliferators. 
Serum triglyceride level of PPARa (+/+) mice treated with 0.1% Wy-14,643 
was decreased in all the different time points (24 hours, 1 week, 2 weeks, 6 months 
and 11 months). The decrease in serum triglyceride level is due to the hypolipidemic 
effect of Wy-14,643 (Issemann and Green, 1990). The hypolipidemic drugs enhance 
the triglyceride catabolism by suppressing the ApoCIII and induced the activities of 
lipoprotein lipase which lead to the induction of lipoprotein lysis (Staels et al., 1997). 
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4.4 Liver histology 
Abnormal hepatocytes arrangement and enlarged sinusoidal spaces were 
observed only in the 0.1% Wy-14,643-treated PPARa (+/+) mice and started at 1 week 
treatment. Trabecular cell clusters, hepatocytes without nucleus or dark nucleus and 
invasion of blood was found in 0.1% Wy-14,643-treated PPARa (+/+) mice after 11 
months treatment and all of these are the characteristics of tumor cells. These 
features and severe liver damages were not observed in other treatment groups. 
Hepatocarcinoma caused by chronic exposure of Clofibrate and Wy-15,643 to mice 
were reported in previous studies (Reddy and Qureshi, 1979; Peters et al., 1997). 
Lipid accumulation was observed in both the control and treatment groups of 
PPARa (-/-) mice and Wy-14,643 treated PPARa (+/+) mice. The hepatic lipid 
accumulation in the PPARa (-/-) mice may be due to inhibition mitochondrial fatty 
acid import (Gervois et al” 2000). The lipid accumulation of Wy-14,643 treated 
PPARa (+/+) mice at 2 weeks, 6 months and 11 months may be due to the enhanced 
catabolism of lipid that induced by Wy-14,643. In my study, several 
PPARa-dependent and Wy-14,643-responsive genes that involved in lipid metabolism 
were confirmed. The obvious and early inductions of these genes support the 
PP-induced catabolism of lipid. The accumulation of find lipid droplets in the 
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report (Lalwani et al, 1981; Gorgas and Krisans, 1989). 
4.5 Functions and roles of identified PPARa-dependent 
and Wy-14，643-responsive genes 
Total 17 different genes (12 up-regulated and 5 down-regulated) were 
identified to be PPARa-dependent (Table 4.5.1). Most of the genes identified are 
related to lipid metabolism, whereas the others are involved in peroxisome biogenesis, 
plasma triglyceride metabolism, xenobiotics metabolism, adipocyte differentiation or 
sterol carrier protein, and some are cancer marker genes. 
Mouse peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase (Feci) is 
involved in the p-oxidation of unsaturated fatty acids. Delta3, 
delta2-enoyl-Coenzyme A is found in both peroxisome and mitochondria. The 
breakdown of unsaturated fatty acid requires the enzymes that catalyze the 
isomerzation and reduction of double bonds (Kunau et al., 1995). The peroxisomal 
deltas, delta2-enoyl-Coenzyme A is involved in the 3-c is^ 2-trans and 3-trans 
2-trans activity (Zhang et al., 2002). In this study, it showed that maximum 
induction of Feci was observed at 24 hours treatment. Induction of Feci was started 
at 24 hours and continued to 11 months in PPARa (+/+) mice fed with the 0.1% 
Wy-14,643 diet. However, this time-dependent induction was not observed in the 
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Table 4.5.1. List of PPARa regulated genes in liver (with the genes identified in this 
project) 
Function of gene Genes 
Adipose differentiation Adipose differentiation related 
protein 
Amino acid metabolism Alanine aminotransferase Cysteine sulfmic acid 
decarboxylase function 
Alanine glyoxylate transaminase Cytosolic aspartate 
aminotransferase 
Arginase Glutaminase 
Arginino-succinate lyase Hydroxypyruvate/ gloxylate 
reductase 
Arginino-succinate synthase Mitochondrial aspartate 
aminotransferase 
Carbamoyl-phosphate synthase-I Ornithine transcarbamoylase 
Acute phase response Alpha-1 acid glycoprotein/serine Fibrinogen 
protease inhibitor 
Bile acid metabolism Cytochrome P450 7A1 
Bile salt transport Na+ taurocholate cotransporting 
polypeptide 
Biotransformation Aldehyde dehydrogenase type 3 Glutathione-S-transferase alpha 
Carboxyesterase Cytochrome P450 3A11 
Cytochrome P450 2A5 UDP-glycuronosyltransferase 1A9 
Cytochrome P450 2C29 UDP-glucuronosyltransferase 2b5 
Cytosolic epoxide hydrolase 
Cell cycle c-myc Cyclin D1 
Cell cycle regulation GO/Gl switch gene 2 
Cellular proliferation glucose-regulated protein-94 
Cholesterol metabolism Cytochrome P450 12A1 Liver X receptor a 
Cytochrome P450 27A1 
Cholesterol transport ABCA-a (via LXRa) ABCG-8 (via LXRa) 
ABCG-5 (via LXRa) 
Desaturation of fatty acid Delta-6-Desaturase Stearoyl-CoA desaturase 
Delta-5-desaturase 
Fatty acid activation Long-chain acyl-CoA synthetase 
Fatty acid Cytosolic fatty acid binding 
binding/transport protein 
Fatty acid transport Fatty acid transport protein-1 Fatty acid translocase 
Fatty acid p-oxidation Acyl-CoA oxidase Medium-chain acyl-CoA 
dehydrogenase 
ATP-binding cassette Long-chain acyl-CoA 
half-transporter type 2 dehydrogenase 
ATP-binding cassette Short-chain-specific 
half-transporter type 3 3-ketoacyl-CoA thiolase 
Bifunctional enzyme Short-chain acyl-CoA 
Carnitine palmitoyl-transferase I Sterol carrier protein-X 
Carnitine palmitoyl-transferase II Thiolase B 
Carnitine O-octanoyltransferase Very long chain acyl-CoA 
dehydrogenase 
Dodecenoyl-CoA delta-isomerase Very-long-chain acyl-CoA 
synthetase 
delta3, delta2-enoyl-Coenzyme A 
isomerase 
Fatty acid Cytochrome P450 4A1 Cytochrome P450 4A10 
co-hydroxylation Cytochrome P450 4A3 Cytochrome P450 4A14 
Cytochrome P450 4A6-Z 
Fatty acid synthesis Malic enzyme 
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Table 4.5.1. List of PPARa regulated genes in liver (with the genes identified in 
this project) (con't) 
Function of gene Genes 
Fatty acyl-CoA ester Acyl-CoA binding protein 
transport 
Gluconeogenesis Lactate dehydrogenase A4 . 
Glucose oxidation Pyruvate dehydrogenase kinase 
isoform 4 
Heme biosynthesis Coproporphyrinogen oxidase 
Hepatic sterol Famesoid X receptor/Bile acid 
receptor 
Hepatobiluary lipid Multidrug resistance 2 
transport 
Hydrolysis of Acyl-CoA Cytosolic acyl-CoA thioesterase-I Peroxisomal acyl-CoA 
thioesterase lA 
Cytosolic acyl-CoA thioesterase-II Peroxisomal acyl-CoA 
thioesterase IB 
Mitochondrial acyl-CoA Peroxisomal acyl-CoA 
thioesterase-I thioesterase 2 
Iron-binding protein Lactoferrin 
Inflammation/ apoptosis IKBOC 
Iron transport Transferrin 
Ketogenesis Mitochondrial HMG-CoA Mitochondrial HMG CoA 
synthase synthase 
Oxygen-free radical Superoxide dimutase 
metabolism 
Peroxisome biogenesis Peroxisome biogenesis factor 16 
Plasma HDL metabolism Apolipoprotein-Al Apolipoprotein-AV 
Apolipoprotein-A I (via rev-erba) Apolipoprotein-CIII 
Apolipoprotein-All Phospholipid transfer protein 
Apolipoprotein-A IV Scavenger receptor B-type I 
Pheromone carrier Alpha-2 urinary globulin/MUP-I 
Repressor of gene Rev-erba 
transcription 
ROS production Uncoupling protein-2 
Triglyceride clearance Lipoprotein lipase 
Steroid metabolism 1 l-beta-Hydroxysteroid 17-beta-hydroxysteroid 
dehydrogenase I dehydrogenase XI 
17-beta-hydroxysteroid 
dehydrogenase IV 
Steroid hydroxylase Cytochrome P450 2C11 Cytochrome P450 2C12 
Vascular inflammation Interleukin-6 Interleukin-6 receptor 
Interleukin-1 recpetor-type 1 
Genes that highlighted were confirmed in this study. 
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controls. This suggested that the induction of Feci was mediated by PPARa and 
Wy-14,643-responsive. Up-regulation of Feci was reported in 2 weeks Wy-14,643 
treatment (Cherkaoui-Malki et al., 2001). Up-regulation of the genes involved in 
peroxisomal (3-oxdiation was the effect of peroxisome proliferators. The induction of 
Feci increase peroxisomal P-oxidation which will increase the production of H2O2. 
Imbalance between production and catabolism of H2O2 will lead to oxidative stress, 
which is one of the proposed mechanisms of PP-induced hepatocarcinogenesis. 
Mouse apolipoprotein A-V (ApoA5) is suggested to be involved in regulations 
of plasma triglyceride levels. Human ApoA5 is induced with the administration of 
Wy-14,643 and this induction is associated with suppression of plasma triglyceride 
(Vu-Dac et al., 2003). However, mouse ApoA5 that identified in this project is 
down-regulated with the chronic exposure of Wy-14,643. This species difference in 
gene regulation between human and rodents in response to peroxisome proliferators 
treatment is also observed for ApoAl and ApoA2 (Desvergne and Wahli, 1999). 
ApoAl and ApoA2, which are major HDL apolipoproteins and PPARa mediated, are 
down-regulated in rodents but up-regulated in humans. The reason for difference in 
species gene regulation of ApoAl, ApoA2 and ApoA5 is still not known. PPRE is 
identified in the human ApoA5 genes and human ApoA5 is believed as a positive and 
a direct target gene of PPARa activators (Desvergne and Wahli, 1999; Vu-Dac et al., 
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2003). Identification of PPRE in ApoA5 will help to explain its role in plasma 
triglyceride regulation in rodent and also the difference in species gene regulation 
between human and rodent. 
Mouse medium-chain acyl-CoA dehydrogenase (MCAD; C4-C12) catalyses the 
formation of 2-enoyl-CoA from the fatty acyl-CoA (Eaton et al., 1996). 
PPARa regulates the mitochondrial P-oxidation by modulating the expression of 
medium-chain acyl-CoA dehydrogenase (MCAD) gene (Gulick et al., 1994). The 
substrates for MCAD included medium-chain length acyl-CoA thioesters derived from 
medium-chain fatty acids that enter mitochondria by diffusion, products of 
mitochondrial P-oxidation of saturated and unsaturated long-chain fatty acids and 
products of peroxisomal p-oxidation of long-chain and very long-chain fatty acids. 
The mRNA expression of MCAD is predominantly in the tissue that use fatty acids as 
energy substrates, such as liver and heart (Kelly et al, 1989). Induction of MCAD 
was observed started at 24 hours and persisted to 11 months in Wy-14,643-treated 
PPARa (+/+) mice. The induction of MCAD was PPARa-mediated as such 
induction was not observed in Wy-14,643-treated PPARa (-/-) mice. The induction 
of MCAD leads to the increase in mitochondrial P-oxidation. 
Mouse Cyp4al0 and Cyp4al4 belong to the Cyp4a family (Cyp4a). Both 
Cyp4al0 and Cyp4al4 were up-regulated in PPARa (+/+) mice after 24 hours 0.1% 
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Wy-14,643 treatment and the inductions were persisted to 11 months. Such 
inductions were not found in PPARa (-/-) mice suggested that the mRNA expressions 
of Cyp4al0 and Cyp4al4 were PPARa-dependent (Lee et al, 1995). The 
cytochrome monoxygenase system plays a central role in the oxidation of a wide 
variety of endogenase as well as exogenous compounds. The Cyp4a enzymes 
participate in this system as a distinct group of the cytochrome P450 superfamily. 
They catalyze the co-hydroxylation of fatty acids and eicosanoids and are induced by 
fibrates and other peroxisome proliferators in liver and kidney. The first step of 
co-hydroxylation generates co-hydroxy fatty acid which is then dehydrogenated to a 
dicarboxylic acid in the cytosol (Johnson et al., 1996; Reddy and Hashimoto, 2001). 
The dicarboxylic acid is then converted to its CoA derivative which can further 
metabolized via peroxisomal (3-oxidation. The increase in substrates for peroxisomal 
p-oxidation will lead to oxidative stress, co-hydroxylation of fatty acids can also 
generate superoxide and/or H2O2 as the rate of NADPH consumption increases. 
PPARa can provide a negative feedback on the intracellular levels of an endogenous 
ligand and PPARa may have an important role in the detoxification of some 
xenobiotics (Desvergne and Wahli, 1999). 
Mouse peroxisomal bifunctional enzyme (PBFE) is also named enoyl-CoA 
hydratase/L-3-hydroxyacy 1-CoA dehydrogenase. It is induced by Wy-14,643 in 
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PPARa (+/+) mice. Consistent induction of PBFE was observed at 24 hours and 
until 11 months treatment. No induction of PBFE in PPARa (-/-) mice for both 
short-term and long-term Wy-14,643 treatment (Lee et al, 1995). PBFE is involved 
in the L-hydroxy-specific peroxisome proliferator-inducible P-oxidation system while 
the D - P B E is involved in the O-hydroxy-specific P-oxidation system (Qi et al, 1999). 
PBFE acts on long- and very long-straight chain acyl-CoAs, long-chain 
dicarboxylyl-CoAs and the CoA esters of prostaglandins whereas the non-inducible 
D-3-hydroxy-specific peroxisomal P-oxidation system is for branch chain acyl-CoA 
(Figure 4.5.1.1). The induction of PBFE expression and functional PPRE in PBFE 
are reported in previous studies (Zhang et al., 1992; Bardot et al., 1993). 
Mouse very-long-chain acyl-CoA synthetase (VLCAS) is involved very 
long-chain fatty acid metabolism. Induction of VLCAS was observed in PPARa 
(+/+) mice fed with 0.1% Wy-14,643 and started at 24 hours. The induction was 
persisted to 11 months treatment and maximum induction was observed at 1 week 
treatment. VLCAS was up-regulated by Wy-14,643 and PPARa-dependent (Fischer 
et al., 2003). Very long-chain fatty acid (VLCFA; >C22:0) can be P-oxidized 
predominantly in peroxisome. VLCFA is first activated to VLCFA-CoA in the 
P-oxidation. This reaction is catalyzed by very long-chain acyl-CoA synthetase 
















Very-long-chain fatty Propionyl-CoA 
acyl-CoA n-2 
Figure 4.5.1.1. Peroxisome P-oxidation systems, inducible and non-inducible. 
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(Kalish et al, 1995). However, rat liver mitochondria can p-oxidize hexacosanoyl 
Co A but not hexacosanoic acid (C26:0), whereas peroxisome can P-oxidize both 
substrates. It suggests that mitochondria can also P-oxidize VLFAs, provided that it 
is first converted to their CoAs by VLCAS (Singh et al., 1987). 
Mouse peroxisomal acyl-CoA oxidase (AOX) is the rate-limiting step of the 
pathway that show 10- to 30- fold induction with the administration of the peroxisome 
proliferators. The induction of peroxisomal fatty acid oxidation is important in 
protecting the liver against FFA toxicity as steatohepatitis is found in acyl-CoA 
oxidase knock-out mice (Everett et al., 2000). Early and obvious up-regulation of 
AOX was found in PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet. Maximum 
induction was observed at 1 week and continued to 11 months treatment. Induction 
of AOX causes the increase production of H2O2 and oxidative stress when there is no 
sufficient catalase, which is involved in the detoxification of H2O2 (Reddy and Rao, 
1989). 
Up-regulation of mouse carnitine 0-octanoyltransferase (Crot) was found in 
PPARa (+/+) mice for both short-term and long-term treatment with 0.1% Wy-14,643. 
Crot is one of the carnitine acyltransferases in rat liver (CAT, carnitine acetyltransferae; 
Crot, carnitine O-octanoyltransferase; CPT, carnitine palmitoyltransferase), which is 
markedly increased by administration of peroxisome proliferators such as DEHP 
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(Ozasa et al., 1983). Crot is suggested to be a peroxisomal enzyme whereas CAT 
and CPT are mitochondrial enzymes. Recent studies suggested that Crot plays a role 
in the transport of peroxisomal P-oxidation products to mitochondria. CAT, Crot and 
CPT showed different substrate specificities as CAT reacts with short-chain acyl 
derivatives, and CPT reacts with medium-chain and long-chain acyl derivatives. 
Crot is believed to be most active with hexanoyl derivatives although it also catalyze 
the reaction with medium-chain length substrates and to be most active toward 
octanoyl derivatives (Miyazama et al., 1983). Crot can also reactive with the 
substrates with C2-C20. Crot is suggested to play a role in pumping out the 
peroxisomal P-oxidation products (short- and medium-chain acyl-CoA's) to the 
cytosolic compartment by their conversion to carnitine derivatives. 
Mouse cysteine sulfinic acid decarboxylase (CSAD) is suggested to be markers 
genes of heptocarcinogensis. CSAD synthesizes a precursor of taurine, which 
becomes a major component of bile, and a neurotransmitter in brain. CSAD is 
suggested to be important in both maintenance and growth of hepatocytes as it is 
found in normal liver and its expression was induced during liver regeneration 
(Kishimoto et al., 1996). CSAD expression is induced during hepatocarcinogenesis 
in the precancerous liver and maintained its high expression afterward. However, the 
relationship between over-expression of CSAD and hepatocarcinogenesis is still not 
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known. Over-expression of CSAD may cause hepatocarcinogenesis as the action of 
CSAD may result in some actual carcinogenic substrates in vivo in addition to taurine. 
In contrast, the over-expression of CSAD may be due to hepatocarcinogenesis. 
Intrinsic oncogene may transcriptionally activated CSAD. Over-expression of 
CSAD may be also due to the increase in demand for the removal of carcinogenic 
substances from the liver that require more bile (Kishimoto et al., 1996). In this 
study, CSAD was weakly induced in PPARa (+/+) fed with the 0.1% Wy-14,643 diet 
after 24 hours and persisted to 11 months treatment. PPARa (-/-) mice treated with 
the 0.1% Wy-14,643 diet did not show any induction when compared the controls. 
This suggested the regulation CSAD was mediated by PPARa. The over-expression 
of CSAD may be due to the demand for the removal of Wy-14,643 compound. 
Mouse major urinary protein II (MUP II) that also called al- urinary globulin 
(a2U) in rat is induced by the male-specific pulsatile release of growth hormone but 
repressed by inflammation. Obvious down-regulation of MUP II was observed 
started at 1 week Wy-14,643 treatment in PPARa (+/+). The down-regulation of 
MUP with chronic exposure to Wy-14,643 has been mentioned and MUP might serve 
as an early tumor marker during hepatocarcinogenesis of mouse (Anderson et al., 
1999). 
Mouse UDP-glucuronosyltransferase 2 family member 5 (UGT2b5) belongs to 
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the superfamily UDP-glucuronosyltransferases (UGTs). Down-regulation of UGT2b5 
was observed in PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet after 2 weeks 
treatment and this down-regulation was not observed in the controls. UGTs are 
located in the endoplasmic reticulum and perform a key process in endobiotic and 
xenbiotic metabolism. UGTs enhance the eliminations of their substrates via bile, 
faeces and urine through catalyse the conversion of lipophilic molecules into more polar, 
and thus hydrophilic, glucuronides. UGTs substrates include phenolics, steroid 
hormones, carcinogens such as benzo(a)pyrene metabolites and drugs. Thus, UGTs is 
important in the detoxification of endogenous, dietary and clinically administered 
agents as well as environmentally present chemical, which have been reported to be 
carcinogenic (Strassburg et al., 1999). Down-regulation of UGT in pre-malignant 
adenomatous hyperomatous hyperplasia of the liver and malignant hepatocellular 
carcinoma is reported. It is suggested that UGT may be involved in genoprotection, 
however, further studies should be carried out before used it as an early marker in cancer 
development (Tukey and Strassburg, 2000). 
Peroxisome biogenesis factor 16 (Pexl6) is involved in the membrane-assembly 
step of peroxisome biogenesis (Honsho et al., 2002). Pexl6 was up-regulated at 24 
hours Wy-14,643 treatment in PPARa (+/+) mice. The up-regulation was persisted 
to 11 months treatment and was not found in the PPARa (-/-) mice fed with the 0.1% 
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Wy-14,643 diet after short-term or long-term treatment. The up-regulation of Pex 16 
may play a role in peroxisome proliferation. Pex 16 is required for the import of 
certain matrix proteins. Over-expression of Pex 16 caused accumulation of enlarged 
peroxisomes (Subramani, 1998). Peroxisome proliferation, which means increase in 
both numbers and size of peroxisomes, is observed with the administration of 
peroxisome proliferators after short-term treatment, so the induction of Pex 16 is 
responsible for the PP-induced peroxisome proliferation. 
Mouse serine protease inhibitor, clade A, member la (SPI) is also named a - 1 
antitrypsin (ATT). SPI is an acute phase protein which is synthesized primarily in the 
liver. SPI is an important factor in controlling tissue damage by protease in 
inflammatory diseases for example atherosclerosis. The maintenance of balance 
between protease and antiprotease is important in preventing tissue damage induced 
by proteinases in the microenvironment of injury and inflammation where 
inflammatory cells tend to accumulate (Dichtl et al., 2000). Down-regulation of SPI 
was found in PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet after 1 week 
treatment. The down-regulation was not found in PPARa (-/-) mice fed with 0.1% 
Wy-14,643 suggested the regulation of SPI was mediated by PPARa. 
Down-regulation of SPI after chronic (13 weeks) exposure with Wy-14,643 is reported 
in previous study. The suppression of the gene may be due to the anti-inflammatory 
267 
effect in mice that elicit by Wy-14,643 which possibly through increased leukotrine B4 
catabolism or inhibition of IL-1-induced production of IL-6, prostaglandin and 
cycloocygenase-2 (Anderson et al., 1999) 
Mouse hydroxysteroid (17-beta) dehydrogenase 11 (HsdlTpl l ) is a member of 
the 17(3-hydroxysteroid dehydrogenase. The function of human Hsdl7bl l is 
involved in estrogen and androgen inactivation (Mindnich et al., 2004). The 
substrates for Hsdl7p including glucocorticoids, sex steroids, bile acids, fatty acids 
and branched chain amino acids (Shafqat et al., 2003; Mindnich et al., 2004). The 
H s d n p i l may be important for the metabolization of toxic compounds (Chai et al., 
2003; Motojima, 2004). Up-regulation of Hsdl7(311 was started at 1 week treatment 
and only found in PPARa (+/+) mice fed with the 0.1% Wy-14,643 diet. Another 
member of the 17P-hydroxysteroid dehydrogenase, Hsdl7p4 that has the same 
functions as HsdlVbll in human and rodents is induced by peroxiome proliferators 
(Gorton et al, 1996). 
Mouse carboxyesterase plays a role in the metabolism of xenobiotics and 
endogenous lipids. Carboxyesterases are distributed in different tissues and present 
in several subcellular organelles, whereas the highest abundant of carboxyesterase is 
observed in liver microsomes, where they are loosely bound to the lumenal surface of 
the endoplasmic reticulum. They hydrolyze lipid substrates and thus may have 
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different lipid-metabolizing functions. Carboxyesterase was down-regulated after 1 
week 0.1% Wy-14,643 treatment in PPARa (+/+) mice. Carboxyesterase is 
down-regulated with chronic exposure of Wy-14,643 and this suppression is observed 
between 1 and 5 weeks of exposure. The delayed response of carboxyesterase to 
Wy-14,643 treatment suggested that carboxyesterase regulation is not a direct effect of 
PP-regulated activity of PPARa. The down-regulation of carboxyesterase may be 
the secondary event after long-term exposure to high dcses of peroxisome proliferators 
(Poole et al, 2001). 
Mouse adipose differentiation related protein (ADRP) was up-regulated by 
0.1% Wy-14,643 through PPARa. The up-regulation of ADRP was observed started 
at 24 hours and maximum up-regulation was found at 2 weeks Wy-14,643 treatment. 
Expression of ADRP is induced by PPARa ligands (Liu et al.’ 2003). ADRP is a 
lipid droplets-associated protein that stimulates lipid accumulation and lipid droplets 
formation in murine fibroblasts and is expressed early during adipose dfferentiation 
(Imamura et al., 2002). ADRP expression is induced by long-chain fatty acids but 
such induction is stimulated by short-chain fatty acids. ADRP, which bound t) the 
surface of lipid droplets, may serve as concentrate unesterified fatty acids. They ae 
then converted to fatty acyl-CoA thioesters for subsequent cellular utilization (Serrero 
et al, 2000). 
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However, not all PPARa-dependent and Wy-14,643 responsive fragments 
could be confirmed by Northern blot analysis. No differential display patterns (e.g. 
mitochondria) and detectable signals (e.g. EST) were observed. The up-regulation of 
the genes might be not so obvious that could be observed and confirmed by Northern 
blot analysis. 
4.6 Mechanism of PP-induced hepatocarcinogenesis 
Oxidative stress, inhibition of apoptosis and increase cellular proliferation are 
the mechanism suggested so far for the PP-induced hepatocarcinogenesis. However, 
the mechanism(s) of PP-induced hepatocarcinogenesis is/are still not confirmed. 
Identification of PPARa-dependent and Wy-14,643-responsive genes can help us to 
explain the mechanism of PP-induced hepatocarcinogenesis. The genes that 
confirmed in this project are mainly involved in the fatty acid P-oxidation which is 
suggested to increase the oxidative stress (Figure 4.6.1). Increase in oxidative stress 
will lead to DNA damage that is one the proposed PP-induced hepatocarcinogenesis. 
The PPARa dependent and Wy-14,643 responsive genes that confirmed in this 
project and related to oxidative stress was summarized in Figure 4.6.1. Peroxisomal 
deltas, delta2-enoyl-Coenzyme A isomerase, peroxisomal bifmctional enzyme, 












































































































that involved in peroxisomal p-oxidation. The over-expression of these genes 
especially acyl CoA oxidase leads to the induction of peroxisomal P-oxidation that in 
turns, increase the production of H2O2. However, as catalase that act on the H2O2 is 
only induced to 2- to 3-fold (Nemali et al., 1989), excess H2O2 cannot be removed and 
cause oxidative stress. Besides, the increase in co-hydroxylation increases the 
generation dicarboxylaic acids. Dicarboxylaic acids are one of the substrates for 
peroxisomal p-oxidation. The H2O2 generates by co-hydroxylation and in turns of 
increasing substrates for peroxisomal p-oxidation also contribute to the increase in 
oxidative stress. 
The alterations of gene expressions of all of the genes were observed after 
short-term Wy-14,643 treatment. Up-regulation of mouse peroxisomal delta 3, 
delta 2-enoyl-Coenzyme A isomerase, mouse acetyl-Coenzyme A dehydrogenase, 
medium chain, peroxisome biogenesis factor 16, mouse Cyp4al4，mouse peroxisomal 
bifunctional enzyme, mouse Cyp4al0, very-long-chain acyl-CoA synthetase, mouse 
peroxisomal acyl-CoA oxidase, mouse hydroxysteroid (17-beta) dehydrogenase 11, 
mouse adipose differentiation related protein and mouse carnitine 
0-octanoyltransferase were started at 24 hours and persisted to 11 months treatment 
while up-regulation of mouse cysteine sulfinic acid decarboxylase was started at 1 
week and persisted to 11 months. Down-regulation of mouse serine protease 
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inhibitor 1-1, mouse major urinary protein II and mouse carboxyesterase was started at 
1 week and continued to 11 months. Mouse UDP-glucuronosyltransferase 2 family 
member 5 was down-regulated at 2 weeks and persisted to 11 months. As the 
alteration of the genes observed after short-term treatment and persisted to cancer 
stage, these enable these genes to be cancer marker genes. Chemicals which induce 
these genes after short-term exposure to rodents may cause hepatocarcinogenesis after 
long-term exposure. 
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Charpter 5 Conclusion 
Hepatomegaly, loss of body weight and hepatocarcinoma with trabecular 
patterns were observed in the 0.1% Wy-14,643 treated PPARa (+/+) mice after 
chronic exposure. Besides, relative organ weight of white fat, brown fat and spleen 
was lower in the 0.1% Wy-14,643 treated PPARa (+/+) mice compared with the 
controls. 
Alterations of gene expression were also observed after 11 months treatment of 
Wy-14,643. Total 17 PPARa dependent and Wy-14,643 responsive genes were 
identified in this project. Peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase, 
mouse cysteine sulfinic acid decarboxylase, mouse acetyl-Coenzyme A dehydrogenase, 
medium chain, peroxisome biogenesis factor 16, mouse Cyp4al4, mouse peroxisomal 
bifunctional enzyme, mouse Cyp4al0, very-long-chain acyl-CoA synthetase, mouse 
peroxisomal acyl-CoA oxidase, mouse hydroxysteroid (17-beta) dehydrogenase 11, 
mouse adipose differentiation related protein and mouse carnitine 
0-octanoyltransferase were confirmed to be up-regulated by 0.1% Wy-14,643 and 
PPARa dependent. Mouse apolipoprotein A-V, mouse UDP-glucuronosyltransferase 
2 family member 5, mouse serine protease inhibitor 1-1，mouse major urinary protein 
II and mouse carboxyesterase were confirmed to be down-regulated by 0.1% 
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Wy-14,643 and PPARa dependent. Temporal expression of all the identified genes 
except apolipoprotein A-V were also performed. 
Based on the genes identified, oxidative stress is suggested to be the 
mechanism of PP-induced hepatocarcinogenesis. However, whether the PP-induced 
hepatocarcinogenesis is induced by other mechanisms are not still clear. It is 
suggested that PP-induced hepatocarcinogenesis is due to the oxidative stress and also 
the effect of inhibition of apoptosis and increase in cell replication. Further studies 
are necessary to find out the relationship of different mechanisms and the chronic 
effect of peroxisome proliferators on humans. 
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Appendix A. Tables of preparation of reaction mix 
Table A l . Preparation of animal tail genotyping PCR reaction 
Reagent Stock conc. Vol. per reaction (jil) Final conc. 
Nuclease-free water - 19.125 -
Fox PCR buffer IPX — 2.5 IX 
dNTP mix 一10 mM — 0.125 0.05 mM 一 
Forward primer (F1) 10 |aM 0.875 0.35 ^M 
Reverse primer (R3) 10 ^iM 0.875 0.35 piM 
Taq polymerase 5 U/|LI1 ^ 0.1 U/|LI1 
10-fold diluted DNA - 1.0 -
Total I - I 25 -
Table A2. Preparation of DNase I treatment 
Reagent Stock conc. Vol. per reaction (|LI1) Final conc. 
MgCl2 25 mM “ ^ lOmM 
Tris-HCl (pH 7.5) 1 M 5 50 mM 
RNase-free Dnase I 7.5 U/)al ^ 0.3 U/iul 
Total liver RNA ： 50 i^g 
Total I - I 100 -
Table A3. Preparation of reverse transcription of non-fluoroDD and fluoroDD 
Reagent Stock conc. Vol. per reaction (jul) Final conc. 
Nuclease-free water - ： 
Anchored primer (AP) 2 |LIM ^ 0.2 |LIM 
DTT 100 mM ^ lOmM 
dNTP mix 250 i^M ^ 25 i^M 
Superscript™ IIRT buffer 5X 4.0 IX 
Superscript™ II RNase H' ^00 U/^il 0.2 2 U/^il 
reverse transcriptase 
DNase I treated RNA 0.1 |Lig/|al ^ 10 ng/jul 
Total -- 20 _ — 
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Table A4. Preparation of non-fluoroDD and fluoroDD RT-PCR 
Reagent Stock conc. Vol. per reaction (|LI1) Final conc. 
Nuclease-free water - 0.45 -
Anchored primer (AP) 5 |LIM ^ 0.35 |LIM 
Arbitrary primer (ARP) 2 \iM 0.35 
dNTP mix 250 |LIM ^ 50 |LIM 
IPX PCR buffer IPX 1.0 ]X 
Tag polymerase 5 U/|al OA 0.05 U/^il 
RT mixture - ^ -
T o t a l I - I 10 -
Table A5. Preparation of reamplification of differentially expressed cDNA 
fragments 
Reagent Stock conc. Vol. per reaction (^il) Final conc. 
Nuclease-free water - 8 2 -
m PCR buffer IPX 2.0 — IX 
dNTP mix 250 |LIM 20 |LIM 
M l 3 reverse primer 2 juM ^ 0.2 f^M 
T7 promoter primer 2 |LIM ^ 0.2 ^iM 
Tag polymerase 5 U/|il 0 2 0.05 U/[i\ 
Gel band elute - ^ ： 
Total I - I 20 - — 
Table A6. Preparation of PCR reaction for DNA sequencing 
Final 
Reagent Stock conc. Vol. per reaction (|ul) conc. 
IPX Sequencing reaction buffer IPX 2 IX 
dNTP mix - “ 1 -
DdUTP Dye terminator - 2 -
DdGTP Dye terminator ： 2 -
DdCTP Dye terminator ： 2 -
DdATP Dye terminator - 2 -
M13 forward (-20) primer/ M13 丄 2 0.16 一 
reverse pnmer 
Polymerase enzyme - 1 -
DNA template 100 fmol 6 30 fmol 
Total I - I 20 I -
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Table A7. Preparation of PCR reaction for RNA probe 
Reagent Stock conc. Vol. per reaction (jiil) Final conc. 
Nuclease-free water - ^ -
Tbx PCR buffer IPX 2.0 一 IX — 
dNTP mix 250 6A 80 luM 
Anchored primer (AP) 2 ^M ^ 0.2 |LIM 
Arbitrary primer (ARP) 2 |LIM ^ 0.2 JUM 
Tag polymerase 5 U/|LI1 ^ 0.05 U/|LI1 
Plasmid DNA 1 ng/|Lil W 2 ng/\x\ 
Total 二 I 20 -
Table A8. Preparation of PCR reaction for cDNA probe 
Reagent Stock conc. Vol. per reaction (|il) Final conc. 
Nuclease-free water - 24.6 -
TOX PCR buffer IPX 5.0 一 IX 
PCR-DIG labeling mix 2 mM 200 luM 
MgCl2 25 mM “ 3.0 1.5 mM 
Anchored primer (AP) 10 ^M ^ 1 i^M 
Arbitrary primer (ARP) 10 |aM ^ 1 |uM 
Tag polymerase 5 U/}il ^ 0.04 U/|Lil 
Plasmid DNA 20 ng/|Ltl 0.8 ng/]ul 
Total - I 50 -
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 GAATGTTACG ACTCACTATA GGGCGAATTG GGCCCTCTAG ATGCATGCTC GAGCGGCCGC 
61 CAGTGTGATG GATATCTGCA GAATTCGGCT TAGCGGATAA CAATTTCACA CAAGGAGCTA ARP2* 
121 GCATGGCGGC AGTGACCTGG AGTCGGGCTC GATGCTGGTG TCCGAGGTCT TCAGATTACA 
181 AGTGGCTAAA CTGCACTTGG GCAGACCAAC AATGAGAGCC AGTCAGCAGG ACTTTGAAAA 
241 TGCATTGAAC CAGGTGAAAC TCTTGAAGAA GGACCCGGGA AACGAAGTGA AGCTAAGACT 
301 CTATGCACTG TACAAGCAGG CCACAGAAGG ACCCTGTAAT ATGCCTAAGC CTGGTATGCT 
361 TGACTTTGTC AACAAAGCCA AGTGGGATGC ATGGAGTGCC CTGGGCAGCC TACCCAAGGA 
421 AACTGCCAGG CAGAACTATG TGGATCTCGT ATCCAAAAAG AGTNCCTCAT CTGAAGCCNC 
481 GAGCCAGGGA NAGCGTGGAG CTGATGAGAA AGCCGGGGAG TCCAAAGACA TNCTGNTAAC 
541 TTCTGANGAT GGTATCACGA AGATCACGTT CANNCCGNCC NCCCAAAAGA NTGCCATATN 
601 CTNNCAGATG TATCNNGATA TNATACTCGC CCTTAAAATG NCAGCNNNGA TACACTNTNA 
661 TGCTGTTNNA CANGANCTNN GACACTACTG CNNNGGANGA CNGACTACNT NCTANTGCAG 
721 G 
B 1.2: Sequencing alignment of cDNA subclone AA1#2 with mouse peroxisomal delta 3, delta 2-enoyl-
Coenzyme A isomerase (Feci) by BLAST searching against the National Center for 
Biotechnology Information database 
AA1#2 ： 165 agqtcttcaqattacaaqtgqctaaactqcacttqgqcaqaccaacaatgagaqccaqtc 224 
. iTTiiimTiiiimTiTTiiimiTiiiiiTTfii 了mmm丫 iTiTm丫 II 
Mouse Peci： 296 aggtcttcagattacaagtggctaaactgcacttgggcagaccaacaatgagagccagtc 355 
AA1#2 ： 225 agcaqgactttgaaaatgcattqaaccaggtgaaactcttgaagaagqacccqgqaaacq 284 
. I 丫 iiffiiml^iiiiYiml^iiiiffi 丫 imiiiiYii 丫 iiffiiiifffiiiit 
Mouse Peci： 356 agcaggactttgaaaatgcattgaaccaggtgaaactcttgaagaaggacccgggaaacg 415 
AA1#2 ： 285 aagtgaagctaagactctatqcactqtacaaqcaggccacaqaagqaccctgtaatatgc 344 
. 了 l l l l了 l l l l l l l丫m i n i m丫 l l f f l l l l l T l l f f i MITIMIMTI 
Mouse Peci： 416 aagtgaagctaagactctatgcactgtacaagcaggccacagaaggaacctgtaatatgc 475 
AA1#2 ： 345 ctaaqcctqgtatqcttqactttgtcaacaaaqccaagtqggatgcatgqagtgccctqg 404 
i i i i l ^ i i f f i i i t i i i t i i i i i Y i i i i i i i i n m Y i l T f i i T i i i f f i III 11 ITT 
Mouse Peci： 476 ctaagcctggtatgcttgactttgtcaacaaagccaagtgggatgcatggaatgccctgg 535 
AA1#2 ： 405 qcaqcctacccaaggaaactgccaggcagaactatgtqgatctcgtatccaaaaagagtn 464 
. tiitmmiiiffimiYiiiffiiyiiiiiiYi 行 imiTiiiiii Tiii 
Mouse Peci： 536 gcagcctacccaaggaaactgccaggcagaactatgtggatctcgtatccagtttgagtt 595 
AA1#2 ： 465 cctcatctqaaqccncgagccaggganagcgtggagctgatgagaaagccgqgqagtcca 524 
IIIIIIIITIITII ITITIMTTTI l l I丫 l � l 11丫 11 f f f l t l 111 
Mouse Peci： 596 cctcatctgaagccccgagccagggaaagcgtggagctgatgagaaagcccgggagtcca 655 
AA1#2 ： 525 aaqacatnctgntaacttctganqatggtatcacgaagatcacqttcannccgnccnccc 584 
IITIIIl MI l i l l l l l lTI TllTTIIIIIITIITIIIIIlllll I 1 II II 
Mouse Peci： 656 aagacatcctggtaacttctgaagatggtatcacgaagatcacgttcaatcggcccacca 715 
AA1#2 ： 585 aaaagantgccatatnctnncagatqtatcnngatatnatactcgcccttaaaa 638 
. IIIITI ITIIIIII II MTMTIIM Tllll IIIIIITI 1111111 
Mouse Peci： 716 aaaagaatgccatatccttccagatgtatcgggatattatactcgcacttaaaa 769 B 1.3: Summary of sequence alignment of cDNA subclone AA1#2 with mouse Peci 
FluoroDD gel AA (API + ARP2) Subcloning Sequencing 
FrjmmPiif PPARa (+/+) PPARa (-/-) FluoroDD . Size of insert Gene homology to E-value 
l^ragment fragment ^ u f ^ n e after 五⑶RI Primer Blast search (% no. CTL Wy CTL Wy size (bp) . . cut (bp) (Transcript size) Identity) 
Mus musculus 
M13 peroxisomal delta 3, delta 0 
AAl - + - - 1400 AA1#2 1400 forward 2-enoyl-coenzyme A 447/474 
(-20) isomerase (Peci) (94%) I I I I I (1581 bp) * Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 TTACGACTCA CTATAGGGCG AATTGGGCCC TCTANNTGCA TGCTCGAGCG GCCGCCAGTG 
61 TGATGGATAT CTGCAGAATT CGGCTTAGCG GATAACAATT TCACACAAGG AGCTAGCATG ARP2* 
121 GCGGCAGTGA CCTGGAGTCG GGCTCGATGC TGGTGTCCGA GTGTCCTGCA GGTCTTCAGA 
181 TTACAAGTGG CTAAACTGCA CTTGGGCAGA CCAACAATGA GAGCCAGTCA GCAGGACTTT 
241 GAAAATGCAT TGAACCAGGT GAAACTCTTG AAGAAGGACC CGGGAAACGA ACGTGAAGCT 
301 AAAGACTCTA TGCACTGTAC AAGCAGGCCA CAGNAAGGAC CCTGTAATAT GACACATNNA 
361 NCNAAAAAAA AAACAAAANA ANNNNTACAC CNNAAGCCCA AGGTNGGGAT TGCATNGGGA 
421 ATGCCCTGGG NAGCCTACCC AAAGGAAACT GCCAGGCAGA ACTNTGTGGA TCTCGTATCC 
481 NGTTTGAGTT CCTCATCTGA AGCCCCGAGC CAGGGAAAGC GTGGAGCTGA TGAGAAAGCC 
541 CNGGAGTCCN AAGACNTNCT GGTAACTTCT GAAGATGGTA TCCCGAAGAT CNNGTNCATT 
601 CNGCCCCCCA AAAGANTGCC TATCCTTCCG ATGTTTCGGA TNTNTCTCGC CNTANNTNCN 
661 GCCTGNNNCC TGTNTGNTGT NNNNGGACTG TGACT 
B 2.2: Sequencing alignment of cDNA subclone AA1#3 with mouse peroxisomal delta 3, delta 2-enoyl-
Coenzyme A isomerase (Feci) by BLAST searching against the National Center for 
Biotechnology Information database 
AA1#3 ： 161 qtqtcctqcaggtcttcaqattacaaqtgqctaaactqcacttqgqcaqaccaacaatga 220 
. 丫丨了 i i i i 化 f f m i i 丨丫mmi 侦 m i m 丫 i i m f f f i i 化 i i i i i i i 丫 I 
Mouse Peci： 287 gtgtcctgcaggtcttcagattacaagtggctaaactgcacttgggcagaccaacaatga 346 
AA1#3 : 221 gaqccaqtcaqcaqqactttqaaaatqcattgaaccaqqtgaaactcttqaagaagqacc 280 
. Yi 丫 III丫 i i i l ^ i n i i i i i Y i i i i i T i i i i T i i i i i f f i l ^ i i i i i i i l ^ i T i i f f i i i 
Mouse Peci： 347 gagccagtcagcaggactttgaaaatgcattgaaccaggtgaaactcttgaagaaggacc 406 
AA1#3 ： 281 cggqaaacgaacgtgaagctaaagactctatgcactqtacaagcaggccacagnaaqqac 340 
. ITTTIIIITil IITIITII IITIIIIIIITIIIITIIIIITIITTIIIIIT IITTI 
Mouse Peci： 407 cgggaaacgaa-gtgaagct-aagactctatgcactgtacaagcaggccacag-aaggaa 463 
AA1#3 ： 341 cctgtaatatg 351 
. IIITIIIIIIT 
Mouse Peci： 464 cctgtaatatg 474 B 2.3: Summary of sequence alignment of cDNA subclone AAl#3 with mouse Peci 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
g fragment I.D. after EcoRl Primer Blast search (% 
CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
M13 peroxisomal delta 3, delta 3e-85 
AAl + 1400 AAl#3 1450 forward 2-enoyl-coenzyme A 187/191 
(-20) isomerase (Peci) (97%) 
I I I I I (1581 bp) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 TNNCCAAGCT TGNGTACCGA GACTACNNGA TACCACTATT AAACGGACCG ACACGNGTGA 
61 CTGGAATTNC GGACTTGNTA ATAA.CGACTC ACTATAGGGC TTTTTTTTTT GATTTATGAA API* 
121 AAGTTTTATT TATCAGTACT GTGAAGAATT CTCATCATAA TTGCTACGTT AATCAAGGAA 
181 AAGGCACAGA GAANCATGTG TCGTTTGAGT CCTCAGNAAA CTGGACCTCC CNAGCCCNAT 
241 GCTCCCTATG AGGAGTCTAG CNTGCTGTGG TGGTCTTCAN AGCTTTGGTT TTCTGGAGAC 
301 GAAGCTCNAT GATTGNGTTN CATGCAACTC CNTCTGNACN AGCCACCNTT GCCTTGCCAG 
361 AAGTTAGTNC NACNTCCTTC NAGCAGTNNG ANNTGCNGTN AGCAGCATTT TTCTTTCCTC 
421 CATTTTTTTC NTNGATTNAA CTCCTTNTGG NNNATTCTCC ATGGCGTTTG GGCNGGGAGC 
481 TCCGCANNTG TTTTCCGGCC NGGTCCNNNN NNTCCTGTCT CAAAAAGTGC TCCTCCAGGG 
541 GAAAAACNNN NCAGTTNGAA CNAAANGGCC CTTNGNNANN CNCCCAANNG CCCNTCCTTN 
601 CNNTNNGNCN NTNGNTTCCA AGCCTTTTCN NTNNCCCCCN NAAAAANGNN AGNNANGCNN 
661 ATCNTNCNAA NCNTGGNCCC TTTTTGCNTN GNAGCNNCAA TNNNATCTTT CCNGGNACNN 
721 ANTTNNTTAA GNAAGGANCN NTNGCTTTCC CGGNGCCNCN TGGGCCCGNA GNTNN 
B 3.2: Sequencing alignment of cDNA subclone AA1#4 with mouse peroxisomal delta 3, delta 2-enoyl-
Coenzyme A isomerase (Feci) by BLAST searching against the National Center for 
Biotechnology Information database 
AA1#4 ： 111 qatttatqaaaagttttatttatcagtactqtqaaqaattctcatcataattqctacqtt 170 
T m m m T m m T n i i m n m n ^ i i n T i T i i T i i i i m m m i i m i i I ^ i n T m 
Mouse Peci： 1580 gatttatgaaaagttttatttatcagtactgtgaagaattctcatcataattgctacgtt 1521 
AA1#4 ： 171 aatcaaggaaaaqgcacagagaancatqtqtcqtttqaqtcctcagnaaactqgacctcc 23 0 
. I I I I I I T T I I I I T T I I I I T I T I I I I I T I T I I T I I I T I T I I I I I I I I I I T T I I I I I I 
Mouse Peci： 1520 aatcaaggaaaaggcacagagaagcatgtgtcgtttgagtcctc--gaaactggacctcc 1463 
AA1#4 ： 231 cnaqcccnatqctccctatgaggagtctaqcntgctgtqgtqqtcttcanagctttggtt 290 
I I T I I I I I T I I I I I I I I T I T T I T I I I I T I 111 I T I T T I T T I 1 1 1 1 1 I T I I I I T T I I 
Mouse Peci： 1462 c-agccc-atgctccctatgaggagtctagc-tgctgtggtggtcttcacagctttggtt 1406 
AA1#4 ： 291 ttctqqagacqaagctcnatqattgnqtt 319 
I I I I T T I T I I T I I T I I I I I T I I I T T i l 
Mouse Peci： 1405 ttctggagacgaagctc-atgattgcgtt 1378 B 3.3: Summary of sequence alignment of cDNA subclone AA1#4 with mouse Peci 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
gment fragment I D. after EcoYd Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
- peroxisomal delta 3, delta 8e-80 
AAl + 1400 AAl#4 1450 2-enoyl-coenzyme A 199/209 
isomerase (Peci) (95%) 
I I I I I (1581 bp) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 48.1: DNA sequence ofcDNA subclone AFl #8 (APIO & ARPi:3) using Ml 3 forward (-20) primer 
1 TNTACGACTC ACTATAGGGC GAATTGGGCC CTCTAGAATG CATGCNTNNA CAANCGGCCG 
61 CCANTGTGAT GGATATCTGC AGAATTCGGC TTGTAATACG ACTCACTATA GGGCTTTTTT API* 
121 TTTTTGATTT ATGAAAAGTT TTATTTATCA GTACTGTGAA GAATTCTCAT CATAATTGCT 
181 ACGTTAATCA AGGAAAAGGC ACAGAGAAGC ATGTGTCGTT TGAGTCCTCN NAACTGGACC 
241 TCCCAGCCCA TGCTCCCTAT GACGANATAC TAGCTGCTGT GGTGGTCTTC ACAGCTTTGG 
301 TTTTCTGGAG ACGAAGCTCA TGATTGCGTT CATGCACTCC TCTGACAGCC ACCTTGCTTG 
361 CAGAGTAGTG CACTCTTCAG CGTTGACTGC GTAGAGCTTT TCTTTCTCAT TTTTTCTGAT 
421 TAACTCTTTG GNAAATTCCT CATGGCGTTT GGCGGGAGCT TCGCATATAT TTTCAGCCTG 
481 GTCCCGACTT CTGTCTCAAA AGTGCTCTCA GGGAAAACTT CAGTGACAAG GCCTTGAGCN 
541 CAGGCCTCTC TTGCTGTCAG CTTCTTCCCA AAGAGAAGCA TCTCAGCTGC CTTTGCTGAG 
601 CCCATCATCT TCNGAAACGT GTACGAAGAG CATGCNTCCN NGGCTCTGGC CGAGNTGGGC 
661 TGAATGNAGT ATGAAACGTN GNCCNGTNTG ATGCCNAGAC NNNC 
B 4.2: Sequencing alignment of cDNA subclone AA1#20 with mouse peroxisomal delta 3, delta 2-
enoyl-Coenzyme A isomerase (Feci) by BLAST searching against the National Center for 
Biotechnology Information database 
AA1#20 ： 126 gatttatgaaaagttttatttatcagtactgtgaagaattcteatcataattgctacqtt 185 
. TmrnTmiTmiimmiTimTiTiiTmiiimiiMMi丫 iiiiTii 
Mouse Peci： 1580 gatttatgaaaagttttatttatcagtactgtgaagaattctcatcataattgctacgtt 1521 
AA1#20 ： 186 aatcaaggaaaaggcacagagaagcatgtgtcgtttgagtcctcnnaactgqacctccca 245 
. miiiffmiffmiTi丫丨丨TmiTiTii丫III丫iTiim i i i i t t i i m i m i 
Mouse Peci： 1520 aatcaaggaaaaggcacagagaagcatgtgtcgtttgagtcctcgaaactggacctccca 1461 
AA1#20 ： 246 gcccatgctccctatgacganatactagctgctgtggtqgtcttcacaqctttggttttc 305 
. TIIIIITIIIIIIIITI 11 IIITIITIITITTITTIIIIIIIITIIIITTIIIII 
Mouse Peci： 1460 gcccatgctccctatgaggagt--ctagctgctgtggtggtcttcacagctttggttttc 1403 
AA1#20 ： 306 tggagacgaagctcatgattgcgttcatqcactcctctgacagccaccttqcttgcagaq 365 
. I而丨丨TiiTm 丨丨丫m丫i?iMii?mimii丫 I I I丫miMi?i i i f i i丫 I丫 
Mouse Peci： 1402 tggagacgaagctcatgattgcgttcatgcactcctctgacagccaccttgcttgcagag 1343 
AA1#20 ： 366 tagtgcactcttcagcgttgactgcgtagagcttttctttctcattttttctgattaact 425 . I丨丫I丫Miimii丫iTiiTmi?丨丫iiTiTmmmmmii m i t i m i m i 
Mouse Peci： 1342 tagtgcactcttcagcgttgactgcgtagagcttttctttctcattttgtctgattaact 1283 
AA1#20 ： 426 ctttggnaaattcctcatggcgtttggcgggagcttcgcatatattttcagcctggtccc 485 
IIIITT m i l l l l l l T T I T I I I T T I T n i IIITIIIII 11111 III IITTI11 
Mouse Peci： 1282 ctttgg-aaattc-tcatggcgtttggcgggacgttcgcatatgttttcagcctggtcca 1225 
AA1#20 ： 486 gacttctgtctcaaaagtgctctcagggaaaacttcagtgacaaggccttgagcncaggc 545 . 丫mm丫mim丨丫iTmmfrfiimiiiiTi丫miiHiimTiTi i i t t i ^ 
Mouse Peci： 1224 gacttctgtctcaaaagtgctctcagggaaaacttcagtgacaaggccttgagcccaggc 1165 
AA1#20 ： 546 ctctcttgctgtcagcttcttcccaaagagaagcatctcagctgcctttgctgagcccat 605 
mm丨丫丨丨？m丫mmmm丫丨丫I丨丫mim丫丨丨Tim I丫丨I丫iTimm 
Mouse Peci： 1164 ctctcttgctgtcagcttcttcccaaagagaagcatctcagctgcctttgctgagcccat 1105 
仏1# 2 0 ： 606 catcttcngaaacgtgtacgaagagcatgcntccnnggctctggccgaqntgggctgaat 665 
l l l l l l l T I I I I T I T I I 11 T l T l l l T I I I I T T I I I I T T I I T I T I T T I I T I I I 
4ouse Peci： 1104 catcttcggaaacgtgtaagaggagcatgcttcc-gggctctggccgagtt-ggctgaat 1047 
yu#20 ： 666 gnagtatgaaacgtngnccngtntgatgc 694 . T I T I I I T I I I I T I T I I T l I T I I T I 
louse Peci： 1046 ggagtatgaaacgttgccctgtctgatgc 1018 I 4.3: Summary of sequence alignment of cDNA subclone AA1#20 with mouse Peci 
FluoroDD gel AA (API + ARP2) Sequencing 
P P A R a (+/+) P P A R a (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
ragment fragment I.D. after 五 P r i m e r Blast search (% no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
M13 peroxisomal delta 3, delta 0 
AAI + 1400 AA1#20 1700 forward 2-enoyl-coenzyme A 541/569 
(-20) isomerase (Peci) (95%)) 
I I I I (1581 bp) 
Sequence of primer was not completely matched with the expected sequence. ^^^ 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 ANGNCCCCCC TNATACNNCC CGNNCANNTC CCGNGGNNCN NCTNANNATC GCATCGCNNC 
61 NNNAGCGGCC GCCAGCTGNT GATGGATATC CTGCNANCNA ATNCNCNCCN TGCCTAATAC 
121 NNNACTCACC TATAGGGCTT TTTTTTCTGA CCNNTNCCCA TCCACNNANC NATCTATNNT API* 
181 NCCATCCCNA ACCAAAANGT CAGNNCNCCA CCCCTGCAGC AGCTCCACGN AGGGTACCGG 
241 CACCTGNTAT TGNAATGNAG GNAAGCGCCA CACCAGTCCC NGNTCNNNGN TACCANCGNA 
301 TCCTCCCCTA ACAAAGCCCC TCCCTTCCAT CGTNGGTGGN ATGGCTCAGT CCCCTTNATC 
361 TGGNATCCCA CACTCTCTAA GNGAAATAAG GGCTCTGCCC GGTCCCATCA CTGGGACCCA 
421 CCACCAGGAC ACTGGCAGGA ACGTACACAC TCCATCACAT GTTCNNTGCA TTATGCTCTC 
481 CTCCTGCTCC CTTTNCAACA AANAGCTCCT CAATGAANNA CCCCTGNNGG NANNACANGG 
541 ANNTCCCCTC CTCCCATNGG ACCCAAACTG GTNAAACANG CCCAGCNAAC CCAGGCCTNG 
601 CCGANANTNN ANCAAGAAGC CCCAACTCCA NGGTTGTAGT GGGATGGGTT TTTAGCAGGG 
661 NNAAGCACTG GCTTGCGGTT AGTTACCCCC AAANNNATTN TCCCAATCTT GTTANCTCAC 
721 TTCTTGGCTA NNTTANNGAN TTGCCCAAAT GAGTTNCCAN AANNCTTGGG TTNTGCAAAA 
781 GCCTAANTGG ANNTGTTAAT GCCCCCTGAA GTAGNGGGNA TTNNGAGGAA GGNNTGGGTA 
841 NNGTTGGGGA AANGCAATCC CTNTNGGGTG GTGTNNNNGG NANNCTNNAA CATNNGGCCT 
901 TATTTAAANN NTGNTCGCCT TGNGTGTTAA NNTTNTTNTC CNTTANNGGN NANTNNGGNN 
961 GNNNTTNNGT GG 
B 5.2: Sequencing alignment ofcDNA subclone AA4#1 with mouse apolipoprotein A-V (ApoaS) by 
BLAST searching against the National Center for Biotechnology Information database 
AA4#1 : 374 tctctaaqngaaataagqqctctgcccqqtcccatcactqqqacccaccaccaqqac-ac 432 
I I I I I I I T T l l l l l T T T I I I I T I I I T T I I I I I I I I I I T T I I I I I 111 I i f f 11 I I 
Mouse ApoaS： 1645 tctctaag-gaaataggggctctgcccggtcccatcactgg-acccaccagcaggaccac 1588 
AA4#1 : 433 tqqcagqaacgtacacactccatcacatgttcnntqcattatgctctcctcctgctccct 492 
I T T I I T T I I T I I I I I i l l l l l l l l l l l T I I I I T I I I I I I I 11111111 I I I 11111 
Mouse ApoaS： 1587 tggcagggacgtacacactccatcacatgttctctgcatcatgctctcctcctgctccct 1528 
AA4#1 : 493 t 494 i 
Mouse ApoaS： 1527 t 1527 
B 5.3: Summary of sequence alignment of cDNA subclone AA4#1 with mouse ApoaS 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml3 Mus musculus le-32 
AA4 ++ + ++ ++ 695 AA4#1 725 forward apolipoprotein A-V 112/121 
(-20) (Apoa5) (1819 bp) (92%) 
* Sequence of primer was not completely matched with the expected sequence. 
292 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 NCNCTATTTA GGTGACCTAT AGAATACTCA AGCTATGCAT CAAGCTTGGT ACCGAGCTCG 
61 GATNCACTAG TANCGGCCGC CAGTGTGCTG GAATCGCCCT TAGCGGATAA CAATTTCACA ARP2 
121 CAGQAGCTAG CATGGTCTAT TAGGCAGAGG GTGGAGGGTC CTGCACACCA CCAAAGGTGC 
181 TGCCTGTCCC AACCTACCCA GCCTCCTCAA CNTCCCCTAC TCAGGGGCAT NACANCNTCA 
241 GTAGGCTTTG CAAACCCAGC TTCTGGTACT CATTTGGCAA TCCTAAGTAN CCAGAGTGAG 
301 GTGACAGGNG TGGNNGATGG TGTGTGGGGT GACTGACCGC AACCCAGTGC TTGACCCGTG 
361 CCGGAAACCC CATGCCCACN NACAAACCTG NNAAGTTGGG GCCTCCCCTG GTTAAAATTN 
421 CTTCCCCAAG CCCCTNGGGG NNGCTTGGGC CTNGGTTAAC ACAGGTTGNG GGTNCCNATG 
481 GGGAAGAAAN GGNANCCTCC CCTGGTTTTC CCCNCCNNNN GGTTNGTTNN ATTGAANAAN 
541 CNNTNNTGGT TTGGGGAANN GGGGAANNCA NGGAAAGGAA AAAAACCCAT GGAATGNNNN 
601 NNNAANAAAA CNNTNNGNTG GAATGTGGAA AGTTGGTGTN TTNNCCGTTN NCCCCTTGGG 
661 NNCAAGNTTN GGGTTTNTCN TTGGNCNNNN GGGTGNNNGN NNTNNCNAAG NTTGGAATNT 
721 TNNNGGGGNA CNNCNNGGGG GNAAAAAAAA GNCCCCCNNT TANNNNNNNC NTNTNNAAAA 
781 AAANNNNNNT GNNNANTNNN NNNANATNNN NANNGANAAN NNNNAACNCN TTTNNNNNNN 
841 TTNAANGNGN GNNGGGGGCT NTNNNNTANN NNAANAAATA TTNNNNNNNN NTTNNAAAAA 
901 ANANAANNNN NGGTTGT 
B 6.2: Sequencing alignment of cDNA subclone AA4#9 with mouse apolipoprotein A-V (ApoaS) by 
BLAST searching against the National Center for Biotechnology Information database 
AA4#9 ： 126 qctaqcatggtctattaqgcaqaqgqtqqaqqgtcctqcacaccaccaaaqqtqctgcct 185 
l ^ i i t i i i f f i i i i i i i f f i i Y i f r f i f f i n丫N i l丫 i i i i i i i i i i i i f f i丫 i i t i I 
Mouse ApoaS： 1167 gctagcatggtctattaggcagagggtggagggtcctgcacaccaccaaaggtgctgc-t 1225 
AA4#9 ： 186 qtcccaacctacccagcctcctcaacntcccctactcagggqcatnacancntcaqtaqq 245 
T I I I I I I I I I I I I I I T I I I I I I I i l l M M M M M I T T T T I M I I I 11 i n i f f 
Mouse Apoa5： 1226 gtcccaacctacccagcctcctcaac-tcccctactcaggggcattacac--tcagtagg 1282 
AA4#9 ： 246 ctttqcaaacccaqcttctqqtactcatttqqcaatcctaaqtanccaqagtqaqgtgac 305 
M M T M M M M T M M I T T M M M M I T T M M M I M T M I I T I T I T I T T I T I I 
Mouse ApoaS： 1283 ctttgcaaacccagcttctggtactcatttggcaatcctaagtagcaagagtgaggtgac 1342 
AA4#9 : 306 冗〒n行〒『n竹tj：〒打打打〒〒〒平Ij：竹(jitj：竹(jrcj：〒(！：竹C(j;(j：行1j：〒Cj:1j:tj：竹ccj^cj：竹行c〒〒T 365 
Mouse ApoaS： 1343 aggagtgggagatggtgtgtggggtgactgaccgcaagccagtgcttga-ccgtgctgga 1401 
AA4#9 ： 366 aaccc 370 i i m Mouse ApoaS: 1402 aaccc 1406 
B 6.3: Summary of sequence alignment of cDNA subclone AA4#9 with mouse ApoaS 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
i^ragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
^ - Mus musculus 3e-95 
AA4 ++ + ++ ++ 695 AA4#9 725 apolipoprotein A-V 231/245 
reverse (Apoa5) (1819 bp) (94%) 
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B7.1: DNA sequence of cDNA subclone AA5#5 (API & ARP2) using Ml3 forward (-20) primer 
1 TNNACGACTC ACTATAGGGC GAATTGGGCC CTCTAGATGC ATGCTCGAGC GGCCGCCAGT 
61 GTGATGGATA TCTGCAGAAT TCGGCTTAGC GGATAACAAT TTCACACAAG GAGCTAGCAT ARP2* 
121 GGACGGCTAA ACGAGGGTCC AACTGTCTCT TATCTTTAAT CAGCGAAATT GACCTTTNCA 
181 GTGAAGAGGC TGAAATATAA TAATAAGACG AGAAGACCCT ATGGAGCTTA AATTATATAA 
241 CTTATCTATT TAATTTATTA AACCTAATGG CCCAAAAACT ATAGTATAAG TTTGAAATTT 
301 CGGTTGGGGT GACCTCGGAG AATAAAAAAT CCTCCGAATG ATTATAACCT AGACTTACAA 
361 GTCAAAGTAA AATCAACATA TCTTATTGAC CCAGATATAT TTTGATCAAC GGACCAAGTT 
421 ACCCTAGGGA TAACAGCGCA ATCCTANNTA AGGGTTCATA TCGACAATNA NGGTTNACGA 
481 CCTCGATGTT GGATCANGAC ATCCCAATGG TGTANANGCT ATTAATGGGT TCGTNTTGTT 
541 CANNGATTAA AGTCCTACGT GATCTGAGTT CAGACCCGAG CANTCAGGTN NGTNNCTATC 
601 TATTNACGAT TTTCTCCAGT ACGAAAGGAC ANGAGANNTN NAGNCCNCCT NACNANTAAG 
661 NGCNNTCANC NTANNTTANT GANNTAAATT NTAAATTNAA TATATTCGTT ANCNCCCCTA 
721 NNCNGAAANN 
B 7.2: Sequencing alignment of cDNA subclone AA5#5 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AA5#5 ： 114 ctaqcatggacgqctaaacqaqgqtccaactgtctcttatctttaatcaqcgaaattgac 173 
^ . … . � … M I T I I I T M T T M M M T I T T T M M M I T M M M M M M I M M T T I I I I I T I i 
Mouse mitochondrion： 2061 ctagcatgaacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgac 2120 
AA5#5 : 174 ctttncagtqaagaqqctgaaatataataataaqacgaqaagaccctatqqaqcttaaat 233 
. … . _ M M i i Y i Y i i 侦 1 1 丫 i i i i i i i i i i i i i i l ^ i 丫 I 丫 i i T i m i i i f M i m m 
Mouse mitochondrion： 2121 cttt-cagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaat 2179 
AA5#5 : 234 tatataacttatctatttaatttattaaacctaatqqcccaaaaactatagtataaqttt 293 
. ^ , . I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I T T I I I I I I I I I I I I I T I I I I I T I I I 
Mouse mitochondrion： 2180 tatataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagttt 2239 
AA5#5 ： 294 qaaatttcqqttqgqqtqacctcqqaqaataaaaaatcctccqaatqattataacctaqa 353 
. … . Y i i i i m f f i i 丫丽 m i l 而 i i i i i i m m i i i 丫 I I I 丫 i i i i i i i i i i i t i 
Mouse mitochondrion： 2240 gaaatttcggttggggtgacctcggagaataaaaaatcctccgaatgattataacctaga 2299 
AA5#5 ： 354 cttacaaqtcaaagtaaaatcaacatatcttattgacccaqatatattttgatcaacgqa 413 
. … . m i m 了 丨 m i T i i m m i i i m m m 丫 m i l 丫 i i i i m i i T m i i i f f i 
Mouse mitochondrion： 2300 cttacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacgga 2359 
AA5#5 ： 414 ccaaqttaccctaqgqataacaqcgcaatcctanntaagqgttcatatcqacaatnanqq 473 
. l l l l T l l l l l l l i m i l l l l l T I T I I I I I I I I M I T T M I M M I T I I I I I I IT 
Mouse mitochondrion： 2360 ccaagttaccctagggataacagcgcaatcctatttaagagttcatatcgacaattaggg 2419 
AA5#5 ： 474 ttnacqacctcqatqttqqatcangacatcccaatqgtqtananqctattaatgqqttcg 533 
I I I I T I I I I I T I I T I I T T I i l l T I I I I I I I M I T T I T I I i T l l l l l l l l I I I I IT 
Mouse mitochondrion： 2420 tttacgacctcgatgttggatcaggacatcccaatggtgtagaagctattaat-ggttcg 2478 
AA5#5 ： 534 tnttqttcannqattaaagtcctacgtqatctgaqttcaqacccqaqcant-caqqtnnq 592 
. ^ ^ . 1 I I T I I I I T I I I I I I T I I I I I I T I T I I I I T I T I I I I T I i l T I T I I I I I T T I T 
Mouse mitochondrion： 2479 t-ttgttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccaggtcgg 2537 
AA5#5 ： 593 tnnctatctattnacgattttctccaqtacqaaagqacangaqa 636 
. I l l l l l l l l l I I T I I I I I I I T I I I T I I I T T I I I T i l l 
Mouse mitochondrion： 2538 tttctatctatttacgatttctcccagtacgaaaggacaagaga 2581 B 7.3: Summary of sequence alignment of cDNA subclone AA5#5 with mouse mitochondrion 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after 五coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml3 Mus musculus clone LA9 0 
AA5 + ++ + + 670 AA5#5 710 forward mitochondrion, complete 496/524 
(-20) genome (16300 bp) (94%) * Sequence of primer was not completely matched with the expected sequence. 
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B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 TTACGACTCA CTATAGGGCG AATTGGGCCC TCTAGATGCA TGCTCGNAGC GGCCGCCAGT 
61 GTGATGGATA TCTGCAGAAT TCGGCTTAGC GGATAACAAT TTCACACAAG GAGCTAGCAT A R P 2 * 
121 GGACGGCTAA ACGAGGGTCC AACTGTCTCT TATCTTTAAT CAGTGAAATT GACCTTTCAG 
181 TGAAGAGGCT GAAATATAAT AATAAGACGA GAAGACCCTA TGGAGCTTAA ATTATATAAC 
241 TTATCTATTT AATTTATTAA ACCTAATGGC CCAAAAACTA TAGTATAAGT TTGAAATTTC 
301 GGTTGGGGTG ACCTCGGAGA ATAAAAAATC CCCCGAATGA TTATAACCTA GACTTACAAG 
361 TCAAAGTAAA ATCAACATAT CTTATTGACC CAGATATATT TTGATCAACG GACCAAGTTA 
421 CCCTAGGGAT AACAGCGCAA TCCTATTTAN GAGTTCATAT CGACAATNAG GGTTTACGAC 
481 CTCGATGTTG GATCAGGACA TNCCAATGGT GTAGAAGCTA TTANTGGTTC GTTTGTNCAA 
541 CGATTAAAGT CCTACGTGAT TTGAGTNCAG ANCCGAGCAN TCCAGGNTCN GTTTNTATCT 
601 ATTNACGATN NCTNNCAGTA CGANNGGACA NGANANNTAN ANCCNNCNNN CAANTNNN 
B 8.2: Sequencing alignment of cDNA subclone AA6#1 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AA6#1 : 114 ctaqcatqgacqqctaaacqaqgqtccaactqtctcttatctttaatcaqtqaaattqac 173 
. ^ , . i i i T i i i T i i f f m i i i 丽 i i i i i i i t i i i i i i i m i m m 丫 l Y i i i i i 丫 I I 
Mouse mitochondrion： 2061 ctagcatgaacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgac 2120 
AA6#1 : 174 ctttcaqtqaagaggctqaaatataataataaqacqagaaqaccctatgqaqcttaaatt 233 
. ^ � . mm〒丨了 I I而 1 1 丫 i i i i i m m m l ^ i T i T i i 丫 m i N i 而 i i m i N 
Mouse mitochondrion： 2121 ctttcagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaatt 2180 
AA6#1 : 234 atataacttatctatttaatttattaaacctaatggcccaaaaactatagtataaqtttq 293 
. . i M m i i i i i m i m i i i i i i i i m i i i i i T f i i i m i i i i i N 丫N i i i 丫 i i i Y 
Mouse mitochondrion： 2181 atataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttg 2240 
AA6#1 : 294 aaatttcggttgggqtqacctcqgaqaataaaaaatcccccqaatqattataacctaqac 353 
l l l l l l l f f l l f f f f l t l l l l l f f l T l l l l l l l l l l l l I I T I I I T I I I I I I I I I I I T I I 
Mouse mitochondrion： 2241 aaatttcggttggggtgacctcggagaataaaaaatcctccgaatgattataacctagac 2300 
AA6#1 : 354 ttacaaqtcaaagtaaaatcaacatatcttattqacccagatatattttgatcaacggac 413 
i i i i i i T i i m 〒丨 m i i i i i i i i m i m i 丫 i m i T i i i i i i i i i T i i i m T f i i 
Mouse mitochondrion： 2301 ttacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacggac 2360 
AA6#1 : 414 caagttaccctaqqqataacaqcgcaatcctatttanqaqttcatatcqacaatnaqqqt 473 
I I I T I I I I I I I I T T T I I I I I I T I T I I I I I I I I I I I I T I T M M M M T I M M I TIT I 
Mouse mitochondrion： 2361 caagttaccctagggataacagcgcaatcctatttaagagttcatatcgacaattagggt 2420 
AA6#1 : 474 ttacqacctcgatgttqqatcaggacatnccaatqqtqtagaaqctattantggttcqtt 533 
I I I I T I I I I I T I I T I I T T I I I I T T I I I I 11 i I I T T I T I I I I I I I 11111 I T T I I I T I I 
Mouse mitochondrion： 2421 ttacgacctcgatgttggatcaggacatcccaatggtgtagaagctattaatggttcgtt 2480 
AA6#1 : 534 tqtncaacgattaaaqtcctacqtqatttgagtncaganccqaqcantccaqqntcnqtt 593 
I I I I I I I T I I I I I I T I I I I I I T I T I I I T I T I M i l I T I T I I I I I I I T I I T i l � … 
Mouse mitochondrion： 2481 tgttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccagg-tcggtt 2539 
AA6#1 : 594 tntatctattnacqatnnctnncaqtacqannqqaca 630 
I l l l i l l l l I I T I I I I I I T I I I T I T T I I I � （ 
Mouse mitochondrion： 2540 tctatctatttacgatttctcccagtacgaaaggaca 2576 B 8.3: Summary of sequence alignment of cDNA subclone AA6#1 with mouse mitochondion 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml3 Mus musculus clone LA9 0 
AA6 + ++ + + 660 AA6#1 710 forward mitochondrion, complete 495/517 
(-20) genome (16300 bp) (95%) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 GCCAGCTTGN GTACCGAGCT CGGATCCACT AGTTAACGGC CGCCAGTGTG CTGGAATTCG 
61 GCTTAGCGGA T A A C A A T T T C ACACAAGGAQ TAGCATGGAC GGCTAAACGA GGGTCCAACT A R P 2 * 
121 GTCTCTTATC TTTAATCAGT GAAATTGACC TTTCAGTGAA GAGGCTGAAA TATAATAATA 
181 AGACGAGAAG ACCCTATGGA GCTTAAATTA TATAACTTAT CTATTTAATT TATTAAACCT 
241 AATGGCCCAA AAACTATAGT ATAAGTTTGA AATTTCGGTT GGGTGACCTC GGAGAATAAA 
301 AAATCCTCCG AATGATTATA ACCTAGACTT ACAAGTCAAA GTAAAATCAA CATATCTTAT 
361 TGACCCAGAT ATATTTTGAT CAACGGACCA AGTTACCCTA GGGATAACAG CGCAATCCTA 
421 TTTAAGAGTT CATATCGACA ATNANGGTTT ACGACCTCGA TGTTGGATCA GGACATCCCA 
481 ATGGTGTAGA AGCTATTAAT GGTTCGTTTG TTCAACGATT AAAGTCCTAC GTGATCTGAG 
541 TTCAGACCGG AGCANTCCAG GTCGGTTTCT ATCTATTNAC GATTTCTCCC AGTACGAAAG 
601 GACNAGAGAA NTAGAGCCNN CNTACNAATA NGCGCTCTCA ACTNATTTAN GAATAAAATC 
661 TAAATAANNN NNTNNGTNCN CCCTCTACCN AGAGANNGTC NAAAAAAAAA AGCCNNN 
B 9.2: Sequencing alignment of cDNA subclone AA6#9 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AA6#9 ： 91 tagcatqgacgqctaaacgagggtccaactqtctcttatctttaatcagtqaaattgacc 150 
. … . i i T i M T i i f f i i i i i i 丽 i i i m i T m i m i i i i i i i i i i t i 丫 m i l 丫 I I I 
Mouse mitochondrion： 2062 tagcatgaacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgacc 2121 
AA6#9 ： 151 tttcagtgaaqaqgctgaaatataataataagacqagaagaccctatggaqcttaaatta 210 
. , . i i i i i n 丫 i i Y i f f i i Y i i i i i i i i i i i i i i l ^ i t i 丫 I I 丫 i m i i i f f i � i i i i i i i i i 
Mouse mitochondrion： 2122 tttcagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaatta 2181 
AA6#9 ： 211 tataacttatctatttaatttattaaacctaatqgcccaaaaactataqtataaqtttqa 270 
, ^ , . i m i i i i i i i i i i i i i i m i i i i i m i i i i f f i i i i i i i i i i i i i T i i m丫 I I I丫 I 
Mouse mitochondrion： 2182 tataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttga 2241 
AA6#9 ： 271 aatttcggttggg-tgacctcggagaataaaaaatcctccgaatgattataacctaqact 329 
. ^ � . MMMTTIMTT III I i IITTITI1111111111111 111 I III 111111111 III 11 
Mouse mitochondrion： 2242 aatttcggttggggtgacctcggagaataaaaaatcctccgaatgattataacctagact 2301 
AA6#9 ： 330 tacaagtcaaagtaaaatcaacatatcttattgacccaqatatattttgatcaacqqacc 389 
. ^ , . | 丨 | 丨 | 丫 丨 | | | | 1 ^ | 丨 | 丨 丨 丨 | 丨 | 丨 丨 | | 丨 | | | | | 丫 I N N 丫 m i m i i 化 i m f f m 
Mouse mitochondrion： 2302 tacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacggacc 2361 
AA6#9 ： 390 aaqttaccctaqqgataacaqcqcaatcctatttaaqagttcatatcqacaatnanqqtt 449 
. I I了 i i i i i i i i n M i i i i i T i T i i i i i i i i m i i T i T i i i i i i i i T i N i i i n i l 
Mouse mitochondrion： 2362 aagttaccctagggataacagcgcaatcctatttaagagttcatatcgacaattagggtt 2421 
AA6#9 ： 450 tacgacctcgatqttqgatcaqgacatcccaatgqtgtaqaaqctattaatqqttcqttt 509 
. . i i i t m i i t i i n i f f i i i i f f i i i i i i i i i i f f i 丫 II 丫 i i n i i i i i i i f f i i i Y m 
Mouse mitochondrion： 2422 tacgacctcgatgttggatcaggacatcccaatggtgtagaagctattaatggttcgttt 2481 
AA6#9 ： 510 qttcaacqattaaagtcctacqtqatctqaqttcagaccggagcantccagqtcqqtttc 569 
t i i i m t i m i i 丫 m m 丫 i l ^ m n 丫 i i i i l ^ i i f f i Y i i i i i i t t i i t t i i m 
Mouse mitochondrion： 2482 gttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccaggtcggtttc 2541 
AA6#9 ： 570 tatctattnacqatttctcccagtacgaaaggacnaqagaantagaqccnncntacnaat 629 
l l l l l l l l llTlllillllllTIIITIIITTII ITITII IITITII I III III 
Mouse mitochondrion： 2542 tatctatttacgatttctcccagtacgaaaggacaagagaaatagagccaccttacaaat 2601 
AA6#9 ： 630 anqcgctctcaac-tnatttanqaataaaatctaaataa 667 
. . I Y i t m i i m I i i i i 丨化 m i i i m i i m … 
Mouse mitochondrion： 2602 aagcgctctcaacttaatttatgaataaaatctaaataa 2640 B 9.3: Summary of sequence alignment of cDNA subclone AA6#9 with mouse mitochondrion 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 0 
AA6 + ++ + + 660 AA6#9 710 mitochondrion, complete 563/579 
reverse genome (16300 bp) (97%) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 AATGTTACGA CTCACTATAG GGCGAATTGG GCCCTCTAGA TGCATGCTCG AGCGGCCGCC 
61 AGTGTGATGG ATATCTGCAG AATTCGGCTT AGCGGATAAC AATTTCACAC AAGGAGCTAG ARP2* 
121 CATGGACGGC TAAACGAGGG TCCAACTGTC TCTTATCTTT AATCAGTGAA ATTGACCTTT 
181 CAGTGAAGAG GCTGAAATAT AATAATAAGA CGAGAAGACC CTATGGAGCT TAAATTATAT 
241 AACTTATCTA TTTAATTTAT TAAACCTAAT GGCCCAAAAA CTATAGTATA AGTTTGAAAT 
301 TTCGGTTGGG GTGACCTCGG AGAATAAAAA ATCCTCCGAA TGATTATAAC CTAGACTTAC 
361 AAGTCAAAGT AAAATCAACA TATCTTATCG ACCCAGATAT ATCTTGATCA ACGGACCAAG 
421 TTACCCTAGG GATAACAGCG CAATCCTATT TAAGAGNNCA TATCGACAAT NAGGGTANAC 
481 GANNTCGATG TTGGATCANG ACATCCCCAA TGGTGTAGAA GCTATTAATG GTTCGTTTGT 
541 TCAACGATAA ANGTNCTACG TGATCTGAGT TCAGANCCGA GCNATNCAGG TCGGTTTCTA 
601 TCTATTNACG ATNNCTNNCA GTACGANANG ACANGAGANN NNAGCNCCNT NACNANTNNC 
661 NCTNNNACNT ANTTATGAAT AAATCTAATN AANNNNTCGT NNCCNCTANC NAANGAGTNN 
721 AANAAAAA 
B 10.2: Sequencing alignment of cDNA subclone AA7#3 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AA7#3 : 117 ctaqcatqqacqqctaaacqaqqgtccaactqtctcttatctttaatcaqtqaaattqac 176 
. r iiiTiiiT iiffiiiiii丫iTniiiiiiil^iNmimiiiiii丫I丫Ni旧11 
Mouse mitochondrion： 2061 ctagcatgaacggctaaacgagggtccaactgtctcttatctttaatcagtgaaattgac 2120 
AA7#3 : 177 ctttcaqtqaaqaqgctgaaatataataataaqacgaqaaqaccctatqqaqcttaaatt 236 
. , , . m m 了 I 化 而 i i T m m i i i i i i i i 丫 i i t i t i i 丫 i m i N 而 i i i i i m 
Mouse mitochondrion： 2121 ctttcagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaatt 2180 
AA7#3 : 237 atataacttatctatttaatttattaaacctaatgqcccaaaaactataqtataaqtttq 296 
. ^ , . i i i i i i i m i i i i i i i i i i i i i i i i i i i i m i丫！ i i i i i i i i i i m t i m i丫 I I I丫 
Mouse mitochondrion： 2181 atataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttg 2240 
AA7#3 ： 297 aaatttcqqttgqqqtgacctcqgaqaataaaaaatcctccqaatgattataacctaqac 356 
i i i i i i i f f i i 而 i T i i i i 丨而 m m i i m i i i i 丫 m t i i i i i i i m i t i i 
Mouse mitochondrion： 2241 aaatttcggttggggtgacctcggagaataaaaaatcctccgaatgattataacctagac 2300 
AA7#3 ： 357 ttacaaqtcaaaqtaaaatcaacatatcttatcqacccaqatatatcttqatcaacqqac 416 
I I I I I I T I I I I I T I I I I I I I I I I I I I I I I I I I T l l l l l T l l l i l l I I T I I I I I I T T I I 
Mouse mitochondrion： 2301 ttacaagtcaaagtaaaatcaacatatcttattgacccagatatattttgatcaacggac 2360 
AA7#3 ： 417 caagttaccctaqgqataacagcqcaatcctatttaaqagnncatatcqacaatnaqgqt 476 
M I T M M M M T T T M M M T I T M M M M M I M T I T I I I I M T I I M I I IT 11 
Mouse mitochondrion： 2361 caagttaccctagggataacagcgcaatcctatttaagagttcatatcgacaattagggt 2420 
AA7#3 ： 477 anacqanntcqatgttqgatcangacatccccaatqqtqtagaaqctattaatqqttcgt 536 
M M I I I I T I I T M T T I I I I T I I 1111111ITTITI I I I IT 1111111ITTI11 � 
Mouse mitochondrion： 2421 ttacgacctcgatgttggatcaggacat-cccaatggtgtagaagctattaatggttcgt 2479 
AA7#3 ： 537 ttqttcaacqataaanqtnctacqtqatctgaqttcaqanccqaqcnatncaqqtcqgtt 596 
I I T I I I I I I T I I I I Tl I I I I T I T I I I I T I T I I I I I I I T i l l I I I I T T I I T T I I � � � 
Mouse mitochondrion： 2480 ttgttcaacgattaaagtcctacgtgatctgagttcagaccggagcaatccaggtcggtt 2539 
AA7#3 ： 597 tctatctattnacqatnnctnncaqtacgananqacanqaqa 638 
I l i l l l M I I I I T I I I I I I T I I I T I I T I I I T i l l � � i 
Mouse mitochondrion： 2540 tctatctatttacgatttctcccagtacgaaaggacaagaga 2581 B 10.3: Summary of sequence alignment of cDNA subclone AA7#3 with mouse mitochondrion 
FluoroDD gel AA (API + ARP2) Sequencing : J „„ ^  „ •丄…n , , J FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa ( W ) PPARa ( - / - ) L D . after ^coRI Primer Blast search (% 
no CTL Wy CTL| W^^ size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus clone LA9 0 
AA7 + ++ + + 640 AA7#3 710 forward mitochondrion, complete 495/522 
(-20) genome (16300 bp) (94%) 
* Sequence of primer was not compl tely matched with the expected sequence. 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51 .1 : DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 GCCAAGCTTG NGTACCGAGC TCGGATCCAC TAGTAACGGC CGCCAGTGTG CTGGAATTCG 
61 GCTNGTAATA C G A C T C A C T A T A G G G C T T T T T T T T T T T G A C CTTCTCTAGG TTAGAGGGTG A P I 
121 TACGTATATA TTTTATTTAG ATTTTATTCA TAAATTAAGT TGAGAGCGCT TATTTGTAAG 
181 GTGGCTCTAT TTCTCTTGTC CTTTCGTACT GGGAGAAATC GTAAATAGAT AGAAACCGAC 
241 CTGGATTGCT CCGGTCTGAA CTCAGATCAC GTAGGACTTT AATCGTTGAA CAAACGAACC 
301 ATTAATAGCT TCTACACCAT TGGGATGTCC TGATCCAACA TCGAGGTCGT AAACCCTAAT 
361 TGTCGATATG AACTCTTAAA TAGGATTGCG CTGTTATCCC TAGGGTAACT TGGTCCGTTG 
421 ATCAAAATAT ATCTGGGTCA ATAAGATATG TNGATTTTAC TTTGACTNGT AAGTCTAGGT 
481 NATAATCATT CGGANGATNT TTATTCTNCG AGGTCNNCCN ANNGAAATTT CAACTTATAC 
541 TATAGTTTTN GGNCATANGT TTATAATAAA TAGATAGTAT ATANTTANCN CATAGGTCTC 
601 TGTCTATATA ATTCGCTCTC CTGAAGTCAT CACTATNANA TGAACGTGAN NGTTAGCGTA 
661 GN 
B 11.2: Sequencing alignment of cDNA subclone AA7#5 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AA7#5 ： 99 accttctctaqqttaqaqqqtqtacgtatatattttatttaqattttattcataaattaa 158 
. ^ , . i i i i m m f f i i i 了 i T f f i 了 m Y i m m m i i m Y i m i i i m i m i m 
Mouse mitochondrion： 2674 accttctctaggttagagggtgtacgtatatattttatttagattttattcataaattaa 2615 
AA7#5 ： 159 gttqagaqcqcttatttqtaaqgtqqctctatttctcttqtcctttcqtactqqqaqaaa 218 
. . 丫 iiYi 了 l Y i l ^ i i i i i i Y i i i f f i n m i m m m l ^ m m Y m i f f f i l ^ i i 
Mouse mitochondrion： 2614 gttgagagcgcttatttgtaaggtggctctatttctcttgtcctttcgtactgggagaaa 2555 
AA7#5 ： 219 tcqtaaataqatagaaaccqacctqqattqctccqqtctqaactcaqatcacqtaqqact 278 
. ^ , . i i T i m i i T m T i i m t m i T f m l ^ m T f m 化 m i 了 m i i ? i i n m 
Mouse mitochondrion： 2554 tcgtaaatagatagaaaccgacctggattgctccggtctgaactcagatcacgtaggact 2495 
AA7#5 ： 279 ttaatcqttqaacaaacqaaccattaataqcttctacaccattggqatqtcctqatccaa 338 
. . iMMi了 M丫 imm化mmm 化 mmimiTff 丨 iliiil^iim 
Mouse mitochondrion： 2494 ttaatcgttgaacaaacgaaccattaatagcttctacaccattgggatgtcctgatccaa 2435 
AA7#5 ： 339 catcqaqgtcqtaaaccctaattqtcgatatqaactcttaaataqqattqcqctqttatc 398 
. . MM了iTfii化miimiiT 丨丨 TimTmmmmnml^ 化化 m 
Mouse mitochondrion： 2434 catcgaggtcgtaaaccctaattgtcgatatgaactcttaaataggattgcgctgttatc 2375 
AA7#5 ： 399 cctagqgtaacttqqtccqttqatcaaaatatatctqqqtcaataaqatatqtnqatttt 458 
i i i i f f f i i m i n i i i 了 l i t m i m m i i i T f f i m m l m l i 111111 
Mouse mitochondrion： 2374 cctagggtaacttggtccgttgatcaaaatatatctgggtcaataagatatgttgatttt 2315 
AA7#5 ： 459 actttqactnqtaaqtctaqqtnataatcattcqqanqa-tntttattctncqaqqtc-n 516 
, . I I I I I T I I I T I I I T I I I I T T I I I I I I I I I I I T T I T l I l l l l l l t l I T I T T I I 
Mouse mitochondrion： 2314 actttgacttgtaagtctaggttataatcattcggaggattttttattctccgaggtcac 2255 
AA7#5 ： 517 nccnanngaaatttc-aacttatactatagtttt 549 
II I 化 m i l m m m i m 了 i m 
Mouse mitochondrion： 2254 cccaaccgaaatttcaaacttatactatagtttt 2221 B 11.3: Summary of sequence alignment of cDNA subclone AA7#5 with mouse mitochondrion 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after £coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 0 
AA7 + ++ + + 640 AA7#5 710 mitochondrion, complete 440/454 
reverse genome (16300 bp) (96%) 
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B 51 .1 : DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 TATACGACTC ACTATAGGGC GAATTGGGCC CTCTAGAATG CATGCTCGAG CGGCCGCCAG 
6 1 TGTGATGGAT ATCTGCAGAA TTCGGCTTAG CGGATAACAA TTTCACACAA GGAGCTAGCA A R P 2 * 
121 TGGTGAAGAA GGGGACCATG ATGATTGGCT ACCAGCCCCA TGGGACCCGG GCCAACTTCT 
181 TCCGAATGGT GGTGGCCAAC CCCATACTGG CCCAGGCCGA TATANGATTT CCTTCTNNGG 
241 CGAGCTGGAG CTCCTGGGCC AGGAACCTGT GAGCTGCTTC TGCTCTCTGC CCCACCCAAA 
301 GCTCTGCGTA GTCTCCTGGG TTCTCAAAAT CGACCTTTCT AGGAAACAGT GGCCTTGNAC 
361 TGTGTGTGCT CCCACACACT CACTCTCCCA GCTAAGTATT GGCTGTCAGG AAGGTGTGCT 
421 AAACACACAC ACCTACTGTA TGTTCTTAAA CGAAAATATG CTTANATNAA AAGTNGGGCA 
481 ACAANGGNGC ACACACCCNT TTANCTACCC AGCATTGGGG NGGGACNNAA AGCAGCCCAG 
5 4 1 TNNTGAANGC CAGCCTGAAC TACAGAGCTN GGCTACACAG AAAAACTGTC TCNNANANNN 
601 AAAGCCCNNN TNNTNNATTN NNNTTNCCGC CNGATTNCCN GCCCNCNNGG CNNGGCNGNT 
661 NCNTANGTNG GATNCNGAGC CCTCGGNTAN NCCAAGCCNT NNGGCNGTTA NNTCTTTGGN 
721 NTNNTNNNCG N 
B 12.2: Sequencing alignment of cDNA subclone AA10#1 with mouse cysteine sulfinic acid 
decarboxylase (Csad) by BLAST searching against the National Center for Biotechnology 
Information database 
AA10#1 : 118 qcatqqtqaaqaaqqqqaccatqatqattqqctaccaqccccatgqqacccqqqccaact 177 了iiiTfiYiit ifrffiiiiit itiiiTfmiiil^imiTffmiTffiimi 
Mouse Csad： 1500 gcatggtgaagaaggggaccatgatgattggctaccagccccatgggacccgggccaact 1559 
AA10#1 : 178 tcttccgaatqgtqqtgqccaaccccatactqqcccaqqccqatatanqatttccttctn 237 
m m 丫 M i T f i T f i n i M i M M i M i i T f m i T f i 丨 化 m T i i i i i i i i i i 
Mouse Csad： 1560 tcttccgaatggtggtggccaaccccatactggcccaggccgatata-gatttccttct- 1617 
AA10#1 : 238 nqqcqaqctqqaqctcctgqqccaqqaacctqtqaqctqcttctgctctctqccccaccc 297 
f f l 丫 l l ^ i n i Y l l l l l T T f m T f I I I I T I T I T I I T I I I I I T I I I I I I T I I I I I I I I 
Mouse Csad： 1618 gggcgagctggagctcctgggccagg-acctgtgagctgcttctgctctctgccccaccc 1676 
AA10#1 : 298 aaaqctctgcqtagtctcctqgqttctcaaaatcqacctttctaqqaaacaqtqqccttq 357 
M l i i i Y i Y i i t M r n i f T f i i M m m i h i m m f f m u ^ m i ? 
Mouse Csad： 1677 -aagctctgcgtagtctcctgggttctcaaaatcgacctttctaggaaacagtggccttg 1735 
AA10#1 : 358 nactgtqtgtqctcccacacactcactctcccaqctaaqtattqqctqtcaqqaaqqtqt 417 
mTiYiYitmiiimiimiimmYimtmiTfuhiffuffiYj 
Mouse Csad： 1736 -actgtgtgtgctcccacacactcactctcccagctaagtattggctgtcaggaaggtgt 1794 
AA10#1 : 418 qctaaacacac 428 l l l l l l l l l l 
Mouse Csad： 1795 -ctaaacacac 1804 B 12.3: Summary of sequence alignment ofcDNA subclone AA10#1 with mouse Csad 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after EcoRl Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml3 Mus musculus cysteine e 
AAIO + ++ + + 500 AA10#1 550 forward , sulfinic acid 304/311 
^ … ,，⑴ decarboxylase (Csad) ⑴。/、 
^ (2265 bp) (WZo) 
* Sequence of primer was not completely matched with the expected sequence. 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71 .1 : DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 TCAGCCAGCT TGNGTACCGA GACTCGGATN CACTATTAAC GGCCGCCAGT GTGCTGGAAT 
61 TCGGCTGTAA TACGACTCAC TATAGGQACT TTTTTTTTTT TGAGANCAGT TTCNNTGTGT API 
121 AGACCCAGAC NNTGTAGTCC AGGACTGGNC CTCAAACTGG ACTGCTTCTG TNACCCCCAA 
181 TGCTGGTAGT AAAGGTGTGT GCCCCTGTGN CCCANNTTAA TAAAAGACAT ATTTCGTAAG 
241 ANNATAACTG TAGTGTGTTT AAGAACACCC TTCCTGNNAG CCAATACTTA GACTGGGAGA 
301 GTGAGTGTGT GGGANNNNNA NCAACAGTCA AGGCCNACTG TTTCCCTANG AAAAGGTCCG 
361 ATTTTGANGA NACCCAGGAG AACTANCGNC AGAGCTTGGG TGGGGNCAGA NGANGCAGAA 
421 AGCCGCNCCA CAGGTCCCTG GNCCCAGGAG NCTCCNGNCT CGCCCCAGAA ANNAAAATCT 
481 ATANTCGGCC CCGCCGCCAC GTAATGGGNG NTCGGCCCCC CCCCCCCTNC CCGAANNAAC 
541 GTNNGGNCCC GGGGGTCCCC ANTNNGGGCC TNGGTANGCC CANTTTATTN CNTNGGGTNN 
6 0 1 CCCCCTNTCT TTCCCNCNNT GGCTAGCCTC CCNTNNGNTN GNTGANNNTT TNGNTTANTT 
661 CCCGGNTNAN NGNCCCGAAA TTNTTTGGGC NNNNNTNNTN NNCTTTCCCN CCNNNGGGNG 
721 GGGGGAGGGT TTTNGNNGNC NNT 
B 13.2: Sequencing alignment of cDNA subclone AA10#1 with mouse cysteine sulfinic acid 
decarboxylase (Csad) by BLAST searching against the National Center for Biotechnology 
Information database 
AA10#1 : 133 tqtagtccaggactqgncctcaaactqgactgcttctqtnacccccaatgctqqtaqtaa 192 ^ I T I I T I I I I T T I ITT M M M I M T T I I T I I I I I T I 1111111 I I I ITT I IT 111 
Mouse Csad： 1917 tgtagtccagg-ctgg-cctcaaactgg-ctgcttctgtc-cccccaatgctggtagtaa 1862 
AA10#1 : 193 aggtgtgtgcccctgtqncccannttaataaaaqacatatttcqtaagannataactqta 252 I T T I T I T I T I I I I I T I T M M M M I I M I T I I I I I I I I T I I I T I I I LLLLLL 
Mouse Csad： 1861 aggtgtgtgcccctgtg-cccaacttaataaaag-catatttcgtaagaacat-actgta 1805 
AA10#1 : 253 gtqtgtttaagaacacccttcctgnnagccaatacttagactgggagaqtqagtqtgtqq 312 T I T I T I I I I I I I I I I I I I I T I T I I I I I I I I I I T I I T T T I T I T I T I T I T I T I T T 
Mouse Csad： 1804 gtgtgttta--gaca-ccttcctgacagccaatacttag-ctgggagagtgagtgtgtgg 1749 
AA10#1 : 313 ^a 314 
Mouse Csad: 1748 ga 1747 
B 13.3: Summary of sequence alignment of cDNA subclone AA10#1 with mouse Csad 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
g fragment I.D. after £coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cysteine ^^  ^^ 
AAIO + ++ + + 500 AA10#1 550 M13 s^lfinjc acj^  163^2 
reverse decarboxylase (Csad) 湖o/、 
(2265 bp) (89 Z。） 
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B 71 .1 : DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CCCACCNCAC TTNAGGGCGA ATTGGGCCCT CTAGATGCAT GCTCGAGCGG CCGCCAGTGT 
61 GATGGATATC TGCAGAATTC GCCCTTAGCG GATAACAATT TCACACAGGA GCTAGCATGG ARP2 
121 CAGCGGCGTT CCGCAGAGGC TGCAGGGTCC TGAGAAGTGT TTCTCATTTT GAGTGTCGAA 
181 CACAACACTC GAAAGCGGCT CACAAGCAGG AGCCCGGATT AGGGTTTAGT TTTGAGTTGA 
241 CGGAACAGCA GAAAGAGTTT CAAGCAACTG CCCGCAAGTT TGCCAGAGAG GAGATTATCC 
301 CCGTCGCCCC GGAATATGAC AAAAGCGGGG AGTACCCGTT CCCTCTCATC AAAAGAGCCT 
361 GGGAACTCGG CTTGATCAAC GCGCACATTC CGGAAAGTTG CGGTGGTCTT GGCCTGGGAA 
421 CGTTCGATGC TTGTTTAATT ACCGAAGAGT TGGCGTATGG GTGTACAGGG GTGCAAACTG 
481 CTATTGAAGC AAATTCTTTG GGGCAAATGC CTGTGATTCT TGCTGGAAAT GATCAAAAAA 
541 AAGCCCTATA GTGAGTCGTA TTACAAGGGC GAATTCCAGC ACACTGGCGG CCCGTTACTA 
601 GTGGATNCGA GCTCGGTACC AAGCTTGATG CATAGCTTGA GTATTCTATA GTGTCACCTA 
661 AATAGCTNGG CGTAATCATG GTCATAGCTG TNNCCTGTGT GAAATGGTTA TCCGCTCACN 
721 NTTNCACACA AATACNAGCN GGNANCATAA GTGTAAGNCN GGGNTGCTAA TGAGTGAGCT 
781 AA 
B 14.2: Sequencing alignment of cDNA subclone AA12#4 with mouse acetyl-coenzyme A 
dehydrogenase, medium chain (MCAD) by BLAST searching against the National Center for 
Biotechnology Information database 
AA12#4 ： 116 catqqcaqcqgcqttccqcagagqctgcagqgtcctqaqaagtgtttctcattttgagtg 175 
iiiTfii 丫iffiYiiiiYiil^ ffiiYiifrfiiiiYiYiil^ Yiiiiiiiiml^ Yit 
Mouse MCAD： 3 catggcagcggcgttccgcagaggctgcagggtcctgagaagtgtttctcattttgagtg 62 
AA12#4 ： 176 tcgaacacaacactcqaaaqcqqctcacaagcaggagcccqgattagggtttagttttga 235 
iiYiiiimiimYii 丨浦 iimiiti 丨而mffimtnim丫iiii丫 I 
Mouse MCAD： 63 tcgaacacaacactcgaaagcggctcacaagcaggagcccggattagggtttagttttga 122 
AA12#4 ： 236 qttqacqqaacaqcaqaaagaqtttcaaqcaactqcccqcaaqtttgccagagaqqagat 295 
1^1丫11^?11丨1丫11丫111丫1丫111丨1丨丫1丨1丨丨丫11丨丫丨11丫1丨1化|1^丫1而11 
Mouse MCAD： 123 gttgacggaacagcagaaagagtttcaagcaactgcccgcaagtttgccagagaggagat 182 
AA12#4 ： 296 tatccccqtcqccccqqaatatqacaaaagcgggqaqtacccgttccctctcatcaaaag 355 
i i i i m t i i t m i f f i i i i i 丫 m i l l丫 I 而 i T i i i i i 丫 i i i i i i i i i i m m T 
Mouse MCAD： 183 tatccccgtcgccccggaatatgacaaaagcggggagtacccgttccctctcatcaaaag 242 
AA12#4 ： 356 aqcctgqqaactcqgcttqatcaacqcqcacattccqqaaaqttgcgqtqqtcttqqcct 415 
itiiifffmiiffiiil^imititiiiiiiiiniiitiiYiniffiiiiffiii 
Mouse MCAD： 243 agcctgggaactcggcttgatcaacgcgcacattccggaaagttgcggtggtcttggcct 302 
AA12#4 : 416〒〒竹fcj；〒〒丨Cj；竹〒〒(j；丨〒〒丨丨竹竹竹(|：(|：竹T冗行丨〒〒(j：〒丨flj：〒行〒打fcj：，行〒〒丨〒(j：，475 
Mouse MCAD： 303 gggaacgttcgatgcttgtttaattaccgaagagttggcgtatgggtgtacaggggtgca 362 
AA12#4 ： 476 aactqctattqaagcaaattctttqqqqcaaatqcctqtgattcttgctqgaaatqatc 534 
iMi t i i i i i t i i l ^ i imi i i i t n丫mi l丫 I I I丫 i l ^ i i i i iT i iT fmi了 I I I 。， 
Mouse MCAD： 363 aactgctattgaagcaaattctttggggcaaatgcctgtgattcttgctggaaatgatc 421 B 14.3: Summary of sequence alignment ofcDNA subclone AA12#4 with mouse MCAD 
FluoroDD gel AA (API + ARP2) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I D. after EcoRl Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus acetyl-
M13 coenzyme A 0 
AAI2 + ++ + + 470 AA12#4 500 forward dehydrogenase, medium 419/419 
(-20) chain (MCAD) (100%) 
L _ _ L _ _ J (1857 bp) 
301 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51 .1 : DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AGACTATTAG GTGACNCTAT AGAATACTCA AGNCTATGCA TCAAGCTTGG TACCGAGCTC 
61 GGATCCACTA GTAACGGCCG CCAGTGTGCT GGAATTCGCC CTTGTAATAC GACTCACTAT API* 
121 AGGGCTTTTT TTTGATCATT TCCAGCAAGA ATCACAGGCA TTTGCCCCAA AGAATTTGCT 
181 TCAATAGNCA GTTTGCNCCC CTGTACACCC ATACGACCAA CTCTTCGGTA ATTAAANCAA 
241 GNCATCNGAA ACGTNNCCCA GGGNCCAAGA ANCCANCCGC CAAACTTTTN CCGGGAAATG 
301 GTGNCGNCGN TTGNNNNAAG NCCGANGTNC CCCAGGGCTC TTTTGATGAA GANGGAAACN 
361 GGGTACTCCC CNCTTTTNNT ATATNNCGGG GCGACNGGNN TAATNCTCCT CNCTGNNAAA 
421 CTNNCGGGNN CNNTGCTTGG AAACTCTTTC CTGGCTGTTC CCGGTTAANC CNNAAAAACT 
481 AAAAACCCTN AAATNCCGGG GGCTNCCTGC CTTTGGNNNA GNCCGCTTTT CCGAGGTGGT 
541 TGNTGGTTNC GACACCNNAA AAAATGANNA AAACNCTTTC NNAGGGAACC CTGNAGGNCT 
6 0 1 CCTGGGCGAA NCGNCCGNCN GNNCANTGCC AACCNNCCCT GGTGNNNAAA AATTGNTTAA 
661 TTNCCGCTAA NGGGGGCGAA TTNNTNGNNN NANTNATTNC ACTNCNNACN NNGGNCNNCC 
721 GCGNTTCNNA CNTTNNNNNN NANGANNNNC CCCNNTTTNN CCCTANTNNN TGGANNTNGT 
781 AANTTAAANN AAATTTAACN NNNGNNNCGG 
B 15.2: Sequencing alignment of cDNA subclone AA12#4 with mouse acetyl-coenzyme A 
dehydrogenase, medium chain (MCAD) by BLAST searching against the National Center for 
Biotechnology Information database 
AA12#4 ： 134 gatcatttccagcaagaatcacaqgcatttqccccaaaqaatttqcttcaataqncaqtt 193 
？ M M M M I l T l M l ^ M M M T f m i l 化 l i m l ^ M I 丨化 i m u Y l l T l l 
Mouse MCAD： 421 gatcatttccagcaagaatcacaggcatttgccccaaagaatttgcttcaatag-cagtt 363 
AA12#4 ： 194 tqcncccctqtacacccatacgaccaactcttcgqtaattaaa 236 
111 I I I I I T I I I I I I I I I I I T l l l l l l l l l l T T I l l l l l l l 
Mouse MCAD： 362 tgcacccctgtacacccatacg-ccaactcttcggtaattaaa 321 
B 15.3: Summary of sequence alignment ofcDNA subclone AA12#4 with mouse MCAD 
FluoroDD gel AA (API + ARP2) Sequencing 
p, P P A R a (+/+) P P A R a (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
^ fragment I.D. after EcoRl Primer Blast search (% 
• CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus acetyl-
M n coenzyme A 5e-38 
AAl2 + ++ + + 470 AA12#4 500 dehydrogenase, medium 100/103 
reverse chain (MCAD) (97%) 
I I I I I (1857 bp) I 
* Sequence of primer was not completely matched with the expected sequence. 
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B 48.1: DNA sequence ofcDNA subclone AFl #8 (APIO & ARPi:3) using Ml 3 forward (-20) primer 
1 TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG CAGAATTCGC 
61 CCTTAGCGGA T A A C A A T T T C ACACAGGAGA CCATTGCAAA CCTGCTAAAC CATTGCCTAA ARP3 
121 GGAAATGGAA GACTTTGTTC AGAGCTCTGG AGAGCATGGT GTGGTGGTGT TTTCTCTGGG 
181 GTCAATGGTC AGTAATATGA CAGAAGAAAA GGCCAATGCA ATTGCATGGG CTCTTGCCCA 
241 GATTCCACAA AAGGTTCTTT GGAGATTTGA CGGCAAAACT CCAGCCACCT TAGGACCCAA 
301 TACCAGAATC TACAAGTGGC TTCCCCAAAA TGATCTTCTT GGTCATCCAA AAACCAAAGC 
361 CTTTATAACT CATGGTGGCG CGAATGGACT CTACGAGGCG ATCCATCATG GAATCCCTAT 
421 GATTGGCATT CCTTTGTTTG GAGAACAACA TGATAACATT GCTCACATGG TGGCCAAAGG 
481 AGCAGCTGTT ACATTGAATA TCAGAACGAT GTCCAGGTCA GATTTGCTCA ATGCACTGGA 
541 GGAAGTCATA GACAATCCTT TCTATAAAGA GAATGCTATG TGGTTGTCAA CCATTCACCA 
601 TGACCAGCCT ATGAAGCCCC TGGACAGAGC AGTCTTCTGG ATNGAGTTTG TCATGCGCCA 
661 CAAAGGNGCC AAGCATCTGA GACCACTNGC ATACNACCTC ACCTGGTANC AGTACCACTC 
721 TCTGNATGTG ATNGNATCCT GNNGCNTTNG TANNTNNTGT ACCCNCATGT AAATCTTTTG 
781 TGGTAACCAN NNT 
B 16.2: Sequencing alignment of cDNA subclone AB7#2 with mouse UDP-glucuronosyltransferase 2 
family, member 5 (UGT2b5) by BLAST searching against the National Center for 
Biotechnology Information database 
AB7#2 ： 91 ccattqcaaacctqctaaaccattgcctaagqaaatqgaagactttgttcagaqctctqq 150 
I I I I I T I I I I I I I T I I I I I I I I I T I I I I I T T I M T T I I T i I I I T I I I T I T I I I I T T 
Mouse UGT： 868 ccattgcaaacctgctaaacccttgcctaaggatatggaagaatttgtccagagctctgg 927 
AB7#2 ： 151 agagcatqgtgtgqtggtgttttctctgqgqtcaatgqtcaqtaatatgacagaagaaaa 210 
111 M I T T I I I T T I T T I l l l l l l l l T T T M I M T T I i T I I I I IT 11 I I I I I I 111 
Mouse UGT： 928 agaccatggtgtggtggtcttttctcttgggtcaatggttagtaacatgacagaagaaaa 987 
AB7#2 ： 211 qqccaatqcaattgcatggqctcttqcccagattccacaaaaggttctttgqagatttga 270 
T T I I l I T I I I I I T I I I T T T 111 I I I 11 I I I 111111111iT l l1111 ITT T I I I I T 
Mouse UGT： 988 agccaacgcaattgcatgggcccttgcccagattccacaaaaggttctttggaaatttga 1047 
AB7#2 ： 271 cqqcaaaactccaqccaccttaqqacccaataccaqaatctacaagtqqcttccccaaaa 330 
I T T I I I l l M i l l I I I I I I T T I I I I I I I I I I T I M M M T I T T I l l l l l I I 
Mouse UGT： 1048 tggcaaaaccccagcaactttaggacacaataccagagtgtacaagtggctcccccagaa 1107 
AB7#2 ： 331 tgatcttcttqgtcatccaaaaaccaaagcctttataactcatqqtqqcgcgaatqqact 390 
I I I I I I I I T T I I I I I I l l l l l l l l i l T I I I I I M M I M I T T I T T 11 M I T T I 
Mouse UGT： 1108 tgacctccttggtcatccaaaaaccaaagcctttgtaactcatggtggggccaatggtgt 1167 
AB7#2 ： 391 ctacqaqgcgatccatcatggaatccctatgattggcattcctttgtttgqaqaacaaca 450 
iiiiTiTTiTiii miiffiiiiiiiiitmffiiiiiiiii丫iiiff丨化II II 
Mouse UGT： 1168 ctacgaggcgatctatcatggaatccctatgattggcattcctttgtttggagaacagca 1227 
AB7#2 ： 451 tgataacattqctcacatqqtqgccaaagqaqcaqctgttacattqaatatcagaacgat 510 
I T I I I I I I I I T I I I M T T I T T M M I T T I T M T M T M 111 111 11111 I I I 11 I I � 
Mouse UGT： 1228 tgataacattgcccatatggtggccaaaggagcagctgttgcattgaatatcagaacaat 1287 
AB7#2 ： 511 gtccaqgtcaqatttqctcaatqcactqgaqgaagtcataqacaatcctttctataaaga 570 
T i l I T I I I T I I I T I I I I I I T I I I I T T I T T I T I M I I T I M M M M M I M M I 
Mouse UGT： 1288 gtcaaagtcagatgtgctcaatgcactggaggaggtcatagaaaatcctttctataaaaa 1347 
AB7#2 ： 571 qaatgctatqtqqttgtcaaccattcaccatgaccaqcctatqaagcccctqqacaqaqc 630 
T M I T M I I T I T T I I T M I M M M M M M T M I I T I M M T I I M I M T T M I T TI 14。， 
Mouse UGT： 1348 gaatgctatgtggttgtcaaccattcaccatgaccagcctatgaaacccctggacagggc 1407 
AB7#2 ： 631 agtcttctggatnqaqtttgtcatqcqccacaaaggngccaagcatctqagaccactngc 690 
I T I I I I I I T T I I T I T I I I T I M T I T I I I I I I T I T I I I I T I M I T I T I M M I ^口 
Mouse UGT： 1408 tgtcttctggattgagtttgttatgcgccacaaaagagccaagcacctgagaccacttgg 1467 
AB7#2 ： 691 atacnacctcacctqgtancaqtaccactctctqnatqtqat 732 
I I M M I I I I T T I I I I T I I I I I I I I I I I T I I T I T I I … � 
Mouse UGT： 1468 acataaccttacctggtaccagtaccactctctggatgtgat 1509 B 16.3: Summary of sequence alignment of cDNA subclone AB7#2 with mouse UGT2b5 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
: I , … I F l u o r o D D Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment LD. after EcoRI Primer Blast search (% 
no. CTL Wy— CTL size (bp) cut (bp) (Transcript size) Identity) 
M13 Mouse UDP- 。 AB7 + ++ + + 850 腦 2 900 forward 呂丨：；二二se 2 (-20) (UGT2b5) (1648 bp) (”*,。） 303 
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B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 TAGAATACTC AAGCTATGCA TCAAGCTTGG TACCGAGCTC GGATCCACTA GTAACGGCCG 
6 1 CCAGTGTGCT GGAATTCGCC CTTGTAATAC GACTCACTAT A G G G C T T T T T T T T T T T G G T G A P S * 
121 GTAAAATTTT ATTCATGTAA TGCATTATCA ATGAGTTCTA CTCATTCTTC ATTTTCTTTT 
181 CTTTCTTTAC AAAGAATCGG TAAACAAACA AGAAGCACTT TACAATGAGG GCTACAATGA 
241 ATGTCACAAA AGCAAGCAGG AATCCAATCA CATCCAGAGA GTGGTACTGG TACCAGGTGA 
301 GGTTGTATGC AAGTGGTCTC AGATGCTTGG CCCCTTTGTG GCGCATGACA AACTCAATCC 
361 AGAAGACTGC TCTGTCCAGG GGCTTCATAG GCTGGTCATG GTGAATGGTT GACAACCACA 
421 TAGCATTCTC TTTATAGAAA GGATTGTCTA TGACTTCCTC CAGTGCATTG AGCAAATCTG 
481 ACCTTGACAT CGTTCTGATA TTCAATGTAA CAGCTGCTCC TTTGGCCACC ATGTGAGCAA 
541 TGTTATCATG TTGTTCTCCA AACAAAGGAA TGCCAATCAT AGGGATNCCA TGATGGATCG 
6 0 1 C C T C G T A G A G T C C A T T C G C G C C A C C A T G A G T N A T A A A G G C T T T G G T T N T T G G A T G A C C A A 
661 GAAGATCATT TTGGGGANGC ACTNGTANGT TCTGGTATTG GGTCTAAGGT GGCTGGAGTN 
721 NNCCGTCAAA TCTCCAAGAA CCTTNGTGAA A 
B 17.2: Sequencing alignment of cDNA subclone AB7#8 with mouse UDP-glucuronosyltransferase 2 
family, member 5 (UGT2b5) by BLAST searching against the National Center for 
Biotechnology Information database 
AB7#8 ： 143 cattatcaatqagttctactcattcttcattttcttttctttctttacaaaqaatcggta 202 
M M 111 IT IT l l l i m i l l l i m m i l l l l l l l l i l l l l l l l l T I I I I T T I I 
Mouse UGT： 1633 cattgtcagtgagctctactcattcttcattttattttctttctttacaaagaatcggta 1574 
AB7#8 ： 203 aacaaacaagaagcactttacaatgaqqqctacaatgaatqtcacaaaagcaagcaqqaa 262 
I I I I I I I T I T l l l l l l l l l I ITT I I I I IT IT M M 111 IT I T i l I 
Mouse UGT： 1573 aatgaacaagaggcactttacactaaggactatagtggttgccacacaagagagtaggaa 1514 
AB7#8 ： 263 tccaatcacatccagaqagtggtactggtaccaggtqaqqttgtatgcaaqtqgtctcaq 322 
I I I M I I I I i m i 丫 I丫 I了 i f f l l l l f f l l l l l f f i I T i l I I I I I I T I T T I I I I I T 
Mouse UGT： 1513 tccaatcacatccagagagtggtactggtaccaggtaaggttatgtccaagtggtctcag 1454 
AB7#8 ： 323 atgcttqqcccctttqtqqcqcatqacaaactcaatccaqaaqactqctctgtccaqqqg 382 
I I T I I I T T I I I I I T I T T I l l l T I I I I I I I I I I I I I I T I I T I IT 11 I I I 11ITIT 
Mouse UGT： 1453 gtgcttggctcttttgtggcgcataacaaactcaatccagaagacagccctgtccagggg 1394 
AB7#8 ： 383 cttcataqqctqqtcatgqtqaatqqttqacaaccacatagcattctctttatagaaagq 442 
i m m f f i i f f i i i i f f i Y m f f i i 丫 i i i i i i i i i i i T i i i i i M I M M T M I T 
Mouse UGT： 1393 tttcataggctggtcatggtgaatggttgacaaccacatagcattctttttatagaaagg 1334 
AB7#8 ： 443 attqtctatqacttcctccaqtqcattgaqcaaatctqaccttgacatcgttctgatatt 502 
l i r i l l l l T I I I I I I I I I T I T I I I I T I T I I l l l l l l l I I T I I I I T I I I I T I I I I I 
Mouse UGT： 1333 attttctatgacctcctccagtgcattgagcacatctgactttgacattgttctgatatt 1274 
AB7#8 ： 503 caatqtaacagctqctcctttgqccaccatgtqaqcaatqttatcatqttqttctccaaa 562 
I I I I T I I I I T I I T I I I I I I I T T I I I I I I I i n i l l l T I I I I I I I T I T I I I I I I I I I ， … 
Mouse UGT： 1273 caatgcaacagctgctcctttggccaccatatgggcaatgttatcatgctgttctccaaa 1214 
AB7#8 ： 563 caaaggaatgccaatcataggqatnccatqatqgatcqcctcqtaqaqtccattcgcqcc 622 
I I I I T T I I I T I I I I I I I I I T T T I I I I I I T I i 111 i l l 11 I I I I I I M i l l T l I I 
Mouse UGT： 1213 caaaggaatgccaatcatagggattccatgatagatcgcctcgtagacaccattggcccc 1154 
AB7#8 ： 623 accatqaqtnataaaqqctttqqttnttqqatqaccaaqaaqatcattttgqqq 676 
I I I I I T I T I I I I I T T I I I I T I I I I I T T I I T I I I I I T IT M i l l I TTTT，^� 
Mouse UGT： 1153 accatgagttacaaaggctttggtttttggatgaccaaggaggtcattctgggg 1100 B 17.3: Summary of sequence alignment of cDNA subclone AB7#8 with mouse UGT2b5 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
^ • PDAo" PPARn, ( / ^  FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment LD. after Ecom Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mouse UDP- Q 
AB7 + ++ + + 850 AB7#8 900 glucuronosyltransferase 2 432/534 
reverse family, member 5 <W»/、 
(UGT2b5)(1648 bp) ^ * Sequence of primer was not completely matched with the expected sequence. 
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B 71 .1 : DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CCAGACTATT TAGGTGACCT ATAGAATACT CNANNTATGC NTCAAGCTTG GTACCGAGCT 
61 CGGATCCACT AGTAACGGCC GCCAGTGTGC T G G A A T T C G C CCTTAGCGGA TAACAATTTC ARP3 
121 ACACAGGAGA CCATTGCACA TAGGACTTAT TCTTCTTACA TGACAAAAAA TTGCTCCCCT 
181 ATCAATTTTA ATTCAAATTT ACCCGCTACT CAACTCTACT ATCATTTTAA TACTAGCAAT 
241 TACTTCTATT TTCATAGGGG CATGAGGAGG ACTTAACCAA ACACAAATAC GAAAAATTAT 
301 AGCCTATTCA TCAATTGCCC ACATAGGATG AATATTAGCA ATTCTTNCCT TACAACCCAT 
361 CCCTCACTCT ACTCAACCTC ATAATCTATA TTATTCTTAC AGCCCCTATA TTCATAGCAC 
421 TTATACTAAA TAACTCTATA ACCATCAACT CAATCTCACT TCTATGAAAT AAAACTCCAG 
481 CAATACTAAC TATAATCTCA CTGATATTAC TATCNCTANG AGGCCTNNCA CCACTANCAN 
541 GATTCTNACC CAAATGANTT ATCATCACAG AACTTATAAA AANCACTGTC TANTATAGCA 
601 NACTCATAGC ANTATAGCTC TACTAACCTT CTTATCCGCC TATNANNANT ATACAATTCA 
661 CACATNNCAA A 
B 18.2: Sequencing alignment of cDNA subclone AB17#16 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AB17#16 ： 135 tgcacataqqacttattcttcttacatqacaaaaaattgctcccctatcaattttaattc 194 
. , , . I 了 i i i m f f i i i i i i i i m m i i i 丫 i m i i m i T i m m i m m i i i m i 
Mouse mitochondrion： 4284 tgcacataggacttattcttcttacatgacaaaaaattgctcccctatcaattttaattc 4343 
AB17#16 : 195 aaatttacccqctactcaactctactatcattttaatactagcaattacttctattttca 254 
. ^ , . iiiiiiiiiil^mimimmmiiiiiimiiiYiiiimiiiimim 
Mouse mitochondrion: 4344 aaatttacccgctactcaactctactatcattttaatactagcaattacttctattttca 4403 
AB17#16 ： 255 taqgqgcatqaqqaqqacttaaccaaacacaaatacqaaaaattatagcctattcatcaa 314 
i i f i T f i i i丫 i T f i M i i i i i M i i m i i i i i i i i t i i i i i i i i M T i i i i i m i i i i 
Mouse mitochondrion： 4404 taggggcatgaggaggacttaaccaaacacaaatacgaaaaattatagcctattcatcaa 4463 
AB17#16 ： 315 ttqcccacataqqatqaatattagcaattcttnccttacaacccatccctcactctactc 374 . ^ , . M T M I M M I T T I I T M I M M T I M M I M M M M M M M M M M M I I I M M 
Mouse mitochondrion： 4464 ttgcccacataggatgaatattagcaattctt-ccttacaacccatccctcactctactc 4522 
AB17#16 ： 375 aacctcataatctatattattcttacagcccctatattcataqcacttatactaaataac 434 
iiiimiiiiiiiiiiiiimiiii7iiimimiiii 化丨iMiimmm 
Mouse mitochondrion： 4523 aacctcataatctatattattcttacagcccctatattcatagcacttatactaaataac 4582 
AB17#16 : 435 tctataaccatcaactcaatctcacttctatqaaataaaactccaqcaatactaactata 494 . . M M M M M M M M M M M M M M M I T I M M M M M M T M M M M M M M 
Mouse mitochondrion： 4583 tctataaccatcaactcaatctcacttctatgaaataaaactccagcaatactaactata 4642 
AB17#16 ： 495 atctcactgatattactatcnctanqagqcctnncaccactancanqattctnacccaaa 554 . . I I I I I I I I T I I I I I I I I I I I I I I T I T T I I I LLLLLLLL I I T l l l l l I I I I I I _ 
Mouse mitochondrion： 4643 atctcactgatattactatccctaggaggccttccaccactaacaggattcttaccaaaa 4702 
AB17#16 ： 555 tqanttatcatcacaqaacttataaaaanc-actgtct-antatagc-anactcataqca 611 
I I I LLLLLLLLLLLTLLLLLLLLLLLL I I I I丫 I I I I MIL丫I I I I I I I I I T I I 
Mouse mitochondrion： 4703 tgaattatcatcacagaacttataaaaaacaactgtctaattatagcaacactcatagca 4762 
AB17#16 ： 612 nt-ataqctctactaa 626 I I I I T I I I I I I M I 
Mouse mitochondrion： 4763 ataatagctctactaa 4778 B 18.3: Summary of sequence alignment of cDNA subclone AB17#16 with mouse mitochondrion 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after ^-coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 0 
AB17 + ++ + + 620 AB17#16 650 mitochondrion, complete 478/496 
reverse genome (16300 bp) (96%) 
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B 71 .1 : DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 TATACGACTC ACTATAGGGC GAATTGGGCC CTCTAGATGC ATGCTCGNAG CGGCCGCCAG 
6 1 TGTGATGGAT ATCTGCAGAA TTCGGCTTAG CGGATAACAA T T T C A C A C A Q GAGACCATTG A R P 3 
121 CACATAGGAC TTATTCTTCT TACATGACAA AAAATTGCTC CCCTATCAAT TTTAATTCAA 
181 ATTTACCCGC TACTCAACTC TACTATCATT TTAATACTAG CAATTACTTC TATTTTCATA 
241 GGGGCATGAG GAGGACTTAA CCAAACACAA ATACGAAAAA TTATAGCCTA TTCATCAATT 
3 01 GCCCACATAG GATGAATATT AGCAATTCTT CCTTACAACC CATCCCTCAC TCTACTCAAC 
361 CTCATAATCT ATATTATTCT TACAGCCCCT ATATTCATAG CACTTATACT AAATAACTCT 
421 ATAACCATCA ACTCAATCTC ACTTCTATGA AATAAAACTC CAGCAATACT AACTATAATC 
481 TCACTGATAT TACTATCCCT ANGANGCCTC CACCACTAAC AGGATNCTNA CCAANATGAA 
541 TTATCATCAC AGAACTNATA AAAAACNACT GCCTAATTAT AGCANACTCA TAGCCATANT 
601 AGCTCTCTAA NCTATTCTTT ATACTCNNNT ANTTATTCAC TNNNCTANNN NATNNCCACC 
661 CACAATACCC AAAANAANN 
B 19.2: Sequencing alignment of cDNA subclone AB18#4 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AB18#4 : 119 tqcacataqqacttattcttcttacatqacaaaaaattgctcccctatcaattttaattc 178 
^ , , . i T i i i i i i 了 n i i i i i i i i i m i i i i T i i i i i i i i i i 丫 i i i i i i i m i i i i i i i i i i i 
Mouse mitochondrion： 4284 tgcacataggacttattcttcttacatgacaaaaaattgctcccctatcaattttaattc 4343 
AB18#4 ： 179 aaatttacccgctactcaactctactatcattttaatactaqcaattacttctattttca 238 
. , , . i i i m i m l ^ i i i i i i i i i i i i i i i i i i i m i m i i i Y m i i m m m i i i i 
Mouse mitochondrion： 4344 aaatttacccgctactcaactctactatcattttaatactagcaattacttctattttca 4403 
AB18#4 ： 239 tagqgqcatqaqqagqacttaaccaaacacaaatacgaaaaattataqcctattcatcaa 298 
. ^ 』 . 1丨而111侦1^?1丨1111丨1111丨1丨1丨1丨1|7||||||||||丫丨11丨丨11丨1丨1丨 
Mouse mitochondrion： 4404 taggggcatgaggaggacttaaccaaacacaaatacgaaaaattatagcctattcatcaa 4463 
AB18#4 ： 299 ttqcccacataqqatgaatattagcaattcttccttacaacccatccctcactctactca 358 
. , , . I I T I I I I I I I I T T I I T I I I I I I M I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Mouse mitochondrion： 4464 ttgcccacataggatgaatattagcaattcttccttacaacccatccctcactctactca 4523 
AB18#4 ： 359 acctcataatctatattattcttacaqcccctatattcataqcacttatactaaataact 418 
. ^ ^ . i m i i i m i m i i i m i i i i i i T i M i i i i i m i i i 化 m m i i i M N N i 
Mouse mitochondrion： 4524 acctcataatctatattattcttacagcccctatattcatagcacttatactaaataact 4583 
AB18#4 ： 419 ctataaccatcaactcaatctcacttctatgaaataaaactccagcaatactaactataa 478 . ^ . l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l T I I I I I I I I I I I I I T I I I I I I I I I I I I I I I 
Mouse mitochondrion： 4584 ctataaccatcaactcaatctcacttctatgaaataaaactccagcaatactaactataa 4643 
AB18#4 ： 479 tctcactgatattactatccctangangcc-tccaccactaacaqqatnctnaccaanat 537 
. . I I I I I I I T I I I I I I I I I I I I I I I Tl Tl I I I I I I I I I I I I I I I T I I I I M i l l I I 
Mouse mitochondrion： 4644 tctcactgatattactatccctaggaggccttccaccactaacaggattcttaccaaaat 4703 
AB18#4 ： 538 gaattatcatcacaqaactnataaaaaacnactgcctaattatage-anacteataqcca 596 
. . T l i l l l l l l l l i l l T I I I I i m i m i M I T I I I I I I I I I T I I I I I I I I I T I I 
Mouse mitochondrion： 4704 gaattatcatcacagaacttataaaaaacaactgtctaattatagcaacactcatagcaa 4763 
AB18#4 ： 597 tantaqctct 606 
11 I I 化 I I 
Mouse mitochondrion： 4764 taatagctct 4773 B 19.3: Summary of sequence alignment of cDNA subclone AB18#4 with mouse mitochondrion 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus clone LA9 0 
AB18 + ++ + + 595 AB18#4 655 forward mitochondrion, complete 477/490 
(-20) genome (16300 bp) (97%) 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 NGCCAAGCTT GNGTACCGAG CTCGGATCCA CTAGTAACGG CCGCCAGTGT GCTGGAATTC 
61 GGCTNGTAAT A C Q A C T C A C T A T A G G G C T T T T T T T T T T T T G GGTTATTGTT GGTTGGAAAT AP3 
121 ATTGTTAGTG AAGTGGAATA AATTAGGCGA GTATAAAAGA ATAGGTTTAG TAGAGCTATT 
181 ATTGCTATGA GTGTTGCTAT AATTAGGCAG TTGTTTTTTA TAAGTTCTGT GATGATAATT 
241 CATTTTGGTA AGAATCCTGT TAGTGGTGGA AGGCCTCCTA GGGATAGTAA TATCAGTGAG 
301 ATTATAGTTA GTATTGCTGG AGTTTTATTT CATAGAAGTG AGATTGAGTT GATGGTTATA 
361 GAGTTATTTA GTATAAGTGC TATGAATATA GGGGCTGTAA GAATAATATA GATTATGAGG 
421 TTGAGTAGAG TGAGGGATGG GTTGTAAGGA AGAATNGCTA ATATTCATCC TATGTGGGCA 
481 ATTGATGAAT ANGCTATAAT NTNTCGTATN TGTGTTTGGT NAAGTCCTCC TCATGCCCCT 
541 ATGAAAATAG AAGTAATTGC TAGTATNAAA ATGATAGTAG AGTTGAGTAG CNGGTAAATT 
601 TGAATTAAAT TGATANNGGA GCANTTTTTG TCATGTAGAG ATAGTCTATG TGCATGTCTC 
661 GTGTAATGTA TCGTAGCGAT CGCNAT 
B 20.2: Sequencing alignment of cDNA subclone AB18#4 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AB18#4 ： 102 qttattgttqqttqgaaatattqttagtqaaqtqgaataaattaqqcqaqtataaaagaa 161 
. , , . T i i i i i M i f f i i f f i i i i i i i T i i i T i T i i T i f f m i i m i f f i 丫 l Y i i i m i t i i 
Mouse mitochondrion： 4843 gttattgttggttggaaatattgttagtgaagtggaataaattaggcgagtataaaagaa 4784 
AB18#4 ： 162 taqqtttagtaqaqctattattqctatgagtgttgctataattaggcaqttgttttttat 221 
. , , . l l f f l l l lTl lYlt l l l l l l l l丫 l l l l丫I丫I丫 l ini l l l l l l iy IITIITIIIIIIil 
Mouse mitochondrion： 4783 taggtttagtagagctattattgctatgagtgttgctataattagacagttgttttttat 4724 
AB18#4 ： 222 aaqttctqtqatqataattcattttqgtaagaatcctgttaqtqgtggaaggcctcctag 281 
II 了miTi 丫11 丫丨 i i i i i i m i i f f i i i T i m i i T m 浦 i f f i i f f m m i Y 
Mouse mitochondrion： 4723 aagttctgtgatgataattcattttggtaagaatcctgttagtggtggaaggcctcctag 4664 
AB18#4 ： 282 qqataqtaatatcaqtqaqattataqttaqtattqctqqaqttttatttcataqaaqtqa 341 
f f i i i丫 i i m i i i Y i Y i T i i m i Y i i i T i i i i Y i i n i T i i i i i m i i i i T i i l ^ T i 
Mouse mitochondrion： 4663 ggatagtaatatcagtgagattatagttagtattgctggagttttatttcatagaagtga 4604 
AB18#4 ： 342 qattqaqttqatqqttataqaqttatttaqtataaqtgctatgaatataqgqqctqtaaq 401 
t i i i t i t i i l ^ i f f i i i i i l ^ t i i i i m l ^ m i Y i Y i i i i 丫 i m i i f f f f i i Y i i i Y 
Mouse mitochondrion： 4603 gattgagttgatggttatagagttatttagtataagtgctatgaatataggggctgtaag 4544 
AB18#4 ： 402 aataatataqattatqaqgttgagtaqagtgaqqgatggqttgtaaqgaaqaatnqctaa 461 
I I I I I I I I I L ^ I I I I丫 I F F I I Y I丫 I I丫 I丫 L Y I F F F I I F F F I I Y M行 I I丫 I I I T I I I I 
Mouse mitochondrion： 4543 aataatatagattatgaggttgagtagagtgagggatgggttgtaaggaagaattgctaa 4484 
AB18#4 ： 462 tattcatcctatqtqqqcaattgatqaatanqctataatntntcqtatntgtqtttqqtn 521 
IIIIIIIIIIIITITTTIIIIITIIIIIII T l l l l l l l I IITIII ITITIIITTI 
Mouse mitochondrion： 4483 tattcatcctatgtgggcaattgatgaataggctataatttttcgtatttgtgtttggtt 4424 
AB18#4 ： 522 aaqtcctcctcatgcccctatqaaaatagaaqtaattqctaqtatnaaaatqataqtaga 581 
. IITIIIIIIIIIITIIIIIIITIIIMITIITIIIIITIIITIII 1111 111 I III III … � 
Mouse mitochondrion： 4423 aagtcctcctcatgcccctatgaaaatagaagtaattgctagtattaaaatgatagtaga 4364 
AB18#4 ： 582 gttgaqtagcnqqtaaatttgaatt-aaattqatannqqaqc-antttttqtcatqta 637 
TMTITMTI TTMIMMTIMI MIMTIM TTITI I 1111ITI11 III I 
Mouse mitochondrion： 4363 gttgagtagcgggtaaatttgaattaaaattgataggggagcaattttttgtcatgta 4306 B 20.3: Summary of sequence alignment of cDNA subclone AB18#4 with mouse mitochondrion 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 0 
AB18 + ++ + + 595 AB18#4 655 mitochondrion, complete 524/538 
reverse genome (16300 bp) (97%) 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B21.1: DNA sequence of cDNA subclone AB19#2 (AP3 & ARP3) using Ml 3 forward (-20) primer 
1 T G G G C C C T C T A G A T G C A T G C T C G A G C G G C C G C C A G T G T G A T G G A T A T C T G C A G A A T T C G C 
6 1 CCTTGTATAC G A C T C A C T A T A G G G C T T T T T T T T T T T T G G G TGGAATAAAT TAGGCGAGTA A P S 
121 TAAAAGAATA GGTTTAGTAG AGCTATTATT GCTATGAGTG TTGCTATAAT TAGACAGTTG 
181 TTTTTTATAA GTTCTGTGAT GATAATTCAT TTTGGTAAGA ATCCTGTTAG TGGTGGAAGG 
241 CCTCCTAGGG ATAGTAATAT CAGTGAGATT ATAGTTAGTA TTGCTGGAGT TTTATTTCAT 
301 AGAAGTGAGA TTGAGTTGAT GGTTATAGAG TTATTTAGTA TAAGTGCTAT GAATATAGGG 
361 GCTGTAAGAA TAATATAGAT TATGAGGTTG AGTAGAGTGA GGGATGGGTT GTAAGGAAGA 
421 ATNGCTAATA TTCATCCTAT GTGGGCAATT GATGAATAGG CTATAATTTT TCGTATNTGT 
481 GTNNNGGTTA AGTCCTCCTC ATGCCCCTAT GAAAATAGAA GTAATTGCTA GTATTAAAAT 
541 GATAGTAGAG TTGAGTAGCG GGTAAATTTG AATTAAAATT GATANGGGAG CAATTTTTTG 
601 TCATGTAAGA AGAATAAGTC CTATGTGCAA TGGTCTNCTG TGTGAANTNG TNATCCGCTA 
661 AGGGCGAATN CCAGCACACT GGCGNCCGTA ACTAGTGGAT CGAGCTCNGT ACCANGCCTG 
721 ATGCATAGCN TGANNNTTCT ATAGTGTNAN CTAATA 
B 21.2: Sequencing alignment of cDNA subclone AB19#2 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AB19#2 ： 100 gtqgaataaattaqqcgagtataaaaqaataqqtttagtaqagctattattgctatqaqt 159 
. ^ , . l ^ f f i i i i i i i i i n i Y i Y i i i i i i i T i i i i f f i m丫 I I丫 i 1 ^ i i i i i i i � i N i丫 
Mouse mitochondrion： 4812 gtggaataaattaggcgagtataaaagaataggtttagtagagctattattgctatgagt 4753 
AB19#2 : 160 qttgctataattaqacagttqttttttataaqttctgtqatqataattcattttggtaaq 219 
. . 丫 iitiimiiiitiiiTii丫 immMiTiiiiTiTNTimiNNmffmt 
Mouse mitochondrion： 4752 gttgctataattagacagttgttttttataagttctgtgatgataattcattttggtaag 4693 
AB19#2 ： 220 aatcctgttaqtggtgqaaqgcctcctagggataqtaatatcagtgagattatagttagt 279 
. . m m 丫 i i i l ^ f f i f f i i f f i i i i m n 丫 i i i Y i i i i i i i i 丫 i T i T i m i i t m 丫 I 
Mouse mitochondrion： 4692 aatcctgttagtggtggaaggcctcctagggatagtaatatcagtgagattatagttagt 4633 
AB19#2 ： 280 attgctggaqttttatttcataqaaqtgagattgaqttgatqgttatagagttatttaqt 339 
mYi i f f 丨丫 i i i N i i i i i i i 丫 11丫丨川 iiiYi 丫 ||丫丨|^?丨||||丫|丫丨丨|||||丫| 
Mouse mitochondrion： 4632 attgctggagttttatttcatagaagtgagattgagttgatggttatagagttatttagt 4573 
AB19#2 ： 340 ataagtgctatgaatataqqgqctqtaaqaataatatagattatqaggttgagtaqaqtq 399 
i i i i l^ 丫 i i i i n i i i i i T l T f i i 丫 i i iTi i i i i i i i iTi i i i iTiTfi iTiTi iTiTi 丫 
Mouse mitochondrion： 4572 ataagtgctatgaatataggggctgtaagaataatatagattatgaggttgagtagagtg 4513 
AB19#2 ： 400 aggqatqggttgtaaqqaagaatngctaatattcatcctatqtqggcaattqatgaatag 459 
i f f f l l T f f l l l ^ l l T f l l Y l l l T I I I I I I I I I I I I I I I I T I T T T I I I I I T I I T I I M T 
Mouse mitochondrion： 4512 agggatgggttgtaaggaagaattgctaatattcatcctatgtgggcaattgatgaatag 4453 
AB19#2 ： 460 qctataatttttcqtatntgtqtnnnggttaagtcctcctcatgcccctatqaaaataga 519 
T I I I I I I I I I I I I T I I I I T I I I T T M M T M M M M M T M M M I T M M M T I 
Mouse mitochondrion： 4452 gctataatttttcgtatttgtgt-ttggttaagtcctcctcatgcccctatgaaaataga 4394 
AB19#2 ： 520 aqtaattgctagtattaaaatgataqtagagttqagtagcgggtaaatttqaattaaaat 579 
itmiitm1^iiiiiiiitiiiYiinYii�iYiiYitniimiiTmiiiiii 
Mouse mitochondrion： 4393 agtaattgctagtattaaaatgatagtagagttgagtagcgggtaaatttgaattaaaat 4334 
AB19#2 ： 580 tqatanqqqagcaattttttqtcatgtaagaagaataagtcctatqtqca 629 
I T I I I 丽 I I I I I I I I ITIM丫 I I I丫 I I丫MIL丫 I I IMTITI I 
Mouse mitochondrion： 4333 tgataggggagcaattttttgtcatgtaagaagaataagtcctatgtgca 4284 B 21.3: Summary of sequence alignment of cDNA subclone AB19#2 with mouse mitochondrion 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after 五coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus clone LA9 0 
AB19 + 575 AB19#2 620 forward mitochondrion, complete 523/530 
(-20) genome (16300 bp) (98%) 
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Appendix B. DNA sequences and sequencing alignments of Fluor oDD fragments 
B 22 .1 : DNA sequence of cDNA subclone AB19#10 (AP3 & ARP3) using M13 reverse primer 
1 TAGANTACTC AAGCTATGCA TCAAGCTTGG TACCGAGCTC GGATCCACTA GTAACGGCCG 
61 CCAGTGTGCT GGAATTCGCC CTTAGCGGAT AACAATTTCA CACAGGAGAC CATTGCACAT ARP3 
1 21 AGGACTTATT CTTCTTACAT GACAAAAAAT TGCTCCCCTA TCAATTTTAA TTCAAATTTA 
181 CCCGCTACTC AACTCTACTA TCATTTTAAT ACTAGCAATT ACTTCTATTT TCATAGGGGC 
241 ATGAGGAGGA CTTAACCAAA CACAAATACG AAAAATTATA GCCTATTCAT CAATTGCCCA 
301 CATAGGATGA ATATTAGCAA TTCTTCCTTA CAACCCATCC CTCACTCTAC TCAACCTCAT 
361 AATCTATATT ATTCTTACAG CCCCTATATT CATAGCACTT ATACTAAATA ACTCTATAAC 
421 CATCAACTCA ATCTCACTTC TATGGAATAA AACTCCAGCA ATACTAACTA TAATCTCACT 
4 81 GATATTACTA TCCCTAGGAG GCCTTCCACC ACTAACAGGA TTCTTACCAA AATGAATTAT 
541 CATCACAGAA CTTATAAAAA ACAACTGTCT AATTATAGCA ACACTCATAG CAATAATAGC 
601 TCTACTAAAC CTATTCTTTN ATACTCGCCC CAAAAAAAAA AAGCCCTATA GTGAGTCGTA 
661 TNACAAGGGC GAATTCTGCA GATATCATCA CACTGNCGGG CGCTCGAGCA TGCATNNANA 
721 GGCCNCATTT CNCCNTATAG TGAGNTTGTA TNACNATNCA CNGCCNGNTG NTNAACANCG 
781 GTGTGACNNG NNAACNNNGC C 
B 22.2: Sequencing alignment of cDNA subclone AB19#10 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AB19#10 114 ITIIIIIITTIIIIIIIIIIIIIIIIITIIIIIIIIIITIIIIIIIIIIIIIII1II111 173 Mouse mitochondrion : 4284 tgcacataggacttattcttcttacatgacaaaaaattgctcccctatcaattttaattc 4343 
AB19#10 174 IIIIIIIIIITIIIIIIIIIIIIIIIIIIIIIIIIIIIIIITIIIIIIIIIIII11111I 233 Mouse mitochondrion: 4344 aaatttacccgctactcaactctactatcattttaatactagcaattacttctattttca 4403 
AB19#10 234 IITTTTIIITITTITTIIIIIIIIIIIIIIIIIIIITIIIIIIIIIITIIIIII1I11II 293 Mouse mitochondrion : 4404 taggggcatgaggaggacttaaccaaacacaaatacgaaaaattatagcctattcatcaa 4 4 63 
AB19#10 294 ttTcccacataTTatTaatattaTcaattcttccttacaacccatccctcactctactca 353 
1 1 111 1 1111 11 1111111 11111111111111111111111111111111 11 11 Mouse mitochondrion: 4464 ttgcccacataggatgaatattagcaattcttccttacaacccatccctcactctactca 452 3 
AB19#10 354 acctcataatctatattattcttacaTcccctatattcataTcacttatactaaataact 4 13 
11111111111111111111111111 11111111111111 111111111111111111 Mouse mitochondrion : 4524 acctcataatctatattattcttacagcccctatattcatagcacttatactaaataact 4583 
AB19#10 414 1IIIIIIIIIIIIIIIIIIIIIIIIIIIIITgIIIIIIIIIIIITIIIIIIIII11I1II 4 73 Mouse mitochondrion: 4584 ctataaccatcaactcaatctcacttctatgaaataaaactccagcaatactaactataa 4643 
AB19#10 474 IIIIIIITIIIIIIIIIIIIIIITTITTIIIIIIIIIIIIIIIITTIIIIIIII1IIII1 533 Mouse mitochondrion: 4644 tctcactgatattactatccctaggaggccttccaccactaacaggattcttaccaaaat 4 703 
AB19#10 534 TIIIIIIIIIIIIITIIIIIIIIIIIIIIIIIITIIIIIIIIIITIIIIIIIIIIITIII 593 Mouse mitochondrion: 4704 gaattatcatcacagaacttataaaaaacaactgtctaattatagcaacactcatagcaa 47 63 
AB19#10 594 taataTctctactaaacctattctttnatactcTcc 629 
11111 11111111111111111111 111111 11 Mouse mitochondrion : 4764 taatagctctactaaacctattcttttatactcgcc 4799 
B 22.3: Summary of sequence alignment of cDNA subclone AB19#10 with mouse mitochondrion 
FluoroDD gel AB (AP3 + ARP3) Sequencine 
PPARa (+1+) PPARa (-1-) FluoroDD Subclone Size of insert Gene homology to E-value Fragment fragment I.D. after EcoRI Primer Blast search (% 
no. 
size (bp) cut (bp) (Transcript size) Identity) CTL Wy CTL Wy 
Mus musculus clone LA9 0 
AB19#10 610 M13 mitochondrion, complete 513/516 AB19 - + - - 575 reverse genome (16300 bp) (99%) 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CANTTGGGCC CTCTAGATGC NTGCTCGAGC GGCCGCCAGT GTGATGGATA TCTGCAGAAT 
61 TCGCCCTTGT AATACQACTC ACTATAGGGC TTTTTTTTTC TTGGCACTAC CAGAGTCAGG A P 3 * 
121 TTTATTAGAG AAGAGGGGCT TGGGGGAACT GGAGGGCTGA GGGGCCCTGC CCAGAGCAGC 
181 AGAGCACAGC ACATGGCCCT CTGCCCCAGC TCCCTCATGG CTGTCAGCCC CAACTGTAGA 
241 AATAGATTTT CTGCCAGGAG GGCAAGTAGT CCATGAGCGG CCTTGCCACC AGACCCACGC 
301 CAGGGATGTG GTCTGTAAGC AGCTGGAGCA GGAAGAGGAT CTTGGCTTCA GAGAAGCGGT 
361 NATAAGAACC GGTGAGCGTA GCAGGTANTA TAGCAGCAGG ATTGTGCGAC CGCCTCAGTT 
421 CTAGCCGCTC CCTCCGGGTC AAGTTCTTCC TGTNCNTCAG GAANACTCAG GCTATTCNTA 
481 TTTACCACAC CANANNGTTN NCCAGGGTGT NNNACGATCG CTGACCCCCT AAGCNANCTG 
541 ACCNAGTGCA CAGGGGCCNN GGCGATGTAC AAAANANTTG CCATGGTTTT CNTGTTGTNA 
601 AAATTGTATC NGCTTANGGG NNANTNNGGG CNGCNTNNTN TGATCCACNN NNNNNTNNTN 
661 ANTTTTNNT 
B 23.2: Sequencing alignment of cDNA subclone AB22#9 with mouse peroxisome biogenesis factor 16 
(Pexl6) by BLAST searching against the National Center for Biotechnology Information database 
AB22#9 : 105 (j：竹竹(|：(|：丨〒，打(j；，〒〒，1|：丨竹丨，竹〒T〒丨〒〒行Cj:t：〒〒丨〒〒T界〒打〒164 
Mouse Pexl6： 1196 cactaccagagtcaggtttattagagaagaggggcctgggggaactggagggctgagggg 1137 
AB22#9 ： 165 ccctqcccaqaqcaqcaqaqcacaqcacatqqccctctqccccaqctccctcatqgctqt 224 
iiiitim丫丨丫 II 了 iiTiTim了 iimffiiiiiiTiiiiitiiiiimiffNTi 
Mouse Pexl6： 1136 ccctgcccagagcagcagagcacagcacatggccctctgccccagctccctcatggctgt 1077 
AB22#9 ： 225 cagccccaactqtaqaaataqattttctgccaqqaqggcaaqtagtccatqaqcqgcctt 284 iitiiiiiiiiYii 丫 iiiiiYiiiiiiiYiiiffinyiiil^iYiiiii 丫 lYiffiiii 
Mouse Pexl6： 1076 cagccccaactgtagaaatagattttctgccaggagggcaagtagtccatgagcggcctt 1017 
AB22#9 ： 285 qccaccaqacccacqccagqqatgtqgtctqtaaqcaqctggaqcagqaagaqqatcttq 344 til I I I iti I I I I it I ufff I 丨浦 III丫 lilt I it I iff iff I丫丨ff mil丫 
Mouse Pexl6： 1016 gccaccagacccacgccagggatgtggtctgtaagcagctggagcaggaagaggatcttg 957 
AB22#9 ： 345 qcttcaqaqaaqcgqtnataaqaaccqqtqaqcqtaqcaqgtantataqcaqcaqqattq 404 T I I I I I T I T I I T I T T I I I I T I I I T T I T I T I T I 1 1 1 I T T I I 111 I I I 111ITTI i IT 
Mouse Pexl6： 956 gcttcagagaagcggtcat-agaa-cggtgagcgtagcaggtagtatagcagcaggattg 899 
AB22#9 ： 405 tqcqaccqcctcaqttctaqccqctccctccqqgtcaaqttcttcctqtncntcaqqaan 464 I T I T I I T I I I I I T I I I I I I I I T I I I I I I I T T T M M T M M M M T I M I T T I 
Mouse Pexl6： 898 tgcga-cgcctcagttctagccgctccctctgggtcaagttcttcctgtcactcagg-ag 841 
AB22#9 ： 465 actcaggctattcntatttaccacaccanannqttnnccaqqqtgtnnnacqatcqctqa 524 
M M I T T I M I I I I I l l l l l l l l l l I T I M I T T T I T I I I T I I I T I I T I � � 
Mouse Pexl6： 840 actcaggctagtcatatctaccacaccagacag-tagccagggtgt-ccacgatcgctga 783 
AB22#9 ： 525 ccccctaaqc 534 M M M i l l 
Mouse Pexl6： 782 ccccataagc 773 B 23.3: Summary of sequence alignment of cDNA subclone AB22#9 with mouse Pexl6 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus peroxisome e-178 
AB22 + ++ + + 530 AB22#9 580 forward biogenesis factor 16 405/430 
I I I I I (-20) (Pex 16) (1221 bp) (94%) * Sequence of primer was not completely matched with the expected sequence. 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AATACTCAAG CTATGCATCA AGCTTGGTAC CGAGCTCGGA TCCACTAGTA ACGGCCGCCA 
61 GTGTGCTGGA ATTCGCCCTT AGCGGATAAC AATTTCACAC AGGAGACCAT TGCAGAGTCT ARP3 
121 TTGTACATCG CCCGGCCCCT GCTGCACTTG CTCAGCCTGG GCTTATGGGG TCAGCGATCG 
181 TGGACACCCT GGCTACTGTC TGGTGTGGTA GATATGACTA GCCTGAGTCT CCTGAGTGAC 
241 AGGAAGAACT TGACCCGGAG GGAGCGGCTA GAACTGAGGC GTCGCACAAT CCTGCTGCTA 
301 TACTACCTGC TACGCTCACC GTTCTATGAC CGCTTCTCTG AAGCCAAGAT CCTCTTCCTG 
361 CTCCAGCTGC TTACAGACCA CATCCCTGGC GTGGGTCTGG TGGCAAGGCC GCTCATGGAC 
421 TACTTGCCCT CCTGGCAGAA AATCTATTTC TACAGTTGGG GCTGACAGCC ATGAGGGAGC 
481 TGGGGCAGAG GGCCATGTGC TGTGCTCTGC TGCTCTGGGC AGGGCCCCTC AGCCCTCCAG 
541 TTCCCCCAAG CCNCTCTTCT CTAATAAACC CTGACTCTGG TAGTGCCAAG ANAAAAAAAG 
601 CCCTATAGTG AGTNTTATNA CAAGGNCGAA TTCTGCAAAT ATCCATCACA CTGGCGGCCG 
661 CTCNANCCTG CATTTAGAGG GCCCNATCCC CCTATAGTGA GTNNTATNAC NNNNNCTGGC 
721 CGTTTTTTAC ATCTTNTTGA CTGGAAANCN CTGGGTTA 
B 24.2: Sequencing alignment of cDNA subclone AB22#9 with mouse peroxisome biogenesis factor 16 
(Pex 16) by BLAST searching against the National Center for Biotechnology Information database 
AB22#9 ： 100 caqqaqaccattqcagagtctttqtacatcgcccggcccctgctqcacttqctcaqcctq 159 
I 丨而 M i i i i丫 i i t i丫 m i l丫 i i i i i i T m f f i i i i i 丫 i i t m i i 丫 |1丫丨1丨丫 
Mouse Pexl6： 712 caggagaccattgcagagtctttgtacatcgcccggcccctgctgcacttgctcagcctg 771 
AB22#9 : 160 qgcttatgqqqtcagcgatcqtqgacaccctqqctactgtctqqtgtqqtaqatatqact 219 ffiiiiifiTfiiiTiTiiiTiffiiiiiiiniiiiiYmffiYiffiiTiiiiyiii 
Mouse Pexl6： 772 ggcttatggggtcagcgatcgtggacaccctggctactgtctggtgtggtagatatgact 831 
AB22#9 ： 220 agcctgaqtctcctgagtqacaqgaagaacttqacccggaqggaqcqqctaqaactqagq 279 
I丫III丫I了iimiTiTi丫iiiTfiiTmiiTiiii I I T T T I T I T T M I T I I M T I T T 
Mouse Pexl6： 832 agcctgagtctcctgagtgacaggaagaacttgacccagagggagcggctagaactgagg 891 
AB22#9 ： 280 cgtcqcacaatcctgctqctatactacctqctacgctcaccqttctatgaccqcttctct 339 
I 〒丨丨了mmm化 t i i m i i i i i i T i i i i T m m 〒丨 i i i i i T i i i T i i m i i 
Mouse Pexl6： 892 cgtcgcacaatcctgctgctatactacctgctacgctcaccgttctatgaccgcttctct 951 
AB22#9 ： 340 gaagccaaqatcctcttcctqctccaqctqcttacaqaccacatccctqgcqtqqqtctq 399 
t i i Y i m 了 i i i i i i i i i i i T i i i i i 丫 i i T i i i i i i T i i i i i i i i i i i f f i T i n T i i i T 
Mouse Pexl6： 952 gaagccaagatcctcttcctgctccagctgcttacagaccacatccctggcgtgggtctg 1011 
AB22#9 ： 400 qtqqcaaqgccgctcatqqactacttqccctcctqqcaqaaaatctatttctacaqttqq 459 tiffmffiiYiiiiiffimiiitiiiiiiiTniTiiiiiiiiiiiiiiiiniTT 
Mouse Pexl6： 1012 gtggcaaggccgctcatggactacttgccctcctggcagaaaatctatttctacagttgg 1071 
： 4eO〒衍〒丨丨丨预丨衍预丨衍预预预丨预衍丨衍谓衍丨衍衍衍行519 
Mouse Pexl6： 1072 ggctgacagccatgagggagctggggcagagggccatgtgctgtgctctgctgctctggg 1131 
AB22#9 ： 520 caqqgcccctcaqccctccaqttcccccaaqccnctcttctctaataaaccctqactctq 579 I I T T T I I I I I I I T I I I I I I I T I I I I I I I I 111 I I I I I I I I I I I I I M I I I T I I I I I T 1 … 
Mouse Pexl6： 1132 cagggcccctcagccctccagttcccccaggcccctcttctctaataaa-cctgactctg 1190 
AB22#9 : 580 ^ta^t^ 585 
Mouse Pexl6： 1191 gtagtg 1196 
B 24.3: Summary of sequence alignment of cDNA subclone AB22#9 with mouse Pex 16 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus peroxisome 0 
AB22 + ++ + + 530 AB22#9 580 biogenesis factor 16 482/486 
reverse (Pex 16) (1221 bp) (99o/o) 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B25.1: DNA sequence of cDNA subclone AB24#9 (AP3 & ARP3) using M13 forward (-20) primer 
1 CCNCAACTAT AGGGCAATTG GGCCCTCTAG ATGCNTGCTC GAGCGGCCGC CAGTGTGATG 
61 GATATCTGCA GAATTCGCCC TTAGCGGATA ACAATTTCAC ACAGQAGACC ATTGCACTGA ARP3 
121 CAGAGGAAGA TATATTTTAG AGGGAGACAC TTGTACCTTT CTCTCCCTTC AGTTATTAGA 
181 CTCTTGGGAC AATGGACATC ATGAATTAAA ACGTTCTTAG AAATCACATG CTGGGAGAAA 
241 ATTAACACTA AAATCTGGTA CCAGCCAGAG GAAGGAACTT GACTCAAAAT AAGAGATTTT 
301 TAGATATTTC TGTCTGTCTC ATAGTTAAAA TTAATGTTCT CCTGCTTTCT GGCATATGCC 
3 61 TCATCTTTTC TATGAAGTAG TAATACTGAT ACAGAAAGGT AGAGAGAAAT GAATAGTTTT 
421 TGCTACTTTG GGCCAAACTG TGAAAAAATC CATTTTATTT CACCAAAAAA AAAAAAGCCC 
481 TATAGTGAGT CGTATTACAA GGGCGAATNC CAGCACACTG GCGGCCGTTA CTAGTGGATC 
541 CGAGCTCGGT ACCAAGCTNG ATGCATAGCT TGAGTATTCT ATAGTGTCAC CTAAATAGCT 
601 TGGCGTAATC ATGGTAATAG CTGTTTCCTG TGTGAAATNG TNATCCGCTC ACNATTCCAC 
661 ACAACATACG ANCCNGANCC NTAANGTGTA AAGCNTGGGG TGCCTAATGA GTGANCTACT 
7 2 1 CACATANNTG CGTGCNCTAC TGCCGNNTCA GTNGGNAACT GTNTCNNCNG CNTATANNNC 
781 CACCCGNGGA AGCGGTGNNT TGGCCCTTCC TTNNNTAAAT GNGCCGGTTT TGGGGGAG 
B 25.2: Sequencing alignment of cDNA subclone AB24#9 with mouse Cyp4al4 by BLAST searching 
against the National Center for Biotechnology Information database 
AB24#9 ： 108 accattqcactgacaqaqgaaqatatattttaqagqgaqacacttgtacctttctctccc 167 m i i i T m i T i i i T j f f i i T i m i i i i i i T i f f T i T i i m i T m i i i i i m m 
Mouse Cyp4al4： 1823 accattgcactgacagaggaagatatattttagagggagacacttgtacctttctctccc 1882 
AB24#9 ： 168 ttcagttattagactcttgqqacaatqqacatcatqaattaaaacqttcttagaaatcac 227 
i i i i t m i i i T i i i i i i M T i i i i i n i M i i i i T i m i m i T i i i i i i 了 i i i i i i i 
Mouse Cyp4al4： 1883 ttcagttattagactcttgggacaatggacatcatgaattaaaacgttcttagaaatcac 1942 
AB24#9 ： 228 atgctqqqaqaaaattaacactaaaatctqqtaccagccaqaqqaaqqaacttgactcaa 287 
I I 了 i i f f f i T i i m i i m i i m m i T f m i i T m T i f f i i T T i i i i i T m m 
Mouse Cyp4al4： 1943 atgctgggagaaaattaacactaaaatctggtaccagccagaggaaggaacttgactcaa 2002 
AB24#9 ： 288 aataaqaqatttttagatatttctqtctgtctcataqttaaaattaatqttctcctqctt 347 
I M I L ^ T I I I I M L ^ I M M Y M Y I I M I I T I I I I M M I 丫 I I I M I T I M 
Mouse Cyp4al4： 2003 aataagagatttttagatatttctgtctgtctcatagttaaaattaatgttttcctgctt 2062 
AB24#9 : 348 tctgqcatatgcctcatcttttctatqaagtagtaatactgatacagaaaqgtagaqaqa 407 
i i i f f i i i i i T i i i i i i i i i i i i m Y i i 〒丨I 丫 i m i i i 丫 l l l l l 丫 i i i f f i i 丫丨丫 i t i 
Mouse Cyp4al4： 2063 tctggcatatgcctcatcttttctatgaagtagtaatactgatacagaaaggtagagaga 2122 
AB24#9 ： 408 aatqaataqtttttqctactttqqgccaaactqtgaaaaaatccattttatttca 462 m t i i i i l ^ i i i i t i i m i i f f f i i i i i i i Y i T m i m i m m m m 
Mouse Cyp4al4： 2123 aatgaatagtttttgctactttgggccaaactgtgaaaaaatccattttatttca 2177 B 25.3: Summary of sequence alignment of cDNA subclone AB24#9 with mouse CvD4al4 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
i^ragment fragment I D. after 五 P r i m e r Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
MUS musculus cytochrome ^ 
AB24 - + - - 420 AB24#9 460 forward ？‘;。，二么y 4 subfamily 354/355 
a, polypeptide 14 
(-20) (Cyp4al4) (2547 bp) (997。） 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AANNNTATTT AGGTGACACT ATAGAATACT CAAGCTATGC ATCAAGCTTG GTACCGAGCT 
6 1 CGGATCCACT AGTAACGGCC GCCAGTGTGC TGGAATTCGC CCTTGTAATA CGACTCACTA APS 
121 TAGGGCTTTT TTTTTTTTGQ TGAAATAAAA TGGATTTTTT CACAGTTTGG CCCAAAGTAG 
181 CAAAAACTAT TCATTTCTCT CTACCTTTCT GTATCAGTAT TACTACTTCA TAGAAAAGAT 
241 GAGGCATATG CCAGAAAGCA GGAGAACATT AATTTTAACT ATGAGACAGA CAGAAATATC 
3 01 TAAAAATCTC TTATTTTGAG TCAAGTTCCT TCCTCTGGCT GGTACCAGAT TTTAGTGTTA 
361 ATTTTCTCCC AGCATGTGAT TTCTAAGAAC GTTTTAATTC ATGATGTCCC ATTGTCCCAA 
421 GANTTATTAA TAACTGAAGG GAGAGAAAGG TACAAGTGTC TCCCCCTCTA AAATATATCC 
4 81 TTCCCTCCTG TCAGTGCNAA TGGGTCTCCT GTGTGNAAAT TGTTATCCGC TAAGGGCGAA 
541 TTNTGCAGAT ATCCAATNNA AACAAAATAA AACAAACAAG CCNTGCNNTT TAGANNGGGC 
601 CCAATTTGGC CCNTATAGTT GANGTNGTAT TACAAATNNA NNTGGGCCGT TGTTTTNANN 
661 ANNTNNNTGA ATGGNAAAAC CCTGGCNGTN ACNNNNNTNA ATGNCNNTNG NNGCNNNTTC 
721 CCTTTTNNCN NCTGGGNTNN TANNAAAAAG NCCNCCCGAA TGCCTTTCCA ACANTTGGCC 
781 NCCTGAATGN NNNTNGNCCN CCNNNTTNNN GCCNNTNNNN NNGNNGGTTG NTTNNNNNTN 
841 NNNT 
B 26.2: Sequencing alignment of cDNA subclone AB24#9 with mouse Cyp4al4 by BLAST searching 
against the National Center for Biotechnology Information database 
AB24#9 ： 141 tqaaataaaatgqattttttcacaqtttqqcccaaagtaqcaaaaactattcatttctct 200 I I I I I I I I I I i l T l I I I I I I I I I I I I I I M l I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Mouse Cyp4al4： 2177 tgaaataaaatggattttttcacagtttggcccaaagtagcaaaaactattcatttctct 2118 
AB24#9 ： 201 ctacctttctgtatcagtattactacttcatagaaaagatgaggcatatgccagaaagca 260 111111111 I I I 111 I I I 1111111111111 I I I 11 111ITITTI111 111 I I I I I I I I I 
Mouse Cyp4al4： 2117 ctacctttctgtatcagtattactacttcatagaaaagatgaggcatatgccagaaagca 2058 
AB24#9 ： 261 qqaqaacattaattttaactatqaqacaqacaqaaatatctaaaaatctcttattttqaq 320 IT I I I I I I I I I I I I I I I I I I I T I T I I I T I I I T I I I I I I I I I I I I I I I I I I I I I I I I T I T 
Mouse Cyp4al4： 2057 ggaaaacattaattttaactatgagacagacagaaatatctaaaaatctcttattttgag 1998 
AB24#9 ： 321 tcaaqttccttcctctgqctqgtaccagattttaqtqttaattttctcccagcatqtqat 380 iiiiTimiiimiffiiTfmiil^iiiiitiTmiiimmiiTiiiTil^i 
Mouse Cyp4al4： 1997 tcaagttccttcctctggctggtaccagattttagtgttaattttctcccagcatgtgat 1938 
AB24#9 ： 381 ttctaagaacqttttaattcatqatqtcccattqtcccaaqanttattaataactgaagg 440 
I I I I I I T I I I T I I i l l l l l l l l T I I T I I I I I I T I I I I I I T I I M M M M T M T T � � 
Mouse Cyp4al4： 1937 ttctaagaacgttttaattcatgatgt-ccattgtcccaagagt--ctaataactgaagg 1881 
AB24#9 : 441 gaqaqaaaqqtacaagtgtctccccctctaaaatatatc 479 T I T I T I 1 1 1 1 1 1 1 1 M i l l 11 M l l l l l i l l l l l l l l 
Mouse Cyp4al4： 1880 gagagaaaggtacaagtgtct--ccctctaaaatatatc 1844 B 26.3: Summary of sequence alignment of cDNA subclone AB24#9 with mouse Cvp4al4 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome j ^^  
AB24 - + - - 420 AB24#9 460 M13 P450, family 4 subfamily 336-1,339 
reverse a, polypeptide 14 
(Cyp4al4) (2547 bp) 、” 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AACTCACTCA TACGGGNCAN TCNGGGCCCN CTAGNATGCN TGCTCGAGCG GCCGCCAGTG 
61 TGATGGATAT CTGCAGAATN CNGCCCTTAG CGGATAACAA TTCTCACACA GGAGACCATT ARP3 
121 GCACTGACAG AGGAAGATAT ATCCTNCAGA GGGAGACACT TGTACCTTTC TCTCCCTTCA 
181 GTTATTANCA CTCTTGGGAC AATGGACATC ATGAATTAAA ACGTNCNTTA GAAATCACCA 
241 TGCTGGGAGA AAATTAACCA CCTAAAATCT GGTACCCAGC CCAGCAGGNA AGGGAACTTG 
301 CACCTCACAA ATAANGAGNA TTNNTTANCA TATTNCCTGT CNTGGTCTCA TAGTTAAAGT 
361 TAATGTTTTC CCTGCCTTTC TGGGCATATG CCCCTCATCT TTTTCNTATN NAAGNTAANT 
421 TAANTAACCT GNANTAACNA AGAAAAAGGG TTAAAAAGAA GNAAAAATTG NAANTTANGN 
481 TTTTTTTGGN CCNNNCTTTT NGGGGNCCCA AAANNTGGTN NAAAAAAAAT TCCATNTTTN 
541 ATTTCTAACC AAAAAAAAAA AAAAGCCCCT ATNAGTGNAG CTCNNTTATT AAAAAGGGGG 
601 CGAAAATNNC CCANCCCACC NCNTGGGGNC NNGGGGCNCG TTTAAANNTT AAANTTGGGG 
661 NGATTCNCCC GGAAAAGNCN TCCCNGNNGG GTTNAACCNC NAAAAAAACA ANCANAAGAA 
721 AATNTNTGNN CCNNTTNANN CCACCCCTTT GNGNNAAGNG TTTNATTTTT TCCTTTCNTT 
781 TTTATNTNNG TTTNGTGTNT TNTTCANANN CNNTTTNAAN AAAANNNTTA TNNNGNCNNT 
8 4 1 TTTNTGGGGG NGNNNGNNGN NTTNNNNAAA TTTTTAAANT TNTGGGGGGN NTTTNCNNTT 
901 TNNNTANNCC CTNNNNGGTT TTNTTNNCCN TTNGGTGTTG GTGTTNGAAN AAAATTNTTN 
961 GGTTTTNNNN NN 
B 27.2: Sequencing alignment of cDNA subclone AB25#6 with mouse Cyp4al4 by BLAST searching 
against the National Center for Biotechnology Information database 
AB25#6 ： 115 accattqcactgacaqaggaagatatatcctncagaggqaqacacttgtacctttctctc 174 I I I I I I T I I I I T I I I T I T T I I T I I I I I I I I T I T T T I T M M M T M M M M M M 
Mouse Cyp4al4： 1823 accattgcactgacagaggaagatatat--tttagagggagacacttgtacctttctctc 1880 
AB25#6 ： 175 ccttcagttattancactcttgqqacaatgqacatcatqaattaaaacqtncnttaqaaa 234 I I I I I I T I I I I I I M M M T T T M I M T T M I M M T M I M M M T I I I I I T I I I 
Mouse Cyp4al4： 1881 ccttcagttattag-actcttgggacaatggacatcatgaattaaaacgttc-ttagaaa 1938 
AB25#6 ： 235 tcaccatqctqqqagaaaattaaccacctaaaatctgqtacc 276 I I I M I T I I T T T I T I M M M M 11111111 ITT 1111 
Mouse Cyp4al4： 1939 tca-catgctgggagaaaattaac--actaaaatctggtacc 1977 B 27.3: Summary of sequence alignment of cDNA subclone AB25#6 with mouse Cvp4al4 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome _ , _ 
M13 r •, ^  . f ., 7e-47 
AB25 - 405 AB25#6 450 forward P450, family 4 subfamily 
a, polypeptide 14 
(-20) (Cyp4al4) (2547 bp) (92,。） 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 TAATACGACT CACTATAGGG CGAATTGGGC CCTCTAGATG CATGCTCGAG CGGCCGCCAG 
61 TGTGATGGAT ATCTGCAGAA TTCGGCTTAG CGGATAACAA TTTCACACAG GAGACCATTG ARP3 
121 CACTGACAGA GGAAGATATA TTTTAGAGGG AGACACTTGT ACCTTTCTCT CCCTTCAGTT 
181 ATTAGACTCT TGGGACAATG GACATCATGA ATTAAAACGT TCTTAGAAAT CACATGCTGG 
241 GAGAAAATTA ACACTAAAAT CTGGTACCAG CCAGAGGAAG GAACTTGACT CAAAATAAGA 
301 GATTTTTAGA TATTTCTGTC TGTCTCATAG TTAAAATTAA TGTTTTCCTG CTTTCTGGCA 
361 TATGCCTCAT CTTTTCTATG AAGTAGTAAT ACTGATACAG AAAGGTAGAG AGAAATGAAT 
421 AGTTTTTGCT ACTTTGGGCC AAACTGTGAA AAAATNCATT TTATTTCACC AAAAAAAAAG 
481 CCCTATAGTG AGTCGTATTA CAAGCNGAAT NCCAGCACAC TGGCGGCCGT AACTAGTGNA 
541 TNCGAGCTCN GTANCAAGCT GGGCGTAATC ATGGTCAAGC TGTTTCTGTG TGAANTGTAT 
601 CGCTCNCANT CCCACAACTA CGANCCGANC TAAGTGTAAG CNNNNNGCTA TNNACTACTC 
661 ATANTGNNCC CTACGCGNTC GTNGAACGG 
B 28.2: Sequencing alignment of cDNA subclone AB26#17 with mouse Cyp4al4 by BLAST 
searching against the National Center for Biotechnology Information database 
AB26#17 ： 114 accattqcactqacagaqqaaqatatattttaqaqqgaqacacttqtacctttctctccc 173 
m m ? 11 i iTmTi f f 11 化 I m i Ml 丫丨丽 II Mil丫 m m 11 Ml III 
Mouse Cyp4al4： 1823 accattgcactgacagaggaagatatattttagagggagacacttgtacctttctctccc 1882 
AB26#17 ： 174 ttcagttattagactcttqqgacaatgqacatcatqaattaaaacqttcttaqaaatcac 233 
m i l ^ i i i i i T i i i i i i f n i i i i i T f l l l l l l l l ^ l l l l l l l l 了 MMii 丫 III IIII 
Mouse Cyp4al4： 1883 ttcagttattagactcttgggacaatggacatcatgaattaaaacgttcttagaaatcac 1942 
AB26#17 ： 234 atqctgqgaqaaaattaacactaaaatctgqtaccaqccaqaqqaaqqaacttqactcaa 293 
M T l _ T l M M M I M m i i m i T f M M I ? l l l T l T f M f f M M I 了 m i l l 
Mouse Cyp4al4: 1943 atgctgggagaaaattaacactaaaatctggtaccagccagaggaaggaacttgactcaa 2002 
AB26#17 ： 294 aataaqaqatttttaqatatttctgtctqtctcataqttaaaattaatgttttcctqctt 353 
I M I I T I T I M M M T I I M M M 了 l l l T l l l M l l T l l M M M M l T l l l l M l T m 
Mouse Cyp4al4： 2003 aataagagatttttagatatttctgtctgtctcatagttaaaattaatgttttcctgctt 2062 
AB26#17 ： 354 tctqqcatatgcctcatcttttctatqaagtaqtaatactqatacaqaaaqqtaqaqaqa 413 
Mouse Cyp4al4： 2063 tctggcatatgcctcatcttttctatgaagtagtaatactgatacagaaaggtagagaga 2122 
AB26#17 ： 414 aatgaataqtttttqctactttqggccaaactqtgaaaaaatncattttatttca 468 
M I T I M I T M I M T M I M M T T T M I M M T I T M I M M I I I I M I I M M � 
Mouse Cyp4al4： 2123 aatgaatagtttttgctactttgggccaaactgtgaaaaaatccattttatttca 2177 B 28.3: Summary of sequence alignment of cDNA subclone AB26#17 with mouse Cvp4al4 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after E c o m Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml2 Mus musculus cytochrome � 
AB26 - + - - 390 AB26#17 450 forward ^ ' ' Y Z ^ t ^ ^ l T ' ' ' 354/355 
a, polypeptide 14 
(-20) (Cyp4al4) (2547 bp) (外,。） 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 TACCAAGCTT GAGTACCGAG CTCNGATCCA CTAGTAACGG CCGCCAGTGT GCTGGAATTC 
6 1 GGCTTGATAA TACGACCCAC TATAGGGCTT TTTTTTTTTG GTGAAATAAA ATGGATTTTT A P 3 * 
1 2 1 TCACAGTTTG GCCCAAAGTA GCAAAAACTA T T C A T T T C T C TCTACCTTTC TGTATCAGTA 
1 8 1 TTACTACTTC ATAGAAAAGA TGAGGCATAT GCCAAAAAGC AGGAAAACAT TAATTTTAAC 
2 4 1 TATGAGACAG ACAGAAATAT CTAAAAATCT CTTATTTTGA GTCAAGTTCC TTCCTCTGGC 
3 0 1 TGGTACCAGA T T T T A G T G T T AATTTTCTCC CAACATGTGA TTTCTAAGAA CGTTTTAATT 
3 6 1 CATGATGTCC ATTGTCCCAA AGAGTCTAAT AACTGAAGGG AGAGAAAGGT ACAAGTGTCT 
4 2 1 CCCTCTAAAA TATATCTTCC TCTGTCAGTG CAATGGTCTC CTGTGTGAAA TTGTNATCCG 
4 8 1 CTAAGCCGAA TTCTGCAGAT ATNCATCACA CTGGCGGCCG CTCGAGCATG CATCTAGAGG 
5 4 1 CCCAATNCGC NNTATAGTGA GTCGTATTAC AATTCACTGC CNGTCGTNTN ACAACGTCGT 
6 0 1 GACTGGNANA ACCCNGGCGT NANCCACCNT ANTCGCNTGC AGCNCANTCC CCTTTCGCNA 
6 6 1 CTGNNGTNNA CGAGANGCNN NNNGATNCCC TCCACAGTGC CNNCGTG 
B 29.2: Sequencing alignment of cDNA subclone AB26#30 with mouse Cyp4al4 by BLAST 
searching against the National Center for Biotechnology Information database 
AB26#30 ： 102 tqaaataaaatqqattttttcacaqtttqqcccaaaqtaqcaaaaactattcatttctct 161 
i l ^ i i M i m T f i i i i i i i i N i丫 m T f i i m i T i i t i m i i i m i i i m i i i i 
Mouse Cyp4al4： 2177 tgaaataaaatggattttttcacagtttggcccaaagtagcaaaaactattcatttctct 2118 
AB26#30 ： 162 ctacctttctqtatcaqtattactacttcataqaaaaqatqaqqcatatqccaaaaaqca 221 
i i i i i i m i T i i m T N i m i i N i i i i i丫 i i i i T i i T i f f i i i i i n i i iiiTii 
Mouse Cyp4al4： 2117 ctacctttctgtatcagtattactacttcatagaaaagatgaggcatatgccagaaagca 2058 
AB26#30 ： 222 qqaaaacattaattttaactatqagacaqacagaaatatctaaaaatctcttattttqaq 281 
f f m m i m i i m m i i 丫 I丫 Ml丫 m T N i i i N i i i i i i i i i i i N i m T i 丫 
Mouse Cyp4al4： 2057 ggaaaacattaattttaactatgagacagacagaaatatctaaaaatctcttattttgag 1998 
AB26#30 ： 282 tcaaqttccttcctctqqctqqtaccaqattttaqtqttaattttctcccaacatqtqat 341 
M I 丫 丨 i i i m i m f f i i T f i i m l ^ i i i i i 丫 i T m i i i i i m m M I T I T I I 
Mouse Cyp4al4： 1997 tcaagttccttcctctggctggtaccagattttagtgttaattttctcccagcatgtgat 1938 
AB26#30 ： 342 ttctaaqaacqttttaattcatqatgtccattgtcccaaaqagtctaataactqaaqqqa 401 M i M I T M I T M I M M M M T I I T M i l M T I I M I IT IT I11111111 I I I ITTTI 
Mouse Cyp4al4： 1937 ttctaagaacgttttaattcatgatgtccattgtccc-aagagtctaataactgaaggga 1879 
AB26#30 ： 402 qaqaaaqqtacaaqtqtctccctctaaaatatatcttcctctqtcaqtqcaatqqt 457 
丫 i t m f f i i i i i Y i 丫 i m M i i i m i i i m i M i m i T i i i T i T i i i i f f i 
Mouse Cyp4al4： 1878 gagaaaggtacaagtgtctccctctaaaatatatcttcctctgtcagtgcaatggt 1823 B 29.3: Summary of sequence alignment of cDNA subclone AB26#30 with mouse Cvp4al4 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after EcoRl Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome ^ 
〜A . … M13 P450, family 4, subfamily 
AB26 + 390 AB26#30 450 I H 353/356 
reverse a, polypeptide 14 
(Cyp4al4) (2547 bp) …。^  
* Sequence of primer was not completely matched with the expected sequence. 
316 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 NCNNTCACNT ATAGGGCGAA TTGGGCCCTC TAGATGCNTG CTCGAGCGGC CGCCAGTGTG 
61 ATGGATATCT GCAGAATTCG CCCTTGTAAT ACGACTCACT ATAGGGCTTT TTTTTTTTGG APS* 
1 2 1 GACAGGGTTT CTCGGTGCAG CCCTGGCTGT CCTGGAACTC ACTGTGTAGA CCAGGCTGGC 
1 8 1 CTCGAACTCA GAGATCACCT GCCTCTGCCT CTGGACTGCT AAGATTAAAG GTGTACAACA 
2 4 1 CCACCACCTG ATTAAATAGT TTAAACAAAC AAACAACAAC AACAAAAACC AGAAGAAAAG 
3 0 1 AGAGCTGGAG AGATGGCTCA GCAGTTAAGA GCACCAACTG CTCTTCCAGA GGTCCTGAGT 
3 6 1 TCAATTCCCA GCAACCACAT GGTGGCTCCC AACCATCTGC AATGGTCTCC TGTGTGAAAT 
4 2 1 GGTTATCCGC TAAGGGCGAA TTCCAGCACA CTGGCGGCCG TTACTAGTGG ATCCGAGCTC 
4 8 1 GGTACCAAGC TTGATGCATA GCTTGAGTAT NCTATAGTGT CACCTAAATA GCTTGGCGTA 
5 4 1 ATCATGGTCA TAGCTGTTTC CTGTGTGAAA TTGTNATCCG CTCACAATTN CACACAACAT 
6 0 1 ACGAGCCGGA AGCATAAAGT GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT AACTCACATN 
6 6 1 AATNGCGTNG CGCTCACTGC CCGCTTTCCA GTCNGGAAAC CTGTCGTGCA GCTGCATTAA 
7 2 1 TGAATNNCCA CGCGCGGGAN NNCGGNNGCG TNTNGGCNCT CTCCNCTCCC GCTCCTGACT 
7 8 1 GCTGCCTNNT GTTGGNNNNC NNN 
B 30.2: Sequencing alignment of cDNA subclone AB29#7 with mouse catalase by BLAST searching 
against the National Center for Biotechnology Information database 
AB29#7 ： 439 aattccagcacactqqcgqccgttactagtgqatccgagctcqgtaccaaqct-tgatgc 497 
M I M I丫 i i imniTf i i丫mm丫 i f f im丫 i t i i i f f i i im丫 i I T M T I 
Mouse catalase： 31 aattccagcacactggcggccgttactagtggatccgagctcggtaccaaggtgtgatgc 90 
AB29#7 ： 498 atagcttqaqtatnctataqtqtcacctaaatagcttgqcqtaatcatqgtcatagctqt 557 
I I I T I I I T I T I I I l l l l l Y l 化 l l l l l l l l l 丫 I I I 而 l l l l l l l f f l i m 丫 I I 丫 I 
Mouse catalase： 91 atagcttgagtattctatagtgtcacctaaatagcttggcgtaatcatggtcatagctgt 150 
AB29#7 ： 558 ttcctgtgtqaaattgtnatccgctcacaattncacacaacatacgagccqgaagcataa 617 
M M I T I T I T I M M T i 11 丨 i t 111111111 11 丨 11111111 i t I丫I i f f 11丫11111 
Mouse catalase： 151 ttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataa 210 
AB29#7 ： 618 aqtqtaaagcctqqqqtgcctaatqaqtgaqctaactcacatnaatnqcgtnqcqctcac 677 
I 丫 l l ^ l l l ^ ^ l l f f f f l Y m i l l T l 丫 i T l 丫 I I I I I I I I I I I T i l l T I T I I I I I 
Mouse catalase： 211 agtgtaaagcctggggtgcctaatgagtgagctatttctcattaattgcgttgcgctcac 270 
AB29#7 : 678 tqcccqctttcca 690 
I 丫 I I I 丫 l l l l l l l 
Mouse catalase： 271 tgcccgctttcca 283 B 30.3: Summary of sequence alignment of cDNA subclone AB29#7 with mouse catalase 
FluoroDD gel AB (AP3 + ARP3) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
if84a04.xl Kaestner ngn3 
M13 - _ subtracted Mus e 114 
, , inA r 1 musculus cDNA 3' similar -
AB29 • + - • 335 AB29#7 380 forward to SW:CATA CAMJE 
(-20) Q59296 CATALASE (灼 乂。） 
I I I I I (283 bp) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 48.1: DNA sequence ofcDNA subclone AFl #8 (APIO & ARPi:3) using Ml 3 forward (-20) primer 
1 ACCCTNACTA TAGGGCGAAT TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA 
61 TGGATATCTG CAGAATTCGC CCTTGTAATA CGACTCACTA TAGGGCTTTT TTTTTTGCCC AP2* 
121 GGCCCATTCA TTCTTTATTC AGGTGGCATA AAAATCACTA CAAAAACTTT ACAAAAGAGT 
181 CTTGGGAGCT AAAGGGTCCC TTCCTTGCCT CAGTCCCCAA GATTCCTGGC AGGGGAGGAC 
241 AAGAGAGAGA AGAAGGAGGA AGACTCCTGG CAGTGTTGGC ATCTCCAAAT ACCAGAGGGG 
301 TGACTTGGGT GACAGGACAC AGGTNGGGGA CCTGAATGTC TTCAGCAAGG GACACTCTTG 
361 TAGGGTAGGT CAGCCTCCAA CCATGAAGTA TAACACCCAA GGCCAGTCTA AGCTTGGGAG 
421 ACCAACACTT GTCTCTCCTT TTCCCCACCC AGGGTGTCTG GAATATGTCT AAAGATGGCC 
481 TCTCCAGCCT CTGCTTACAA ATGTGGAGGN NCCCTAAGTT AGGGACTTGC CTAACCTACC 
541 TCTAGCCCAA ACTGTGTNCA CAAGTGCCAG CCCACAAAAG ATCACCCCCT GAGCCCCTTG 
601 GGNAAGAAAT GAAGATTCCC CATGNCCTGC CNNNCCTCCA GGCCCCCACC CCCNCCTGGC 
661 TGCNNANAAA ACNNGNTTNT ANNACTGNTG NATGGTTCNT TCCNGNTCCC ACCCTTATCC 
721 CCCCAAAGCN GGNTAAAAAA GAGTTNNAGG AGCNGAAAGN TGGTCAGGTN GGACTAAGAT 
781 TTNNTGNNGG NCNNTNNNNT GGGGGANNNG AATGGGNNNN 
B 31.2: Sequencing alignment of cDNA subclone AC1#1 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC1#1 : 122 qcccattcattctttattcaqqtqqcataaaaatcactacaaaaactttacaaaaqaqtc 181 T m i m i m i i i i m i f f i f f m N i i i i i i m i i i i i i i i i m i m T i T i i 
Mouse SPI: 2166 gcccattcattctttattcaggtggcataaaaatcactacaaaaactttacaaaagagtc 2107 
AC1#1 : 182 ttgggagctaaaqqgtcccttccttqcctcaqtccccaagattcctggcagggqaqqaca 241 
i i f r f i Y i i i i i Y n i i i i i i i i i i Y i i m Y i m i i i Y i m i i f f i i f i T f i n i i i 
Mouse SPI： 2106 ttgggagctaaagggtcccttccttgcctcagtccccaagattcctggcaggggaggaca 2047 
AC1#1 : 242 aqaqagaqaagaaqgaqgaaqactcctqqcaqtgttgqcatctccaaataccaqaggqqt 301 
Mouse SPI： 2046 agagagagaagaaggaggaagactcctggcagtgttggcatctccaaataccagaggggt 1987 
AC1#1 : 302 qacttqqqtgacagqacacaqqtnggggacctqaatqtcttcaqcaagqgacactcttqt 361 
T I I I I T T T I T I I I T T I I I I I T T I f f f f i 1 1 1丫 1 1 l Y l I I I I l Y l I i f f f l l l I I I I I丫I 
Mouse SPI： 1986 gacttgggtgacaggacacaggttggggacctgaatgtcttcagcaagggacactcttgt 1927 
AC1#1 : 362 agqqtaggtcagcctccaaccatqaaqtataacacccaaqgccaqtctaagcttqqgaga 421 I T T T M T T M I T M M M M M I I M T M I M M 1 1 1 I T T I I I I I 111 I I I I I T T T I T I 
Mouse SPI： 1926 agggtaggtcagcctccaaccatgaagtataaca-ccaaggccagtctaagcttgggaga 1868 
AC1#1 : 422 ccaacacttqtctctccttttccccacccagqqtgtctqgaatatqtctaaaqatqqcct 481 
i i i i i i i i i T i i i i i M i i M i N i i i N 丽 i i i f f i i m 丫 m m 丫 i i f f m 
Mouse SPI： 1867 ccaacacttgtctctcctttt-cccacccagggtgtctggaatatgtctaaagatggcct 1809 
AC1#1 : 482 ctccagcctctgcttacaaatqtqqaqqnnccctaagttaqggacttqcctaacctacct 541 I I I I I T I I I I I T I I I I I I I I I T I T T I T T 11111 111 I I T T T I 1 1 I T I 1 1 1 1 1 1 1 1 1 1 1 
Mouse SPI: 1808 ctccagcctctgcttacaaatgtggagggaccctaagttagggacttgcctaacctacct 1749 
AC1#1 : 542 ctaqcccaaactqtgtncacaagtgccagcccacaaaaqatcaccccctgaqccccttqg 601 
I M T I I I I I I I T I T I I I I I I T I T I I I T I I I I I I I I I T I I I I I I I I I I T I T I I I I I I T T … � 
Mouse SPI： 1748 ctagccaaaactgtgtccacaagtgccagcccacaaaagatcaccccctgagccccttgg 1689 
AC1#1 : 602 qnaagaaatqaagattccccatg 624 1 I I T I I I I T I I T I I I I I I I I I T Mouse SPI: 1688 g-aagaaatgaagattccccatg 1667 B 31.3: Summary of sequence alignment of cDNA subclone AC1#1 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
r „ „ ,丄/丄、ni^AD , , . FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment I.D. after EcoRl Primer Blast search (% 
no. CTL Wy CTL size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
M13 cysteine) proteinase 0 
ACl + - + + 1800 AC1#1 1830 forward inhibitor, clade 495/503 
(-20) F, member 2 (98%) 
I I I I I (Serpinf2) (2187 bp) * Sequence of primer was not completely matched with the expected sequence. ^^^ 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CNTATTTAGG TGACACTATA GAATACTCAA GCTATGCATC CAAGCTTGGT ACCGAGCTCG 
61 GATCCACTAG ATAACGGCCG CCAGTGTGCT GGAATTCCGC CCTTAGCGGA TAACAATTTC ARP19 
1 2 1 ACACAGGATT TTGGCTCCCG CATCTACTGA GCCATTTCTA CCAGAACCTA GGCCCAGGGA 
181 CAATCCGGCT GGCTGCCAGA ATATACCTGC AGAAAGGATT TCCCATCAAA GACGATTTCC 
241 TGGCANGCCA CTCGGAACNG GCTCTTTGGT GCGAAGCCCN GTGNNNNACC TGACTGGACA 
301 AGCAGGACGG AAGACCTGGC GACNCNNTCN CNCAATGGGT GAAGGANGGC NNAGAGGGGA 
361 CAGATTGANG GATTTCTNTC TGAGCCTGCC GGATNGCCCG TGCTGTTTNT CTCACGCATC 
421 CTTNANGTTT NTGGAGGANN NGTTNGACCC NNNNTNNNNN ATNNNNNTGG CTGANNNGTN 
481 TGTNGTGGNT GNTNNNNGTG GTNTTNTTNT GGGTCTGNTG NNNNNNNTNG TGNNNNNNNN 
541 NNNNNTNNNN TGGTNNTNNN NTNNNTNNNT TNGTNNNNNN NTNNNNNNNN NNNGGTNNNN 
601 NNN 
B 32.2: Sequencing alignment of cDNA subclone AC1#1 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC1#1 : 121 acacaqqattttqqctcccqcatctactqaqccatttctaccagaacctaqgcccagqga 180 
l l l l l T T l l IT l l l l l T l l l l l l l l T l 丫 l l l l l l l l l l l l 丫 m i l l f f l l l l f f f l 
Mouse SPI: 439 acacaggatcctgcctcccgcatctactgagccatttctaccagaacctaggcccaggga 498 
AC1#1 : 181 caatccgqctgqctgccaqaatatacctqcaqaaaqgatttcccatcaaaqacgatttcc 240 
i i i i i i T i i f f i 丨丫 M i l ^ i m i m 丫 i i t m f f i i i i i i i m i i i 丫 I I 化 I N I 
Mouse SPI: 499 caatccgactggctgccagaatatacctgcagaaaggatttcccatcaaagacgatttcc 558 
AC1#1 : 241 丨〒〒 243 
Mouse SPI： 559 tgg 561 
B 32.3: Summary of sequence alignment of cDNA subclone AC1#1 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
ragmen fragment I.D. after EcoRI Primer Blast search (% 
CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
cysteine) proteinase 7e-52 
ACl + - + + 1800 ACl#l 1830 inhibitor, clade 119/123 
reverse F, member 2 (96%) 
I I I I I (Serpinf2) (2187 bp) 
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B 33.1: DNA sequence of cDNA subclone AC1#2 (AP2& ARP 19) using M13 forward (-20) primer 
1 GGGCCCTCTA GATGCATGCT CGAGCGGCCG CCAGTGTGAT GGATATCTGC AGAATTCGCC 
61 CTTGTAATAC GACTCACTAT AGGGCTTTTT TTTTGCTGTA GCATCAGGCA CGAGCCAGGC AP2* 
121 CAGCCTGTGT TTAATGGAAG GAACCCAATT CAGAAGGAAG GATGACATTT TAGGGTGGTC 
181 ATTTATGTGT GGGATCTACC ACTTTTCCCA CAAAGATGGG GCTCTGAGTG TGTTCTTCAA 
241 ATATTATGAA AAGGAAAGGG TGGTCNAAGC GCAGGATAGG GGGCATAGAC ATAGGAACCA 
301 TTTGTAAGAC TGTAACTGCT GCAGCTTCTG TTCCTGTCTC ATCGATGGTC AGCACAGCCT 
361 TATGCACAGC CCTGGCTGAG CTTTCCAGGG GAGCATTCNT CCCTCTGTGA TTCCGGAGAG 
421 GTCAGCCCCC ATTGTTGAAG ATCCGGGTGA TGCCCCAGTN GGACTNATGA GTGTTTTNAA 
481 GNNATATTCT CCAGAGATGG GACAGTCTGG GGAAGTTNGA TNNTGGGGGC TNCCCCTTTN 
541 TGNGNCNTGN TNNNAGCNGG GAACNTTAAA ANNATGAAGC CTCNTTNGNN TGAAAAGTTT 
601 TGGCTCCAAN ATGCTGCCTT TTTCCNNTNT TNNTTGGGGC CAAAANNGAA NNNCAGCACT 
661 TGGGTTTNNN NTTGCNNTNN TTCCTTTTCC CCGCCAACCC ACCCTGNAAC GGCTTTCGTG 
721 ACCNTGGNTT CNNCNTTCNC CCCTTNCACC GAAAANGGTN NNNNNNNNNN NNNNNNNNNN 
781 NNNN 
B 33.2: Sequencing alignment of cDNA subclone ACl#2 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC1#2 ： 95 gctgtaqcatcaqgcacgagccaggccaqcctgtgtttaatqgaagqaacccaattcaqa 154 
！II化了丨imffiii丫丨丫 ||丨^?丨||丫|丨|丫|丫 i i i m f f i i f f i i i i i m i i i t i 
Mouse SPI: 1376 gctgtagcatcaggcacgagccaggccagcctgtgtttaatggaaggaacccaattcaga 1317 
AC1#2 ： 155 aqgaaqgatgacattttagggtggtcatttatqtqtgqgatctaccacttttcccacaaa 214 
i f f i i f f i i 丫 i i i i i i i i T f f i f f i i i i i i i i l ^ Y i f f f i i i m i m i i i i i i i i i i i 
Mouse SPI： 1316 aggaaggatgacattttagggtggtcatttatgtgtgggatctaccacttttcccacaaa 1257 
AC1#2 ： 215 qatqqggctctgagtgtqttcttcaaatattatqaaaaqgaaaggqtqgtcnaagcgcaq 274 
丫 l l f f f f l l l l丫 I丫 I丫 I丫 l l l l l l l l l l l l l l l丫 l l l i n i l l f T f l T f l l I I T I T I I T 
Mouse SPI: 1256 gatggggctctgagtgtgttcttcaaatattatgaaaaggaaagggtggtcgaagcgcag 1197 
AC1#2 ： 275 gataggqqqcatagacatagqaaccatttgtaagactqtaactqctqcaqcttctgttcc 334 
了 i i i f f f n i m T i i i i i f f i i i i i i i i T i i i T i i i T i m i T i i T i i T i i m T i i i i 
Mouse SPI： 1196 gatagggggcatagacataggaaccatttgtaagactgtaactgctgcagcttctgttcc 1137 
AC1#2 ： 335 tqtctcatcgatgqtcagcacagccttatqcacagccctggctgagctttccaqgggagc 394 I T I I I I I I I T I I T T I I I T I I I I T I I I I I I T I I I I T 1 1 I T T I I T I T 1 1 1 M T T T T I T I 
Mouse SPI: 1136 tgtctcatcgatggtcagcacagccttatgcacag-cctggctgagctt--caggggagc 1080 
AC1#2 ： 395 attcntccctctqtqattccqgagaggtcagcccccattgttgaaqatccgggtgatgcc 454 M M I I I I I T I T I I I I I T T I T I T T I I I T 111111 111 I I I IT 111ITTT I I I IT I 
Mouse SPI： 1079 attct--cctctgtgattccggagaggtcag-ccccattgttgaagatccgggtgatg-c 1024 
AC1#2 ： 455 ccaqtngqactnatqaqtqttttnaagnnatattctccagaqatgqqacaqtctqqqgaa 514 
I M T I T T M I I I T I T I T I I I M I 111111111 IT IT I I TT 11 I I I I I T T T T I I � _ 
Mouse SPI: 1023 ccagt-ggactcatgagtgtcttcaagttatattctccagagat-ggacagtctggggaa 966 
AC1#2 ： 515 yt 516 
Mouse SPI: 965 gt 964 
B 33.3: Summary of sequence alignment of cDNA subclone ACl#2 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
Ml 3 cysteine) proteinase 0 
ACl + - + + 1800 ACl#2 1600 forward inhibitor clade A, 406/422 
(-20) member la (SPI) (96%) 
I I I I I (1393 bp) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 GATACTCAAG CTATGCNTCA AGCTTGGTAC CGAGACTCGG ATCCACTAGT AACGGCCGCC 
61 AGTGTGCTGG AATTCGCCCT TAGACGGATA ACAATTTCAC ACAQQATTTT GGCTCCTACT ARP19 
121 GCTTAAATAC AGACTAGGAC AGGGCTCTGT CTCCTCAGCC TCGGTCACCA CCCAGCTCTG 
181 GGACAGCAAG CTGAAAATGA CTCCCTCCAT CTCATGGGGT CTACTGCTTC TGGCAGGCCT 
241 GTGTTGCCTG GTCCCCAGCT TTCTGGCTGA GGATGTTCAG GAGACAGACA CCTCCCAGAA 
301 GGATCAGTCC CCCCAGCCTC CCATGAGATC GCCTACAAAC CCTGGGAGAC TTTGCAATCA 
361 GCCTATACCG GGAGCTGGTC CATCAGTNCN AACACTTTCC AACCATNNTT CTTCTCCCNN 
421 AGTGAGCCAT NNGCNACACC CNTTTGCNTA TGCTCTCCCT ANGGGANNCN AGGGTGACNN 
481 TNCNNNCCGA TCTAAGGGCT GANTNNNNNN NNTNNNGTNN NNTNTNNNCT NNNNNNANNN 
541 NCNNNNNNNT GGNTNNTNNN NNCNNTNNNN NNNNNNNNNN NN 
B 34.2: Sequencing alignment of cDNA subclone ACl#2 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC1#2 ： 147 ctgtctcctcaqcctcqgtcaccacccaqctctqqqacaqcaaqctgaaaatqactccct 206 
M T m i i m T i m f f i m i i i M i l ^ m f r f m 丫 I I I 化 T i m i 丫 i m i i i 
Mouse SPI： 1 ctgtctcctcagcctcggtcaccacccagctctgggacagcaagctgaaaatgactccct 60 
AC1#2 ： 207 ccatctcatqqqgtctactqcttctggcagqcctgtqttgcctqgtccccaqctttctqq 266 
i m m i i f i T f N i i i i T i i i i i f f N f f i i i T i T i i T i i i f f i i i m 丫 m i i i f f 
Mouse SPI: 61 ccatctcatggggtctactgcttctggcaggcctgtgttgcctggtccccagctttctgg 120 
AC1#2 ： 267 ctqagqatgttcaqgagacaqacacctcccagaaggatcagtccccccagcctcccatga 326 
i i t i f f i i l ^ i i i 而 I N 了 i m m i i i 丫丨 i f f i i N 丫 I i i i i i T i i i i i i i i T i 
Mouse SPI： 121 ctgaggatgttcaggagacagacacctcccagaaggatcagt--ccccagcctcccatga 178 
AC1#2 ： 327 gatcqcctacaaaccctqqqagactttgcaatcaqcctataccgqqagctgqtccatcaq 386 
TiiiT i i i i i i i i i i f f f i t i i i i i y i i i i i i丫 i i i i i m f f f i丫 i i f f i i i i i i i T 
Mouse SPI： 179 gatcg-ctacaaa-cctgggagactttgcaatcagcctataccgggagctggtccatcag 236 
AC1#2 : 387 t 387 I Mouse SPI: 237 t 237 B 34.3: Summary of sequence alignment of cDNA subclone ACl#2 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. a f t e r £ • � R I Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
cysteine) proteinase e-116 
ACl + - + + 1800 ACl#2 1600 inhibitor clade A, 237/241 
reverse member 1 a (SPI) (98%) 
I I I I I (1393 bp) 
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B 48.1: DNA sequence ofcDNA subclone AFl #8 (APIO & ARPi:3) using Ml 3 forward (-20) primer 
1 ANGCCTATTT AGGTGACNCT ATAGAATACT CNAGACTATG CATCAAGCTT GGTACCGAGC 
6 1 TCGGATCCAC TAGTAACGGC CGCCAGTGTG CTGGAATTCG CCCTTAGCGG ATAACAATTT A R P 1 9 
121 CACACAGGAT TTTGGCTCCC CTATTACAAC CAGGGCTATT TCTTGATAGA GGAAGGTAGT 
181 AAGCCAGAGG ATGTAGATGG GGTCTTAGAA GAGTNTGGTT TTAGAATGGG ACCCTTCAGG 
241 GTGTCTGACC TCGCAGGGCT AGATGTGGGT TGGAAAGTNC GCAAAGGGCA AGGCCTTACT 
301 GGACCGTCCT TACCTCCAGG AACCCCCACC CGAAAGAGGG GCAATACCAG GTATCCCCCA 
361 ATTGCTGATA TGCTCTGTGA AGCTGGGCGA TTTGGTCAGA AGACAGGTAA GGGCTGGTAT 
421 CAGTATGACA AGCCACTGGG TCGGATCCAC AAACCTGATC CCTGGCTTTC TGAGTTTCTG 
481 TCACAGTATA GAGAAACCCA TCACATCAAG CAGCGCTCCA TCAGCAAGGA GGAAATCCTG 
541 GAGCGTNGCT TATATTCCCT TATCAACGAG GCATCCCGCA TNTNGGANGA GGGGATGGCC 
601 GCTAGCCCAG AGCACANNAT GTCATCTACT GCATGGGTAT NGNTGGCCAN GCACGTGGTG 
661 GGCCATGTAC TATGCTGCNC AGTGGGCTGC CACAGNNTAA GANNTGCAGA ATATANCACC 
721 NACTCCGACN NCCCACNCTG ACCCNNGACN CNNGANGAGG GGNTNNCNNN GANNCCCCCC 
781 TGANNANGGA AAGNTGNNGA ANNATAT 
B 35.2: Sequencing alignment of cDNA subclone AC2#2 with mouse bifunctional enzyme 
(PBFE) by BLAST searching against the National Center for Biotechnology Information database 
AC2#2 ： 139 ccctattacaaccaqgqctatttcttqatagaqgaaggtagtaagccaqaqqatqtaqat 198 
M dd卯 I M � i i i i i i i i i i i i i i t n i i i i i i i i i 丫 I I I 丫 i f f i i f f i i � i N Y m � i f f i T i i T i i 
Mouse PBFE： 1469 ccctattacaaccagggctatttcttgatagaggaaggtagtaagccagagggtgtagat 1528 
： 1S9预衍衍〒丨丨丨丨丨竹丨丨丨丨衍讯丨预丨丨丨丨衍丨〒術衍丨丨丨衍兩丨丨行258 
Mouse PBFE： 1529 ggggtcttagaagagtttggttttagaatgggacccttcagggtgtctgacctcgcaggg 1588 
： 253丨衍衍丨预衍們丨化Tfmmmmmmmnmmm丨mT 
Mouse PBFE： 1589 ctagatgtgggttggaaagttcgcaaagggcaaggccttactggaccgtccttacctcca 1648 
AC2#2 ： 319 ggaacccccacccqaaagagqgqcaataccaggtatcccccaattqctgatatqctctqt 378 
M . . . . 1 � � f f l l l l l l l l l l l Y l l l Y l f i T f l l l 川 l l f f 丄 I I I I I I I I I T I I T I I I I T I I I I T i 1 1 � � 
Mouse PBFE： 1649 ggaacccccacccgaaagaggggcaataccaggtactccccaattgctgatatgctctgt 1708 
AC2#2 ： 379 gaagctggqcgatttggtcagaagacaggtaagggctggtatcagtatqacaagccactg 438 
Mouse PBFE： 1709 gaagctgggcgatttggtcagaagacaggtaagggctggtatcagtatgacaagccactg 1768 
AC2#2 ： 439 qqtcqcatccacaaacctgatccctggctttctqaqtttctqtcacaqtatagaqaaacc 498 
M … � 川 l l l l l l l 丄 丄 i i i ! f f i 山 山 I 丄 t 川 i � � � 
Mouse PBFE： 1769 ggtcgcatccacaaacctgatccctggctttctgagtttctgtcacagtatagagaaacc 1828 
AC2#2 ： 499 catcacatcaagcagcgctccatcagcaaqgaqgaaatcctggagcgtngcttatattcc 558 
M M M M M I T I I T I T M I M M I T M I T T I T T M I M M T T I T I T I T M I M I M M ��� 
Mouse PBFE： 1829 catcacatcaagcagcgctccatcagcaaggaggaaatcctggagcgttgcttatattcc 1888 
AC2#2 ： 559 cttatcaacgaggcatcccgcatntnggangagggqatggccgctagcccagagcaca-n 617 M M M I M T I T T I M I I T I I I I TTI T I T T T T I I T T I I I I I I T I 1 1 IT IT 1111 ^ … 
Mouse PBFE： 1889 cttatcaacgaggcattccgcatcttggaggaggggatggccgctagcccagagcacatt 1948 
AC2#2 ： 618 natgtcatctac-tgcatgggtatnqntggcc-anqcacgt-ggtggg-ccatgtactat 673 
I I T I I I M I I I I T I M T T T I M T I TTI I I T I I I T I TTITTT I M I T I I I I I I � _ � 
Mouse PBFE： 1949 gatgtcatctacttgcatgggtatgggtggccaaggcacgtgggtgggcccatgtactat 2008 
AC2#2 : 674 ^ct^c 678 
Mouse PBFE： 2009 gctgc 2013 
B 35.3: Summary of sequence alignment of cDNA subclone AC2#2 with mouse PBFE 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
^ 丄 • n / • / 1 � • n / / � F l u o f o D D Subclonc Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment LD. after ^  Primer Blast search (% 
no. CTL Wy CTL| Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
peroxisomal bifunctional 
enzyme (PBE) (PBFE) 
[includes: enoyl-coA ^ 
AC2 - + - - 1600 AC2#2 1630 ^13 hydratase (EC 4.2.1.17); 525/545 
reverse 3,2-trans—enoyl-coA fQf^o/、 
isomerase(EC 5.3.3.8); 3- “ 
hydroxyacyl-coA 
dehydrogenase (EC I I I I I 1.1.1.35)1 (2979 b^)^^ I 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 ACTATTTAGG TGACACTATA GAATACTACA AGACTATGAC ATACAAGACT TGGTACCGAG 
61 ACTCGGATCC ACTAGTAACG GCCGCCAGTG TGCTGGAATT NCGCCCNTTA GACGGATAAC ARP19 
1 2 1 AATTTCACAC AGGATTTTGG CTCCAGGGAC ACTNNATGCA TGATATGGCA AATANNNNAG 
181 CAGGGAGGCA CTCCTGTGGG CTTAAGCACC TAAACCTTTT CAAATTCTCT ATGGACACAC 
241 TGATGAGATA CTGAAGCGTG GGTATCAGCA CTGAACTCCA CNNGNNANNA TCAGGGGTCN 
301 AGGNNTGGCA CTGTGATNNT CCATACCGTT CAGAAAGGTC NGTACNTGAG ANCCCTACGA 
361 CTGCCTTGNG AGAGTTCNNT GTTCCTGACA ATTCCCAGGT TTGGGCCCTN TTCCGGGGAA 
421 AANACCCCNT TGGTTGTTNT AATTCCCGNC NTGGGNNAGN AGGAANNGTC CGNTTCCCNC 
481 CAAAGGGAAT NNAAGAAANN CNNNAATTTA NCACATTTTG GNNTTTTTTT NNTTANTTAA 
541 ANATGNGGNN NAAAGGTTAA TNNNTGGGGG GGGGGGTNTT TCCNANNGTT TTCCCCTGAA 
601 AGCTGTGNNA NCACAAANAT TNNTTNNANN NCCNNTGGTT GGCCNNTNNA NNTNGGGAAA 
661 NAAACCACAA NNTTAATNNA AANNNNNNNN NNNAGNNCTT AAAANNAAAG GGGGGGNNCC 
721 NNNTNNCNNG NNTTTTTTAA NNTNNNNNAN NNAAAGACCN TNNCACCANN GGGCNTNNNA 
781 ANAAGCNNNN NNNNTTTTNN TNNNNTTTTN NNNNNNNNNN NNNANANNNN NNNNNNTATA 
841 TTNTTANNNN NNNNGNNNN 
B 36.2: Sequencing alignment of cDNA subclone AC2#5 with mouse catalase by BLAST searching 
against the National Center for Biotechnology Information database 
AC2#5 ： 2 ctatttaqqtqacactataqaatactacaaqactatqacatacaaqacttqgtaccgaqa 61 I I I I I I I T T I l l l l l l l l l T I I I I I I M I T I I I I T I I I M I T M I T T M M T I T 
Mouse catalse： 123 ctatttaggtgacactatagaatact-caag-ctatg-cat-caag-cttggtaccgag- 70 
AC2#5 ： 62 ctcqqatccactaqtaacqqccgccagtqtgctggaatt 100 
l l l f f M I M M l t l l l l f f l l 丫 111丫 I丫丨丫 l l f f l l l l 
Mouse catalse： 69 ctcggatccactagtaacggccgccagtgtgctggaatt 31 
B 36.3: Summary of sequence alignment of cDNA subclone AC2#5 with mouse catalase 
FluoroDD gel AC (AP2 + ARP 19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
if84h05.xl Kaestner ngn3 
--subtracted Mus ^^ 1 ^ 
• m . .. , M13 musculus cDNA 3' similar o^ /^oo 
AC2 - + - - 1600 AC2#5 1620 reverse to SW:CATA CAMJE 二 
Q59296 CATALASE ^ ) 
l l l l l (280 bp) 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 NCNTCACTNN AGGGCGAATT GGGCCCTCTA GATGCATGCT CGAGCGGCCG CCAGTGTGAT 
61 GGATATCTGC AGAATTCGCC CTTGTAATAC GACTCACTAT AGGGCTTTTT TTTTTGCCCA AP2* 
121 TTCATTCTTT ATTCAGGTGG CATAAAAATC ACTACAAAAA CTTTACAAAA GAGTCTTGGG 
181 AGCTAAAGGG TCCCTTCCTT GCCTCAGTCC CCAAGATTCC CGGCAGGGGA GGACAAGAGA 
241 GAGAAGAAGG AGGAAGACTC CTGGCAGTGT TGGCATCTCC AAATACCAGA GGGGTGACTT 
301 GGGTGACAGG ACACAGGTTG GGGACCTGAA TGTCTTCAGC AAGGGACACT CTTGTAGGGT 
361 AGGTCAGCCT CCAACCATGA AGTATAACAC CAAGGCCAGT CTAAGCTTGG GAGACCAACA 
421 CTTGTCTCTC CTTTTCCCAC CCAGGGTGTC TGGAATATGT CTAAAGATGG CCTCTCCAGC 
481 CTCTGCTTAC AAATGTGGAG GGACCCTAAG TTAGGGACTT GCCTAACCTA CCTCTAGCCA 
541 AAACTGTGTC CACAAGTGCC AGCCCACAAA AGATCACCCC CTGAGCCCCT TGGGAAGAAA 
601 TGAAGATTCC CCATGCCTGC CTTCCTCCAG GCCCCACCCC ACCTGCTGCA AGAGANCAGC 
661 TTCTACACTG GTGATGGTCN NTCCNGTCCC ACCCTATCCC ACAAAGCTGG TTAGANAGAG 
721 TNACAGGAGC TGAGAGGCTG ATNCAGGTGG GGACTCNNAA, G 
B 37.2: Sequencing alignment of cDNA subclone AC2#6 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC2#6 ： 116 qcccattcattctttattcaqgtqqcataaaaatcactacaaaaactttacaaaaqagtc 175 
了 i i i m i i M i i i M M M 誦 m i m i i i m i i i i M i m i m m 丫 丨 丫 N 
Mouse SPI: 2166 gcccattcattctttattcaggtggcataaaaatcactacaaaaactttacaaaagagtc 2107 
AC2#6 ： 176 ttqggaqctaaaqqgtcccttccttgcctcagtccccaagattcccqqcagqgqagqaca 235 l l t n i T m i l f f f l l l l l l l l l l Y l l l l l l ^ l l l l l l l ^ l l l l T T I I T T I T I T T I I I 
Mouse SPI: 2106 ttgggagctaaagggtcccttccttgcctcagtccccaagattcctggcaggggaggaca 2047 
AC2#6 : 236 aqagagaqaagaaggagqaagactcctggcagtgttgqcatctccaaataccaqagqqqt 295 
iTiti丫 I力 lYiini行 i iYii i i i i f f i iYi 丫 i i n i i i i i i i i i i i i i i i T i f i T f i 
Mouse SPI： 2046 agagagagaagaaggaggaagactcctggcagtgttggcatctccaaataccagaggggt 1987 
AC2#6 ： 296 gacttgggtgacaggacacagqttqggqacctqaatgtcttcagcaagqgacactcttqt 355 Y i i i i n Y i T i i i f f i i i i i T f i i f f f f i i i i T i i i T i i i i i i T i i i T n i m i m T i 
Mouse SPI： 1986 gacttgggtgacaggacacaggttggggacctgaatgtcttcagcaagggacactcttgt 1927 
AC2#6 : 356 aggqtaqgtcagcctccaaccatgaagtataacaccaaqgccagtctaaqcttggqaqac 415 
l u t i i f f i M 丫 i i i i i i i i i i i 丫 i i T i i i i i i i i i i i f f i i i y i i i i i Y i i i 丫 n i 丫 II 
Mouse SPI： 1926 agggtaggtcagcctccaaccatgaagtataacaccaaggccagtctaagcttgggagac 1867 
AC2#6 ： 416 caacacttqtctctccttttcccacccaqgqtgtctggaatatgtctaaaqatqgcctct 475 
i i M i m 丫 i i i i i i i i i i i i i i i i i i i f r f i T i i i f f i i i i i T i i i i i i T i i f f i i i i i 
Mouse SPI： 1866 caacacttgtctctccttttcccacccagggtgtctggaatatgtctaaagatggcctct 1807 
AC2#6 ： 476 ccaqcctctgcttacaaatqtgqaqggaccctaagttaqqgacttqcctaacctacctct 535 
i i i t i i i i i l ^ i i i i i i i i Y i f f i f f f i i i i i i i Y i i i f r f m i 丫 i i i iMi iMi i i i 
Mouse SPI: 1806 ccagcctctgcttacaaatgtggagggaccctaagttagggacttgcctaacctacctct 1747 
AC2#6 ： 536 aqccaaaactqtgtccacaaqtgccaqcccacaaaagatcaccccctgagccccttgqqa 595 
i � M i i i M i 1 ^ t i m i i i Y i Y i i i 1 ^ i i m i i i Y i i i i i i M i i 丫 i T i i m i T n i 
Mouse SPI： 1746 agccaaaactgtgtccacaagtgccagcccacaaaagatcaccccctgagccccttggga 1687 
AC2#6 ： 596 agaaatgaaqattccccatgcctqccttcctccagqccccaccccacctqctqcaaqaga 655 
i l ^ i i i t i i t i m m i i l ^ i i t i i i i i i i i i i M m m m i m T i i T i i i T i T i ( � 
Mouse SPI: 1686 agaaatgaagattccccatgcctgccttcctccaggccccaccccacctgctgcaagaga 1627 
AC2#6 ： 656 ncaqcttctacactqqtgatggtcnntccnqtcccaccctatcccacaaagctqqttaga 715 
i i t iMi i i i i i i f f i丫 i i f f i i III l ^ i i i i i i i i i i i i i i i i i i T i i n i i i T i 1 (， 
Mouse SPI： 1626 acagcttctacactggtgatggtccttccggtcccaccctatcccacaaagctggttaga 1567 
AC2#6 ： 716 n!〒打1j:n竹I〒〒冗cj：〒〒竹冗〒cj:t|:〒|1j:n(j：打打〒〒〒竹cj：打756 
Mouse SPI： 1566 aagagtcacaggagctgagaggctgatccaggtggggactc 1526 B 37.3: Summary of sequence alignment of cDNA subclone AC2#6 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
^ 丄 nn • n / • / • � � « • � / / � F l u o r o D D Subclone Size of insert Gene homology to E-value Fragment P P A R a fragment I.D. after ^ c . R I Pr imer Blast search (<>/« 
no. CTL Wy CTL| Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
M13 cysteine) proteinase 0 AC2 + 1600 AC2#6 1800 forward inhibitor, clade 633/641 (-20) F, member 2 (98%) l__L__J (Serpnf2) (2187 bp) * Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CNACNTCACT ATAGGGCGAA TTGGGCCCTC TAGATGCATG CTCGAGCGGC CGCCAGTGTG 
6 1 ATGGATATCT GCAGAATTCG CCCTTGTAAT ACGACTCACT ATAGGGCTTT TTTTTGCCAT A P 2 * 
121 AAATAATATC TACTTTTATT ATTTTATTAT CCCTATAGAC AACATAGTAT AAATTTCCCT 
181 CTTCTTTGGC TACCTTTGAA ATATCCTCTG CAAGTCTACT CTGTGTNCCT CTNNTTCTTC 
241 TGTACCTTTG ACCTTTTCTA AGTTTCAACC CCTGNACTTG GTCTGNNCTC AATCATTCCC 
301 TTTAACCTCA TGCAGCCCAG GNTCAACGGG ACNAGAAACT CNTAGTGTAG GTTGGTGGGN 
361 TCCTGGCCAA GCCCACNANT CTAANNAACN CNTCGATGTT CCGGGGTGCC CGTGTGGATT 
421 TGAAGTGGAA GTTCTGCATN ATGTNNGTNA AGGAGNNAAG AATTCCCTCC TAACCAGTNC 
481 TTCTNCCAAA CCATACCGNN TCCCATNGAA AANGGCCNAA AGNCNTCATT CTTCCNNAAN 
5 4 1 NGGTTCCCNN TCAATTTAAG GAAGTGCCTT NGGGTNGAAT TTTTTGGNGT NGGAAAANAC 
601 CTGGGGGTCT TTCACCAAAA AACCCCACNN AAGGANCCCN TTAATAACCC TGGGGGAGAA 
661 GGAATTTCCA AAACTNGGGT CCTGNNTGAC CCTNAANCCC GCCCCAGGGN ATTGGNTTTA 
721 NNTACCTTGC TCCTNNNAAC TCAAGGCGGA ATGCT 
B 38.2: Sequencing alignment of cDNA subclone AC4#3 with mouse Cyp2a5 by BLAST searching 
against the National Center for Biotechnology Information database 
AC4#3 : 116 qccataaataatatctacttttattattttattatccctatagacaacataqtataaatt 175 T i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i M i T i i i i i m Y i m m i 
Mouse Cyp2a5： 1688 gccataaataatatctacttttattattttattattcctattgacaacatagtataaatt 1629 
AC4#3 ： 176 tccctcttctttqgctacctttqaaatatcctctgcaaqtctactctgtqtncctctnnt 235 l l l i l l l l l l l l T T I I I I I I I I T I I I I I I I I I I I T I I I T I I I I I I I I T I T I M i l l I 
Mouse Cyp2a5： 1628 tccctcttctttggctacctttgaaatatcctctgcaagtctactctgtgt-cctctgtt 1570 
AC4#3 ： 236 tcttctgtacctttqaccttttctaaqtttcaacccctgnacttgqtctgnnctcaatca 295 M I M I T M I M M T M I M M M M T M I I M M M I T M M T I N T M M M M 
Mouse Cyp2a5： 1569 tcttctgtacctttgaccttttctaagtttcaacccctg-actt-gtctggtctcaatca 1512 
AC4#3 ： 296 ttccctttaacctcatgcagcccaqgntcaacgggacnagaaactcntaqtqtaqqttqg 355 l l l l l i l l l l l l l l l l T I I T I I I I T T I I I I I T T T I I I T I I I I I I I I T I T I ITTI ITT 
Mouse Cyp2a5： 1511 ttccctttaacctcatgcagcccaggctcaacgggacaagaaactcatagtgtaggttgg 1452 
AC4#3 ： 356 tqqqntcctqqccaagcccacnantctaannaacncntcqatgttccqqqgtqcccqtqt 415 
ITTT I I ITTI I I T I I I I I I M M I I I I I T I I T I I T T T T I T I I TITI，二。。 
Mouse Cyp2a5： 1451 tgggatcgtggcaaagcccacgagtctaggagacacatcgatgtcctggggtgcctgtgt 1392 
AC4#3 ： 416 qqatttgaagtgqaagttctqcatnatqt 444 
T T I I I I T I I T i T T I I T I I I I T I I I M i l，,。 
Mouse Cyp2a5： 1391 ggatttgaagtggaagttctgcatgatgt 1363 B 38.3: Summary of sequence alignment of cDNA subclone AC4#3 with mouse Cvp2a5 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after 五 P r i m e r Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
, M u s musculus cytochrome ,^ , M13 。…^ 。 Lf -1 e-121 
AC4 ++ + ++ ++ 1100 AC4#3 1050 forward P450, family 2 subfamily 302/329 
(-20) a,p�lype(g^()Cyp2a5)(鴨） 
* Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CNCCNGANCA TTTAGGTGAC CTATAGAATA CTCAAGCTAT GCATCAAGCN TTGGTACGAC 
6 1 TCGGATCCAN NTAGTANGGC CNCCAAGTGT GCATGGNAAN NGCCCTTACN GGNTACAATT A R P 1 9 
121 TCACACAGGA TTTTGGCTCC CACTGCTTAA ATACAGACTA GGACAGGGCT CTGTCTCCTC 
181 AGCCTCGGTC ACCACCCAGC TCTGGGACAG CNAAGCTGAA AATGACTCCC TCCATCTCAT 
241 GGGGTCTACT GCTTCTGGCA GGCCTGTGTT GCCTGGTCCC CANGCNTTTC TGGCTGAGGA 
301 TGTTCAGGAN ACAGACACCT CCCNAGAAGG ATCCAGCCCC CAGCCTCCCA TGAGATCGCT 
361 ACAAACCTGG GNANACTTTG CAATCNAGCC TATACCGGGN AGCNGGGTCC ATCCAGNNCC 
421 AACACCNTCC CAACATNCCC TCCTTCCTCC CCCCAGGTGG AGNCANTTTG NCCCACCAGC 
481 CCNNNTTTGN CNTTATTGNC CTCCCTCCCC CNTNAGNGGG NAGNCCAAAG GGGNNTTGNA 
541 CAANCCTTCC ACCANCCGGC CCAAGAATCC CCCCCCCATT GGGGGGCCCC CTTGGGGCNC 
601 TTTCGGAAAN NGGNNNTNCC ACCCCCAAAA GGGGGACCAA CNNCAAAAAG GTTTTTCCGN 
661 NAAAGNAAAT TTTTTTNNCC TTTTCCCCTC CCCCCCCCCC AAAAAGNNGG GNTNNANNAT 
721 TTGGGAAAAN GTTGGGGTTT TTTCCNNTCN AATNTGCGNN TTGGGGGGGC CTTTTTTTGN 
781 TGTTTGNNNN TTGGNAAAAA AAGANAACNN CNNCCCCCAA AAAGGTTNTT TTTNTNTTTT 
841 TTTNNNNNNN NCNNNNNNNN 
B 39.2: Sequencing alignment of cDNA subclone AC4#3 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC4#3 ： 171 ctqtctcctcagcctcqqtcaccacccaqctctqqgacaqcnaaqctgaaaatqactccc 230 M T M I M M I T M I I T T M I M M M I T M I I T T T M I T I M T I I T M I M T M I M I 
Mouse SPI: 1 ctgtctcctcagcctcggtcaccacccagctctgggacagc-aagctgaaaatgactccc 59 
AC4#3 ： 231 tccatctcatgqgqtctactqcttctgqcaqqcctgtgttgcctqgtccccangcntttc 290 
l l l l l l l l l l f f f f l l l l l l t l l l l l f f l l f f l l l 丫 I 丫 l l l ^ l l f f l l l l l l T l M M 
Mouse SPI： 60 tccatctcatggggtctactgcttctggcaggcctgtgttgcctggtcccca-gc-tttc 117 
AC4#3 ： 291 tqqctqaqgatqttcagganacaqacacctcccnaqaaqgatccagcccccaqcctccca 350 1 T T 1 I T I T T I I T I I I I T T 1 11 I I I 11111111 I T I I I T I I I I I I i 11 I I I 11 i 111 
Mouse SPI： 118 tggctgaggatgttcaggagacagacacctccc-agaaggat-cagtccccagcctccca 175 
AC4#3 ： 351 tgagatcgctacaaacctqgqnanactttgcaatcnagcctataccggg 399 I T I T I I I T I I I I i l l l l l T T T I I I I I I T I I I I I I I I 111111ITTT 
Mouse SPI： 176 tgagatcgctacaaacctggg-agactttgcaatc-agcctataccggg 222 B 39.3: Summary of sequence alignment of cDNA subclone AC4#3 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
- cysteine) proteinase 4e-85 
AC4 ++ + ++ ++ 1100 AC4#3 1050 inhibitor clade A, 219/229 
reverse member la (SPI) (9^ %) 
I I I I I (1393 bp) 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AACNCTCACG TATAGGGCGA ATTGGGCCCT CTAGATGCAT GCTCGAGACG GCCGCCAGTG 
6 1 TGATGGATAT CTGCAGAATT CGCCCTTGTA ATACQACTCA CTATAGGGCT TTTTTTTTTT AP2 
1 2 1 TGCTGTAGCA TCAGGCACGA NGNCCAGGCC AGCCTGTGTT TAATGGAAGG AACCCAATTC 
1 8 1 AGAAGGAAGG ATGACATTTT AGGGTGGTCA CTTTATGTGT GGGATCTACC ACTTTTCCCA 
2 4 1 CAAAGATGGG GCTCTGAGTG TGTTCTTCAA ATATTATGAA AAGGAAAGGG TGGTCGAAGC 
3 0 1 GCAGGATAGG GGGCATAAGA CATAGGAACC ATTTGTAAGA CTGTAACTGC TGCAGCTTCT 
3 6 1 GTTCCTGTCT CATCGATGGT CAGCACAGCC TTATGCACAG CCTGGCTGAG CTTCAGGGGA 
4 2 1 GCATTCTCCC TCTGTGATTC CGGAGAGGTC AGCCCCATTG TTGAAAATCC NGGGTGATGC 
4 8 1 CCAGTGGACT CATGAGTGTN CTTCNANGTT ATATTCTCCA AAGATGGGAC AGTNNGGGNG 
5 4 1 AAGTGGATTT GGNGCTAACT GGTGGGTNGG TAANANTNTN NTNNGAGTNN TGGGGATNNG 
6 0 1 GNTTTGNTNA NNNNGTNGAN TNNTNNNNTG GNTCTNNNTG TNNTNGNNTN NNNNNNNNGN 
6 6 1 NNNNGNNNNN NNTTNN 
B 40.2: Sequencing alignment of cDNA subclone AC7#5 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AC7#5 ： 122 qctgtagcatcaggcacqangnccaggccagcctqtgtttaatqqaaqqaacccaattca 181 TlllllTillllTTIllTI lllffmtlll 丫 iTllllllffllffllimillll 
Mouse SPI： 1376 gctgtagcatcaggcacgag--ccaggccagcctgtgtttaatggaaggaacccaattca 1319 
AC7#5 ： 182 qaaqqaaqgatqacattttagggtgqtcactttatgtgtqqqatctaccacttttcccac 241 
t l l f f l l f f l l Y l l l l l l l l 丫 n i f f l l l I I I I I T I T I T T T I I I I I I I I I I I I I I I I I I 
Mouse SPI: 1318 gaaggaaggatgacattttagggtggtca-tttatgtgtgggatctaccacttttcccac 1260 
AC7#5 ： 242 aaaqatqqqqctctqagtgtgttcttcaaatattatgaaaaggaaagqqtqgtcqaagcg 301 I旧iiffffiiiitititiYiiiiiiiimiiiiYiiiiniiifffiffiiYiiyiY 
Mouse SPI： 1259 aaagatggggctctgagtgtgttcttcaaatattatgaaaaggaaagggtggtcgaagcg 1200 
AC7#5 ： 302 caqqataqgggqcataagacataggaaccatttgtaaqactgtaactqctgcaqcttctq 361 
M T T M I T T T T T M M 丫1111 i f f I I I I I I I l Y l l l T l I i T l 1111丫I i T l I了1111 iT 
Mouse SPI： 1199 caggatagggggcata-gacataggaaccatttgtaagactgtaactgctgcagcttctg 1141 
AC7#5 ： 362 ttcctgtctcatcqatqgtcaqcacagccttatgcacaqcctqqctgaqcttcagqqgaq 421 
i i i i i t i i i M i i ^ i t t i i i l ^ i i i 力 i i i i i t i i i i Y i i i f f i i l ^ l ^ i i i i f i T f i Y � 
Mouse SPI： 1140 ttcctgtctcatcgatggtcagcacagccttatgcacagcctggctgagcttcaggggag 1081 
AC7#5 ： 422 cattctccctctgtgattccqqagaggtcaqccccattqttqaaaatccngqqtqatqcc 481 l l l l l l I I I I I T I T I I I I I T T I T I T T I I I T I I I I I I I I I I T I I M M T T T I T I I T I I，… 
Mouse SPI： 1080 cattct-cctctgtgattccggagaggtcagccccattgttgaagatcc-gggtgatgcc 1023 
AC7#5 ： 482 caqtqqactcatgagtqtncttcnanqttatattctccaaaqatgq 527 
I I T I T T I I I I I I T I T I T I M M I T111111111111 I 丫丨丨丫丫。,� 
Mouse SPI: 1022 cagtggactcatgagtgt-cttc-aagttatattctccagagatgg 979 B 40.3: Summary of sequence alignment of cDNA subclone AC7#5 with mouse SPI 
FluoroDD gel AC (AP2 + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. sifter EcoRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
M13 cysteine) proteinase 0 
AC7 + - + + 770 AC7#5 790 forward inhibitor clade A, 394/406 
(-20) member la (SPI) (97%) 
l l l l l (1393 bp) 
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B41.1: DNA sequence of cDNA subclone AD6#4 (AP2 & ARP 18) using M13 reverse primer 
1 AGACTATTTA GGTGACACTA TAGAATACTA CNAGACTATG ACNTNCAAGA CTTGGTACCG 
61 AGACTCGGAT CNCTAGTANN GGCCGCCAGT GTGCTGGAAT TCGCCCTTAG ACGGATACAA ARP18 
1 2 1 TTTCACACAG GATGATGCTA CCACTTGTCA CATTGTAGTC CTGAGACATA CAGGAAATGG 
181 GGCAACCTGC CTGACACATT GTGATGGATC TGACACCAAA GCTGAAGTCC CCTTGATAAT 
241 GAGCTCCATA AAATCCTTCT CTGAACATGC TGAGTGTGGA AGGCTGGAAG TACATCTTGT 
301 GGGAGGCTTC AGTGATGACA GGCAGCTGTC ACAGAAACTT ACTCATCAGC TTCTCAGTGA 
361 ATTTGACAAA CAGGATGATG ACATTCACTT AGTGACATTA TGTGTAACAG AGTTAAATGA 
421 CCGTGAAGAN AAATGAAAAT CACNTTTCCA ATCATTTATG GCATCGCCTG TCAACATNAA 
481 AACTGCCAGA GATTTACAGA GCTNCCCTTT CAAGATCGTG GTCCCAGAGG AGCAACTGCG 
541 TGCTGCAAGA GCTTTAGCAC GANGCCCAAT GATTAGCATT TATGATGCCA NGACAGNNCA 
601 CCTCCGANNA GGCNCGTGTT CCTGNACCNN ATTCCCCACA AAGTGGATCN TCTGGGTTGC 
661 CGCAAAGAAT GACNNNGCCN ANTTTCNTAA NANAAGNCCT TTTCCNACGN TNNTTCCTCT 
721 GGNNCCNCGC CCCCCCCCCC CTNTNGGTTG AANTCTTAAA CTCCTNNCCC TGATTNTTNN 
781 TNNNTNNNTT TTTNNNNNNN TTTCTCTTNT TTGGAATTTC CCCCNCCNNN NCCNNNCTNT 
841 NNNTGNTGTN GTGTNNNNNN NTNNTTCGG 
B 41.2: Sequencing alignment of cDNA subclone AD6#4 with mouse N-terminal Asn amidase (Ntanl) 
by BLAST searching against the National Center for Biotechnology Information database 
AD6#4 ： 131 gatqatqctaccacttqtcacattqtagtcctqaqacatacaqqaaatgqgqcaacctqc 190 
Y l l Y l l t l M l i m i T l l l l l l l Y l l T l l l l t l Y l M I M l f f l l N f i T f l l l l M 力 
Mouse Asn： 285 gatgatgctaccacttgtcacattgtagtcctgagacatacaggaaatggggcaacctgc 344 
AD6#4 ： 191 ctgacacattgtgatqqatctgacaccaaaqctgaagtccccttgataatgagctccata 250 iitimmti 丫丨iffiiii 丫Miiiiii 丫 iitii 丫 IIIIIII 丫 iiii 丨丫 I丫miMi 
Mouse Asn： 345 ctgacacattgtgatggatctgacaccaaagctgaagtccccttgataatgagctccata 404 
AD6#4 ： 251 aaatccttctctqaacatqctqaqtqtggaaqqctqqaagtacatcttqtqqgagqcttc 310 
imiiiiiiiitmiitiiYiti丫ittiiffiittiiTiiim丨丨丽iffim 
Mouse Asn： 405 aaatccttctctgaacatgctgagtgtggaaggctggaagtacatcttgtgggaggcttc 464 
AD6#4 ： 311 agtqatgacagqcagctqtcacaqaaacttactcatcaqcttctcagtqaatttqacaaa 370 lYiYiiYiiiffiitiil^ iml^ iiiimiiiiiitiiiiiiitiTiiiii丫丨im〔。力 
Mouse Asn： 465 agtgatgacaggcagctgtcacagaaacttactcatcagcttctcagtgaatttgacaaa 524 
AD6#4 ： 371 caggatgatqacattcacttaqtqacattatqtqtaacagaqttaaatqaccqtqaagan 430 
I I〒？ i iTi i〒丨mmimti丫mmiti t i i i i i t i t i i i i i i丫 I I I丫丨丫 i i t i … 
Mouse Asn： 525 caggatgatgacattcacttagtgacattatgtgtaacagagttaaatgaccgtgaaga- 583 
AD6#4 ： 431 aaatqaaaatcacntttccaatcatttatqqcatcqcctqtcaacatnaaaactqccaqa 490 I I I I T I I I I I I I I I I I I I I I I I I I I I I I T T I I I I T I I T I I I I I I I l i l l l l T l l T l m 
Mouse Asn： 584 aaatgaaaatcac-tttccaatcatttatggcatcg-ctgtcaacattaaaactg-caga 640 
T I I I I I I I T I T I I l i m i M 力 I I 丫 i f f i M I T I T T I T I M I I T I T I T M T I M T I 
Mouse Asn： 641 gatttacagagctt-cctttcaagatcgtggt-ccagaggagcaactgcgtgctgcaaga 698 
AD6#4 ： 551 qctttagcacgangcccaatqattaqcatttatgatqccangacaqnncacctccganna 610 
？ l l l l l T l l T1 T l l i l l l T l l l l T I I I I I I I T I I T I I T I I I T I I I I I I T I I ^^^ 
Mouse Asn： 699 gctttagcaggaggcccaatgattagcatttatgatgcaaagacagaacaactccgaata 758 
AD6#4 : 611 qgcncqtqttcctq 624 
TTI I T I T I M M T � 
Mouse Asn： 759 ggcccgtgttcctg 772 B 41.3: Summary of sequence alignment of cDNA subclone AD6#4 with mouse Ntanl 
FluoroDD gel AD (AP2 + ARP18) Sequencing 
: I 加 AD / 丄 /丄、DD A … F l u o r o D D Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (•/_) fragment LD. after Primer Blast search (% 
no. CTL Wy CTL I Wy size (bp) cut (bp) (Transcript size) Identity) 
- Mus musculus N-terminal 0 
AD6 + ++ + + 840 AD6#4 860 Asn amidase (Ntanl) 476/494 
I I I I I reverse (1184 bp) (96。/。） 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AACNNAACCN NTANNGGCGA ATNGGGCCCT ACTAGATGCT GACTCAGACN NCCGNCACGN 
61 TNNGAATNGA NTNTCNGACG AANTTCGACC CTGANNANNT ACGACTCACT ATAGGGCTTT AP2 
1 2 1 T T T T T T T T T G C A T G A A C A C T T G G A A C C T T T A T T G N C A G A A A G G A G G G A A G A T G G A G A A A A 
1 8 1 C T T G T G T G A G G A T T A A T A G G G T A G A G A G A G A C T A T G A C A G G G T A G A T T T A G A T G A A C A N A 
2 4 1 T T A G G T A A T T G T C A T G T G A A A A T G A T A C T A G G C T G A A T A A T G G C T T C A C A A T G A C A T T N C 
3 0 1 A G G C C T T G G G T T T G G A G N C C C A T G G T A C A T A T T G A A T A A T T C C T C A T A A T T C A A A A G G A A 
3 6 1 C T T A G T A G G T T A G A T T G A A T A A G A T A T A T T T A G A T G A A G A A A A T A T C T T G G A G C T T T T A G 
4 2 1 G G A T C T T G A T G A T G T C A T A A G C A T T T G T A A A A G G G A A G G A G A T T A G A A G A G A C A G G A C G A 
4 8 1 G G A G G G T G G T G G C A T T G A A G C A G G G G A A T A T T C C A G T G C C C A A G G A A T G A T G A T C T A T A C 
5 4 1 T G A A C A G A G G A T G A G A G G A C T C C T C T G G A G T A C T C T T C T G A A G A A N G T N G G T C A C A C C A A 
6 0 1 C A A C T T A G N N T T C T G C C A G T G A N A C T C A T C T C A G A C N T G G A G C T C C A C A A C T G T A A G A T A 
6 6 1 A C C A C T N C A A A T T A T N C A A A N N N C C A N G G T G N G A C A A T G A T A T T G T A A A T G A N N A G N N T G 
7 2 1 T N N G A A A A T A G A T G T A G A G T G A A . G C A N G A A A T G N N G A G A G N N A N G T T T A T N G T T N G T N N N 
7 8 1 N T N G T T A A T G T N C G G T G G C N N T C N N N N N N G C G T N T N A N N G 
B 42.2: Sequencing alignment ofcDNA subclone AD6#10 with mouse Cyp4al0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD6#10 : 147 ctttattqncaqaaaggaggqaagatqgagaaaacttqtgtgaqqattaataqqqtagaq 206 I I I I I I l T I I T I I I T T I T T T I I T I I T T I T I I I I I T I T I T I T T i 11111 T T I I T I 
Mouse Cyp4alO： 2054 ctttattg-cagaaaggagggaagatggagaaa-ctcgtgtgaggattaatcaggtagaa 1997 
AD6#10 : 207 aqagactatqacagggtagatttaqatgaacanattaqgtaattqtcatqtqaaaatgat 266 I T I T I I I I I T I I T T T I I T I I I I I T I I T I I I I I I I ITT I 11 I I I 11 IT 111 111 IT 11 
Mouse Cyp4alO： 1996 agagactatg-cagggtagatttagatgaacacattaggtaactgtcatgtgaaaatgat 1938 
AD6#10 : 267 actaqgctgaataatqgcttcacaatqacattncaggccttggqttt-qgaqncccatqq 325 M M T I I T I I I I I I T I I I I I I I I I T I I I I ITT I 11 ITT I I I TTIT I I I ITT 
Mouse Cyp4al0： 1937 actaagctgaataatgtcttcacaatgatgtt-caggccttggattttggagacc-atgg 1880 
AD6#10 : 326 tacatattgaataattcctcataattcaaaaqqaacttagtagqttaqattqaataagat 385 I I I I I I I I T I I I l l l l l l l l l l l l l l l M T T M M M T M T T M I T M I T M I M T M 
Mouse Cyp4alO： 1879 tacatattgaatgattcctcataattcagaaggaacttagtaggttagattgaataagat 1820 
AD6#10 : 386 atatttaqatgaagaaaatatcttqgaqcttttaqqgatcttgatqatqtcataaqcatt 445 I I I I I I T I I T I I I M M M T T I T M M M T T T I M M I I I I IT I 1111 111 11 
Mouse Cyp4alO： 1819 acatttagatgggaaaactatcttggagcttttagggatcttaatgatgtcataagcatc 1760 
Aomo ： -e丨衍丨丨预g衍丨竹丨帶广预c：竹预预丨〒g丨预a衍丨丨预预5�5 
Mouse Cyp4alO： 1759 tgtaaaaggtaaggacattagaagagaggggatgaggagggtgctggctttgaagcaggg 1700 
AD6#10 ： 506 gaatattccaqtqcccaaqqaatgatqatctatactgaacagaqqatgagaqqactcctc 565 
T I I I I I I I I I T I T l l l l f f m ^ l 力 l l l l l l l l 丫 l l l l T l f f l l l ^ t l f f l l l I I I � 
Mouse Cyp4al0： 1699 gaatattccagtg-ccaaggaatgatgatctatactgaacagaggatgagaggact-ctc 1642 
AD6#10 : 566 tqqaqtactcttctqaaqaanqtnggtcacaccaacaacttagnnttctqccaqtqanac 625 I T T I T I I M I M I T M I I T i T T I I I I I I I I I I I I I I I I T M M I I I T I T I I I ^^^^ 
Mouse Cyp4alO： 1641 tggagtattcttctgaaaaaggtaggtcacaccaacaacttagctttct-ccagtgaaac 1583 
AD6#10 : 626 tcatctcagac-ntggagctccacaac 651 
I I I I I I I T I I I 而 l l l l l l l l l …（ 
Mouse Cyp4alO： 1582 tcttctcagacattggagctccacaac 1556 B 42.3: Summary of sequence alignment of cDNA subclone AD6#10 with mouse Cvp4al0 
FluoroDD gel AD (AP2 + ARP18) Sequencing 
“ ,丨 / 丨、A D . / X FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment LD. after EcoRI Primer Blast search (% 
no. CTL Wy CTL ^ ^ size (bp) cut (bp) (Transcript size) Identity) 
Ml3 musculus cytochrome 
AD6 + ++ + + 840 AD6#10 850 forward 卩柳广^乂丄二bf二 Y 460/507 
( a , polypeptide 10 
(-20) (Cyp4al0) (2085 bp) (907。） 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AGCCTATTTA GGTGACACTA TAGAATACTC AAGCTATGCA TCAAGCTTGG TACCGAGCTC 
6 1 GGATCCACTA GTAACGGCCG CCAGTGTGCT GGAATTCGCC CTTAGCGGAT AACAATTTCA A R P 1 8 
1 2 1 CACAGGATGA TGCTACCTAT ACCTGATCAT GAACCTTCTC CCTCCTCCAG CCATCTCTCC 
181 TTGCCTCTCA CTTCCTACCA TCTTATTTTT CCCTACATGA CTTCTTCATT TTACAAATAA 
241 TCAATTGTCA CAAGCTTGGT GGTCTGAAAT AATTGAAAGT TGTTATCTTA CAGTTGTGGA 
301 GCTCCATGTC TGAGATGAGT TTCACTGGCA GAAAGCTAAG TTGTTGGTGT GACCAACCTT 
361 CTTCAGAAGA GTACTCCAGA GAGTCCTCTC ATCCTCTGTT CAGTATAGAT CATCATTCCT 
421 TGGCACTGGA ATATTCCCCT GCTTCAATGC CACCACCCTC CTCGTCCTGT CTCTTCTAAT 
481 CTCCTTCCCT TTTACAAATG CTTATGACAT CATCAAGATC CCTAAAAGCT CCAAGATATT 
541 TTCTTCATCT AAATATATCT TATTCAATCT AACCTACTAA GTNCCTTTTG AATTATGAGG 
601 AATTATTCAA TATGTACCAT GGGCTCCAAA CCCCAAGGCC TGAATGTCAT AGNCACCCCA 
661 TAATACAGCC TAGTATCATT TCCACATGAC AATNNNCTAA TGTGTNCATC TAAATCTACC 
721 CTGCATAGTC TCTCTCTACC CTATTAATCC TCACACAAGT NNCTCATCNT CCCTCCTTCT 
781 GCANNAAAGG TCNNNGTGNT ATGCAAAAAA ANNANNCCCN NATAGTGAA 
B 43.2: Sequencing alignment of cDNA subclone AD6#10 with mouse Cyp4a l0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD6#10 : 293 gttgtqgaqctcca-tgtctgaqatgagtttcactqqcaqaaaqctaagttqttqqtqtq 351 T M T I T T I T I M M I T I M T I T I T I T I I I I I I I T T I I I I I I I 11 I I I I I I I T T I T I T 
Mouse Cyp4alO： 1556 gttgtggagctccaatgtctgagaagagtttcactgg-agaaagctaagttgttggtgtg 1614 
AD6#10 : 352 accaaccttcttcagaaqaqtactccagagaqtcctctcatcctctqttcaqtataqatc 411 I I I M i l l I I I I T I I T I I I I I I I I T I T I T I I I I I I I I I I I I I I T I I I I T I I I I T I I I 
Mouse Cyp4alO： 1615 acctacctttttcagaagaatactccagagagtcctctcatcctctgttcagtatagatc 1674 
AD6#10 : 412 atcattccttggcactggaatattcccctqcttcaatqccaccaccctcctcgtcctgtc 471 I I I I I I I I I I T T I I I I T T I I I I I I I I I I I T I I I I i l T I M l l l l l l l l l l I I I I I 
Mouse Cyp4alO： 1675 atcattccttggcactggaatattcccctgcttcaaagccagcaccctcctcatcccctc 1734 
AD6#10 : 472 tcttctaatctccttcccttttacaaatgcttatgacatcatcaaqatccctaaaaqctc 531 l l l l l l l l l I M M I I I M M M I I I I I I I I T I I I I I I I I I T I I I I I I I I I I T I I I 
Mouse Cyp4alO： 1735 tcttctaatgtccttaccttttacagatgcttatgacatcattaagatccctaaaagctc 1794 
AD6#10 : 532 caagatattttcttcatctaaatatatcttattcaatctaacctactaaqtnccttttqa 591 
M I ? I M I M i m i M I I I M I M M M M I M M M M I I I I ? I M M lYl，。口& 
Mouse Cyp4alO： 1795 caagatagttttcccatctaaatgtatcttattcaatctaacctactaagttccttctga 1854 
AD6#10 : 592 attatgagqaattattcaatatgtaccatgqgctccaaaccccaaqgcctqaatgtcata 651 
I I I I I T I T T I I I I I I I I I I I I T I I I I I I T T l l l l l l l M M T T M I T M M M � 
Mouse Cyp4alO： 1855 attatgaggaatcattcaatatgtaccatggtctccaaaatccaaggcctgaacatcatt 1914 
AD6#10 : 652 gncaccccataatacaqcctagtatcatttccacatqacaatnnnctaatgtqtncatct 711 
T I I I I I I M i l I I T I I I I I I I l I I I I I T I I I I I I I I I T I T I M i l l � M 
Mouse Cyp4alO： 1915 gtgaagacattattcagcttagtatcattttcacatgacagttacctaatgtgttcatct 1974 
AD6#10 : 712 aaatctaccctgcatagtctctctctaccctattaatcctcacacaagtnnct-catcnt 770 I I I I I I I I I I I T I I I I T I I I I I l l l l l l l l l l l l l l l l l l l l 111 I I I N I I Mouse Cyp4al0： 1975 aaatctaccctgcatagtctctttctacctgattaatcctcacacgagtttctccatctt 2034 
AD6#1〇 ： 7 7 1 ccctcctt 778 l l l l l l l l Mouse Cyp4al0: 2035 ccctcctt 2042 B 43.3: Summary of sequence alignment of cDNA subclone AD6#10 with mouse Cyp4al0 
FluoroDD gel A D (AP2 + ARP18) Sequencing 
“ 丄、L„ , / � F l u o r o D D Subclone Size of insert Gene homology to E-value 
Fragment P P A R a (+/+) P P A R a (-A) fragment LD. after 五coRI Primer Blast search (% 
no CTL W 厂 CTL W ^ size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome ^^^ 
AD6 + ++ + + 840 AD6#10 850 P450, famUy 4 subfamily ；;^^^^^ 
reverse a, polypeptide 10 (Cyp4al0) (2085 bp) ( 
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B44.1: DNA sequence of cDNA subclone AD8#2 (AP2 & ARP 18) using M13 forward (-20) primer 
1 TGGGCCCTCT AGATGCATGC TCGAGCGGCC GCCAGTGTGA TGGATATCTG CAGAATTCGC 
61 CCTTGTAATA CGACTCACTA TAGGGCTTTT TTTTTGCATG ACACTTGGAC CTTTATTGCA AP2* 
121 GAAGGGAGGG AAGATGGAGA AACTTGTGTG AGGATTAATA GGGTAGAGAG AGACTATGCA 
181 GGGTAGATTT AGATGAACAC ATTAGGTAAT TGTCATGTGA AAATGATACT AGGCTGAATA 
241 ATGGCTTCAC AATGACATTC AGGCCTTGGG TTTGGAGCCC ATGGTACATA TTGAATAATT 
301 CCTCATAATT CAAAAGGAAC TTAGTAGGTN AGATTGAATA AGATATATTT AGATGAAGAA 
361 AATATCTTGG AGCTTTTAGG GATCTTGATG ATGTCATAAG CATNTGTAAA AGGGAAGGAG 
421 ATNAGAAGAG ACAGGACGAG GAGGGTGGTG GCATNGAAGC AGGGGAATAT TCCAGTGCCA 
481 AGGAATGATG ATCTATACTG AACAGAGGAT GAGAGGACTC TCTGGAGTAC TCTTCTGAAG 
541 AAGGTTGGTC ACACCAACAA CTTAGCTTTC TGCCAGTGAN ACTCATCTCA GACATGGAGC 
601 TCCACAACTG TAAGATAACA NCTTTCAATT ATNNCAACCA CCAGGGTGTG ACANTGATAT 
661 TGTNAATAGA GTNGTNGGAA ATAGATGTAG AGGAAGCAGA AATCNGAGAG NAAGTATATC 
721 GTTNGTCCTN TCGGTANGNN CCAGNCA 
B 44.2: Sequencing alignment of cDNA subclone AD8#2with mouse Cyp4al0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD8#2 ： 96 gcatqacacttqqacctttattqcaqaaqgqaqggaagatqgaqaaacttqtgtqagqat 155 T I I I T l l l l l I T I I I I I I I I T I I T M T T I T T T I I T I I T T I T I I I I I T I T I T I T T I I 
Mouse Cyp4alO： 2069 gcatgacactgggaactttattgcagaaaggagggaagatggagaaactcgtgtgaggat 2010 
AD8#2 ： 156 taataggqtagagagagactatqcaqgqtaqatttaqatgaacacattaggtaattgtca 215 M M I I I I T I I T I T I I I I I T I I N Y I I T I M I T I I T M I I I I I I T F I I I I T I M 
Mouse Cyp4al0： 2009 taatcaggtagaaagagactatgcagggtagatttagatgaacacattaggtaactgtca 1950 
AD8#2 ： 216 tqtqaaaatgatactaqqctqaataatqgcttcacaatqacattcaqqccttqqqttt-q 274 I T I T I I I I I T I i l l M T I I T I I I I I i r i l l l l l l i l T I I I I I T T I I I I T T M I T 
Mouse Cyp4al0： 1949 tgtgaaaatgatactaagctgaataatgtcttcacaatgatgttcaggccttggattttg 1890 
AD8#2 ： 275 qagcccatqqtacatattqaataattcctcataattcaaaagqaacttaqtaqqtnaqat 334 
TIT i i i i t t i i m m t i i i i i i i m i m i m I I T T I I I I I I T I I T T I I T I I 。 
Mouse Cyp4alO： 1889 gagaccatggtacatattgaatgattcctcataattcagaaggaacttagtaggttagat 1830 
AD8#2 ： 335 tqaataaqatatatttagatqaagaaaatatcttgqaqcttttaqqgatcttgatqatqt 394 
I T M I M T I M I I I I I T I I T I I I 1 1 1 1 1 I T T I T I 1 1 1 1 I T T T I 1 1 1 1 I I T I I T I … � 
Mouse Cyp4alO： 1829 tgaataagatacatttagatgggaaaactatcttggagcttttagggatcttaatgatgt 1770 :395 丨T丨T丨预nmm??gn??r?rmm?r，nT??m?丨r丨m^ T 
Mouse Cyp4alO： 1769 cataagcatctgtaaaaggtaaggacattagaagagaggggatgaggagggtgctggctt 1710 
AD8#2 ： 455 nqaaqcaggggaatattccaqtqccaaqqaatqatqatctatactqaacaqaqqatqaqa 514 
？ 1 1 〒丨 1 誦|丨丨 | |丨丨 |丫 i t m i f f m 丫丨丨 t m i i i m 丫 m i M i i T 丨了 I ， … 
Mouse Cyp4alO： 1709 tgaagcaggggaatattccagtgccaaggaatgatgatctatactgaacagaggatgaga 1650 
AD8#2 ： 515 qqactctctqgagtactcttctqaaqaaqqttgqtcacaccaacaacttaqctttctgcc 574 T T M I M M T T I T M M I M I T I I M T T I T T M I M M M M M M I T I I M M I I 1 … 
Mouse Cyp4al0： 1649 ggactctctggagtattcttctgaaaaaggtaggtcacaccaacaacttagctttct-cc 1591 
AD8#2 ： 575 aqtqanactcatctcaqaca-tgqaqctccacaac 608 I T I T I M M I I I I I T I I I I T T I T I I I I I I I I I …， 
Mouse Cyp4al0： 1590 agtgaaactcttctcagacattggagctccacaac 1556 B 44.3: Summary of sequence alignment of cDNA subclone AD8#2 with mouse Cvp4al0 
1 FluoroDD gel AD (AP2 + ARPl8) Sequencing 
“ , , / , A T^  … I FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) fragment LD. after 五⑶RI Primer Blast search (% 
no* CTL W y _ CTL Wy— size (bp) cut (bp) (Transcript size) Identity) 
MUS musculus cytochrome ^ 
AD8 + ++ + + 720 AD8#2 780 forward ''''' n；,^fr'' 474/515 
/ 90^  A , polypeptide 10 /Q^O/N 
(-20) (Cyp4al0) (2085 bp) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 ACTATTTAGG TGACACTATA GAATACTACA AGACTATGNC ATNCAAGACT TGGTACCGAG 
6 1 ACTCGGATCN ACTAGTAACG GCCGCCAGTG TGCTGGAATT CGCCCTTAGC GGATAACAAT ARP18 
121 TTCACACAGG ATGATGCTAC CTATACCTGA TCATGAACCT TCTCCCTCCT CCAGCCATCT 
181 CTCCTTGCCT CTCACTTCCT ACCATCTTAT TTTTCCCTAC ATGACTTCTT CATTTTACAA 
241 ATAATCAATT GTCACAACCT TGGCGGTCTG AAATAATTGA AAGTTGTTAT CTTACAGTTG 
301 TGGAGCTCCA TGTCTGAGAT GAGTTTCACT GGCAGAAAGC TAAGTTGTTG GTGTGACCAA 
361 CCTTCTTCAG AAGAGTACTC CAGAGAGTCC TCTCATCCTC TGTTCAGTAT AGATCNATCA 
421 TTCCTTGGCA CTGGAATATT CCCCCTGCTT CAATGCCACC ACCCTCCCTC GTCCTGTCTC 
481 TTCTAATCTC CTTCCCCTTT TACAAATGCT TATGACATCA TCAAGNATCC CTAAAAGCTC 
541 CAAGATATTT TCTTCATCTA AATATATCTT ANNCAATCTA ACCTACTAAG TTCCTTTTGA 
601 NTTATGANGA ATTATTCAAT ATGTACCATG GGCTCCAAAC CCAAGGGCCT GAATGTCATT 
661 GTGANGCCAT TATCCAGCCC TAGTATCATT TNNACANTGA CAAATTACCC TAANTGTGNT 
7 2 1 TCATCTAAAN NNCTACCCNT GCCATAGNTT T T C T N T T C T T ACNCCNTANT NNANTTTNCN 
781 TCACANNNAN GTTNNTCCTC CNANTNTTNC CCNNTNCNTT TTTCNTGCAA 
B 45.2: Sequencing alignment of cDNA subclone AD8#7 with mouse Cyp4al0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD8#7 ： 297 qttqtgqagctcca-tqtctqagatqagtttcactgqcagaaaqctaaqttgttgqtgtq 355 T M T I T T I T I M M I T I M T I T I T I T I I I I I I I T T I T I I I T I I I I T I I T I I T T I T I T 
Mouse Cyp4al0： 1556 gttgtggagctccaatgtctgagaagagtttcactgg-agaaagctaagttgttggtgtg 1614 
AD8#7 ： 356 accaaccttcttcaqaaqagtactccagagagtcctctcatcctctgttcagtatagate 415 
III Mill IIIITIITI I I I I I I I T I T I T I I I I I I I I I I I I I I T I I I I T I I I I T I I I 
Mouse Cyp4al0： 1615 acctacctttttcagaagaatactccagagagtcctctcatcctctgttcagtatagatc 1674 
AD8#7 ： 416 natcattccttqqcactggaatattccccctgcttcaatqccaccaccctccctcgtcct 475 
IIIIIIIIIITTIIIITIIIIIIIIIII ITIIIIII TIM MMMM II III 
Mouse Cyp4alO： 1675 -atcattccttggcactggaatattcccc-tgcttcaaagccagcaccctcc-tcatccc 1731 
AD8#7 ： 476 qtctcttctaatctccttccccttttacaaatqcttatqacatcatcaaqnatccctaaa 535 
i i i i m i i i i i i i i i I I l l l l l l l i i T m i i 化 m i l iiT i i i i i i i i i 
Mouse Cyp4alO： 1732 ctctcttctaatgtccttacc-ttttacagatgcttatgacatcattaag-atccctaaa 1789 
AD8#7 ： 536 agctccaagatattttcttcatctaaatatatcttanncaatctaacctactaagttcct 595 
iTi i i i i iTi i i III IIIIIIIII l l l l l l l i m i i m i m i i i 7 i i i i i 
Mouse Cyp4alO： 1790 agctccaagatagttttcccatctaaatgtatcttattcaatctaacctactaagttcct 1849 
AD8#7 ： 596 tttganttatqangaattattcaatatqtaccatgqgctccaaacccaagggcctgaatg 655 
I III IIIITI TIM MMMMITMMMTT l l l l l l l I I TTIIITII 
Mouse Cyp4al0： 1850 tctgaattatgaggaatcattcaatatgtaccatggtctccaaaatccaaggcctgaaca 1909 
AD8#7 ： 656 teattgtganqccattatccaqccctaqtatcattt 691 
MIMTITI T m m 111 I IIIIMIIIII 
Mouse Cyp4alO： 1910 tcattgtgaagacattattcag-cttagtatcattt 1944 B 45.3: Summary of sequence alignment of cDNA subclone AD8#7 with mouse Cvp4al0 
FluoroDD gel AD (AP2 + ARP18) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after 五 P r i m e r Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome ^ 丨 ^ ^ 
ADS + ++ + + 720 AD8#7 780 ^13 P450, family 4 subfamily 3^ 3/39^  
reverse a, polypeptide 10 <^89。/、 
(Cyp4al0) (2085 bp) ( ) 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 46.1: DNA sequence of cDNA subclone AD9#2 (AP2 & ARP 18) using M13 forward (-20) primer 
1 CCCTCACTAT AGGGCGAATT GGGCCCTCTA GATGCNTGCT CGAGCGGCCG CCAGTGTGAT 
6 1 GGATNTCTGC AGAATTCGCC C T T G T A A T A C G A C T C A C T A T A G G G C T T T T T T T T T T T G C A T A P 2 * 
121 GACACTGGGA ACTTTATTGC AGAAAGGAGG GAAGATGGAG AAACTCGTGT GAGGATTAAT 
181 CAGGTAGAAA GAGACTATGC AGGGTAGATT TAGATGAACA CATTAGGTAA TTGTCATGTG 
241 AAAATGATAC TAGGCTGAAT AATGGCTTCA CAATGACATT CAGGCCTTGG GTTTGGAGCC 
301 CATGGTACAT ATTGAATAAT TCCTCATAAT TCAAAAGGAA CTTAGTAGGT TAGATTGAAT 
3 6 1 A A G A T A T A T T T A G A T G A A G A A A A T A T C T T G G A G C T T T T A G G G A T C T T G A T G A T G T C A T A A 
421 GCATTTGTAA AAGGGAAGGA GATTAGAAGA GACAGGACGA GGAGGNNGGT GGCATTGACG 
481 CAGGGGAATA NNCCAGTGCC AAGGAATGAT GATCTATACT GAACAGAGGA TGAGAGGACT 
541 CTCTGGAGTA CTCTTCTGAA GAGGGTNGGT CACACCACCA ACTTAGNNTT NTGCCAGTGA 
6 0 1 N A C T C A T C T C A G A C A T G G A G C T C C A C A C T G T A A G A T A C N C C T T T T N A T A A T N T A A A N C A N 
661 CNANNTGTGA CAANNATTAT NNGTAAATGA AANNTTTGTA NNNANNATAG ATGNTAGANT 
721 TAAAGCCAGG AAAATNNTGA AGAGGNNNAG TCNTNATNGT TTNGTNTTTN GGGTANTTTT 
B 46.2: Sequencing alignment of cDNA subclone AD9#2 with mouse Cyp4al0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD9#2 ： 117 qcatqacactqqqaactttattqcaqaaaqqagqqaaqatqqagaaactcqtqtqaqqat 176 
t i i i t i i i i i 丫 n i i i i i i i i i 丫 i i Y i i i f f i T f f i i 丫 i i f f i 丫 i i i i i iYiYi 丫 i f f i i 
Mouse Cyp4alO： 2069 gcatgacactgggaactttattgcagaaaggagggaagatggagaaactcgtgtgaggat 2010 
AD9#2 ： 177 taatcaqqtagaaaqaqactatqcaqgqtagatttaqatgaacacattagqtaattqtca 236 iiimffiitiiiYil^mitiifffiitimitiiYiiiiiiiiiffm I T I M 
Mouse Cyp4al0： 2009 taatcaggtagaaagagactatgcagggtagatttagatgaacacattaggtaactgtca 1950 
AD9#2 ： 237 tqtqaaaatqatactaqqctqaataatqgcttcacaatqacattcaqqccttqggttt-q 295 I T I T I I I I I T I I l l l l T M T M M M T I I I I I I I I I T I I I I I T T I I I ITT M I T 
Mouse Cyp4alO： 1949 tgtgaaaatgatactaagctgaataatgtcttcacaatgatgttcaggccttggattttg 1890 
AD9#2 ： 296 qaqcccatqqtacatattqaataattcctcataattcaaaaqqaacttaqtaqqttaqat 355 
T I T imffiimm了III mmiiiiiiiii M T T M I M I T I I T T M I T I ! 
Mouse Cyp4alO： 1889 gagaccatggtacatattgaatgattcctcataattcagaaggaacttagtaggttagat 1830 
AD9#2 ： 356 tqaataaqatatatttaqatqaaqaaaatatcttqqaqcttttaqqqatcttgatqatqt 415 I T I M M T I M I I I I I T I I T I I I I I I I I I T T I T I I I I I I T T T I I I M M T M T I 
Mouse Cyp4alO： 1829 tgaataagatacatttagatgggaaaactatcttggagcttttagggatcttaatgatgt 1770 
AD9#2 ： 416 cataaqcatttqtaaaaqggaaqqagattagaaqaqacaqqacqaqgagqnnqgtqqcat 475 I I I I I T l l l I I I I I I I T T I I T T I I I I I T I I T I T I TTI T I T T I T T T ITT I I 
Mouse Cyp4alO： 1769 cataagcatctgtaaaaggtaaggacattagaagagaggggatgaggagggtgctggctt 1710 
AD9#2 ： 476 tqacqcaqqqqaatannccaqtgccaaqqaatqatqatctatactqaacaqaqqatqaqa 535 
I T I T I I T T T T I I I I l l l � l � M l i n i l l ? l l ? I I I I I I I N T l l l l 丫 i n m i 丫 I 
Mouse Cyp4al0： 1709 tgaagcaggggaatattccagtgccaaggaatgatgatctatactgaacagaggatgaga 1650 
AD9#2 ： 536 qqactctctqqaqtactcttctqaaqaqqqtnqqtcacaccaccaacttaqnnttntgcc 595 T T I I I I I I I T T I T I I I I I I I I T I I I TTI T T I I I I I I I I M I I M I T 11 I 11，… 
Mouse Cyp4alO： 1649 ggactctctggagtattcttctgaaaaaggtaggtcacaccaacaacttagctttct-cc 1591 
AD9#2 ： 596 aqtqanactcatctcaqaca-tqqaqctccaca 627 I T I T I M M I I I I I T I I I I T T I T I I I I I I I 
Mouse Cyp4alO： 1590 agtgaaactcttctcagacattggagctccaca 1558 B 46.3: Summary of sequence alignment of cDNA subclone AD9#2 with mouse Cvp4al0 
FluoroDD gel AD (AP2 + ARP18) Sequencing 
: � „ „ • „ " / . � A n / / � l FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) f r ^ e n t I.D. after 五⑶RI Primer Blast search (% 
no. CTL Wy CTL! size (bp) cut (bp) (Transcript size) Identity) 
M12 Mus musculus cytochrome ^ 
AD9 + ++ + + 710 AD9#2 765 forward P450, family 4 subfamily 
a, polypeptide 10 
(-20) (Cyp4al0) (2085 bp) (^之^。） * Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CCNTATNTAG GTGACACTAT AGAATACTCA AGCTATGCAT CAAGCTTGGT ACCGAGCTCG 
6 1 GATCCACTAG TAACGGCCGC CAGTGTGCTG GAATTCGCCC TTAGCGGATA ACAATTTCAC A R P 1 8 
121 ACAGGATGAT GCTACCTATA CCTGATCATG AACCTTCTCC CTCCTCCAGC CATCTCTCCT 
181 TGCCTCTCAC TTCCTACCAT CTTATTTTTC CCTACATGAC TTCTTCATTT TACAAATAAT 
241 CAATTGTCAC AACCTTGGTG GTCTGAAATA ATTGAAAGTT GTTATCTTAC AGTTGTGGAG 
301 CTCCATGTCT GAGATGAGTT TCACTGGCAG AAAGCTAAGT TGTTGGTGTG ACCAACCTTC 
361 TTCAGAAGAG TACTCCAGAG AGTCCTCTCA TCCTCTGTTC AGTATAGATC ATCATTCCTT 
421 GGCACTGGAA TATNCCCCTG CTTCAATGCC ACCACCCTCC TCGTCCTGTC TCTTCTAATC 
481 TCCTTCCCTT TTACAAATGC TTATGACATC ATCAAGATCC CTAAAAGCTC CAAGATATTT 
541 TCTTCATCTA AATATATCTT ATTCAATCTA ACCTACTANG TTCCTTTTGA ATTATGAGGA 
601 ATTATTCATT ATGTACCATG GGCTNCAAAN CCCAAGGCCT GAATGTCATT GTGAAGCCAT 
661 TATTCAGCCT AGTATCATNN TCACATGACA ATNANNTAAT GTGTCCATCT ANATCTACCC 
721 TGCATAGTCC NNCTCTANNC NATTAATCCC CCACCAAGTT TCTCCNNTCT NCCCNCNNNN 
781 CTGCAAATAA NNGG 
B 47.2: Sequencing alignment of cDNA subclone AD9#3 with mouse Cyp4al0 by BLAST searching 
against the National Center for Biotechnology Information database 
AD9#3 ： 292 gttgtqqagctcca-tgtctgagatgagtttcactqqcaqaaaqctaaqttgttqqtgtq 350 T I I T I T T I T I I I I I I T I M T I T I I I T M I M M T T I I I I 111 11 I I I I I I I T T I T I T 
Mouse Cyp4alO： 1556 gttgtggagctccaatgtctgagaagagtttcactgg-agaaagctaagttgttggtgtg 1614 
AD9#3 ： 351 accaaccttcttcagaaqagtactccagagagtcctctcatcctctqttcagtataqatc 410 i l l M i l l I I I I T I I T I I I I I I I I T I T I T I I I I I I I I I I I I I I T I I I I T I I I I T I I I 
Mouse Cyp4al0： 1615 acctacctttttcagaagaatactccagagagtcctctcatcctctgttcagtatagatc 1674 
AD9#3 ： 411 atcattccttgqcactgqaatatncccctqcttcaatgccaccaccctcctcqtcctqtc 470 I I I I I I I I I I T I I I I I T T I I I I I I I I I I T I I I I I I T I M l l l l l l l l l l I I I I I 
Mouse Cyp4alO： 1675 atcattccttggcactggaatattcccctgcttcaaagccagcaccctcctcatcccctc 1734 
AD9#3 ： 471 tcttctaatctccttcccttttacaaatqcttatgacatcatcaagatccctaaaaqctc 530 l l l l l l l l l M i l l l l l l l l l l l i l T I I I I I T I I I I I I I I I T I I I I I I I I I I T I I I 
Mouse Cyp4al0： 1735 tcttctaatgtccttaccttttacagatgcttatgacatcattaagatccctaaaagctc 1794 
AD9#3 ： 531 caagatattttcttcatctaaatatatcttattcaatctaacctactanqttccttttqa 590 i i i t m I I I l l l l l l l l l i i m i m i i i m i i i i i M i n i i i m 
Mouse Cyp4alO： 1795 caagatagttttcccatctaaatgtatcttattcaatctaacctactaagttccttctga 1854 
AD9#3 ： 591 attatgaqqaattattcattatqtaccatgggctncaaancccaaqqcctgaatgtcatt 650 I I I I I T I T I I I I M i l l I I I T I I I I I I T T I I M M I I I I T T I I I T I I M i l l 
Mouse Cyp4alO： 1855 attatgaggaatcattcaatatgtaccatggtctccaaaatccaaggcctgaacatcatt 1914 
AD9#3 ： 651 gtqaaqccattattcaqcctaqtatcatnntcacatgacaatnanntaatqtqtccatct 710 
T l T I I T I I I I I I I I I T I I I T I I I I I I I I I I I I T I I I I I llll丫丨了I M i l l 
Mouse Cyp4alO： 1915 gtgaagacattattcagcttagtatcattttcacatgacagttacctaatgtgttcatct 1974 
AD9#3 : 711 anatctaccctgcataqtc 729 
I l l l l l l l l l 丫 m i T i i … 
Mouse Cyp4alO: 1975 aaatctaccctgcatagtc 1993 
B 47.3: Summary of sequence alignment of cDNA subclone AD9#3 with mouse Cvp4al0 
FluoroDD gel AD (AP2 + ARP18) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cytochrome ^ ^ ^^  
AD9 + ++ + + 710 AD9#3 765 P450, family 4 subfamily 3^ 8/439 
reverse a, polypeptide 10 
(Cyp4al0) (2085 bp) ^ ' 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 48.1: DNA sequence ofcDNA subclone AFl #8 (APIO & ARPi:3) using Ml 3 forward (-20) primer 
1 ACTNNCTATA GGGCNAATTG GGCCCTCTAG ATGCTGCTCG AGNCGGCCGC CAGTGTGATG 
6 1 GATATCTGCA GAATTCGCCC TTAGCGGATA ACAATTTCAC ACAGGAGTTG CACCATTTAT ARP13 
121 TGGCTATGCT GGAGGAAAGA CCCAGACAGA GAAGAAAAAA CTCAGAGATG TCTTTAAGAA 
181 AGGCGACATC TACTTCAACA GCGGAGACCT CCTGATGATC GACCGTGAGA ACTTCGTCTA 
241 CTTTCACGAC AGGGTTGGAG ATACTTTCCG GTGGAAAGGA GAGAACGTAG CTACCACAGA 
301 AGTCGCTGAC ATCGTGGGAC TGGTAGATTT TGTTGAAGAA GTGAATGTGT ATGGCGTGCC 
361 TGTGCCAGGT CATGAGGGTC GAATTGGGAT GGCCTCCCTC AAGATCAAAG AAAACTACGA 
421 GTTCAATGGA AAGAAACTCT TTCAACACAT CGCGGAGTAC CTGCCCCAGT TACGCGAGGC 
481 CTCGGTTCCT GAGGATACAA. GATACCATTG AGATCACTGG GACTTTTAAA CACCGCAAAG 
541 TGACCCTGAT GGAAGAGGGC TTCAATCCCA CAGTCATCAA AGATACCTTG TATTTCATGG 
601 ATGATGCAGA GAAAACATTT GTGCCATGAC TGAGAACNNT TATAATGCCT AATTGATAAA 
661 AATCTGANGC TNTGAATATT CCCTGGTGGN TTAAGCTNAT GACATNNCCA AAAAGAANCT 
721 CNATANACCT CCCANANCAC TTNNCTCGTN NAATCAATTT NNNTGGATNG AGGNTTTANG 
781 TGNNTTTATT TNNNGAATAT TNTTNAG 
B 48.2: Sequencing alignment of cDNA subclone AF1#8 with mouse very-long-chain acyl-coA 
synthetase (VLACS) by BLAST searching against the National Center for Biotechnology 
Information database 
AF1#8 ： 111 caccatttattgqctatqctgqaqgaaaqacccagacaqaqaagaaaaaactcaqaqatq 170 
m i i m m f f i i i i t i i n i f f i i i 丫 l l l l l 丫 II丫丨丫 i i T i i i i m i i i t i 丫 l i t 
Mouse VLACS： 1310 caccatttattggctatgctggaggaaagacccagacagagaagaaaaaactcagagatg 1369 
AF1#8 ： 171 tctttaaqaaagqcqacatctacttcaacagcggagacctcctgatgatcgaccqtgaqa 230 
i M i m 丫 I I 丨而 m i m i i i i m i t i 而 m m i T i i T i i i T i i i T i 丫 i T i 
Mouse VLACS： 1370 tctttaagaaaggcgacatctacttcaacagcggagacctcctgatgatcgaccgtgaga 1429 
AF1#8 ： 231 acttcqtctactttcacqacaqggttgqaqatactttccqgtgqaaagqagaqaacgtaq 290 iiiiiYiiiiiiiiiiil^iitniinitiiiiiimffiniiiffiTiYiii 丫 II 丫 
Mouse VLACS： 1430 acttcgtctactttcacgacagggttggagatactttccggtggaaaggagagaacgtag 1489 
AF1#8 ： 291 ctaccacaqaaqtcqctgacatcgtqqgactqqtaqattttqttgaaqaaqtgaatqtqt 350 
Mouse VLACS： 1490 ctaccacagaagtcgctgacatcgtgggactggtagattttgttgaagaagtgaatgtgt 1549 
: 351衍预丨预顶预丨衍丨衍丨预丨丨馆丨術丨衍预衍丨丨丨丨丨〒衍丨丨41。 
Mouse VLACS： 1550 atggcgtgcctgtgccaggtcatgagggtcgaattgggatggcctccctcaagatcaaag 1609 
AF1#8 ： 411 aaaactacqagttcaatqqaaagaaactctttcaacacatcqcqqaqtacctqccccaqt 470 
i i i i i M i t i t i i i m f f i i i t i i i i i i i i i i i i i i i m 丫 i f f i Y i i i i i 丫 I I I I T I 1 “ � 
Mouse VLACS： 1610 aaaactacgagttcaatggaaagaaactctttcaacacatcgcggagtacctg-cccagt 1668 
AF1#8 ： 471 tacqcgagqcctcqqttcctqaqqatacaaqataccattqaqatcactqggacttttaaa 530 
i i i T i T i f f i i i i f f i i i i i t i f f i i i i i i 丫 i i i i i i i i Y i 丫 i i m i f f f i i i 丄丄丄 I I I 1 ” � 
Mouse VLACS： 1669 tacgcgaggcctcggttcctgaggatacaagataccattgagatcactgggacttttaaa 1728 
AF1#8 ： 531 caccqcaaagtgaccctgatqgaaqagggcttcaatcccacagtcatcaaaqataccttq 590 iiii�iiiiTiTiiiiitiiffii�itniiiiiimmi1^iiiiiiiniiiiiiT 
Mouse VLACS： 1729 caccgcaaagtgaccctgatggaagagggcttcaatcccacagtcatcaaagataccttg 1788 
AF1#8 ： 591 tatttcatqqatgatqcaqagaaaacatttgtg-ccatqactgaqaacnnttataatqcc 649 
M I M M I T T M T M T M T I T M M M M I T I T I I I I T I I I T i T I I I I I I丄 I I丄Ti l 
Mouse VLACS： 1789 tatttcatggatgatgcagagaaaacatttgtgcccatgactgagaacatttataatgcc 1848 
AF1#8 ： 650 -taattgataaaaatctqangctntqaatattccctqqtggnttaaqctnatqacatnnc 708 I I I I I T I I I I I I I I I T I I I I I T I I I I I i l l l l T T I T T I I I T l l l l l l l l l l , , , , 
Mouse VLACS： 1849 ataattgataaaactctgaagctctgaatattccctggtggttt-agctcatgacatttc 1907 
AF1#8 ： 709 caaaaagaanctcnatanacctc 731 
I I i i i T i i I丨丨 I I I i m i 
Mouse VLACS: 1908 cagaaagaaactcgatagacctc 1930 B 48.3: Summary of sequence alignment of cDNA subclone AF1#8 with mouse VLACS 
FluoroDD gel AF (APIO + ARP13) Sequencing 
“ J b d a d ^ r-uz-u^lpDAu^ ( / aI FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) ^ ^ ^ ^ ^ ^ ^ ^ I.D. after ^CORI Primer Blast search (% no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus very-long- 0 AFl + ++ + + 945 AF1#8 990 forward chain acyl-coA snthetase 606/623 (-20) (VLACS) (2209 bp) (97%))^
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AGCNTATTTA GGTGACACTA TAGAATACTC AGNCTATGCT NAAGNCTTGG TACCGAGNCN 
61 CGATCCACTA GTAACGGCCG CCAGTGTGCT GGAATNCGCC CTTGTAATAC GACTCACTAT APIO 
1 2 1 AGQQCTTTTT T T T T T T T A Q T GTTAATATAG TTTATTATGT CTTTAAAAAA ATAAGGCCCT 
181 CTCTCCAAGA AGCTTAGTTT GCAAGGACAA ATGGCAGGTG CACATTGAAA AATAATTGTT 
241 TCTAAATCTT TTTACTTGNA AAGGNTCAGG TGTACTCCAA AAAAAAAACA AACAAACTAT 
301 CCTTTTAATG AATAATTTCC TAAAAATAAA ATCGCACCTT ATAGCCCTCA NNCAAGTTAA 
361 AGTTGNNTTC NACGTATGAA GTGGCTCTGC GAGGTCTATC GAGTTTCTTT CTGGANATGT 
421 CATGAACTAA ACCCCCCAGG NANNATTCAG ACCTTCAGAN TTTTATCCAN TNATGGCATN 
481 ATAAATGTCC TCAGTCATGG NCACAAANGT NTCNTCTGCA TCANCATGAN ATCCAAGTAT 
541 CTTGATAACT GGGGGATGAN CCCCCTTCAT CAGGGTCCCT TGCGGTGTTA AAAGTCCAGT 
601 GATCCAATGG ATTTNNNTCC CAAGACCGAG GCNCCCCTAC NGNNNGGTCC CCCGAGTGTG 
661 AANANTNNTT CCATGACCTT ATTTCTGATT GANGAGCATC ATTNAACTAT ACNGCCAGCA 
721 CCATANATNN TTTAAATANT TCCGAGTNNA TTTGACCCTC TNCTTCCG 
B 49.2: Sequencing alignment of cDNA subclone AF1#8 with mouse very-long-chain acyl-coA 
synthetase (VLACS) by BLAST searching against the National Center for Biotechnology 
Information database 
AF1#8 ： 294 aaactatccttttaatqaataatttcctaaaaataaaatcqcaccttataqccctcannc 353 miMiiiiiiMii化iiiimiiiiiiiiiimiTiiiimn I ii i 
Mouse VLACS： 2027 aaactatccttttaatgaataatttcctaaaaataaaatcgcaccttatggtctccaatc 1968 
AF1#8 ： 354 aaqttaaagttqnnttcnacgtatgaagtqqctctqcgaqqtctatcgagtttctttctq 413 
i i T i i i i i T i T I I I i i T i i � i i M m?iMiiiiii?i?imiim丫� 
Mouse VLACS： 1967 aagttaaagtgggtttctacgtttgaagtggttctgcgaggtctatcgagtttctttctg 1908 
AF1#8 ： 414 qanatgtcatqaactaaaccccccagqnannattcaqaccttcaqanttttatccantna 473 
T l I I T I I I I T I l l l i l I I M I T T I l l l l l T l I I I I I T I l l l l l l I i i I �� 
Mouse VLACS： 1907 gaaatgtcatgagctaaa-ccaccagggaatattcagagcttcagagttttat-caatta 1850 
AF1#8 ： 474 tqqcatnataaatgtcctcagtcatggncacaaanqtntcntctqcatca 523 inill IIIIIITI IIIITIIIITT llllll Tl I IIITIIIII Mouse VLACS： 1849 tggcattataaatgttctcagtcatgggcacaaatgttttctctgcatca 1800 B 49.3: Summary of sequence alignment of cDNA subclone AF1#8 with mouse VLACS 
FluoroDD gel AF (APIO + ARP13) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus mRNA for j ^^ 
AF1#S 990 : ^ ^ ^ 
(2209 bp) (86 Zo) 
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B 71.1: DNA sequence of cDNA subclone A 0 2 # 6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AAGACTATTT AGGTGACCTA TAGAATACTC AAGCTATGCA TCAAGCTTGG TACCGAGCTC 
6 1 GGATCCACTA GTAACGGCCG CCAGTGTGCT GGAATTCGCC CTTAGCGGAT AACAATTTCA A R P 1 3 
121 CACAGGAGTT GCACCATCAG GCTTGGGGTC TGCAGTGTAC CCTAGGTAAC CAAGCTGACT 
181 CCATCCTAAC AGATCTGTAC ACTGCCTTGT TCCTCTGGCC TGTACATCTT CCTGAAGAAT 
241 GCTACCTGTC TTCCCTCCAC TCCTGCCTTC CACATACCCT GCAGAACCAC AGCCTTNNCC 
301 CCTGCATNCC TGATNCCCAC CGTAATCGCT GCTTCATCTA GGTTCTTACT GACGCCTACC 
361 CCTAAGATNC TGCATACCAA CGGGCCACTG TCCCTAGCTT TACTACAAGA TAACTTTCCC 
421 CTAAAAAAAA AAAAGCCCTA TAGTGAGTCG TATTACAAGG GCCAATTCTG CAGATATCCA 
481 TCACACTGGN CGGCCGCTCC AGCATGCATC NNGAGGGCCC AAATTCGCCC CTATAGTGAG 
541 NTCGNNTTAC CAATTCACTG GNCCGTCGGT TTTTANAACC GTCGGTGACT GGGGAAAAAC 
601 CCNTGGGCGT TAACCCAANC CTAAATCGGC CTTGGCAGCA AAATTCGCCC TTTTGCCAAG 
661 CGGGCGTAAT AGCGANGAGN NCCCACCGAT GCCCTTNCAA CAGTTGCNCN GCCTNNTTGC 
721 GNATGGACCC CCCCNGTANG CGCCCCATAA GCGCCNGNCG GNNGGTGGTG GNTACCGCNC 
781 NGCGGTGACC GCCTACNNTT NGGCAGCGNC CCCTAGCGNC CCNNNNNTCC TTNNGCTTTT 
841 TTTCCTTTCT TTTTNNCCAN NNNNN 
B 50.2: Sequencing alignment of cDNA subclone AF21#5 with mouse cell death-inducing DNA 
fragmentation factor, alpha subunit-like effector B (Cideb) by BLAST searching against the 
National Center for Biotechnology Information database 
AF21#5 ： 131 qcaccatcagqcttggggtctqcagtqtaccctagqtaaccaaqctqactccatcctaac 190 
丫 M i i i i i i f f m n f f m 丫 1 1 力〒 m i m丫！ i i i i i i i丫 1 1 丫 m i i i i i i m i 
Mouse Cideb： 850 gcaccatcaggcttggggtctgcagtgtaccctaggtaaccaagctgactccatcctaac 909 
AF21#5 ： 191 agatetqtacactqccttgttcctctqqcctqtacatcttcctqaagaatqctacctgtc 250 iTiiiiT mil丫iiiitimmffmtiiiiiiiiiiititiiiTiimi丫11 
Mouse Cideb: 910 agatetgcacactgccttgttcctctggcctgtacatcttcctgaagaatgctacctgtc 969 
AF21#5 ： 251 ttccctccactcctgccttccacataccctqcaqaaccacaqccttnncccctqcatncc 310 I I I I I I I I I I I I I I T I I I I I I I I I I I I I I I T I I T I I I I I I I T I I I I M I M T I I I 11 
Mouse Cideb： 970 ttccctccactcctgccttccacataccctgcagaaccacagccttgtcccctgcat-cc 1028 
AF21#5 ： 311 tqatncccaccgtaatcqctgcttcatctaqgttcttactqacqcctacccctaagatnc 370 
. i T i i m m 丫 i i i i i T i i t i m m M f f i i M i m 丫 I I 丫 i m m i m 丫 11 i � 
Mouse Cideb： 1029 tgat-cccaccgtaatcgctgcttcatctaggttcttactgacgcctacccctaagatcc 1087 
AF21#5 ： 371 tqcataccaacgggccactqtccctaqctttactacaagataactttcccct 422 I T I I I I I I I M T T I I I l l T i l l l l l T I I I I I I I I I I I T I I I I I I I I I I I I i 
Mouse Cideb： 1088 tgcataccaac-ggccactgtccctagctttactacaagataactttcccct 1138 
B 50.3: Summary of sequence alignment of cDNA subclone AF21#5 with mouse Cideb 
FluoroDD gel AF (APIO + ARP13) Sequencing 
„ PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
gment fragment I D. after 五c^ R^I Primer Blast search (% CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus cell death-
inducing DNA e 140 
AF21 + ++ + + 340 AF2l#5 370 MD fragmentation factor, 285/292 
reverse alpha subunit-like 川^ o^/、 
effector B (9"。） 
I I I I I (Cideb) (1182 bp) 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 NNTNNCTCAT ATGGGCNAAT TGGGCCCTAC TAGATGCATG CTCGAGACGG CCGCCAGTGT 
6 1 GATGGATATC TGCAGAATTC GCCCTTAGCG GATAACAATT TCACACAGGA QTTGCACCAT A R P 1 3 
121 CATCCCTTCC TATCCATACA GCATCCCCAG TATAAATTCT GTGATCTGCA TNCCATCCTG 
181 TCTCACTGAG AAGTCCAATT CCCAGTCTAT CCACATGTTA CCNTAGGATA CCTCATCAAG 
241 AATCAAAGAC TTCTTTAAAT TTCTCTTTGN ATATACCCAT NACAATTTTT CATGAATTTC 
301 TTCCTCTTCC TGTTCAATAA ATGATTACCC TTGCACTAAA AAAAAAAGCC CTTATAGTGA 
361 GTCGTATTAC AAGGGGCGAA TTCCAGCCAA CCTGGGCGGG CCGTTNACTT AGGTGGGATC 
421 CGAAGCCTTC GGGTAACCCC AGCCNTTTGG NTGGCAATNN ACCTTTGGGA AGGTANTTTC 
481 CNTANTNAAG GTGGGTTCAN CCCCCTAAAN AATNAGNNCC NTTGTGGNCN NGTTATNAAT 
541 TCAAATTGGG NTTCAATTAA GGCCCTTGGT TTTCCCNTNN GGTTNGGTTG NNAAAANTNT 
601 GGNTNNNNNT TCCCGCCTCC CACACNCAAA NTTTNTCCCA ACACANACCA AACAANATTN 
661 ACCGNNANGN GCCNNCGGNN NAAGANNCAA NTAAAAAAG 
B 51.2: Sequencing alignment of cDNA subclone AF25#6 with mouse major urinary protein 2 
(MUP II) by BLAST searching against the National Center for Biotechnology Information 
database 
AF25#6 : 115 caccatcatcccttcctatccatacaqcatccccaqtataaattctqtqatctqcatncc 174 I I I I I I I I I I I I I I I I I I I I I I I I I I T I I I I I I I I T I I I I I I I I I I T I T I I I I T I I I I I 
Mouse MUP： 652 caccatcatcccttcctatccatacagcatccccagtataaattctgtgatctgcattcc 711 
AF25#6 ： 175 atcctqtctcactqaqaaqtccaattcccaqtctatccacatqttaccntaqqatacctc 234 I I I I I T I I I I I I I T I T I I T I I I I I I I l i l T I I I I I I I I I I I T I I I I I I I T T I I I I I I I “ 
Mouse MUP： 712 atcctgtctcactgagaagtccaatt-ccagtctatccacatgttacc-taggatacctc 769 
AF25#6 ： 235 atcaagaatcaaaqacttctttaaatttctctttgnatatacccatnacaatttttcatq 294 
I I I I I T I I I I I I I T I I I I I I I I I I I I I I I I I I I I T l l l l l l l l l l l l l l l l imilY��� 
Mouse MUP： 770 atcaagaatcaaagacttctttaaatttctctttg-atatacccatgacaatttttcatg 828 
AF25#6 ： 295 aatttcttcctcttcctqttcaataaatqattacccttqcact 337 
I I I I I I I I I I I I I I I I I T I I I I I I I I I I T I I I I I I I I I T I I I I 。，1 
Mouse MUP: 829 aatttcttcctcttcctgttcaataaatgattacccttgcact 871 B 51.3: Summary of sequence alignment of cDNA subclone AF25#6 with mouse MUP II 
FluoroDD gel AF (APIO + ARP13) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus major e-103 
AF25 ++ + ++ ++ 275 AF25#6 310 forward urinary protein 2 218/223 
(-20) (MUP II) (891 bp) (97%) 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AGAATACTCA AGCTATGCAT CAAGCTTGGT ACCGAGCTCG GATCCACTAG TAACGGCCGC 
61 CAGTGTGCTG GAATTCGCCC TTAGCGGATA ACAATTTCAC ACAGGAGTTG CACCATCATC ARP13 
121 CCTTCCTATC CATACAGCAT CCCCAGTATA AATTCTGTGA TCTGCATTCC ATCCTGTCTC 
181 ACTGAGAAGT CCAATTCCAG TCTATCCACA TGTTACCTAG GATACCTCAT CAAGAATCAA 
241 AGACTTCTTT AAATTTCTCT TTGATACACC CTTGACAATT TTTCATGAAT TTCTTCCTCT 
301 TCCTGTTCAA TAAATGATTA CCCTTGCACC TAAAAAAAAA AAGCCCTATA GTGAGTCGTA 
361 TTACAAGGGC GAATTCTGCA GATATCCATC ACACTGGCGG CCGCTCGAGC ATGCATCTAG 
421 AGGGCCCAAT TCGCCCTATA GTGAGTCGTA TNACAATTCA CTGGCCGTCG TTTTACAACG 
481 TCGTGACTGG GAAAAACCCT GGCCGTNACC CAACTTAATC GCCTTGCAGC CACATCCCCC 
541 TTTNGCCAGC TGGCGTAATA GCGAAGAGGC CCGCACCGAT CGCCCTTCCN NACAGTTGCC 
601 GCAGCCTGAA TGGCGAATGG ACGCNNCCCT GTAGCGGGNG CATTAAGNGC GGGGGGGTGT 
661 GGTGGTNACC NNCAGNGTGA NNGNTANNTT GCCAGNNCNC TAACGCCGGT CTTTTNNTTT 
721 TTTTCCTNNT TTTTGCCAGT TGNNGNTNCC NNTNACTTTA NNNGGGGNNN NN 
B 52.2: Sequencing alignment of cDNA subclone AF25#7 with mouse major urinary protein 2 
(MUP II) by BLAST searching against the National Center for Biotechnology Information 
database 
AF25#7 ： 111 caccatcatcccttcctatccatacaqcatccccaqtataaattctqtgatctqcattcc 170 iimmiiiiiiimiiiiiiii 化丨 iiiiitiiiiiiiiiil^TmiTiiim 
Mouse MUP： 652 caccatcatcccttcctatccatacagcatccccagtataaattctgtgatctgcattcc 711 
AF25#7 ： 171 atcctgtctcactgaqaaqtccaattccaqtctatccacatgttacctaggatacctcat 230 imitmmi丫I丫 1丨丫11丨1丨丨11丨1!11丨1丨1丨1111丫iimfimimi _ 
Mouse MUP： 712 atcctgtctcactgagaagtccaattccagtctatccacatgttacctaggatacctcat 771 
AF25#7 ： 231 caaqaatcaaaqacttctttaaatttctctttgatacacccttqacaatttttcatqaat 290 I I I T I I I I I I I T I I I I I I I I I I I I I I I I I I I I T I I I M M I T I I I I I I I I I I I I I I I I , , , 
Mouse MUP： 772 caagaatcaaagacttctttaaatttctctttgatatacccatgacaatttttcatgaat 831 
AF25#7 ： 291 ttcttcctcttcctgttcaataaatqattacccttqcac 329 iiiiiiiiimii化 mmii 丫丨 iiimii〒丨II � 
Mouse MUP： 832 ttcttcctcttcctgttcaataaatgattacccttgcac 870 B 52.3: Summary of sequence alignment of cDNA subclone AF25#7 with mouse MUP II 
1 FluoroDD gel AF (APIO + ARP13) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus major e-114 
AF25 ++ + -H- ++ 275 AF25#7 310 urinary protein 2 217/219 
reverse (muP II) (891 bp) (99%) 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 GACTCACTAT AGGGCGAATC GGGCCCTCTA NATGCATGCT CGAGCGGCCG CCAGTGTGAT 
61 GGATATCTGC AGAATCGCCC TTGTATAGAC TCACTATAGG GCTTTTTTTT TTAGTATCGG APIO* 
121 GGGTGATCAT AGAGGTCCTC TTCTAATNNT GTGTGCTTAA TTATNATGAT GAAGNTNGGA 
181 GTAATCAATC CTCGATGGTC CGGGACATCG GTCGATGTAT GAGGTCGATG ATGTTNGGAG 
241 TNATGTNCGG AAGGNAGGGA TNNGGGGTAC CCGGCCAATA TATTAGTTNG TGCCTACCTT 
301 NNNAANNGGT GCCAACNTCC CTGGTGGTGN AAANTTGGTT AATCCCGCTT AAAGGGGCNN 
361 TANTNCCCAG CCACANCTGG GCNNGCCCGT TAAACTAGTT GGGATCCGAG CCTNNGGTAC 
421 CAAGCCCTTG AATGGCATTN NCTTGAAGTT ATNNTTATNA NNTGTTCACC NNAAANTTAG 
481 NCTTGGGCGT TTAATTNNTN GGGTNNNTTA ANNNGGTTTT CNNGGTTGGT TTGAAAATTT 
541 GGTTTATAAA AAAAAAAAAA AAANNCCCAA AAAAAAAAAA ANNAAAAAAG CCCNGGGAAA 
601 CCCTTTTTNA GTTTGTTTAA ANNNNTTGGG GGGGGTGGCC CTTAANTTTG AAANTGGAAC 
661 CCTAACTTTT CAACTTTTTA ATTNGCGTTN GGGCCCCNTT NNNTGNNCCN NATTTTTCTC 
721 AATTTTGGGG NNAAANNCTN GNTTNCNTNC CACAACNNNG CCTTTTAANT TTAANNTNTG 
781 GGCCCAANNC CCCCCNGGGG GGAAAANGGC NGNNTTNGGC GNTNTTNNNN NNNNNNNNNN 
841 NNNNNNNNNN NNNNNN 
B 53.2: Sequencing alignment of cDNA subclone AF30#4 with mouse mRNA for suppressor of actin 
mutations (SACl gene) by BLAST searching against the National Center for Biotechnology 
Information database 
AF3 0#4 ： 1 qactcactataqgqcqaatcqqqccctctanatgcatqctcgaqcqgccqccaqtgtqat 60 
T l l l l l l l l l l T T T I T I I I T T T I M M M I l Y l 11丫 11 l Y l T l f f 11丫 111力丫 I丫 11 
Mouse SACl： 4 gactcactatagggcgaattgggccctctagatgcatgctcgagcggccgccagtgtgat 63 
AF30#4 ： 61 ggatatctgcagaa-tcgcccttgt 84 T T I I I I I I T I I T I I M T I M M T I 
Mouse SACl： 64 ggatatctgcagaattcgcccttgt 88 
B 53.3: Summary of sequence alignment of cDNA subclone AF30#4 with mouse SACl 
FluoroDD gel AF (APIO + ARP13) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
fragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
� … Mus musculus mRNA for , 
M13 . le-29 
AF30 + ++ + + 240 AF30#4 290 forward ^ " " T ^ ^ T n e ^ 82/85 
mutations (SACl gene) …。/、 
^ (2029 bp) (•) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 ANNTNNTNTT ANNGTGANAN NCATAGAAAT ANCTACAAGN NCTNATGCAT CAAGCNTTGN 
61 GNTACAGCAN CANCNGGCAT NCACAATNAN NTNACAAGGC CNGNCAANNT GTGCATGGCA 
121 ANNAGCCCAT TNNCAGGCAT ANCCAATTTC AACAACAAGG NAGTNQCNAN CCAATCNATT ARP13* 
181 CNAAGTAGNN CAACTATATA TTGCCGCTAC CCCAATCCCT CCTTCCAACA TAACTCCAGC 
241 ATCATCAACC TCATACATCA ACCAATCTCC CAAACCATCA AGATTAATTA CTCCAACTTC 
3 0 1 ATCATAATAA TTAAGCACAC AAATTAAAAA AACCTCTATA ATCACCCCCA ATACTAAAAA A P I O 
3 6 1 AAAAAAQCCC TATAGTGAGT CGTATTACAA GGGCCAATTC TGCAGATATC CATCANACTG 
421 GCGGCCGCTC NAGAATGCAT TTAAGAGGNN CCCAATNCCG CCCCNNNNNG TGGANGTTNG 
481 NTATNNACAA ATTTTCAANN TNGGGCCCGG TTTGGTNTTT TTAACANAAA CCGTNTTNGG 
541 TNGGAAACNT TGGGGGNAAA AAAAAACCCC CCTNGGGNAC CGTTTTAAAC CCCCCAAAAN 
601 NCCTTTTAAA ATTTTNCGGC CCCNTTTGGG NNANGGACAA AAANANTTNT TCCCCCCCCA 
661 NTTTTNTTTA GGGCNCNCAA GGCCNNTTGG GGNNCNGNNT ATAANTTNAA NNNCCNGGNA 
721 NNNANAANNN GGNGCCCCCC CGGGCAAAAA CCNCNGGNNN ATTTTCGGGG CCCACCCCTT 
781 GTNNNNNNNN AAAAACANAG GNNTTTTTGG GGNNNNNNNN NNNNNNNNTN GGNNAANNNT 
841 NGNNGGGGGG NNNNNANNNN NTTNNGNGGG NNNNNNNNNN NNNCCNNNNN NNNNCCTTNT 
901 NTTGTNNNTN TTTAA 
B 54.2: Sequencing alignment of cDNA subclone AF30#5 with mouse mitochondrion by 
BLAST searching against the National Center for Biotechnology Information database 
AF30#5 ： 183 aaqtaqnncaactatatattqccqctaccccaatccctccttccaacataactccagcat 242 . Ill 111 i i i i I I l l l l l l l 111 l l l l l l l 11 m i l I I m i l m i l m i l I I I I 
Mouse mitochondrion： 13624 aagtagcacaactatatattgccgctaccccaatccctccttccaacataactccaacat 13683 
AF3〇#5 ： 243 catcaacctcatacatcaaccaatctcccaaaccatcaagattaattactccaacttcat 302 l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l T I I I I I I I I I I I I I I I I I I I I 
Mouse mitochondrion： 13684 catcaacctcatacatcaaccaatctcccaaaccatcaagattaattactccaacttcat 13743 
AF30#5 ： 303 cataataattaaqcacacaaattnnnnnnncctctataatcacccccaatact 355 
i i i i i i i i i i i i T i i i i i i i i i i i i m i i i m i m m i i m � -
Mouse mitochondrion： 13744 cataataattaagcacacaaattaaaaaaacctctataatcacccccaatact 13796 B 54.3: Summary of sequence alignment of cDNA subclone AF30#5 with mouse mitochondrion 
FluoroDD gel AF (APIO + ARP13) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 le-72 
AF30 + ++ + + 240 AF30#5 290 mitochondrion, complete 170/173 
reverse genome (16300 bp) (98%) 
* Sequence of primer was not completely matched with the expected sequence. 
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B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 CCTCACTATA GGGCGAATNG GGCCCTCTAG ATGCATGCTC GAGCGGCCGC CAGTGTGATG 
61 GATNTCTGCA GAATTCGCCC TTAGCGGATA ACAATTTCAC ACAGGATTTT GGCTCCCCTG ARP19 
121 CAGAAATCCC AAGCCCTGAT GTGTACTGCC TGCTCTTTAG CTCTCCTGAT TTAGTGATTT 
181 ATGAGGACCT CGGGAGCATG ACACTTGCTG TATGACTCCT ACATCCATAG ATCCTTAAAA 
241 TCACATCTCA TGATGCTGAT AGAAGATTTT AAGAAAGATA TTAATAACCC CCTTGAAAAA 
301 ATACAGGAGA ACAGATTTAA AAGGGAGAAG GTTTTAAAGA GAAAACACAA AAATCCATTA 
361 AAAAATTACA AGAAAACACA ACCAAACAGG TGAAGGAATT GAACAAAACT ATCCAGGATC 
421 TAAAAATGGA AGTAGAAACA ATACAGGAAT CACAATGGGA GAAAACTTCA GAGATATAAA 
481 TCCTAGGAAA GAGATCAGAA GTCATAGATT CAGGCATCAC CAAAAGAATA CAAGAAATAG 
541 AAGAGAGACT TTCATGTACA GAAGATACCA TAGAAAACAT TGACACAACA GTCAAAGAAA 
601 GTGCAAAATG CAAAAACTTT CTAACTCAAA ACATCCAAGC AATCCAGAAC GCAATGAGAA 
661 GAACAACCCT AAGGATAACA NGNATAGANA AGANCAAAAA TNCCNAACTN AANNGGCCAG 
721 TAAATATTNN CAACAAAANT AGAAAANANA ACATTCNGAN NNTAAANGAT AAAAAAAAAG 
7 8 1 CCTANNGTGA GTNNNNTACA GGGCNAATNC ANCCANNGGC GCCGTTACTN TNNATCNANC 
8 4 1 TNGGNNC 
B 55.2: Sequencing alignment of cDNA subclone AH1#6 with mouse EST by BLAST searching against 
the National Center for Biotechnology Information database 
AH1#6 ： 237 aaaatcacatctcatqatqctqataqaagattttaaqaaaqatattaataacccccttqa 296 
m m i i i m i i 丫 I I 丫 I 化 丨 M l m i l I I 了I I I m i l I i i i i I 
Mouse EST： 16 aaaatcacttctcatgatgatgatagaggaatttaaaaaggacataaataaactccttta 75 
AH1#6 ： 297 aa-aaatacaqqaqaacagatttaaa-agqgagaagqttttaaagaqaaaacacaaaaat 354 I I I I I I I I I T I I T I I I I I M M IT I T I I T l l l i l T I T 1 1 1 1 1 1 1 1 1 1 1 1 
Mouse EST： 76 aagaaatacaggagaacacaggtaaacagctagaagcccttaaagaggaaacacaaaaat 135 
AH1#6 ： 355 ccattaaaaaattacaaqaaaacacaaccaaacagqtqaaqgaattgaacaaaactatcc 414 
I I M i l l I m i l 了 l l l l l l l l l I I I I I I T T I T I I T T I I I T I l l l l l l l M M � 
Mouse EST： 136 cccttaaagagttacaggaaaacacaatcaaacaggtgaaggaaatgaacaaaaccatcc 195 
AH1#6 ： 415 aqqatctaaaaatqqaagtagaaacaatacaggaatcacaatqgqagaaaacttcaqaqa 474 I T l l l l l M M I T T I r i l T I M i l l I I IT l l l l l l l l T T T I T I I I I T I T ^ 
Mouse EST： 196 aagatctaaaaatggaactagaaacaataaagaaatcacaaagggagacaaccctggagt 255 
AH1#6 ： 475 tataaatcctaggaaagagatcagaaqtcataqattcaggcatcaccaaaaqaatacaaq 534 I I I I I I I I I T T I I I T I T I I I I T I T I I I M T I I I I T l l l l l l l l l I T I M M M T 
Mouse EST： 256 tagaaaacctaggaaagagatcaggagtcatagatgcaagcatcaccaacagaatacaag 315 
AH1#6 ： 535 aaataqaaqaqaqactttca——tgtacaqaaqataccataqaaaacattqacacaacag 591 I M l T l l T I T I T I I I I I T l I T I l T l l l l l l l l T l l l l l l l l T l l l l l l i l t ^^ 
Mouse EST： 316 acatagaagagagaatctcagagggtgcggaagataccatagaaaacattgacacaacag 375 
AH1#6 ： 592 tcaaagaaaqtqcaaaatqcaaaaactttctaactcaaaacatccaagcaatccaqaacg 651 
I I I I I T I M I T I I I I I m i l l I M i l l l l l l l l l l l T I I I I I I T I I … 
Mouse EST： 376 tcaaagaaaatgcaaaaaccaaaaagctcctaacccaaaacatctgggaaatccaggaca 435 
AH1#6 ： 652 caatqaqaaqaacaaccctaaqqataa 678 I I I I T I T I I T I 111 I I I I I T T I 111 
Mouse EST： 436 caatgagaagaccaaacctaaggataa 462 B 55.3: Summary of sequence alignment of cDNA subclone AH1#6 with mouse EST 
FluoroDD gel AH ( A P l l + ARP19) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
vm09c03.rl Knowles 
Solter mouse blastocyst 
M13 B1 Mus musculus cDNA 2e-82 
AHl + - + + 720 AH1#6 750 forward clone IMAGE:989668 5' 377/447 
(-20) similar to (84%) 
gb:U15647—cdsl Mus 
musculus (624 bp) 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 GGGCCCTCTA GATGCATGCT CGAGCGGCCG CCAGTGTGAT GGATATCTGC AGAATTCGCC 
6 1 CTTAGCGGAT AACAATTTCA CACAGGAGCT AGCAGACCCA GGGAATGATC AAGGAACTCA ARP4 
121 TCTCAGAACT GGATGAGAGG ACATTGATGG TGCTGGTGAA TTACATCTAC TTTAAAGGCA 
181 AATGGAAGAT ATCCTTTGAC CCCCAGGACA CATTTGAGTC TGAGTTCTAC TTGGATGAGA 
241 AGAGATCTGT GAAGGTNCCC ATGATGAAAA TGAAGTTACT GACCACNACG CCACTTCCGT 
301 GATGAGGAGC TATCGGTGCT CTGTGTTGGA GCCGAAGTAC ACAGGAANAT GCCAGCGNNC 
361 TGCTNCATCC TCCCTGACCA GGGCAGGATG CANNNCAGGT GGAAGCCAGC TTACAACCAG 
421 NAGACCCTGA GGAAATGGAN GGAAAACTNT TGTCNTCCCA NCCAAATATG AGGATNCTAA 
481 ACCTGCCCCT AGTNCNNCAN CGCCTATTAA CTTCAGGNTT GGANGACGAT TTCCTNNNAN 
541 ANGTGTGGAT TAAGGAANNT NNCANNGATA CATTCTGACC CATCTGTGGA TCTCATGAAA 
601 CCGGGGATNC TTGTGNTGNT GTCTCAANGT GGTCCCAATC GTGNCTATTN CATTGCATGT 
661 GGTAATGNAC ACNNNTCTCN CNANCCTAGT TTGGTTGCTA CNNAGGGTAA TTGNATNNNC 
721 NTTTCATAAG GGGCNCTANT ACCNANGCA 
B 56.2: Sequencing alignment of cDNA subclone AI1#5 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AI1#5 ： 93 caqacccagqgaatqatcaaggaactcatctcagaactqgatgaqaqqacattqatqqtg 152 
II丫iiiiifTfiii 丫 i i i i i f f i i i i i i i i i i iY i i i iT f i iY iYi f f i i i i i丫 i i f f i t 
Mouse SPI ： 610 cagacccagggaatgatcaaggaactcatctcagaactggatgagaggacattgatggtg 669 
AI1#5 ： 153 ctggtqaattacatctactttaaaggcaaatqqaagatatcctttgacccccagqacaca 212 
i i f f i 了 i i i i i i i i i i i i i m i i n i i i i i T f i i l ^ i i i i i i i i T i m i i i f f i i i i i 
Mouse SPI： 670 ctggtgaattacatctactttaaaggcaaatggaagatatcctttgacccccaggacaca 729 
AI1#5 ： 213 tttgaqtctqagttctacttgqatgagaaqaqatctgtgaaqqtncccatgatqaaaatq 272 
iiiti丫iiiYi丫iiiimiTf丨丨丫il^iTi丫iiiiTitiiTfi M M I T I I T I I M I T 
Mouse SPI： 730 tttgagtctgagttctacttggatgagaagagatctgtgaaggttcccatgatgaaaatg 789 
AI1#5 : 273 aaqttactqaccacnacqccacttccqtgatgaqqaqctatcgqtgctctqtqttqqaqc 332 
M T M I M T I M M I I I I 1 1 1 1 1 1 I T I T I I T I T I I T I 1 1 1 1 T i l l 11ITITI ITT IT I。卩 
Mouse SPI: 790 aagttactgaccac-acgccacttccgtgatgaggagctatc-gtgctctgtgttggagc 847 
AI1#5 ： 333 cqaagtacacaggaanatqccaqcgnnctgctncatcctccctqaccaqggcaggatqca 392 
I T I I T I I I I I I T T I M I T I M T r IIITI 1111111111 I I I 11ITTTIITTI IT I 。。： 
Mouse SPI： 848 tgaagtacacaggaa-atgccagcgccctgct-catcctccctgaccagggcaggatgca 905 
AI1#5 ： 393 nnncaqgtqqaaqccagcttacaaccagnaqaccctgaqgaaatqganqqaaaact 448 
M T T I T T M T M I T M M M M M T IT I 1 1 1 I T I T T I 1 1 ITT I T T I I I I I I。。 
Mouse SPI： 906 --gcaggtggaagccagcttacaaccag-agaccctgaggaaatgga-ggaaaact 957 B 56.3: Summary of sequence alignment of cDNA subclone AI1#5 with mouse SPI 
FluoroDD gel Al (AP6 + ARP4) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
M13 cysteine) proteinase 0 
All + - + + 1100 All#5 1110 forward inhibitor clade 343/356 
(-20) A, member 3K (Spi2) (96%) 
I I I I I (1645 bp) 
343 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 GGNCNTATTT AGGTGACACT ATAGAATACT CAAGCTATGC ATCAAGCTTG GTACCGAGCT 
61 CGGATCCACT AGTAACGGCC GCCAGTGTGC TGGAATTCGC CCTTGTAATA CGACTCACTA AP6 
1 2 1 TAGGGCTTTT TTTTTTTTCC CGGTATTGGA ACTCTGTGTA TTTGCAAATG CCTAGGTTTG 
181 GGGTACAGAC ACATAAAGAG GAGTCACCCG GGAAGAAGAA TAAAGGCAGA TTCCAGGTNC 
241 AGAAATATGC ACAGATGCTC CCAAGACAAC CGAGAGCCTG ACACTGAGAG TCCAAAGTCT 
301 TATGTGCATG TGGGATCACA GAGATAGTTA ANTGTACCTG TCTAAGNCCA ACTTTGCAAC 
361 AGCCAANTCA GAGCTTGAAT GACAGGATGT ATATNNGAGA TCCACATGCA NNACTTTGTN 
421 NCCACAGCCC TGNNACAGNA ACCCATGAGN AACTTGGNTG AGCTTTTNNG TNNTACTTGG 
481 GNGTNATTCG ACTTTGGCCC NTANAANGAG NGATACTCTT TATCCATCTT NGNNGTGTAT 
541 AATNANTAAT TCANNAACAT TGTAAANTGG GCCCCCNGTT AGAAAAATTN GNNATCAGNC 
601 NTATNNGGTN AANNTTNGTT CCCCTTACCC AAATTGNCNT TTCCCTTTNT TCCCCCNTTT 
661 GGTTANGNTC ATTCTGCCAT NNNNNTNGNN TTGNTNNATN NNTTTNNTNT TTNNNNNCTC 
721 NNNNNNTTTT TTNNNANNCA TCCTTNATTA TCNANNCGNN CANCTTTNTT NTCGGNGNTT 
781 TCTNCGGGNN GGANTCCCNN NAAATNNNTT NNNTNNNTAN GNANTNNNNA ATNNTNN 
B 57.2: Sequencing alignment of cDNA subclone AI1#5 with mouse serine (or cysteine) proteinase 
inhibitor (SPI) by BLAST searching against the National Center for Biotechnology Information 
database 
AI1#5 ： 142 qqtattqqaactctqtqtatttgcaaatqcctaqgtttgqgqtacagacacataaagagq 201 
f f i i i i f f i i i i i i Y i Y m i i Y m i i T i i i i n i i i f f f f i i i i T i i i i i i i i i Y i f f 
Mouse SPI： 1629 ggtattggaactctgtgtatttgcaaatgcctaggtttggggtacagacacataaagagg 1570 
AI1#5 ： 202 aqtcacccgqqaagaaqaataaaqgcaqattccaqqtncagaaatatgcacaqatqctcc 261 
I 丫 l l l l l l t n i l 丫 M 了 l l l l l i n i l 了 l l i m f f i M T M I M I I M M T I I T I I I I 
Mouse SPI: 1569 agtcacccgggaagaagaataaaggcagattccaggttcagaaatatgcacagatgctcc 1510 
AI1#5 ： 262 caagacaaccqaqaqcctgacactqaqaqtccaaagtcttatqtqcatgtgqgatcacaq 321 
i i i T i i i m t i 丫 i t i i i l ^ i m 丫 I 丫 i t i i m i T i i i i i i T i T m 丽 m i l l 丫 
Mouse SPI： 1509 caagacaaccgagagcctgacactgagagtccaaagtcttatgtgcatgtgggatcacag 1450 
AI1#5 ： 322 aqataqttaantgtacctqtctaagnccaactttqcaacagccaantcaqagcttqaatq 381 
I T I I I T I I I I I T I I I I T I I I I I T I I I I I I I I I I I I I I T I I I I M I T I T M I T I M T � 
Mouse SPI： 1449 agatagttaa-tgtagctgtctaag-ccaactttgcaacagccaa-tcagagcttgaatg 1393 
AI1#5 ： 382 acaggatgtatatnnqaqatccacatqca 410 I I I T T I I T I l l l l T I T I I I I I I I I T I I 1 … 
Mouse SPI: 1392 acaggatgtatata-gagatccacatgca 1365 
B 57.3: Summary of sequence alignment of cDNA subclone AI1#5 with mouse SPI 
FluoroDD gel AI (AP6 + ARP4) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after EcoRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus serine (or 
^^ - cysteine) proteinase e-123 
All + - + + 1100 All#5 1110 inhibitor clade 262/269 
reverse 八，member 3K (Spi2) (97%) 
I I I I I (1645 bp) 
344 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CCNTCCACTA TNNGGCGAAT NNCGGGCCCT ACTAGATGCT GCTCAGACGG CCGCNNGNGT 
61 GAATGGATTT CTGNNGAANT TCGNCCCTTG NTAAATACGA CCTCACTATA GGGCTTTTTT AP6 
121 TTTTTTCCCT GTTTCTTCAG GGACTTCACC TTTATTGGGG ACGACCGCTT TGGGTGGGAC 
181 GGGATCTAGG GCTCCTGGGC TTGCCAAGTA GGGCCCGCAC CTGCCTGATC TGCCATTCGA 
241 CACTGGATTT CGCTGTGCCA CCCAAGGCAC TGTACTGTTC CACGCTGTGA CTGTAGTCCC 
301 ACACGTGACT CACATCACCT GAGAACAGGG GACTGATGGT CTGCTAGCTC CTGTGTGAAA 
361 TTGTATCCGC TAAGGGCGAA TTCCAGACAC ACTGGCGGCC GTTACTAGTG GATCCCGAGC 
421 TCCGGTACCC AAGCTTGATG CATAAGCTTG AGTATCCCTA TAGTGTCACC TAAAATAGCT 
481 GGGCGTAATC ATGGTCATAG CTGTNNCCTG TGTGAAATTG TTATCCGCTC ACAATNCCAC 
541 ACAACATACG AGCCGGAAGC ATAAAGTGTA AAGCCTGGGG NGCCTAATGA GTGACCTAAA 
601 CTTNAATTAA TNGCGTTGCG CTCCCTGCCC GCTTCCCAGT NNGGGAAACC TGTTGTGCCA 
661 GCTGCATTAN TGAATTGGGC ANNGCGCGGG GAGAGGCGGT TNGGNTNTGG GNCNNNTTTC 
7 2 1 GNTTTNTNNT NNTGANNTGC TGNGCTNGNT NTTNGGTGNG NNANGGTNTT NNTNNTTNNN 
781 GGTAATNNGT NTNNNNAATN NNNATNNNCC GAAAATTTNA CCAGGGNNCA AGGCAAACTT 
841 ANNGNGNNTN TT 
B 58.2: Sequencing alignment of cDNA subclone AI18#6 with mouse argininosuccinate lyase (Asl) 
by BLAST searching against the National Center for Biotechnology Information database 
AI18#6 ： 167 〒(！：丨竹〒〒〒!〒〒，3(|：〒〒〒竹(|；1|：丨〒行cj:tcj:tj：〒〒〒！：〒<j:caT〒〒’〒？〒(|：(|：(|；〒(|；’(|：(|：’〒(！：竹 226 
Mouse Asl： 1494 gctttgggtggg-cgggatctagggctcctgggcttgc--agtagggcccgcacctgcct 1438 
AI18#6 ： 227 gatctgccattcgacactggatttcgctgtgccacccaaqqcactgtactgttccacqct 286 T m i T m r n T i i M i T f i m i T i i T i T i M M m T M i N T i M i T i m i i T i i 
Mouse Asl： 1437 gatctgccattcgacactggatttcgctgtgccacccaaggcactgtactgttccacgct 1378 
AI18#6 ： 287 gtgactgtaqtcccacacqtgactcacatcacctgagaacagqqgactgatggtctgcta 346 
丫 i l ^ i i 丫 N t i i i i i i i i Y i Y i i i i i i i i i i M i Y i l ^ i i i f i T f i i i 丫 i i Y T i i i n I 
Mouse Asl： 1377 gtgactgtagtcccacacgtgactcacatcacctgagaacaggggactgatggtctgc-a 1319 
AI18#6 : 347 gctcctgt 354 T I I I I I T I Mouse Asl: 1318 gctcctgt 1311 B 58.3: Summary of sequence alignment of cDNA subclone AI18#6 with mouse Asl 
FluoroDD gel Al (AP6 + ARP4) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after ^coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mus musculus 6e-84 
All8 ++ + ++ ++ 270 AI18#6 300 forward argininosuccinate lyase 184/188 
(-20) (Asl) (1589 bp) (97%) 
345 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 NCNTATTTAG GTGACACTAT AGAATACTCA AGCTATGCAT CAAGCTTGGT ACCGAGCTCG 
61 GATCCACTAG TAACGGCCGC CAGTGTGCTG GAATTCGCCC TTAGCGGATA ACAATTTCAC ARP4 
121 ACAGGAGCTA GCAGACCATC AGTCCCCTGT TCTCAGGTGA TGTGAGTCAC GTGTGGGACT 
181 ACAGTCACAG CGTGGAACAG TACAGTGCCT TGGGTGGCAC AGCGAAATCC AGTGTCGAAT 
241 GGCAGATCAG GCAGGTGCGG GCCCTACTGC AAGCCCAGGA GCCCTAGATC CCGCCCACCC 
3 0 1 AAAGCTGCTC CCCAATAAAG TGAAGCCCTG AAGAAACAGQ AAAAAAAAAA AAQCCCTATA AP6 
361 GTGAGTCQTA TCACAAGGGC GAATNNCTGC AGATATCCAT CACAACTGGC GGCCGCTCGA 
421 GCATGCCATC TAGAGGGCCC CAATTNCCGC CCTATAGTGA GTCGTATTAC AATTCACTGG 
481 NCCGTCGTTT TACAACGTGG TGACTGGNGA AAACCCTGGC GTTACCCAAC TTAATTGCCT 
541 TGCAGCACAT CCCCCTTNCG CCAGCTGGCG TAATAACGAA GAGGCNNGAA CCGATCGCCC 
601 TTNCCAACAG TNGGCCCNGC TGAATGGCGA ATGGACCCCC CCTGTAGNNC CCCATTAAGC 
661 GCNGGNGGTG GTGGTGGTAA CCCCCNNNNT GAACGTTNNA CTTNGCCAAG GNNNNTANNC 
721 NNNNNTTTCT TTTTTTTTTT TCCCCNTTCT TTTTNNNCAA NNNTTGGCGG GCTTTCACAC 
781 TTNNNCCNNT TNNNTTGGGG GCTCCNTTTN NGNNNNNTNT NNNNNNNNAN NNNCTNACTN 
841 NNNNNNNTGN NN 
B 59.2: Sequencing alignment of cDNA subclone AI18#6 with mouse argininosuccinate lyase (Asl) by 
BLAST searching against the National Center for Biotechnology Information database 
AI18#6 ： 121 acaqqaqctaqcaqaccatcaqtcccctqttctcaqqtqatgtqagtcacgtqtqqqact 180 
i i i T T i T i i l ^ i T i i m i i Y m m T i i i m 而 i i T i Y i T m i l ^ 而 丫 I I I 
Mouse Asl： 1311 acaggagct-gcagaccatcagtcccctgttctcaggtgatgtgagtcacgtgtgggact 1369 
AI18#6 ： 181 acaqtcacaqcqtggaacagtacagtqccttqqqtqqcacaqcgaaatccagtqtcgaat 240 
I I I 化 M l 丫 l Y i f f i i i i 丫 i m 丫 i T i i i i f T f i f f i m 〒 丨 T i i i m i T i T i i 了 I I I �� 
Mouse Asl： 1370 acagtcacagcgtggaacagtacagtgccttgggtggcacagcgaaatccagtgtcgaat 1429 
AI18#6 ： 241 qqcaqatcaqqcaggtqcgqqccctactgcaagcccagqagccctagatcccqcccaccc 300 
〒 ？ i i � i i i i � � i m i � i 〒 〒 ？ i i m i i � i i i � i i i i n i ? m N t i i i i i Y i i i i i i i ， “ 。 
Mouse Asl： 1430 ggcagatcaggcaggtgcgggccctactgcaagcccaggagccctagatcccgcccaccc 1489 
AI18#6 ： 301 aaagctgctccccaataaaqtqaaqccctqaagaaac 337 l i l T I I T I I I I l l l l l l l l T I T I T I I I I T I I T I I I I 
Mouse Asl： 1490 aaagctgctccccaataaagtggagccctgaagaaac 1526 B 59.3: Summary of sequence alignment of cDNA subclone AI18#6 with mouse Asl 
FluoroDD gel Al (AP6 + ARP4) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after EcoRl Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus e-110 
All8 ++ + ++ ++ 270 AI18#6 300 argininosuccinate lyase 215/217 
reverse (Asl) (1589 bp) (99%) 
346 
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B60.1: DNA sequence of cDNA subclone AJ1#4 (AP6 & ARP 14) using M13 forward (-20) primer 
1 CNTCACTATA GGGCGAATTG GGCCCTCTAG ATGCNTGCTC GAGCGGCCGC CAGTGTGATG 
6 1 GATATCTGCA GAATTCGCCC TTGTAATACG ACTCACTATA GGGCTTTTTT TTTTTTCCTC A P 6 
1 2 1 TGAAGAGCTT TATTAATGTG CTGGACTGTA CCATACAGCA AGGGTNCAAG TCACTTTAGG 
1 8 1 AAGAAACAGC AGTATGTTCA ATGATCAAGA AGTAGAAACC AGATTGGTAA CATNTAGTGG 
2 4 1 TCCACCATAC TGGTCTTNNA GGGGCTGACG ATTTAAGAAA CATGGGCTCA CAGCAGCATG 
3 0 1 GTCCAAGCTA AAGTCTCTGA ACAGAAACCA AAAGANGTGG TAGTTGCCCT GCTTGGGATC 
3 6 1 CTACTANNCT TGGGNNNGCC CCAGTCAAGG ANGGTNCAAG TTANGTCTGG CCCTCANAGC 
4 2 1 TCCTCTGGGA A C T T N C C T G C T T C T C T G C T C TCCGTGCCAT TCTGANNNTT CTTGGCAGTN 
4 8 1 T C T C T G T C C A NACTGTACCC GACCCTCTTT NNCTCACCCC ATCCGTGTNN TAAACATCTC 
5 4 1 CAGTATGTNC TACTGTNNAT NGGCCAAGAG CACCCTGCCT GGGATNCCGG CTGCACTGCC 
6 0 1 CTTGGGCATA TGTTAGCCAC TGCTNCTCCC TGTNNCCGGN ANGCCAGAGG ACCTCTCANT 
6 6 1 GAGAAGACCC AAAACANNCT TNCNGAGATG TCACNTCCCA GCGCTGACT 
B 60.2: Sequencing alignment of cDNA subclone AJW4 with mouse carboxylesterase by BLAST 
searching against the National Center for Biotechnology Information database 
AJ1#4 ： 117 cctctqaagaqctttattaatgtqctqqactqtaccatacaqcaaqqgtncaaqtcactt 176 ^ , I I I I I T I I T I T I I I I I I I I I I T I T I I N I I I T I I I I I I I I I L ^ I I T N I M I T M I M I 
Mouse carboxylesterase： 2005 cctctgaagagctttattaatgtgctggactgtaccatacagcaagggttcaagtcactt 1946 
AJ1#4 ： 177 tagqaagaaacagcagtatgttcaatgatcaaqaagtagaaaccaqattgqtaacatnta 236 
^ 1 i i f f i i丫 i i i i i Y i i T i i i l ^ m i i丫 l l l l l l l丫 i i l ^ i m i T m f f i i i i i i ii 
Mouse carboxylesterase： 1945 taggaagaaacagcagtatgttcaatgatcaagaagtagaaaccagattggtaacattta 1886 
AJ1#4 : 237 gtgqtccaccatactggtcttnnagqggctgacgatttaaqaaacatqqqctcacaqcaq 296 T I T T I I I I I I I I I I I T T I I I I i T T T T M T I T11111 111 1111ITTTI1111 I I I IT 
Mouse carboxylesterase： 1885 gtggtccaccatactggtcttgtaggggctgatgatttaagaaacatgggctcacagcag 1826 
AJ1#4 ： 297 catgqtccaaqctaaaqtctctgaacaqaaaccaaaaganqtgqtaqttqccctqcttgq 356 I I I T T l l l l T M I M T M I M T M I I T I M I I I I I T I 11 T l I I I 111 i I 111 11 T 
Mouse carboxylesterase： 1825 catggtccaggctaaagtctctgaacagaaacaaaaagaagttgtagttgccctgctt-g 1767 
AJ1#4 ： 357 gatcctactanncttggqnnngccccagtcaagqangqtncaaqttanqtctqqccctca 416 
I I I m m 11 ITTT T l l l l T l l I T T I TT I I IT I I Til ITT M M 
Mouse carboxylesterase： 1766 gatgctactattcttgggttgg-cccagtc-aggaaggtcc-aggtaggtctgg-gctca 1711 
AJ1#4 ： 417 naqctcctctgqgaacttncctgcttctctqctctccgtqccattct--gannnttcttq 474 
I T I I I I I M T T I I I I i I I I T I I M I I I T I I I I I T I T I I I I I I I I I I I M i ， “ � 
Mouse carboxylesterase： 1710 g a g c t c c t c t - g g a a c t t t c c t g c t t c t c t g c t c t c g g t g c c a t t c t t g a a t t t t t c t t g 1652 
AJ1#4 ： 475 qcaqtntctctqtcca-nactgtacccqaccct 506 T l l l l I I I I I T I I I I I I I T I I I I T I M I I … 
Mouse carboxylesterase： 1651 gcagtgtctctgtccagaactgtagccgaccct 1619 B 60.3: Summary of sequence alignment of cDNA subclone AJ1#4 with mouse carboxylesterase 
FluoroDD gel AJ (AP6 + ARP14) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 Mouse carboxylesterase e-123 
AJl ++ + ++ ++ 1200 AJ1#4 990+220 forward (Carboxylesterase) 354/393 
(-20) (2006 bp) (90%) 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 GNNCATTTAG GTGANCCTAT AGAATACTCA AGACTATGCA TCAAGCTTGG TACCGAGCTC 
6 1 GGATCCACTA GTAACGGCCG CCAGTGTGCT GGAATTCGCC CTTAGCGGAT AACAATTTCA ARP14 
121 CACAGGATCC ATGACTCCTT CTTCCCACAA AGGCCCCAGA AGCTCCTAGN CAAACAAGNC 
181 AATTCCCCAC TGTGCCCTAC CTCTTGGGAG TCACCAACCA TGAGTTTGGC TGGCCTTCTA 
241 NCTCAAATTC TGGAATATCC TGGATAAGAT GGAACCATTT GAGACCAGGA AGACCTGTTG 
301 GAGAATTCAA GGCCCTTATT AGACCNCATA TGCCACTGCC CCCTGAGATC ATGCCCNNCC 
361 GTCATAGATG ANNACCTAGA CAATGGCTCA NGATGAATCA GCTACCAGGT ATGCCCTCCA 
421 GGAATTGCTG GGTGATATCA CATNGGTCAT TCCTACCCTN GNNCTTCTCA AAATACCCTN 
481 AAAGATGCTG GGNTGCCCCT GTTTTCTTGG TAACGANGTN NCANGCATAC ANCCCANGTT 
541 NCTTTTTGNC AAAGGTTNCA AGCCCAAGCC TGGGGNTGAA AGGNCTGAAC CATTCCCTCN 
601 TGAGNAATGN CCTTTGTTTT TTGGGAANNT TCNTTTTCCT NNCTGATTGA GANNTTTCCC 
661 CTCCTGGCCC TTCCCNAGAN GGCCAACNGA AGNNAAAAAA AANGCANNNT NGAGCCCTGA 
721 CCCNTTGANT GGGNCNCAAT TGGGNNACCN NNTNTNTTGG ACNNCCCCCN NGGGAAAAAA 
781 TTNACAACAA AANAGNNNAA AAANNNGGGG GNGNGTGGGG CCNTTTNCNC TTTGNGGG 
B 61.2: Sequencing alignment of cDNA subclone AJ1#5 with mouse carboxylesterase by BLAST 
searching against the National Center for Biotechnology Information database 
AJ1#5 ： 131 atqactccttcttcccacaaagqccccagaaqctcctaqncaaacaaqncaattccccac 190 M T M M M M M M M M M M M M I T M T M M M T M I I M I T l l l l l l l l l l l 
Mouse carboxylesterase： 947 atgactccttcttcccacaaaggccccagaagctcctag-caaacaag-caattccccac 1004 
AJ1#5 ： 191 tqtqccctacctcttqqgagtcaccaaccatgagtttqgctggccttctanctcaaattc 250 
丫 M i i i m i i i f r f i T i i m i i m i T i l ^ i i f f i i f f i m i l i i i i i i i i i 
Mouse carboxylesterase： 1005 tgtgccctacctcttgggagtcaccaaccatgagtttggctggc-ttcta-ctcaaattc 1062 
AJ1#5 ： 251 tqqaatatcctqqataaqatqqaaccatttgaqaccaqgaaqacctqttqqaqaattcaa 310 
I T T I I I I I I I I T T I I I I T I I T T I I I M I l T l T 11 I T T I 111 11 I I I I T T I T I 111111 八 
Mouse carboxylesterase： 1063 tggaatatcctggataagatggaac-atttgag-ccaggaagacctgttggagaattcaa 1120 
AJ1#5 ： 311 qqcccttattagaccncatatqccactqccccctgagatcatqcccnnccqtcataqatg 370 
T T I I I I I I I I I T I I I I I I T I i i i l ^ m i i t i 丫 m i l 丫 I I I iitmi丨丫丨丨？ 
Mouse carboxylesterase： 1121 ggcccttattag--cccatatgcaactgccccctgagatcatgccca-ccgtcatagatg 1177 
AJ1#5 ： 371 annacctagacaatqqctcanqatqaatcaqctaccagqtatqccctccaqqaattqctq 430 
I l l l l l 丫 l l l l i n i l l l T I I T I I I I I T I I I I I T T I I I T I I I I I I I T T I I I i T I I T 
Mouse carboxylesterase： 1178 aatacctagacaatggctca-gatgaatcagctacaaggtatgccctccaggaattgctg 1236 
AJ1#5 ： 431 qgtqatatcacatnqgtcattcctaccctngnncttctcaaaataccctnaaagatqctq 490 I T I T I I I I I I I I I T T I I I I I I I I I M I T l l l l l l l l l l l l I I I M T M T I I T ^^^^ 
Mouse carboxylesterase: 1237 ggtgatatcacattggtcattccta-ccttgatcttctcaaaata-ccttcaagatgctg 1294 
AJ1#5 ： 491 ggntgcccctgttttcttq 509 TT IT l i l l T I I I I I I I T Mouse carboxylesterase： 1295 gg-tg-ccctgttttcttg 1311 B 61.3: Summary of sequence alignment of cDNA subclone AJ1#5 with mouse carboxylesterase 
FluoroDD gel AJ (AP6 + ARPl4) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mouse carboxylesterase e-127 
AJl ++ + ++ ++ 1200 AJl #5 990+220 (Carboxylesterase) 353/379 
reverse (2006 bp) (93%) 
348 
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B 62.1: DNA sequence of cDNA subclone AJ2#10 (AP6 & ARP 14) using M13 forward (-20) primer 
1 NNATAGGGCG AATNGGGCCT CTAGATGCAT GCTCGAGACG GCCGCCAGTG TGATGGATAT 
6 1 CTGCAGAATN NCGCCCTTAG CGGATAACAT TTCACACAGG ATCCATGACT CCACTTCCTG ARP14 
121 ACACAGCTAA GTTGCTTGTC TTTACCTCCA GGCTTTCGGC CGTTGCCTGG ACTTCAATCA 
181 TGGTGGCTGA CCTTCCCTTT CTTGCTTTGC TTCTCCTCAA AGAGATAATA GAGACAATGA 
241 CCAGTCTTTC CTCATAGATC AAGTATGGGG AGAGCCCTCA GCTATGGTAT TCCTGTATTT 
301 TGGTGACTTA TTTAAGTAAA TTTCCTGGGA CAATCCAGAT TTGAAAGATT CTGTCTTCTT 
361 GTNGTCATAA ACTATTAAAA TGCTTGGTGG TCACCAAAGT ATTTGACATA AAAATAAATA 
421 AATAAATCAT TCAGGCCACC TTTTACACCA GAAATCACAG GAAAGCCCTG GGCCCCAGCC 
481 ATCTGCTGAG TGTTAGTNGA GAAGATGGAT CCTAAGCCAG CTGAAGACTG AGTGCAGGCT 
541 GTGGGGAGGT TCTTGCTGAG TAGCTGGCTT TGTGGTAAGC TGCTAGCAGC CTTACAGNGG 
601 TGGCGAAGCA GCCCCCCCTT NGGATGCAGA GCAGCCNTCT ACAATNATTN NTGACCNTNA 
661 AAGGTAGANN ATNGNACNTT TTTGTNGGTA TGTGTGTGNT NTGCNTCTCT NCTATTNNAG 
721 NTGANTTTTT TTTTNNTNGA GAACNNNGNC CCCAGAGNTN GGCCNTGNAN CTNNTGANTN 
781 CNTCAGNNNT NCCANANGNN NNNNGGTTAA NNGNTTNGNN CTGANNNNNN NGNNTAGNTG 
841 GNACCTTTNG NTTTAANGAC AAGNTAAGAA ATTTGTGANC NTTT 
B 62.2: Sequencing alignment ofcDNA subclone AJ2#10 with peroxisomal acyl-coA oxidase (AOX) 
by BLAST searching against the National Center for Biotechnology Information database 
Mouse AOX: 111 ccacttcctqacacagctaaqttgcttqtctttacctccaqqctttcgqccgttgcctqq 170 immii 丫丨mil^ iiiYii 化 itmiiimmffimiTfii 丫iiTiiiff 
AJ2#10 : 2732 ccacttcctgacacagctaagttgcttgtctttacctccaggctttcggccgttgcctgg 2791 
Mouse AOX： 171 acttcaatcatqqtqqctgaccttccctttcttqctttgcttctcctcaaaqaqataata 230 
I I I I I I I I I I I T T I T T I I T i l i l l l l l l l l l l l T I I I T I I I i l l i l l l l l l l T l l l l l l � … 
AJ2#10 : 2792 acttcaatcatggtggctgaccttccctttcttgccttgcttctcctcaaagagataata 2851 
Mouse AOX： 231 gagacaatqaccaqtctttcctcataga-tcaagtatgqqgaqaqccctcagctatqqta 289 
T I T I I I I I T I I I I T I I I I I I I I I I I I T i l l l l Y l l l f f f h � l Y l l l l l l t l 丄 I 丄 n 丄 I 
AJ2#10 : 2852 gagacaatgaccagtctttcctcatagactcaagtatggggagagccctcagctatggta 2911 
Mouse AOX： 290 ttcct--gtatttt-ggtgacttatttaagtaaatttcctqqqacaatccaqatttqaaa 346 
M M T i l M l T T I T I I I I I I I I T I I I I I I 11ITTTI111111 111 11 111 I � 一 
AJ2#10 : 2912 ttccgtagtaatttaggtgactttgttaagtaaatt-cctgggacaatccagatttgaa- 2969 
Mouse AOX： 3 4 7 q a t t c t - q t c t t c t t q t n g t c a t a a a c t a t t a a a a t q c t t g g t g q t c a c c a a a q t a t t t g 4 0 5 TI I I T i m M i l T i l M l I I M M M M M i l I I M I T I I I I I T I I I I I T 
AJ2#10 : 2970 gactatcgtcttgttgttgtcataaactattaaaatgcttggtcgctaacaaagtatttg 3029 
Mouse AOX： 406 acataaaaataaataaataaatcattcaggccaccttttacaccaqaaatcacaqqaaaq 465 I I I I I M I I I I I M I I I I I I I I I I I I I i n i l l l l l l l l l i m i T M M I I I M I I I T , , , , 
AJ2#10 : 3030 acataaaaataaataaataaatcattcaggccaccttttacaccaggaatcacaggaaag 3089 
M o u s e AOX： 4 6 6 c c c t g g g c c c c a g c c a t c t g c t g a g t g t t a g t n g a g a a g a l j i g g a l f c p c p t p a a g c p c p a q c p t q a a 5 2 5 
M M T T T M I M T M I M I T I I T I T I T M I T I 了 i T l l t l i f f i 111川T l I iTl丄 T l I 
AJ2#10 : 3090 ccctgggccccagccatctgctgagtgttagttgagaagatggatcctaagccagctgaa 3149 
M�use AOX： 52e T 丨 仿 丨 〒 丨 r m m 〒 衍 
AJ2ttlO ： 3150 gaatgagtgcaggctgtgggggaggttcttgctggagtagctggctttgttggtaagctg 3209 
Mouse AOX： 583 (：1|：^〒(|：^〒(|：(|：1|：1|：^(|；^甲]1 〒平：〒^卞甲了^〒 611 
AJ2#10 ： 3210 -tagcagccttacag-ggtggcgaagcag 3236 B 62.3: Summary of sequence alignment of cDNA subclone AJ2#10 with mouse AOX 
FluoroDD gel AJ (AP6 + ARP14) Sequencing 
~ T T r 7 ~ FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment PPARa (+/+) PPARa (-/-) ^agment I D. after £a?RI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Ml3 Mus musculus 0 
AJ2 + ++ + + 1100 AJ2#10 1130 forward PTxi re l rOxT^ 481/509 
(-20) ox^pC^X) (94%) 
349 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AATAGAATAC TCAAGCTATG CATCAAGCTT GGTACCGAGC TCGGATCCAC TAGTAACGGC 
61 CGCCAGTGTG CTGGANTTCG CCCTTGTAAT ACQACTCACT ATAGGGCTTT TTTTTTTTTC AP6 
121 CAGTCATTTA AATTTATTGG CTATTTTCCA GAATATGAAT TACTGTCAAA TAGAAACCCC 
181 ACAGGTGACA TGCTGCTTAC TGTCAATCTT CAGGGATTAT CAGTCATTCC AGGAGAAAGG 
241 TTAAGACTGT GTCAGCAAAT CTGATGGCTT TGACTTGATG TCATTTCCAC TCCATTAATA 
301 CTGTGTTCTC AGAACTGCTC TGAAAGAACT GTTCTCACGA TGCCAATGCC ACAGACACAG 
361 ACTTAATAGG TCACAATGAT CTCTCTCACT GTGCTTTTAA GAACAAAGAG TTCCAACTAG 
421 CCAGGCATGT CAGCGCAAAC CTGTAACCCC AGCATCTGGG AGGCTGAGGA TCAGANGTCA 
481 AGGCCACTCT GGGCCCTGTC TCAAGAAAAA AAAATCACTA CATAGAAAAA AGCATACACA 
541 CACATACCAC AANNNNNTCC ATACTCTANC TTTANNGTCA GAATGATTGT AGAGGCTGCT 
601 CTGCATCCNA AGGGGGGCTG CTCCCCCACC CTGNTANNGG CTGCNTAGCC AGCNTNANCC 
661 ACAAAAGCCC NAGCCNTACC TCAGNCNNAN GAANNCNNNN CCCCCCACAA GCCCC 
B 63.2: Sequencing alignment of cDNA subclone AJ2#10 with peroxisomal acyl-coA oxidase (AOX) 
by BLAST searching against the National Center for Biotechnology Information database 
Mouse AOX： 122 agtcatttaaatttattggctatttt-ccagaatatgaattactgtcaaatagaaacccc 180 ^ I T I I I I I I I I I I I I I I I T l l l l l l l I I I T I I I I I T I I I I I I T I I I I I I I T I I I I I I I 
AJ2#10 : 3744 agtcatttaaatttatttgctatttttccagaatatgacttactgtcaaatagaaacccc 3685 
Mouse AOX: 181 acagqtqacatqctgcttactqtcaatcttcaqggattatcaqtc attccaggaga 236 
i i i f f i t i i i i Y i i 丫 m m 丫 i i i i i i i i i i f f f i i i i i i i y I i i i i i i T T i T i 
AJ2#10 : 3684 acaggtgacatgctgcttactgtcaatcttcagggattatcagaccttgattccaggaga 3625 
Mouse AOX： 237 aagqttaaqact-gtqtcaqcaaatctgatggctttgacttqat--gtcatttccactcc 293 I I T T I I I I T I I I T I T M I T M M M I T M T T M M T M M T I T I M l l l l l l l l l , “ 
AJ2#10 : 3624 aaggttaagacttgtgtcagcaaatctgatggctttgacttgaatagtcaattccactcc 3565 
Mouse AOX： 294 attaatactgtqttctcaqaactqctctgaaagaactgttctcacgatqccaatgccaca 353 
mmmtitmiiiYmi丫mi丫iiiYmiTimm丫N了|丨|丨丨化丨丨| 
AJ2#10 : 3564 attaatactgtgttctcagaactgctctgaaagaactgttctcacgatgccaatgccaca 3505 
Mouse AOX： 354 gacacaqacttaatagqtcacaatqatctctctcactqtgcttttaaqaacaaaqagttc 413 
T l l i l l T l l l l i l l l T T I I I I I l l T I I I I I I I I I I 丨丫 I 丫 I I I I I I I 丫 m m了丨丫 I I I � … 
AJ2#10 : 3504 gacacagacttaataggtcacaatgatctctct-actgtgcttttaagaacaaagagttc 3446 
Mouse AOX： 414 caactagccaggcatgtcagcgcaaacctgtaaccccaqcatctqqqagqctqaqqatca 473 
I m i t i i i f f i i i t i i i丫 I丫 i i M i i i Y i i i i i i i i ? i m i ? n i f f i丄T i T f i丄 I I 
AJ2#10 : 3445 cgactagccaggcatgtcagcgcaaacctgtaaccccagcatctgggaggctgaggatca 3386 
Mouse AOX： 474 qangtcaaggcca-ctctgqqccctqtctcaaq 505 Tl I I I I ITT I 11 M M T T T M I I T I M M I T ” ㈡ 
AJ2#10 : 3385 gaggtcaaggccaactctgggccctgtctcaag 3353 B 63.3: Summary of sequence alignment of cDNA subclone AJ2#10 with mouse AOX 
FluoroDD gel AJ (AP6 + ARP14) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus ^ 7 � 
AJ2 + ++ + + 1100 細 0 1130 : e ^ ^ 
(3778 bp) ^ ^^  
350 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CCCACNNTAA TNNAGANNGG AGTANNNGGC GCCTCTANAN NNNCNTNNGC TNCNGCANNC 
61 GGNCNGCCCA GTGTGATGGA TATNCGNNNN NAATTNCACC CTGATAATAA CACCTNNACT AP6 
121 ATAGGGCTTT TTTTTTTTTC CCTACTTAAA AAGGAA.TTAA GTTTATTCTT TCACAGTTAT 
181 ACCCACAGAT ACAGTTATGA GCTCATACAT TACAGGGAAT TTTGTTCCAT TTTCACAGGG 
241 TACACATCCA GTAAAACCAG CTTCCAGATC AGGAACTAGC CTTACGAACA TCTCTGCCGT 
301 TACCCCACAG CATCCTTTTG CTTTGCTGAT ACCCAGCACT TCTTCACACC AGAGTAGTTA 
361 GGTTGCATTA GTCTTTGACT GTTGCTGACC TTTCTACAAA TGGAGTCATG GATCCTGTGT 
421 GAAATTGNNA TCCGCTAAGG GCGAATTCCA GCACACTGGC GGCCGTTACT AGTGGATCCG 
481 AGCTCGGTAC CAAGCTTGAT GCATAGCTTG AGTATTCTAT AGTGTCACCT AAATAGCTTG 
541 GCGTAATCAT GGTCATAGCT GTTTACTGTG TGAAATTGTT ATCCGCTCAC CATTCCACAC 
601 AATATTACGA GCCGGGAAGC ATAAAGTGTA AAGCCTGGGG GTGCCTAATG AGTGAGGCTA 
661 ANTCACATTT AATTGCGTTT GCGCCTCAAN TGGCCCCGCT TNCNAGTTNG GGNANACCTT 
721 GTNNNGTGCC ANNCTNNNNA TNNTNTGANN TNNNGGGNAA CCGCCNCCGG GGNANANGCN 
781 NGNTTNNNNN NTANTNNGGG CGCTTTTTCC GCTTTTTTTG CATTNNNTGN ANNTTCCTTG 
841 NNNCTNNGNT TTTTTNGGNN TGNNGNNNAN CNNNTNTTTG GTTTTNNTTN NNNNGNNNNT 
901 NTTGNNNAT 
B 64.2: Sequencing alignment of cDNA subclone AJ9#1 with mouse catalase by BLAST searching 
against the National Center for Biotechnology Information database 
AJ9#1 : 444 aattccagcacactgqcqgccqttactagtggatccqagctcgqtaccaaqcttqatqca 503 
m m i t m i i i f f i T f i 丨丫 m m M i i i i t i t i i i f f i i m i y m y 丨 丨 丫 N 
Mouse catalase： 31 aattccagcacactggcggccgttactagtggatccgagctcggtaccaagcttgatgca 90 
AJ9#1 : 504 taqcttgaqtattctataqtqtcacctaaataqcttggcqtaatcatggtcataqctgtt 563 
i i t m t i t i i i i i i i i i l ^ t i i i m m i i 丫 I I I 而 M i m i f f i i m t 丨iTN 
Mouse catalase： 91 tagcttgagtattctatagtgtcacctaaatagcttggcgtaatcatggtcatagctgtt 150 
AJ9#1 : 564 tactqtqtgaaattgttatccgctcaccattccacacaatattacgaqccgqqaaqcata 623 
I I I T I T I I I I I I I T I I I I I I T I I I I I LLLLLLLLLLL I I I I T I T M T T I I T I I I I � � 
Mouse catalase： 151 tcctgtgtgaaattgttatccgctcacaattccacacaaca-tacgagcc-ggaagcata 208 
AJ9#1 : 624 aaqtqtaaaqcctgqgqgtgcctaatqagtqa 655 I I T I T I I I I T I M T T T T I T I I I I I I T I T I T I 
Mouse catalase： 209 aagtgtaaagcct-ggggtgcctaatgagtga 239 B 64.3: Summary of sequence alignment of cDNA subclone AJ9#1 with mouse catalase 
FluoroDD gel AJ (AP6 + ARP14) Sequencing PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value Fragment fragment I.D. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
ifB4h05.xl Kaestner ngn3 
Ml3 - _ subtracted Mus le_93 
^^ ^ • ^^ ^ „ J cDNA 3'similar one/oio 
AJ9 + - + + 320 AJ9#1 360 forward o^ SW:CATA CAMJE 二〉》 
(-20) Q59296 CATALASE 
I I I I I (280 bp) 
351 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CNCANNTTAN GGTGNNCNCT ATANGAATAC TACAAGNCTA TGCATCAAGC NTTGGTANCN 
61 GNACATCGGC ATNCNATCAN TCACAGGCCG CCAANTGTGC NTGGCAATNC GCCCTTCACG 
1 2 1 GCANACAATT TCACACAGGA TCCATGACTC CATTTGTAGA AAGGTCAGCA ACAGTCAAAG ARP14 
181 ACTAATGCAA CCTAACTACT CTGGTGTGAA GAAGTGCTGG GTATCAGCAA AGCAAAAGGA 
241 TGCTGTGGGG TAACGGCAGA GATGTTCGTA AGGCTAGTTN CCTGATCTGG AAGCTGGTTT 
301 TACTGGATGT GTACCCTGTG AAAATGGAAC AAAATTCCCT GTAATGTATG AGCTCATAAC 
361 TGTATCTGTG GGTATAA.CTG TGAAAGAATA AACTTAATTC CTTTTTAAGA GGAAAAAAAA 
421 AAAAGCCCTA TAGTGAGTGT ATTACAAGGG CGAATNNTGC AGATATNCAT CACACTGGCG 
481 GCCGNTCGAG CATGCTTNTA GAGGGCCCAA TTAGCCCTAT AGTGAGTNTA TNACATTNCT 
541 GGCGTCGTTT TNNNGTCTGN TGGGAANCCT GGNGTNNNNT NNTNTTGACC TCCCTNNNNT 
601 GGNTNNTCAN AGCGNNTNNT NNTGNCCNNA TGNNNTNGNC NNGTNNNCTN NNNNGGTNTG 
661 GTNTNNTNNN NNNNNNNNTT 
B 65.2: Sequencing alignment of cDNA subclone AJ9#1 with mouse suppressor of actin mutations 
(SACl gene) by BLAST searching against the National Center for Biotechnology Information 
database 
AJ9#1 : 444 acaaqqqcqaatnntgcagatatncatcacactqqcgqccgntcgaqcatqcttntaqaq 503 I I I I T T T I T I I I I T I I T I I I I I I I I I I I I I T T I T T I I T I I I I T I I I T I I I I T I T 
Mouse SAC： 88 acaagggcgaattctgcagatatccatcacactggcggccgctcgagcatgcatctagag 29 
AJ9#1 : 504 gqcccaattaqccctataqtqaqt 527 T T I I I I I l l T I I I I I I I T I T I l l 
Mouse SAC： 28 ggcccaattcgccctatagtgagt 5 
B 65.3: Summary of sequence alignment of cDNA subclone AJ9#1 with mouse SACl 
FluoroDD gel AJ (AP6 + ARP14) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. afitr E c o m Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus suppressor 2e-24 
AJ9 + - + + 320 AJ9#1 360 of actin mutations 77/84 
reverse (呂八匚！ gene) (2029 bp) (91%) 
352 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B66.1: DNA sequence of cDNA subclone AL2#8 (AP7 & ARP 15) using Ml3 forward (-20) primer 
1 CCTCACTATA GGGCGAATTG GGCCCTCTAG ATGCATGCTC GAGCGGCCGC CAGTGTGATG 
6 1 GATATCTGCA GAATTCGCCC TTGTAATACG ACTCACTATA GGGCTTTTTT TTTTTCGAGT AP7* 
121 CATTGATTTT CCTTTTATTT AAAGGTCAAG CCATGGTCTC TGCAGCAGAT GGAGACACTG 
181 AGCGTGAGAT TTGGTCCATT TATTATTTCT GTCTGTCCAT CTGTCCGCGT GTTTTCCAGT 
241 ACGCAGACTG CAATCCCACA GACGCTTTTC CTCCAAGCTC CCTTGGGCTG GTATCTCAGG 
301 AAATAGCGCT GATCCACGGA ATGGAACGTT ACAGAGCACA TGACTCCGCT GTGAAATGAC 
361 ACTACACTCA GTCCTTCATT CCACCGTGAG AGGTTAAGGT TTCTAATTTT ATATGGGGTA 
421 GAAAGTCCTG TGTGAAATNG TTATCCGCTA AGGGCGAATN CCAGCACACT GGCGGCCGTT 
481 ACTAGTGGAT CCGAGCTCGG TACCAAGCTT GATGCATAGC TTGAGTATTC TATAGTGTCA 
541 CCTAAATAGC TTGGCGTAAT CATGGTCATA GCTGTTTNCT GTGTGANNTN GTNATCCGCT 
601 CACAANNCCA CACAACATAC GAGCCNGANG CATAANNTGT AAAGCCTGGG NNGCCTANTG 
661 AGTGAGCTAA CTCACATTAA TTGCGTNGCN CNCACTGNCC GCCTTTCAGT NNGNACACCT 
721 GTCGTGCAGC TGCATNAATG AATNGCCAAC GCNCGNGGAA GGCGGGTTGC GTTTNGGNNC 
781 NNTCCGNNNT CNCTAATGAN NNNGGCCNNG NTNTG 
B 66.2: Sequencing alignment of cDNA subclone AL2#8 with mouse hydroxysteroid (17-beta) 
dehydrogenase 11 (HsdlVpil) by BLAST searching against the National Center for 
Biotechnology Information database 
AL2#8 ： 116 cqaqtcattgattttccttttatttaaagqtcaaqccatqgtctctgcagcagatqqaqa 175 
� I丫 iTiiiii 化 iimiiiiiiiiiiiTfiiii了 miffiiiii化l^iTi 丨而丨 
Mouse HsdlVbll： 1685 cgagtcattgattttccttttatttaaaggtcaagccatggtctctgcagcagatggaga 1626 
AL2#8 ： 176 cactqaqcgtgagatttggtccatttattatttctgtctgtccatctqtccgcgtgtttt 235 
i i i i l ^ t i Y i T i 了 i i i i T f i i i m i i i i i i i i i i 丫 i i i Y i i m i i 丫 iiiTi丫丨化11 
Mouse HsdlVbll： 1625 cactgagcgtgagatttggtccatttattatttctgtctgtccatctgtccgcgtgtttt 1566 
AL2#8 ： 236 ccagtacqcaqactqcaatcccacaqacqcttttcctccaagctcccttgggctqqtatc 295 
i i i t i i i 丫 i i t i i i t i i i i m i i i t i i t i m i i i i i m n m m f f f i i f f i m 
Mouse HsdlVbll： 1565 ccagtacgcagactgcaatcccacagacgcttttcctccaagctcccttgggctggtatc 1506 
AL2#8 ： 296 tcaggaaatagcqctqatccacgqaatggaacqttacaqaqcacatqactccqctqtqaa 355 
i i i f f i i i i i l ^ t i i t i i i i i i f f m n i i i Y i i i i i t i T i i i i i T i i i i i h Y i h 1 _ 
Mouse HsdlVbll： 1505 tcaggaaatagcgctgatccacggaatggaacgttacagagcacatgactccgctgtgaa 1446 
AL2#8 ： 356 atgacactacactcaqtccttcattccaccqtgaqaqgttaaqgtttctaattttatatq 415 
1丨〒11丨111111111�111丨111111丨111 丫ITI肩丄II彻IJLL山川丨广 
Mouse HsdlVbll： 1445 atgacactacactcagtccttcattccaccgtgagaggttaaggtttctaattttatatg 1386 
AL2#8 ： 416 ^y^ta^aa 423 
Mouse HsdlVbll： 1385 gggtagaa 1378 
B 66.3: Summary of sequence alignment ofcDNA subclone AL2#8 with mouse HSD17B11 
FluoroDD gel AL (APT + ARP15) Sequencing 
,PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. aiitr Ecom Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
M13 hydroxysteroid (17-beta) e-171 
AL2 + ++ + + 350 AL2#8 390 forward dehydrogenase 11 308/308 
(-20) (HSDnpil) (100%) 
I I I I I (1713 bp) * Sequence of primer was not completely matched with the expected sequence. 
353 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B67.1: DNA sequence of cDNA subclone AL3#3 (AP7& ARP 15) using M13 forward (-20) primer 
1 ANCNTCACTA TACGGGCAAT CGGGCCCTNC TAGATGCTGC TCGAGACGGC CGCCAGTGTG 
6 1 ATGGATATCT GCAGAATTCG CCCTTAGCGG ATAACAATTT CACACAGGAC TTTCTACCCC ARP 1 5 
121 ATATAAAATT AGAAACCTTA ACCTCTCACG GTGGAATGAA GGACTGAGTG TAGTGTCATT 
181 TCACAGCGGA GTCATGTGCT CTGTAACGTT NCCATTCCGT GGATCAGCGC TATTTCCTGA 
241 GATACCAGCC CAAGGGAGCT TGGAGGAAAA GCGTCTGTGG GATTGCAGTC TGCGTACTGG 
301 AAAACACGCG GACAGATGGA CAGACAGAAA TAATAAATGG ACCAAATCTC ACGCTCAGTG 
361 TCTCCATCTG CTGCAGAGAC CATGGCTTGA CCTTTAAATA AAAGGAAAAT CAATGACTCG 
421 AAAAAAAAAA AGCCCTATAG TGAGTCGTAT TACAAGGGCG AATNNCCAGC ACACCTGGCG 
481 GCCGTTACTA TTGGATCCGA GCTCGGTACC AAGCTTGATG CATACCCTNN GAGTATNCTA 
541 TNNTGTNACC TAAATAGCTT GGCGTAATCN NTGGTCATAG CCTGTTNTNC TGTNGTGAAA 
601 ATTNGTCATN NNCNCTCNNC AATTTTACAC NNCNAACNNT ANCNANCNNC GGAAANNCAT 
6 6 1 AAAANNTGTA NACCNCCNTG GGGGTGCCNT NNTGNAANNN AGNCTANCTC ANNTTTAATT 
7 2 1 GGCTTTGCCC CTCANTGCCC GCCTTTACAT TTTNGGGANN ACTTGTNCTT NCCATCTGCT 
781 TTTAATTAAA TTCGGCNNAA CCCCCCGGGN ANAGGNCGNT NNNTT 
B 67.2: Sequencing alignment of cDNA subclone AL3#3 with mouse hydroxysteroid (17-beta) 
dehydrogenase 11 (HsdlVpil) by BLAST searching against the National Center for 
Biotechnology Information database 
AL3#3 ： 114 ctaccccatataaaattaqaaaccttaacctctcacqgtgqaatqaagqactqaqtqtaq 173 
i i i i i i i i i i i m m i 了 i i i i i i i i i i i i i i i i i T f i n i i i T i i n i i i T i T i T i i l ^ 
Mouse Hsdl7bll： 1380 ctaccccatataaaattagaaaccttaacctctcacggtggaatgaaggactgagtgtag 1439 
AL3#3 ： 174 tqtcatttcacagcqgagtcatqtgctctgtaacgttnccattccqtggatcagcqctat 233 
i tMl l l imi t l t t l丫 l l l l l ^ t l l l l丫 l l l l丫 I I IIIIIIITITTIIIITITIill 1 � � 
Mouse HsdlVbll： 1440 tgtcatttcacagcggagtcatgtgctctgtaacgtt-ccattccgtggatcagcgctat 1498 
AL3#3 ： 234衍丨丨预丨丨丨预丨衍丨预预丨丨丨预丨衍丨〒帶衍丨丨衍，行^ 
Mouse HsdlVbll： 1499 ttcctgagataccagcccaagggagcttggaggaaaagcgtctgtgggattgcagtctgc 1558 
AL3#3 ： 2 94 qtactggaaaacacqcqqacagatgqacagacaqaaataataaatqqaccaaatctcacg 353 
？ i i i i ? � i i i i i i i ? i n i i i ? i i f f i i i ? i i i t i m i i i i i i i n i i N i i 川 I I I 丫 ^ ^ 
Mouse HsdlVbll： 1559 gtactggaaaacacgcggacagatggacagacagaaataataaatggaccaaatctcacg 1618 
AL3#3 ： 354 ctcaqtgtctccatctqctqcaqaqaccatqqcttqacctttaaataaaaqqaaaatcaa 413 
i i i i � i ? i i i i m i i � i i � i i � i T i i i i i n i 丄丄 ? I I I 山 I I I 川 i i f f i m I I I ^ � 
Mouse HsdlVbll： 1619 ctcagtgtctccatctgctgcagagaccatggcttgacctttaaataaaaggaaaatcaa 1678 
AL3#3 : 414 tqactcq 420 
ITIIIIT Mouse HsdlVbll: 1679 tgactcg 1685 B 67.3: Summary of sequence alignment of cDNA subclone AL3#3 with mouse HSD17P11 
FluoroDD gel AL (APT + ARP15) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I D. aUer EcoRl Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
M13 hydroxysteroid (17-beta) e-166 
AL3 + ++ + + 345 AL3#3 380 forward dehydrogenase 11 306/307 
(-20) (HSD17P11) (99%) 
(1713 bp) 
354 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 GNCNTATTTA NGTGACACTA TAGAATACTC NAGACTATGC NTCAAGCTTG GTACCGAGAC 
6 1 TCGGATCCAC TAGTAACGGC CGCCAGTGTG CTGGAATTCG CCCTTGTAAT ACGACTCACT AP7 
121 ATAGGGCTTT TTTTTTTTTC GAGTCATTGA TTTTCCTTTT ATTTAAAGGT CAAGCCATGG 
1 8 1 TCTCTGCAGC AGATGGAGAC ACTGAGCGTG AGATTTGGTC CATTTATTAT TTCTGTCTGT 
2 4 1 NCATCTGTCC GCGTGTTTTC CAGTACGCAG ACTGCAATCC CACAGACGCT TTTCCTCCAA 
3 0 1 GCTCCCTTGG GCTGGTATCT CAGGAAATAG CGCTGATCCA CGGAATGGAA CGTTACAGAG 
3 6 1 CACATGACTC CGCTGTGAAA TGACACTACA CTCAGTCCTT CATTCCACCC GTGAGAGGTT 
4 2 1 AAAGGTTTCT AATNTTTATA TGGGGTANAA AAGTCCTGTG TGAAATTGTT ATCCGCTAAN 
4 8 1 GGGCCGAATT CTGCAAATAT CNATCACACT NGGNGGNNGN TNNANCNTGN NNTNTTANAG 
5 4 1 GGNNNTNNNC TATNNTNANT NTANNNTNTG GGCNTCNNNN ATTNTNNTGN AAACCTNNNT 
6 0 1 NNNTATNNNN NTNNNNTNNN NTNTNNNNNG NNTNNNNNNT NNNNNN 
B 68.2: Sequencing alignment of cDNA subclone AL3#3 with mouse hydroxysteroid (17-beta) 
dehydrogenase 11 (HsdlTpil) by BLAST searching against the National Center for 
Biotechnology Information database 
AL3#3 ： 140 cgaqtcattqattttccttttatttaaagqtcaaqccatgqtctctgcagcagatqqaqa 199 
^ I丫 I丫mil了 i i i i i i i i i i i i i i m i T f i i i i T i m f f i i i i i 丫 1 1 丫 i i T i 丨而丨 
Mouse HsdlVbll： 1685 cgagtcattgattttccttttatttaaaggtcaagccatggtctctgcagcagatggaga 1626 
AL3#3 ： 200 cactqaqcqtgagatttggtccatttattatttctqtctqtncatctqtccqcqtgtttt 259 I I I I T I I I T I T I T I I I I T T I I I I I I I I I I I I I I I I T I I I T I 111 i 111 I I T i l l T I 1 1 1 
Mouse HsdlVbll： 1625 cactgagcgtgagatttggtccatttattatttctgtctgtccatctgtccgcgtgtttt 1566 
AL3#3 ： 260 ccaqtacqcaqactgcaatcccacagacqcttttcctccaagctcccttgggctggtatc 319 
l l l t l l l 丫 I I 丫 l l l t l M M I I I I I 丫 I I 丫 l l l l l l l l l l l l 丫 l l l l l l l l T f l i n i l M 
Mouse HsdlVbll： 1565 ccagtacgcagactgcaatcccacagacgcttttcctccaagctcccttgggctggtatc 1506 
AL3#3 ： 320 tcaqqaaatagcgctqatccacgqaatgqaacqttacagagcacatgactccgctqtqaa 379 
M i f f i m i T i Y i i t i M i i i f f i i i n i i i T i i i i i T i T m i i T i i i i i T i i T i T i i 
Mouse HsdlVbll： 1505 tcaggaaatagcgctgatccacggaatggaacgttacagagcacatgactccgctgtgaa 1446 
AL3#3 ： 380 atgacactacactcaqtccttcattccacccqtgagaqgttaaagqtttctaatntttat 439 I I T I I I I I I I I I I I I T I I I I I I I I I I I I I I T I T I T I T T I I I I I T I I I I I I I I I I I I I 
Mouse HsdlVbll： 1445 atgacactacactcagtccttcattccacc-gtgagaggttaa-ggtttctaat-tttat 1389 
AL3#3 : 440 atqqqgta 447 I l u f f 11 
Mouse HsdlVbll： 1388 atggggta 1381 B 68.3: Summary of sequence alignment of cDNA subclone AL3#3 with mouse HSD17B11 
FluoroDD gel A L (AP7 + ARP15) Sequencing 
P P A R a (+/+) P P A R a (-/-) F luoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I D. after Primer Blast search (% 
no. C T L W y C T L W y size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus 
hydroxysteroid (17-beta) e-155 
AL3 + ++ + + 345 AL3#3 380 dehydrogenase 11 304/308 
reverse (HSD17pil) (98%) 
^ (1713 bp) 
355 
Appendix B. DNA sequences and sequencing alignments of Fluor oDD fragments 
B 69.1: DNA sequence of cDNA subclone A01#2 (APS & ARPI0) using M13 forward (-20) primer 
1 CCNCNCACNT ATANGGCAAT TGGGCCCTCT AGATGCATGC TCGAGACGGC CGCCAGTGTG 
61 ATGGATATCT GCAGAATTCG CCCTTAGCGG ATAACAATTT CACACAGGAG ATCTCAGACT ARPIO 
121 ACATGCCAGA CTGTCCTGGT CAACGCCCAA GGGTTACCAC AGAACATTCA AGATCAGGCC 
181 AGACACTTGG GGGTGATGGC AGGCGACATC TACTCCGTAT TCCGCAATGC TGCCTCCTTT 
241 AAGGAAGTGT CCGATGGCGT CCTCACATCT AGCAAGGGGC AGCTGCAGAA AATGAAGGAA 
301 TCCTTAGATG AAGTTATGGA TTACTTTGTT AACAACNACG CCCCTCAACT GGCTGGTAGG 
361 TCCCTTTTAT CCTCAGTCTA CCGAGGTGAA CAAGGCCAGC CNTGAAGGTC CCAGCAGTCT 
421 GAGGTCNAAN GCTCAGTANA CCCCTCCCTT GTCACCAGAG CATGATGTTG CTGGCCCAGA 
481 TGACCCCCTT TTGCTGCATT GAAATNAACT TGGTAGATGG CTTTAGCTTA GAAAAGCAGC 
541 TTNTNNAGAN CCCAGGGCCT CATTATGGTC CCTCACCGCT CAGTTATGGT CTTGCCCCAG 
601 CTGNNCCTGG CACANGAGTT TCTTACCCTG GCTNGTGAGT GGCCTGTGTN AGTTTNNTGA 
661 NGANCTGNAN GAACCTATAC GCTNGATGCN CTTAAGTTTN GTNTGTNGCC TTTGTTTTGT 
721 NNTGGGNTGT ACAGTTTGTC TGGANNGANT AAGATNCTTT NNNNGNNAAA AAAAAGNNCT 
781 NTNNTNNNTN TTTTTCGGGG GGGANTTCAC ANNNNGNNN 
B 69.2: Sequencing alignment of cDNA subclone AOl#2 with mouse adipose differentiation related 
protein (ADFP) by BLAST searching against the National Center for Biotechnology Information 
database 
A01#2 115 IITIIIIIIITIIITIIITIIIITTIIIIITIIIIITTTIIIIIIIITIIIIIIIIITII 174 
Mouse ADFP: 1036 cagactacatgccagactgtcctggtcaacgcccaagggttaccacagaacattcaagat 1095 
A01#2 175 IITTllIgIIIlllTTTTTITIITTIITTITIIIlllIllllTIIllllTIIIITIITII 234 
Mouse ADFP: 1096 caggccaaacacttgggggtgatggcaggcgacatctactccgtattccgcaatgctgcc 1155 
A01#2 235 IIIIIIIITTIITITIIITIITTITIIIIIIIIIIIITIIITTTTIITIITIITIIIIIT 294 
I"louse ADFP: 1156 tcctttaaggaagtgtccgatggcgtcctcacatctagcaaggggcagctgcagaaaatg 1215 
A01#2 295 IITTIIlllllITIITIITllIITTIllIllllTllllllllnllTllcllll1IITTII 354 
Mouse ADFP: 1216 aaggaatccttagatgaagttatggattactttgttaacaac-acgcctctcaactggct 1274 
A01#2 355 TTIITTllllllllIlllllITlllIllTITTITIIIIITTllITllnlTllTTICIIIT 414 
Mouse ADFP: 1275 ggtaggtcccttttatcctcagtctaccgaggtgaacaaggccagcc-tgaaggt-ccag 1332 
A01#2 415 IITlllTITTllnllnTllllTllnllllllcllllTllllllTITlllTllTIITIITT 474 
Mouse ADFP: 1333 cagtctgaggtc-aaagctcagtaaacccct-ccttgtcaccagagcatgatgttgctgg 1390 
A01#2 475 cccaTatTacccccttttTctTcattTaaatnaacttTTtaTatTTctttaTcttaTaaa 534 
I11 11 I 11111111 11 I11 1111 11111 11 11 11111 1111 I11 1448 Mouse ADFP: 1391 -ccagatga-ccccttttgctgtattgaaattaacttggtagatggctttagcttagaaa 
A01#2 535 aTcaTcttntnnaTancccaTTTcctcattatTTtccctcaccTctcaTttatTTtcttT 594 
I 11 I11 I I I 11 I 111111111 11 11111 1111 1111 11I1 
Mouse ADFP: 1449 agcagcttct-tagaaccaagggcctcattatggtcactcacagctcagttatggtcttg 1507 
A01#2 595 1IIIITIITnnIIITTllllnTITII-lllllcIIITTllnTITITITTIIITITlnlTI 653 
Mouse ADFP: 1508 ccccagctggccctggcacaggagttctctta-cctggctggtgagtggcctgtgttagt 1566 
A01#2 654 ttnntTanTanctgnanTaaccta 677 
I 11 I II1 I I 1I11I 
Mouse ADFP: 1567 cttgtgaggacctggaggaaccta 1590 
B 69.3: Summary of sequence alignment of cDNA subclone AOl#2 with mouse ADFP 
FluoroDD gel AO (AP5 + ARPIO) Sequencing 
PPARa (+1+) PPARa (-1-) FluoroDD Sub clone Size of insert Gene homology to E-value Fragment fragment I.D. after EcoRI Primer Blast search (% 
no. size (bp) cut (bp) (Transcript size) Identity) CTL Wy CTL Wy 
M13 
Mouse adipose 0 
differentiation related 
AOl + ++ + + 700 A01#2 720 forward protein (ADFP) 530/564 (-20) (93%) (1680 bp) 
_1 - ~ 
.) J O 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 ACCCNNNTAG TAGNATACAC ATATAANATC ATCAGACATG TNACATCAGA CTGNGNNANN 
61 CCAGACTNGA ATNACCNAGN NNAACGGNCC GCNNGTGTGC TGGAAATNCN CCCTTAGACG 
121 G A N T A A C A A T T T C A C A C A A G G A G A T C T C A G ACAANAANNG ANNNATAGAA AACCTTGGTA ARPIO 
181 ACNAAGAGTA GGATGGTGAT GTGAACNTGG AAGGAATGTT GACCTTAAAG GAAGACCTGT 
241 TAATGTAGGG TTAGGAGAGT GATGACTCTA CTAGAGTTAT TACTAACNCT TAAAGTCTNN 
301 CTGTGTTNNA AACCANCAAT GNCAAAGTCA GATATAGTGA ATAGAAACTA TGNCAATGTT 
361 TAAGACCNTC AANAAAGCAA ATCTATATAT CTTAANCAAT CCTACTTAAC AAGNCCTCAA 
421 TCAAAGNCAA ATCCTACTCT GATGTTAAAA TAGTTTTGTT GGCACATGTG TAGGCTGCAA 
481 GTCCTCTGTG AANCATGATT ATAGAGTCTA TTTCTCAANG CACTTTAATA CTTTCTAATT 
541 GCCAGAGGGA TAAAGCACAC GGTTAGAAGC TAATNTCTCT GACCNTCAGT GCCTTCCACA 
601 CCCAGCACAG GAGTACAGCC TGTGAGAGTN ATGGGNNACC ACTATTGTAC CATAGTGATC 
661 TAAAATAGCT CCTTTGAGCC ANGCCNNNNG ATCCAGTTGT ATANNAAATT NTTACCCCCC 
721 CCCNNANNAG AATTTTNCAN NCTTNNTATG ATTGTTGAAT NATTTGTGAA TTAAATAAGA 
781 TNCNTTGAAA AAAAANAAGC 
B 70.2: Sequencing alignment ofcDNA subclone A01#5 with mouse carnitine O-octanoyltransferase 
(Crot) by BLAST searching against the National Center for Biotechnology Information database 
A〇l#5 ： 184 aaqaqtaqqatgqtqatqtqaacntgqaagqaatgttqaccttaaagqaaqacctgttaa 243 IITITIITTIITTITIITITI I I IT 11 IT IIITI IT I i MMITTMT IIITIIII 
Mouse Crot： 2052 aagagtaggatggtgatgtga-catggaaggaatgttgac-ttaaaggaag-cctgttaa 2108 
A〇l#5 ： 244 tqtaqqqttaggagagtgatgactctactagagttattactaacncttaaaqtctnnctq 303 
111 ITTll IITTITITITMT IIII IIITITIIIII III IIIIIITIII I IT 
Mouse Crot： 2109 tgtagggttaggagagtgatg-ctct-ctagagttatt-cta--ccttaaagtctc-ctg 2162 
A〇l#5 ： 304 tqttnnaaaccancaatqncaaaqtcaqatataqtqaataqaaactatgncaatqtttaa 363 
III I I！ 111 IIIIT 111 111 I 111 111 ITITI 11 IT 11111 IT IIIITIIIII 
Mouse Crot： 2163 tgttgcaa-cca-caatg-caaagtcagatatagtgaatag-aactatg-caatgtttaa 2217 
A〇l#5 : 364 gaccntcaanaaaqcaaatctatatatcttaancaatcctacttaacaaqncctcaatca 423 
T I IIII 11 III 11111111111111111 M M I M M M M M I T i m i i m 
Mouse Crot： 2218 g--cctcaacaaagcaaatctatatatcttaa-caatcctacttaacaag-cctcaatca 2273 
A〇l#5 ： 424 aaqncaaatcctactctqatqttaaaatagttttqttqqcacatqtgtagqctgcaagtc 483 
I IT l l l l l l l l l l l l 1 1 1 111 111111 III 11 111 illl111ITITIITTIIII IIIII 
Mouse Crot： 2274 aag-caaatcctactctgatgttaaaatagttttgttggcacatgtgtaggctgcaagtc 2332 
;\〇1#5 ： 484 ctctgtqaancatqattataqagtctatttctcaangcactttaatactttctaattgcc 543 
111 ll^l^ I 11 iTm 11 ITITI 11111111111 Tl 111111111 M 1111 M 11III 
Mouse Crot： 2333 ctctgtgaa-catgattatagagtctatttctcaa-gcactttaatactttctaattgcc 2390 
AC1#5 ： 544 aqaqqgataaagcacacqqttaqaaqctaatntctctqaccntcaqtqccttccacaccc 603 
ITITTTIIIIITIIIIITTIIITIITIIIII IIIIITI I 11 IT IT 11111 M 11111 
Mouse Crot： 2391 agagggataaagcacacggttagaagctaatttctctga-catcagtgccttccacaccc 2449 
A〇:L#5 ： 604 agcacagqaqtacaqcctqtgaqaq-tnatqqq-nnaccactattqtaccataqtgatet 661 
ITIIIITTITIIIITIilTITITIT I MTTT 11111111 IT 111 IIITITIMI 
Mouse Crot： 2450 agcacaggagtacagcctgtgagagttcatgggaaaaccactattgtacaatagtgatct 2509 
A01;i5 ： 662 aaaataqctcctttgagc 679 
1 I I I I 111 I I I I I Mill 
Mouse Crot： 2510 aaaatagctcctttgagc 2527 B 70.3: Summary of sequence alignment of cDNA subclone A01#5 with mouse Crot 
FluoroDD gel AO (APS + ARPIO) Sequencing 
Fragment PPARa (+/+) IpPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
fragment fragment I D. after EcoRl Primer Blast search (% 
no. CTL I Wv CTL I Wv size (bp) cut (bp) (Transcript size) Identity) 
j ： r 1 
I Mus musculus carnitine O- e-152 
I A.01 卞 4 十 + 700 A01#5 720 octanoyltransferase (Crot) 461'498 
\ reverse (2804 bp) (92%) I ^ I ^ 1 1 ^ 1 I ^ ^ 
357 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 ACCNNCACTA TACGGGCNAA TNTGGGCCCT CTAGATGCNT GCTCGAGACG GCCGCCAGTG 
6 1 TGATGGATAT CTGCAGAATT CGCCCTTAGC GGATAACAAT TTCACACAGG AGATCTCAGA A R P I O 
121 CAAAAATCCA ACTGGACAGG CTACTCACAA AAGGTGTTAC CCACTTCGTT ATATATACTN 
181 CCCTGTCNAT CCCAAAATGT CATCATTAGG GAAGCCACTA AGAGTTTGGA AATAGGGGCT 
241 GGAGAGATGC CTCTGTGGTT AAGAGCATTG GCTGCTCCTC TAGAGGACCC AGGTTCAATT 
301 CCCCAGTGCC CACACATCAG CTCACAACTG TCTGTAACCC AGTTCTAGGT GATTTGATAC 
361 CCTCACACAG ACATACATGT AGACAGATCC ACCAATACAT ATAAAATTAA AATAAAGATT 
421 TTGGAAATAA CATATTGCCA AAATGAGAAT TACTTGGTAT TATTTTGGTC TGTGGCTTCT 
481 AAGATTTTTT AAAATACATG AAAAATGTAG TAAATCACTA AAATTCATTT ATCTTTCTTT 
541 GAAAGANNTC AATATTTTAG TATAATAAAG AGCTGTATGT NGAGCCATCT GTGTCGGGAT 
601 TTGTGNNTCC TGCTCTTTTT CAGTNCCTCT CTAGTCTATG AACTCTCATG TNCCTTAGTG 
661 TCCCTATACC TTCTGGTCNA ATACAAATGC CCATNANATC CATCATGTGA AAAAAAAAAA 
721 GCCNTATAGT GAGGTNTTAT NACNAGGNCC NAATCCAGCC ACNCTGGGCG GNNGTNAATA 
781 NNTGNATCCN ANCCTCGGTA CCANGCTTGA NNCNNTNNNT 
B 71.2: Sequencing alignment of cDNA subclone A02#6 with mouse RNase A family 4 (Rnase4) by 
BLAST searching against the National Center for Biotechnology Information database 
A02#6 : 111 agatetcaqacaaaaatccaactgqacaqgctactcacaaaagqtqttacccacttcqtt 170 
丨了 m m 丫 i i m i i i i i m i f f i i i f f i m i M i m i T f i T i i i m N m 丫 N 
Mouse Rnase4： 944 agatetcagacaaaaatccaactggacaggctactcacaaaaggtgttacccacttcgtt 1003 
A〇2#6 ： 171 atatatactnccctqtcnatcccaaaatgtcatcattaggqaagccactaagagtttqga 230 l l l l l l l l l I I I I I I I I I I I I I T I I I I I I I I I I T T I I T I I I I I I I T I T I I I T T I 
Mouse Rnase4： 1004 atatatactttc-tgt-tattccaaaatgtcatcattagggaagccactaagagtttgga 1061 
A02#6 ： 231 aataggqqctggaqaqatgcctctgtggttaagagcattgqctqctcctctaqaqqaccc 290 
i i i i f i T f i i f f i t i t i i Y i i i i i l ^ f f i i i i Y i l ^ i i i f f i i Y m i i i i i T i f f i i i i 
Mouse Rnase4： 1062 aataggggctggagagatgcctctgtggttaagagcattggctgctcctctagaggaccc 1121 
A02#6 ： 291 aqqttcaattccccaqtqcccacacatcaqctcacaactgtctgtaacccaqttctaqqt 350 I T T I I I I I I I l l l I T I T I I I I I I I I i l l T I I I I I I I I I T I I I T I I I I I I I T I I I I I T T I 
Mouse Rnase4： 1122 aggttcaattccc-agtgcccacacatcagctcacaactgtctgtaacccagttctaggt 1180 
A〇2#6 ： 351 qatttqataccctcacacaqacatacatqtaqacagatccaccaatacatataaaattaa 410 
T I I I I T I I I I I I l l l l l l l T l l l l l l l l l l l T I I I T I I i m m l l l l l l l l l l l l l … � 
Mouse Rnase4： 1181 gatttgataccctcacacagacatacatgtagacagatc-accaatgcatataaaattaa 1239 
A02#6 ： 411 aataaaqattttggaaataacatattgccaaaatgaqaattacttqgtattattttqqtc 470 
m m t i m i f f m i i i i i i i i i t i i i i i i 丨 丫 i T m i i M i T f m m N ! n 丄 丨 ” � � 
Mouse Rnase4： 1240 aataaagattttggaaataacatattgccaaaatgagaattacttggtattattttggtc 1299 
A〇2#6 ： 471 tgtggcttctaaqattttttaaaatacatgaaaaatgtaqtaaatcactaaaattcattt 530 
i t i f f i i i i m Y i i M i i i i i i i i i M i t m i i i丫丨 i T i m i m i i m i丄1 1 山 ” ; � 
Mouse Rnase4： 1300 tgtggcttctaagattttttaaaatacatgaaaaatgtagtaaatcactaaaattcattt 1359 
A〇2#6 ： 531 atctttctttgaaaga-nntcaatattttagtataataaagaqctqtatqt 580 
I I I imiitml^丨11丨111丨111丫1111丨11丨丨^^?丨丨丫1丨丄丫丄…� 
Mouse Rnase4： 1360 atccttctttgaaagattttcaatattttagtataataaagagctgtatgt 1410 B 71.3: Summary of sequence alignment of cDNA subclone A02#6 with mouse Rnase4 1 FluoroDD gel AO (APS + ARPIO) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Ecom Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
MUS musculus q ，A r , ribonuclease, RNase A �ce//i7i 
A02 + ++ + + 695 A02#6 760 forward familv 4 fRiiase4) 5^8/471 (-20) ( f / i l - r (97%) 
358 
Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 51.1: DNA sequence of cDNA subclone AF25#6 (APIO & ARPi:3) using M13 forward (-20) primer 
1 AGCTATTTAG GTGACACTAT AGAATACTCA AGCTATGCAT CAAGCTTGGT ACCGAGCTCG 
6 1 GATCCACTAG TAACGGCCGC CAGTGTGCTG GAATTCGCCC TTGTAATACG ACTCACTATA A P S 
121 GGGCTTTTTT TTTTTTCACA TGATGGATCT AATGGCCATT TGTATTTGAC CAGAATGTAT 
181 AGGGACACTA AGGGACATGA GAGTTCATAG ACTAGAGAGG AACTGAAAAA GAGCAGGAGA 
241 ACACAAATCC CGACACAGAT GGCTCAACAT ACAGCTCTTT ATTATACTAA AATATTGAAA 
301 ATCTTTCAAA GAAAGATAAA TGAATTTTAG TGATTTACTA CATTTTTCAT GTATTTTAAA 
361 AAATCTTAGA AGCCACAGAC CAAAATAATA CCAAGTAATT CTCATTTTGG CAATATGTTA 
421 TTTCCAAAAT CTTTATTTTA ATTTTATATG TATTGGTGAT CTGTCTACAT GTATGTCTGT 
481 GTGAGGGTAT CAAATCACCT AGAACTGGGT TACAGACAGT TGTGAGCTGA TGTGTGGGCA 
541 CTGGGAATTG AACCTGGGTC CTCTAGANGA GCAGCCCATG CTCTTAANCA CACNCGCATC 
601 TCTCCAGCCC CTATTNNCAA ACTCTTAGTG GCTTCCCTAA TGATGACANT TNTGGAATAA 
661 CAGANNGTAT ATATAACGAN NTGGNTAACA CCTTTNGTGA GTAGCCTGTN CAGTTGGANT 
721 NNTTGTNTGA NANCCTCNTG TGTGAACNTT GTNATCCCCC TAAGNGGCAA NNTNTTGNCA 
781 GATTTCNTT 
B 72.2: Sequencing alignment of cDNA subclone A02#6 with mouse RNase A family 4 (Rnase4) by 
BLAST searching against the National Center for Biotechnology Information database 
A〇2#6 ： 265 caacatacagctctttattatactaaaatattqaaaatctttcaaagaaagataaatqaa 324 I I I I I I I I I M I I I I I I I I I I I I I I I I I I I I I T I I I I I I I I I I I I I T I I T I I I I I I T I I 
Mouse Rnase4： 1412 caacatacagctctttattatactaaaatattgaaaatctttcaaagaaggataaatgaa 1353 
A〇2#6 ： 325 ttttagtqatttactacatttttcatqtattttaaaaaatcttaqaaqccacaqaccaaa 384 
M M I T I T I M I M I I I I I I I I I I M T M I I I M M M M M M 了 l l T l i m了 M M M 
Mouse Rnase4： 1352 ttttagtgatttactacatttttcatgtattttaaaaaatcttagaagccacagaccaaa 1293 
A〇2#6 ： 385 ataataccaagtaattctcattttggcaatatqttatttccaaaatctttattttaattt 444 
I M M M M I 了 I I I I I I I I M I I l f f l i m i T M M I M I M M M M I I M I I M I I I 
Mouse Rnase4： 1292 ataataccaagtaattctcattttggcaatatgttatttccaaaatctttattttaattt 1233 
A〇2#6 ： 445 tatatqtattgqtgatctgtctacatgtatqtctgtgtqaqqqtatcaaatcacctaqaa 504 
I I I I I T l l l l l h t l l l 丨化 m i l t l l l 化 i t l Y l 丽 M I M I I I M M I I 了11 … � 
Mouse Rnase4： 1232 tatatgcattggtgatctgtctacatgtatgtctgtgtgagggtatcaaatcacctagaa 1173 
： SOS T丨预衍丨丨预丨衍彻丨衍？衍丨预预衍预-丨馆丨丨丨预-m 
Mouse Rnase4： 1172 ctgggttacagacagttgtgagctgatgtgtgggcactgggaattgaacctgggtcctct 1113 
A〇2#6 ： 565 aqangagcagcccatgctcttaancacacncqcatctctccagcccctattnncaaactc 624 
I T I T I T I I T I I l l t l l M M I I M I T l 11111111 IT 11111111 IIIIIII，。口， 
Mouse Rnase4： 1112 agaggagcagccaatgctcttaaccacagaggcatctctccagcccctatttccaaactc 1053 
A〇2#6 ： 625 ttaqtggcttccctaatgatgacanttntqqaataacaqannqtatatataacqanntqq 684 
I I I T I T T I I I I I I I I I I T I I T I I I I I I T T I I I I I I I T I T l 11111111 IT I 丨 U � � & 
Mouse Rnase4： 1052 ttagtggcttccctaatgatgaca-ttttggaataacagaaagtatatataacgaagtgg 994 
A〇2#6 ： 685 ntaacacctttngtqagtaqcctgtncagttqqa 718 
l l l l l l l l l l T I T I T I I T I I I T I I I T I I T T I � - � 
Mouse Rnase4： 993 gtaacaccttttgtgagtagcctgtccagttgga 960 B 72.3: Summary of sequence alignment of cDNA subclone A02#6 with mouse Rnase4 
FluoroDD gel AO (APS + ARPIO) Sequencing 
PPARa r+/+) P P A R a (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after £coRI Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus q 
一 ， ， A M13 ribonuclease, RNase A AICIACA 
A02 + ++ + + 695 A02#6 760 reverse family 4 (Rnase4) 
(1412 bp) � 。！ 
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Appendix B. DNA sequences and sequencing alignments of FluoroDD fragments 
B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 AGNCNTATTT AGGTGACACT ATAGAATACN NAGACNATGN CTNCNAGNCT TGGTACCNAG 
6 1 ACNNNGATCA CCTAGTAACG GCCGCCAGTG TGCTGGAATT CGCCCTTGTA ATACQACTCA APS 
1 2 1 CTATAGGGCT TTTTTTTTTT TCAAATGGAA ATGCTTTAA.T TTTATATTCA CAAAATGAAT 
181 TGCAACATAT CATAATGAAT TTTGCTAATA TTCTTTTCTG TGGTAGTGTA AAAATTTCTA 
241 ATACAACTTG ATCCTTTTGC CTGCTCAAAG GAGCTATTTT AGATCACTAT TGTACAATAG 
301 TGGTTTTCCC ATGAACTCTC ACAGGCTGTA CTCCTGTGCT GGGTGTGGAC TTTTTCTGAA 
361 CCCTTCCATC TTCCTTCTGT CTCTAGGACT CTCTCATCAA CATAATGTGC AATGTTCACC 
421 ATGACCATTG CATCGTAAGG AGCATGATCA CAGCAACAGC CAAATATCCC ATTAGCAAAG 
481 GAAATCAAAT TATAGGACTT GTCACCCCAG CGTACTGATG GATCTCCACC AAGAAGCATT 
541 TCAAAGACCT GAGAATATCC TNCTGGGGTN GCATGTGGAC TGCTATCTTC TATGGAATAC 
601 ACAAATAAAC TGGTTNGAAT TTTNTCTAAT AAAGTTAAGT TCTCTGGATC NAGANCTAAT 
661 CAGATATNCT CTNGCCCTTN GNCNNCCCGA GTCCGCTNCC CCCCTAGTNA NNGCNGCTAT 
721 ACTGGCTCCA ACAGNTCNGT CCGACCCNNC CTGCTGCATT NTNTAACTNG NNGCACCTCN 
781 GCTCTNAAAT GTTATCNNTA NNNNCNAATN NTGNNANNTC NATNNNNNNG G 
B 73.2: Sequencing alignment of cDNA subclone A02#8 with mouse carnitine O-octanoyltransferase 
(Crot) by BLAST searching against the National Center for Biotechnology Information database 
A02#8 ： 347 gqactttttctgaacccttccatcttccttctqtctctagqactctctcatcaacataat 406 
f f i i i i i i i i i 丫 i i i i i i i i i i m i i i i m M i i i i i f f i i i i i i i m i i M i i i i i 
Mouse Crot： 1253 ggactttttctgaacccttccatcttccttctgtctctaggactctctcatcaacataat 1194 
A〇2#8 ： 407 qtgcaatqttcaccatgaccattgcatcqtaaqqaqcatqatcacagcaacaqccaaata 466 
Y i T m i丫 l l l l l l l l 丫 l l l l l l 化 I 丨了 1 1 1而 111 丫 m i l l了 i i i i丨丫m m i 
Mouse Crot： 1193 gtgcaatgttcaccatgaccattgcatcgtaaggagcatgatcacagcaacagccaaata 1134 
A〇2#8 ： 467 tcccattagcaaaqgaaatcaaattataqgacttgtcaccccagcgtactqatqgatctc 526 
I i M i i i t i i i i f f i i m i i i i i i i i f f i m y i i i i i i i i丫 I丫 i i i i丫 i i T f i i m 
Mouse Crot： 1133 ttccattagcaaaggaaatcaaattataggacttgtcaccccagcgtactgatggatctc 1074 
A〇2#8 ： 527 caccaaqaaqcatttcaaaqacctgaqaatatcctnctgqqgtngcatqtqgactqctat 586 I I I I I I T I I I I I I I I I I I I T I I I I T I T I I l l l I I I I T T T T I 1 1 1 I T I T T I I I I I 111 
Mouse Crot： 1073 caccaagaagcatttcaaagacctgagaatattcttctggggttgcatgtggactgctat 1014 
A02#8 ： 587 cttctatqqaatacacaaataaactqgttnqaattttntctaataaaqttaagttctctq 646 
I I I I I I I T T I I I l l l l l l I I I I I I I T I I I 了 l l l l l l I I I I I I I I I T I 11了丨NIIIT�口力 
Mouse Crot： 1013 cttctatggaatacacaaataaactggtttgaattttttctaataaagtcaagttctctg 954 
A〇2#8 ： 647 qatcnaganctaatcagatatnctctnqcc 676 T I M I I I l l l l l l l T l l l l M M I I I 
Mouse Crot： 953 gatcaaga-ctaatcagatattctcttgcc 925 B 73.3: Summary of sequence alignment of cDNA subclone A02#8 with mouse Crot 
FluoroDD gel A O (APS + ARPIO) Sequencing 
P P A R a (+/+) P P A R a (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment I.D. after Primer Blast search (% 
no. C T L W y C T L W y size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus carnitine O- e-160 
A02 + ++ + + 695 A02#8 740 octanoyltransferase (Crot) 319/330 
reverse (2804 bp) (96%) 
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B74.1: DNA sequence of cDNA subclone A08#2 (APS & ARPIO) using Ml3 forward (-20) primer 
1 TCANNATAGG GGCNAATTGG GCCCTNCTAG ATGCNTGCTC GAGACGGCCG CCAGTGTGAT 
6 1 GGATATCTGC AGAATTCGCC CTTAGNCGGA TAACAATTTC ACACAGGAGA TCTCAGACAA ARPIO 
121 AAATCCAACT GGACAGGCTA CTCACAAAAG GTGTNACCCA CTTCGTTATA TATACTTTCT 
181 GTTATCNCAA AATGTCATCA TTAGGGAAGC CACTAAAGAG TNTGGGAAAT AGGGGGCTGG 
241 AGAGATGCCT CTGTGGTTAA GAGCATNGNN NTGCTCCTCT AGAGNNCCCA GGTTCANNTC 
301 CCAGTGCCCA CACATCAGCT CACAACTGTC TGTAACCCAG TTCTAGGTGA TTTGATACCC 
361 TCACACAGNA CATACATGTA AAAAGATCAC CAATNNATAT AAAATTANAA TAAAGATTTT 
421 GGGAAATGAA AAAAAAAAGC CCCTATAGTG AGNTCNTATN NCAAGGGGCN ANANNCCAGC 
481 CACACTGGGC GGGCCGTTTA CTANGTGGGA TTCCGAGCCT CGGGTACCCA ACCNNGATGC 
541 CATAGCCTNG AGTAANNCTA TAGTGTAACC TAAATAGCTN GGCGTANTCA TGGTNATANA 
601 AGNNAAANAT NCCCCNCAAG GANNNCCGCC TCACAAATTC CCAACANNAC AATACCGAAN 
661 CCNGGGANNN CACNTAAAAG NNNGTNAAAG GCCCNNNGGG GNTGNCCTNA ANNTGGANNN 
721 TGAGNCCNCA ACCNCACACA NNTTAATTTG NNNGTNGCNC CCTACANTGN NCNNNNTTTC 
7 8 1 CAAGTNNGGN ANCCCTGTNN TGCCCANCTG NNTNATTGAT TCGGCCACGC CCGGGANNNG 
841 NNGTTGGNNN TGGNNCCTTT TCGCCTNNNC CCTANTGACT NNNNNGCCTG GGTGTTGGG 
B 74.2: Sequencing alignment of cDNA subclone A08#2 with mouse RNase A family 4 (Rnase4) by 
BLAST searching against the National Center for Biotechnology Information database 
A〇8#2 ： 108 agatetcaqacaaaaatccaactgqacaqgctactcacaaaaqqtqtnacccacttcqtt 167 
i T m m T i m i i i m i i i i n m f f i i i i i i i i i m T M i I I I I I I I I I T I I 
Mouse Rnase 4: 944 agatetcagacaaaaatccaactggacaggctactcacaaaaggtgttacccacttcgtt 1003 
A〇8#2 ： 168 atatatactttctqttatcncaaaatqtcatcattagqqaagccactaaaqagtntqgga 227 I I I I I I I I I I I I I T I I I I I I I I I I T I I I I I I I I I T T T I I T I I I I I I I I I T I I I I I 
Mouse Rnase 4： 1004 atatatactttctgttattccaaaatgtcatcattagggaagccact-aagagttt-gga 1061 
A〇8#2 ： 228 aataqqqqgctggaqagatgcctctqtggttaagaqcatnqnnntqctcctctaqagnnc 287 
i m n f f i i f f i l ^ Y i i l ^ i i i i 丫 i f f i i i i Y i Y i i i T i T i i i i i i i i i i T I 
Mouse Rnase 4: 1062 aata-ggggctggagagatgcctctgtggttaagagcattg-gctgctcctctagaggac 1119 
A〇8#2 ： 288 ccaqqttcanntcccaqtgcccacacatcaqctcacaactqtctqtaacccagttctagq 347 
M I T T I I M M M I T I T M M M M M I T M M M M I M M T M M M M M M I T T � 
Mouse Rnase 4: 1120 ccaggttcaattcccagtgcccacacatcagctcacaactgtctgtaacccagttctagg 1179 
A〇8#2 ： 348 tqatttgataccctcacacaqnacatacatqtaaaaagatcaccaatnnatataaaatta 407 
I T I I I I T I I I I I I I I I I I I I T l l l l l l l l 丫 I I I I T I I I I i l l l l I N l i m ! 丄 丨 … � 
Mouse Rnase 4: 1180 tgatttgataccctcacacag-acatacatgtagacagatcaccaatgcatataaaatta 1238 
A〇8#2 : 408 naataaagattttgg 422 I I I I I I T I I I I I T T Mouse Rnase 4: 1239 aaataaagattttgg 1253 B 74.3: Summary of sequence alignment of cDNA subclone A08#2 with mouse Rnase4 
FluoroDD gel AO (APS + ARPIO) Sequencing 
PPARa (+/+) PPARa (-/-) FluoroDD Subclone Size of insert Gene homology to E-value 
Fragment fragment LD. after Primer Blast search (% 
no. CTL Wy CTL Wy size (bp) cut (bp) (Transcript size) Identity) 
M13 MUS musculus e-l2\ 
… …o— r J ribonuclease, RNase A oo/ini«; 
AOS + - + + 400 A08#2 400 forward familv 4 fRnase4) 294/315 
(-20) d y 二 ; (93%) 
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B 75.1: DNA sequence of cDNA subclone AP4#4 (API2 & ARP2) using Ml3 forward (-20) primer 
1 CCNCCTATAC GGATCGCGCN NACATCGTCG CCANNNGCCC ANTGTATNAT TTNANAATCC 
61 CCTGTAATAC GACTCACTAT AGGGCTTTTT TTTTTTTCTA ATANCCTCTC TAGGTNCAGG A P I 2 
121 GTGTACGTAT ATATCTTATC CACATCCNNA TNCATAAATC AAGTCGACAC CGCTTATCTG 
181 TAAGGTGGCT CTATTTCTCT TGTCCTTCNC NNTACNCGGG ACANNACTCN NTCAACATAC 
241 ATACAACNCC GACCTGCCAT CGCTCCGGTC TGAANCTCAC ATCCACCCTN ACGACTTTAA 
301 TCGTTGAACA AACAAACCAT TAATACCCTT CTACACCATT GGGATGTCCT GATCCAACCA 
361 TCGAGGTNNT AAACCCTAAT TGTNATATGA ANCTCTTAAA TAGGATCGCG CTGTNATNCT 
421 ANGGTANNTN GGTCGTGATC ATTTNGGGTN TANATTGTNA TNNNNTGTNT NGTNNTNNNN 
481 GATTTNGTNT NTNNNNNNNN 
B 75.2: Sequencing alignment of cDNA subclone AP4#4 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AP4#4 ： 293 gactttaatcgttgaacaaacaaaccattaatacccttctacaccattgqqatqtcctga 352 T l l l l l l l l l T I I T I I I M I I l l l l l l l l l l l I I I I M M I I M I T T T M T M M T I 
Mouse mitochondrion； 2498 gactttaatcgttgaacaaacgaaccattaatagc-ttctacaccattgggatgtcctga 2440 
AP4#4 ： 353 tccaaccatcgaggtnntaaaccctaattgt-natatgaanctcttaaataggatcqcgc 411 . M i l l I I I I T I T T I I I I I I I I I I I I I T I 111 I I I I l l l l l l l l l ITT I I T i l l 
Mouse mitochondrion： 2439 tccaa-catcgaggtcgtaaaccctaattgtcgatatgaa-ctcttaaataggattgcgc 2382 
AP4#4 : 412 t^t 414 
Mouse mitochondrion: 2381 tgt 2379 
B 75.3: Summary of sequence alignment of cDNA subclone AP4#4 with mouse mitochondrion 
F l u o r o D D ge l A P ( A P 1 2 + A R P 2 ) S e q u e n c i n g 
P P A R a ( + / + ) P P A R a ( - / - ) F l u o r o D D S u b c l o n e S i z e o f i n s e r t G e n e h o m o l o g y to E - v a l u e 
l ^ r a g m e n t f r a g m e n t I . D . a f t e r P r i m e r B l a s t s e a r c h ( % 
n o . C T L W y C T L W y s i z e ( b p ) c u t ( b p ) ( T r a n s c r i p t s ize) I d e n t i t y ) 
M13 Mus musculus clone LA9 7e-30 
AP4 + ++ + + 680 AP4#4 720 forward mitochondrion, complete 113/123 
[ _ _ ] _ _ _ J (-20) genome (16300 bp) (91%) 
* Sequence of primer was not completely matched with the expected sequence. 
362 
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B 71.1: DNA sequence of cDNA subclone A02#6 (AP5 & ARPIO) using Ml3 forward (-20) primer 
1 CNNNTATTTA GGTGACACTA TAGAATACTA CAAGACTATN NATNCAAGAC TTGGTACCGA 
6 1 GACTACGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA TTNCGCCCTT AGACGGATAA ARP2 
1 2 1 CAATTTCACA CAGGAGCTAG CATGGACGGC TAAACGAGGG TCCAACTGTC TACTTATCTA 
1 8 1 TAATCAGTGA AATTGACCTT TNCAGTGAAG AGGCTGAAAT ATAATAATAA GACGAGAAGA 
2 4 1 CCCTATGGAG CTTAAATTAT ATAACTTATC TATTTAATNT ATAAAACCTA ATGGCCCAAA 
3 0 1 GACTATAGTA TAAGTTTGAA ATTTNGGTTG GGGTGACCTC GAGAATAAAA AATCNTCAGA 
3 6 1 ATGATTATAA CTAATACACN NNNTNATCCT NTNTATGANA TTTTNATNNA NTCTGNATGC 
4 2 1 CTTTNCANNT ANANTNNANT NNNNTNNNNN NNNNNNANAA AAAAAAAAAN NNNNNGNANN 
4 8 1 NNNNNANANA ANAACAAANA AAAAAAAAAA NNCAAACAAA AAAAAAANAA CANANAACNC 
5 4 1 ACNNAAAANN AAAAAAAACA CAA 
B 76.2: Sequencing alignment of cDNA subclone AP4#4 with mouse mitochondrion by BLAST 
searching against the National Center for Biotechnology Information database 
AP4#4 ： 141 catqqacqgctaaacqaqqgtccaactqtctacttatctataatcaqtqaaattqacctt 200 . Mil I 111 11111II111111111111111 l l l l l l l l l l l l l l i1 III 111 m i l 
Mouse mitochondrion： 2065 catgaacggctaaacgagggtccaactgtct-cttatctttaatcagtgaaattgacctt 2123 
AP4#4 ： 201 tncagtqaaqaggctqaaatataataataaqacqaqaagaccctatggagcttaaattat 260 
. 1 i i l ^ l ^ i 浦 I I 丫 i m m i i i i i i i l ^ i 丫 I 丫 i i T i i i i i i i f M m m i m 
Mouse mitochondrion： 2124 t-cagtgaagaggctgaaatataataataagacgagaagaccctatggagcttaaattat 2182 
AP4#4 ： 261 ataacttatctatttaatntataaaacctaatqqcccaaagactatagtataagtttgaa 320 
. i i i i i i i i i i i i i i i i i i III i i i i m i i f f i i i i i i mill丫im丨〒 
Mouse mitochondrion： 2183 ataacttatctatttaatttattaaacctaatggcccaaaaactatagtataagtttgaa 2242 
AP4#4 ： 321 atttnggttqgqgtqacctc-qaqaataaaaaatcntcagaatqattataac 371 
MM TTIITTTTITIIIII TITI 1111111 i 11 II T M I T M M M M � � 
Mouse mitochondrion： 2243 atttcggttggggtgacctcggagaataaaaaatcctccgaatgattataac 2294 B 76.3: Summary of sequence alignment of cDNA subclone AP4#4 with mouse mitochondrion 
FluoroDD gel A P (AP12 + ARP2) Sequencing 
P P A R a (+/+) P P A R a (-/-) F luoroDD Subclone Size of insert Gene homology to E-value 
l^ragment fragment I D. after ^ c o R I Primer Blast search (% 
no. C T L W y C T L W y size (bp) cut (bp) (Transcript size) Identity) 
Mus musculus clone LA9 7e-95 
AP4 + ++ + + 680 AP4#4 720 mitochondrion, complete 221/232 
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